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Abstract 
Polyketide natural products are a major source of pharmaceutical and agricultural 
compounds.  Their biosynthesis is highly complex and the elucidation of 
intermediate steps is highly desirable to the scientific community for microorganism 
engineering purposes. 
In this work, novel photoactivatable ‘chain termination’ probes were prepared as 
tools for the off-loading and capture of biosynthetic intermediates from polyketide 
synthases (PKSs); novel methods to analyse polyketide biosynthetic intermediates 
via FTICR-MS were also investigated.   
The chemical probes herein reported are nonhydrolysable analogues of ACP-bound 
malonate used in polyketide biosynthesis for carbon chain elongation.  This research 
focused on the preparation of a chemoenzymatically modified acyl carrier protein 
that, upon activation via UV irradiation, should compete with discrete ‘natural’ acyl 
carrier proteins to capture biosynthetic intermediates from challenging type II 
polyketide iterative assemblies.  Promising preliminary results for the use of this tool 
in vitro were obtained in the form of putative actinorhodin ACP-bound intermediates 
observed and characterised by FTICR-MS.  Moreover, a 4,5-dimethoxy-2-
nitrobenzyl group was also prepared and successfully employed for trapping 
biosynthetic intermediates from the in vivo assembly of the antibiotic lasalocid A.  
Lastly, mass spectrometric methods involving alkali metal adduct ions were 
explored in order to improve the characterisation of free and enzyme-bound 
biosynthetic intermediates.  Overall this work contributes further to our current and 
future understanding of polyketide synthases and related systems. 
  
 
 
 
 
Chapter 1: Introduction  
2 
 
1. Introduction 
1.1. Polyketide natural products and their biosynthesis 
Polyketides are a broad family of pharmaceutically and industrially important natural 
products.
1-5
  They are produced by bacteria, fungi, plants, and other organisms, and 
display a plethora of chemical structures and functions.  Examples include lasalocid 
A 1, a coccidiostat biosynthesised from the soil bacterium Streptomyces lasaliensis
6
; 
actinorhodin 2, a complex aromatic antibiotic from Streptomyces. coelicolor
7
; 
phloroglucinol 3, a small aromatic metabolite from Pseudomonas fluorescens that 
displays a range of activities including antibacterial action
8
; resveratrol 4, an 
antioxidant found in grapes commonly reported as being responsible for the so-
called ‘French paradox’9; and lovastatin 5, a cholesterol lowering compound, and 
precursor to the drug simvastatin, biosynthesised by the fungus Aspergillus terreus
10
 
(Figure 1).  Polyketides also include many anticancer and antitumour agents, 
insecticides, antifungals and antiviral compounds.   
 
Figure 1  Examples of polyketides from bacteria (Lasalocid A 1, Actinorhodin 2, and 
Phloroglucinol 3), plants (Resveratrol 4) and fungi (Lovastatin 5). 
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1.1.1. Fundamentals of polyketide biosynthesis 
Polyketides are biosynthesised by polyketide synthase (PKS) enzymes.  PKSs are 
roughly categorised into three types per the organisation of their domains and their 
catalytic activities (Scheme 1).  While type I and type III PKSs are single proteins 
comprising multiple domains/catalytic activities, type II PKSs consist of discrete 
enzymes or domains that act iteratively to produce complex aromatic compounds.
11-
13
  Type I PKSs can be either ‘modular’ or iterative.  Modular PKSs biosynthesise 
polyketides in a step-wise manner, utilising ‘modules’: these are groups of enzymes 
or domains which catalyse loading, elongation or termination of the polyketide chain 
where each domain is used only once.  Conversely, iterative type PKSs use each of 
their domains multiple times.  Type III PKSs are always iterative, but differ from 
type II in that coenzyme A (CoA) is the acyl carrier, whereas an acyl carrier protein 
(ACP) is used in all other types of PKS.  
The common and key step in polyketide biosynthesis is carbon chain formation and 
elongation by decarboxylative Claisen condensation of malonate units (bound to acyl 
carrier proteins (ACPs) in type I and II PKSs or to Coenzyme A in type III PSKs) 
onto acyl groups bound to ketosynthase (KS) domains (Scheme 1).  Upon new 
carbon-carbon bond formation, the extended polyketide chain bound to ACPs or 
CoAs is transferred onto KSs of the same enzyme/module for iterative systems, or to 
downstream modules in modular systems for further elaboration.  This process is 
repeated a pre-programmed number of times until an ACP bound n-ketide is 
generated (Scheme 2).  Starter and extender units include methyl, ethyl or propionyl 
malonyl.  
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Scheme 1 Illustration of different polyketide synthases (PKSs):  From top to bottom: Type I 
modular PKSs use modules for single rounds of chain extension and modification, as 
exemplified by the first two modules of the lasalocid A PKS which are each responsible for 
one round of polyketide chain extension. Type I iterative PKSs use their domains iteratively, 
as shown, for the biosynthesis of Terreic acid 6
14
 via the precursor 6-methylsalicylic acid (6-
MSA) 50, showing the multiple usage of each domain.  Type II PKS such as that responsible 
for the biosynthesis of actinorhodin 2.  Type III PKSs such as that responsible for the 
biosynthesis of resveratrol 4, use coenzyme A (CoA) as the acyl carrier.  KS = ketosynthase, 
AT = acyl transferase, ACP = acyl carrier protein, DH = dehydratase, KR = ketoreductase, 
ER = enoylreductase, and CLF = chain length factor.) 
5 
 
 
Scheme 2 Polyketide chain extension mechanism for the actinorhodin 2 type II minimal 
system. ACP = acyl carrier protein, KS = ketosynthase, CLF = chain length factor. 
 
Acyl transferase (AT) domains are present in type I PKSs; they are responsible for 
selectively loading ACPs with malonyl starter and extender units provided by CoAs.   
ATs can either be cis- or trans-.  The former are paired with a specific ACP, whereas 
the latter can transfer extender units to one or more ACPs.
15
  The 6-
deoxyerthyronolide B synthase (DEBS) contains a cis-AT, and examples that 
harbour trans-ATs include PKSs that biosynthesise leinamycin
16
, bryostatin
17
 and 
disorazole
15, 18
.  However, this domain is not necessary in all PKSs as some ACPs 
can self-malonate, such as in the biosynthesis of actinorhodin 2.
19
   
Further product complexity is achieved by the action of reductive enzymes 
throughout chain extension.  Ketoreductase (KR) domains stereoselectively reduce a 
β-keto group to a hydroxyl group, using nicotinamide adenine dinucleotide 
phosphate (NADPH) as a co-factor.  Further hydrolysis of the hydroxyl group can be 
performed by a dehydratase (DH), producing a double bond that can be even further 
reduced by an enoylreductase (ER).
20
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The acyl carrier protein (ACP) plays a key role in shuttling the growing polyketide 
chains to different domains, and provides the starter unit to the ketosynthase (KS) for 
chain extension to begin (See section 1.2.1 for further detail).   
Thioesterase (TE) domains catalyse the hydrolysis or cyclisation of advanced 
thioester intermediates, releasing the fully biosynthesised polyketide from the PKS.  
However, TEs are not always present in PKSs as spontaneous hydrolysis or 
cyclisation can occur to release the compound from the PKS.   
 ‘Tailoring’ enzymes perform further polyketide structural modifications; they are 
often post-PKS enzymes, and include methyltransferases, cyclases, aromatases and 
glycosyltransferases, amongst many others.  Product tailoring modifications are 
often crucial to their bioactivity.  For example, the glycosylation of erythromycin is 
essential for its antibiotic action.
21
  The tailoring can also take place on the enzyme 
bound intermediates such as the epoxidation of the late stage intermediates leading to 
the polyether rings in lasalocid A 1.
22
 
The biosynthesis of polyketides can be very complex, and include numerous 
stereoselective reactions and tightly regulated steps that, as yet, are not easily 
attainable by synthetic chemistry.  When polyketide generation is achieved by 
synthetic chemistry, the number of steps becomes far greater than that required 
within living organisms, and at far greater cost.  For example, the optimised 
chemical synthesis of the lasalocid A 1 requires 29 chemical steps with 
approximately 0.55% final yield.
23
  Therefore, when the compounds are 
pharmaceutically active it makes economic sense to use microorganism 
fermentation.  
7 
 
Generating analogues of natural products requires a similar long chemical synthetic 
process: if it were possible to produce these analogues by bioengineering organisms 
to introduce the favourable modifications this would cut the time and cost of the 
process, as well as make them environmentally more acceptable by avoiding the use 
of industrial chemicals.  Currently, bioengineering of PKSs is in its early stages and 
understanding the fundamentals of how these enzymes function is crucial towards 
achieving this goal. 
 
1.2. Type II polyketides and their biosynthesis  
At this point, gram-positive actinomycetes are the only known organisms that 
biosynthesise polyketides by type II polyketide synthases.
12
  As outlined in section 
1.1.1, type II PKSs differ from other PKSs in that the enzymes involved are discrete, 
and are always iterative enzymes.  The products of type II PKSs tend to be highly 
aromatic due to the facility of the polyketide chain to undergo cyclisation and 
aromatisation prior to tailoring steps.  Actinorhodin 2 (the polyketide of main 
interest in this thesis), lomaiviticin 8, doxorubicin 9, enterocin 10, jadomycin B 11, 
and resistomycin 12 are all examples of polyketides synthesised by type II PKSs 
(Figure 2).  
The polyketides made by type II PKSs can be classified by their chemical scaffolds 
into 7 different types: the aureolic acids, tetracyclines, benzoisochromanequinones, 
anthracyclines, angucyclines, tetracenomycins and pradimicin-like polyphenols.  The 
compounds from these classes exhibit a wide variety of activities, from cancer 
chemotherapy agents (e.g.  anthracyclines), to antibiotics (e.g.  tetracyclines), to 
antifungal and antiviral activities (pradimicin-like polyphenols).
12
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Figure 2  Examples of polyketides biosynthesised by type II iterative polyketide synthases.  
 
1.2.1. Biosynthesis of type II polyketides 
Polyketide chain initiation and elongation in type II PKSs is carried out by the 
‘minimal system’.  This consists of a ketosynthase (KS) and a chain length factor 
(CLF), also called KSα and KSβ, and an acyl carrier protein (ACP) domain. 4, 24  KS 
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and CLF co-express as a heterodimer complex.  The crystal structure of the KS-CLF 
from the actinorhodin 2 PKS has been solved, showing the growing polyketide chain 
located at the heterodimer interface, in an amphipathic tunnel.
25
  The KS contains an 
active site cysteine, and mass spectrometry has shown that intermediates are bound 
to this cysteine, and not elsewhere in the KS-CLF complex.
25
  
The ACP provides the KS with the starter and extender units for polyketide chain 
formation, and also transports the growing polyketide chain to the KS-CLF, linked 
via a 4’-phosphopantetheinyl (PPant) arm bound to an active site serine.26  The 
PPant arm binds all these different substrates as a thioester by employing its terminal 
thiol moiety (Scheme 2).   
It is believed that the CLF is crucial for the initial decarboxylation of malonyl-ACP 
7 to load an acetyl group onto the KS, and also to initiate the decarboxylative Claisen 
condensation that begins chain elongation.
27
  Subsequently, malonyl-ACP 7 is 
iteratively used for polyketide chain extension as previously described (Scheme 2).  
The most common starter unit for type II PKSs are acetate units, as those used for 
example in the biosynthesis of actinorhodin 2
28
.  However, some PKSs have been 
found that use other starter units, such as propionate (doxorubicin 9
29
 and 
lomaiviticin 8
30
), and benzoate (enterocin 10
31
).  The alternative starter units are 
synthesised by fatty acid synthases (FASs) or by type I PKSs, as in frenolicin 13
32
 
and hedamycin 14
33
 biosynthesis, respectively.  A third loading mechanism uses an 
AT domain to directly load starter units from CoA, as has been established for 
tetracycline biosynthesis.
12, 34
  
As described, malonyl units provide the further extensions of the polyketide chain 
for all known type II PKSs.
12
  The proposed mechanism begins with the loading of 
10 
 
the ACP with a malonyl group.  The ACP can either self-malonylate
19
 or  malonyl-
CoA: holo acyl carrier protein transacylases (MCATs) can transfer the malonyl 
group from malonyl-CoA 15 to the ACP.  It has been found that MCATs are not 
essential for polyketide synthesis in vitro,
19
 however, their importance in vivo is 
unknown.  In vivo gene knock-outs of MCATs are not possible due to their crucial 
function in primary metabolism (fatty acid biosynthesis) in the cell.
35
  
 
1.2.1.1. Ketosynthase-chain length factor – structure-function relationship 
The minimal system, alone, is partially able to control the polyketide chain 
cyclisation by growing the chain within the KS-CLF complex and ‘folding it’ in a 
specific manner, however, additional cyclisations can occur.
36, 37
  Shunt products are, 
thus far, the only clues to the mechanisms by which the polyketide chains are 
synthesised in type II PKSs.   
An X-ray crystal structure with the acetate starter unit bound to the KS-CLF of the 
actinorhodin minimal system has been published.
25
  They show a 17Ǻ long channel 
where the 4’-phosphopantetheinyl arm of the ACP would reside once in contact with 
the KS-CLF, and saw an acetyl group bound to the active site cysteine.  The crystal 
structure of the KS from the R1128 16 biosynthetic pathway has also been solved 
with acetyl-CoA 17, showing a 20Ǻ long channel that places the acetyl group of 
CoA against the key residues, asparagine, histidine and the active site cysteine that 
form the catalytic triad (Figure 3).
38
  
Chain length is controlled by the KS-CLF complex, and can vary from an octaketide, 
such as for actinorhodin 2, to a pentadecaketide, such as for federicamycin.   It has 
been demonstrated, by mutations of the KS-CLF complex of the actinorhodin 
11 
 
minimal system, that the length of the polyketide chain is the controlling factor, and 
not the number of condensations.
25
   
 
Figure 3  Exemplary type II ketosynthase crystal structures.  Left: The ketosynthase (KS) 
dimeric structure from the R1128 16 biosynthetic pathway, shows the 20Ǻ tunnel where 
acetyl-Coenzyme A 17 is bound. (PDB: 1MZJ)
39
  Right: The ketosynthase chain length factor 
(KS-CLF) from the actinorhodin 2 biosynthetic pathway, with acetyl bound to the active site 
cysteine (Cys169), indicated by an arrow. (PDB: 1TQY)
25
  Inset: magnification of the KS-
CLF active site cysteine showing the bound acetyl group and 17Ǻ long channel where the 
4’-phosphopantetheinyl cofactor is thought to reside. 
 
Mutations to the channel of the KS-CLF led to the production of longer polyketide 
chains by mutating key amino acids to smaller ones (see Section 1.3.1).  This was 
12 
 
achieved both in vivo and in vitro, showing promise for further engineering of type II 
PKSs.
40
  However, the KS-CLF does not appear to be the sole determinant of chain 
length, on two occasions the presence of the cyclase or aromatase enzymes has been 
demonstrated to influence the chain length.
41, 42
  This would seem to indicate that a 
larger PKS complex is formed from the discrete enzymes of type II PKSs, and that 
the nature of the product is influenced by the interactions taking place amongst the 
different protein components.     
 
1.2.1.2. Acyl carrier proteins: structure-function relationship 
The ACPs of type II PKSs from the actinorhodin 2
43
, frenolicin 13
44
 and 
oxytetracycline
45
 19 minimal systems have been extensively characterised by NMR.  
A three helix bundle fold is common to all acyl carrier proteins, however, ACPs 
from PKSs are more similar to each other than they are to those from FASs.  For 
example, the PKS ACPs from frenolicin 13 and actinorhodin 2 pathways are 57.5% 
identical, the FAS ACPs from E. coli and B. subtilis are 60.5% identical, whereas, 
the PKS ACP from frenolicin 13 biosynthesis displays only 20.7% of identical 
residues with each of the FAS ACPs from E. coli and B. subtilis.  A visible 
difference between the two kinds of ACPs is that Helix I is approximately one turn 
longer in FAS ACPs than in PKS ACPs (Figure 4).
44
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Figure 4  Exemplary structures of acyl carrier proteins (ACPs) from type II polyketide 
synthases (PKSs).  Top left: NMR structure of the ACP from the oxytetracycline 19 PKS.  
(PDB: 1NQ4)
45
  Top right: NMR structure of the ACP from the Frenolicin 13 PKS.  (PDB: 
1OR5)
44
  Bottom left: NMR structure of the ACP from the actinorhodin 2 PKS.  (PDB: 
2K0Y)
46
  Bottom right: Crystal structure of ACP from the fatty acid pathway (FAS) in E. 
coli, containing Zn
2+
 ions and imidazole ions deriving from the crystallisation conditions.  
(PDB: 1T8K)
47
  Helix I is labelled on each structure.  Note the extra turn in Helix I of the 
FAS ACP. 
 
 
14 
 
1.2.1.3. Ketoreductases 
Ketoreductases in type II PKSs play an important role in controlling when the 
cyclisation will first occur.  KRs stereoselectively reduce a ketone to form a 
secondary alcohol introduces a ‘bend’ in the uncyclised chain that will influence that 
cyclisation.  The effect on cyclisation by the KR has been demonstrated in the 
actinorhodin 2 biosynthetic pathway.
36
  It is notable to mention that KRs have been 
shown to be interchangeable within different PKSs and also hybrid PKSs.
31, 36
  
Ketoreduction can occur both during and after chain elongation, as in enterocin 10 
and actinorhodin 2 biosynthesis, respectively.
31, 48
 
 
1.2.1.4. Cyclases and aromatases 
Cyclase domains are necessary to channel polyketide chains into specific 
arrangements, avoiding incorrect and spontaneous cyclisations to occur.  Type II 
PKS cyclases appear to be highly specific to the PKS system they belong to, and it is 
has not been possible to create hybrid systems by interchanging cyclases.
49
  Utilising 
recombinant expression of just the minimal whiE PKS system in S. coelicolor, the 
Moore group built a library of intermediates that differed in chain length and 
cyclisation pattern, indicating the importance of cyclase domains within type II 
PKSs.
41
   
An aromatase dehydrates alcohols on cyclic structures to create aromatic rings, and 
they often have bifunctionality towards the goal of aromatisation, such as additional 
oxidase or ketoreductase activity.
12, 50, 51
 
 
15 
 
1.2.1.5. Methyltransferases 
Methyltransferases (MTs) perform important tailoring reactions.  They transfer 
methyl groups via the cofactor, S-adenosyl-L-methionine (SAM), to nitrogen, carbon 
or oxygen.  Hydroxyl moieties are the most common sites for methylation in 
polyketides, known specifically as O-methyltransferases.
12
  In Streptomyces there are 
over 20 genes predicted to function as MTs, including DnrK, a carminomycin 4-O-
methyltransferase, which methylates the 4-hydroxyl group of daunorubicin 21 in S. 
peucetius.
52
   
The degree of sequence similarity between MTs of type II PKSs is low, although, a 
SAM binding site is common to all of the known MTs, and a central β-sheet with 
surrounding α-helices, known as a chain-fold, is common to most.12, 53 
 
1.2.1.6. Oxygenases 
A very important class of tailoring enzymes for type II PKSs are oxygenase 
enzymes.   There are four main types found in type II PKSs: anthrone-type 
oxygenases, flavin-dependent monooxygenases, Flavin-dependent dioxygenases, and 
cytochrome–P450 monooxygenases.12  Anthrone-type oxygenases do not require a 
co-factor
54
, an example of this type of oxygenase is found in the actinorhodin 2 
pathway, ActVA-ORF6 (Scheme 3).
55
  It was found that ActVA could be utilised in 
the tetracenomycin 22 pathway in the place of TcmH, demonstrating a broad 
substrate specificity of ActVA.
56
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Scheme 3 Examples of common oxygenases found in type II polyketides synthases.  
Anthrone-type oxygenase
56
 in actinorhodin 2 biosynthesis, flavin-dependent 
monooxygenase
57
 in mithramycin B 26 biosynthesis, flavin-dependent dioxygenase
58
 in 
chartreusin biosynthesis and cytochrome-P450 monooxygenase
59, 60
 in doxorubicin 9 
biosynthesis. 
 
Flavin-dependent oxygenases require flavin adenine dinucleoside (FAD) as a 
cofactor.   The enzymes have two binding sites which are highly conserved among 
these types of oxygenases, one for the flavin and the other for the adenosine parts of 
FAD.
12, 58
  Baeyer-Villiger rearrangements, the formation of an ester or lactone from 
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a ketone or cyclic ketone, respectively, are the most common type of oxygenase 
reactions in type II PKSs performed by FAD-dependent oxygenases.
61-63
  As 
mentioned, there are both mono- and di-oxygenases.   Monooxygenases use FAD 
and NADPH as cofactors to insert molecular oxygen.  The oxygenation step in the 
biosynthesis of mithramycin 26, by a monooxygenase, is crucial to its biological 
activity (Scheme 3).
57
  
The synthesis of chartarin 28, an intermediate in the biosynthesis of an antitumour 
agent, chartreusin, is achieved with a flavin-dependent dioxygenase, ChaP by the 
attack of dioxygen on a dione group within the substrate.
58
  The biosynthesis of the 
antitumour antibiotics daunorubicin 21 and doxorubicin 9 requires a cytochrome-
P450 monooxygenase.  These monooxygenases use molecular oxygen and NADPH 
to oxygenate the substrates (Scheme 3).
59, 60
  
 
1.2.1.7. Glycosyltransferases 
Lastly, sugar modifications can be essential to the bioactivity of a polyketide.   
Jadomycin A, is lacking the sugar, L-digitoxose, moiety that Jadomycin B 11 
possesses, does not display anti-yeast activity.
64
  Highly specific glycosyltransferases 
(GTs) catalyse the addition of sugar moieties to polyketide aglycones.  GTs are 
known as challenging enzymes to purify in active recombinant forms.  Only recently 
a GT from a type II PKS was successfully characterised by X-ray crystallography.
65
  
Claesson et al. revealed that the GT from the biosynthetic pathway of nogalamycin is 
a dimer in solution, and that it has a characteristic fold of the GT-B family of GTs.  
They also established that the GT has two active site histidines that are essential to 
function.
65
  The GTs involved in the biosynthesis of aclacinomycin, from a type II 
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PKS, have been assayed in vitro and found to accept a variety of substrates, leading 
to novel analogues being generated.  
1.2.1.8. The future of type II PKS engineering 
By utilising type II PKSs as biocatalysts, a variety of chemical structures displaying 
different bioactivities can be generated.   Already, libraries of polyketide analogues 
have been generated by a combination of mutagenesis and hybrid PKS engineering.  
For example, by mutagenesis of the KS-CLF of the actinorhodin 2 PKS, longer 
starter units were able to load onto the KS, generating larger cyclised derivatives.
66
  
However, there is still much room for improvement as, thus far, bioengineering has 
been carried out with a great deal of trial and error.
12
   
 
1.3. Biosynthesis of actinorhodin  
Actinorhodin 2 is a benzoisochromanequinone antibiotic produced by a type II PKS 
in S. coelicolor (Figure 5).  This compound is highly conjugated and can be used as 
a pH indicator due to its intense blue colour in alkaline conditions and red colour in 
acidic conditions.  This property gave it its original name of ‘blue pigment’ and its 
host organism the name ‘coelicolor’, meaning ‘sky coloured’.  It was first named and 
isolated from S. coelicolor in Germany in 1950, and its structure was determined in 
1955.
67-69
  Its gene cluster was first identified in 1976.
7
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Scheme 4  Biosynthesis of actinorhodin 2 from acetyl 17 and malonyl-coenzyme A 15.
70
  The 
actinorhodin 2 gene cluster is shown underneath. 
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Figure 5  The chemical structure of actinorhodin 2 (left) and S. coelicolor M510
71
, ΔredD 
mutant lacking the pathway-specific activator of Red synthesis, plated on solid medium, 
showing the intense blue colour caused by production of actinorhodin 2 (right). 
 
1.3.1. Biosynthesis of an octaketide chain by the actinorhodin minimal 
system 
The biosynthetic pathway, eventually leading to actinorhodin 2, begins with the 
generation of an octaketide chain 31 by the actinorhodin 2 ‘minimal system’ (the 
focus of this thesis), via iterative decarboxylative Claisen condensation (section 1.2).  
The act minimal system comprises three enzymes: the acyl carrier protein (ACP) and 
two sub-units, ketosynthase (KS) and chain length factor (CLF). KS and CLF 
express as a homodimer, with close sequence homology (Figure 6).  The CLF lacks 
the active site cysteine that gets primed with an acetyl unit, however, the CLF has a 
glutamine residue in its place that is highly conserved among CLFs of type II PKSs 
(Figure 6).  Bisang et al. have demonstrated that the glutamine plays an important 
role in conferring CLF its decarboxylase activity.  When the glutamine was mutated 
to an alanine, the enzyme lost its decarboxylase activity, and, conversely, when the 
active site cysteine of the KS was mutated to a glutamine, decarboxylase activity was 
observed.
27
  The priming unit of the actinorhodin minimal system is acetyl, which is 
provided by malonyl-ACP 7.  Malonyl-ACP 7 is decarboxylated by the CLF and the 
resulting acetyl-ACP 40 is used to prime the KS with an acetyl group.  In the 
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absence of the KS-CLF, malonyl-ACP 7 remains stable for at least an hour at room 
temperature. When the glutamine residue of the CLF is mutated to alanine, thereby 
removing its decarboxylase activity, the KS-CLF complex is still able to 
decarboxylate malonyl-ACP 7 and to generate SEK4 41 and SEK4b 42, the products 
of the minimal system (discussed later in this chapter, section 1.3.2).  This suggests 
that the KS domain is still able to provide some decarboxylase activity.
27
  
 
 
Figure 6  Protein sequences of ketosynthase (KS) and chain length factor (CLF), from the 
actinorhodin minimal system.  Sequence alignment shows structural similarities and the 
absence of the active site cysteine in the CLF.  Note the glutamine residue, in the CLF, in 
place of the active site cysteine in the KS. 
 
The malonyl group of malonyl-ACP 7 is provided by malonyl-coenzyme A (CoA) 
15, which can be self-loaded from holo-ACP 43 in vitro.
19
  There is some debate as 
to whether this is the method of priming in vivo, or whether a malonyl-CoA:holo-
ACP transacylase (MCAT) is employed to transfer the malonyl group to the holo-
ACP 43.  The actinorhodin 2 biosynthetic gene cluster does not contain a putative 
MCAT gene, however, S. coelicolor has an endogenous MCAT for assembly of fatty 
KS 1 M P L D A A P V D P A S R G P V S A F E P P S S H G A D D D D D H R T N A S K E L F G L K R R V V I T G V G V R A P G G 60
CLF 1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - M S V L I T G V G V V A P N G 15
KS 61 N G T R Q F W E L L T S G R T A T R R I S F F D P S P Y R S Q V A A E A D F D P V A E G F G P R E L D R M D R A S Q F A 120
CLF 16 L G L A P YW S A V L D G R H G L G P V T R F D V S R Y P A T L A G Q I D D F H A P D H I P G R L L P Q T D P S T R L A 75
KS 121 V A C A R E A F A A S G L D P D T L D P A R V G V S L G S A V A A A T S L E R E Y L L L S D S G R DW E V D A A W L S - 179
CLF 76 L T A A DW A L Q D A K A D P E S L T D Y DM G V V T A N A C G G F D F T H R E F R K L - - - - - - W S E F P K S V S V 129
KS 180 R HM F D Y L V P S VM P A E V A W A V G A E G P V T M V S T G C T S G L D S V G N A V R A I E E G S A D VM F A G A A 239
CLF 130 Y E S F A W F - Y A V N T G Q I S I R H G M R G P S S A L V A E Q A G G L D A L G H A R R T I R R G T P L V V S G - G V 187
KS 240 D T P I T P I V V A C F D A I R A T T A R N D D P E H A S R P F D F T R D G F V L A E G A A M F V L E D Y D S A L A R G 299
CLF 188 D S A L D P W G W V S - Q I A S G R I S T A T D P D R A Y L P F D E R A A G Y V P G E G G A I L V L E D S A A A E A R G 246
KS 300 A R I H - A E I S G Y A T R C N A Y HM T G L K A D G R E M A E T I R V A L D E S R T D A T D I D Y I N A H G S G T R Q 358
CLF 247 R H D A Y G E L A G C A S T - - - F D P A P G S G R P A G L E R A I R L A L N D A G T G P E D V D V V F A D G A G V P E 303
KS 359 N D R H E T A A Y K R A L G E H A R R T P V S S I K S M V G H S L G A I G S L E I A A C V L A L E H G V V P P T A N L R 418
CLF 304 L D A A E A R A I G R V F G R E G - - V P V T V P K T T T G R L Y S G G G P L D V V T A L M S L R E G V I A P T A G V T 361
KS 419 T S D P E C D L D Y V P L E A R E R K L R S V L T V G S G F G G F Q S A M V L R D A E T A G A A A 467
CLF 362 S V P R E Y G I D L V L G E P R S T A P R T A L V L A R G R W G F N S A A V L R R F A P T P - - - 407
β strand Helix Active site
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acids, which could be utilised in vivo to catalyse malonylation of act holo-ACP 43.  
Unfortunately, due to the necessity of this MCAT for primary metabolism within the 
cell, this question cannot be answered by enzyme mutagenesis.  
The actinorhodin minimal system produces an octaketide chain from the initial 
priming of the KS with an acetyl group, and then seven subsequent rounds of Claisen 
condensation.  Originally, in vivo experiments suggested that the CLF controlled the 
length of the polyketide chain, at which point that protein was coined ‘chain length 
factor’.72, 73  Burson and Khosla constructed chimeric PKSs in vivo in 2000, and their 
results suggested, by comparison with a KS from E. coli, that chain length was 
controlled by a proposed binding pocket at the KS-CLF interface.
74
  The importance 
of the residues at the interface of KS and CLF was demonstrated in 2003.
40
  Tang et 
al. used a homology model of the KS-CLF dimer (PDB: 1QXG) to choose certain 
residues to mutate to attempt to alter the chain length that the mutant minimal system 
could produce.  Comparisons with CLFs from other minimal systems that produced 
longer chains revealed the importance of residues Phe109 and Phe116 for chain 
length control.  Mutations of Phe109 and Phe116 to smaller amino acids, alanines, 
converted the minimal system to one which could make a decaketide shunt 
product.
40
  They also noticed two other amino acids, Thr112 and Phe133, of the act 
CLF of interest.  These residues are much smaller in CLFs of minimal systems that 
produce longer polyketide chains, however mutations of these residues in the act 
CLF did not yield longer chains for this system.  Keatinge-Clay et al. coined this 
chain length control a ‘gating mechanism’, and hypothesise that if the ‘gate’ was left 
‘open’ it may not be possible to control the length of larger polyketide chains and 
instead engineer new polymers.
25
  This hypothesis has not yet been explored.  
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A simpler experiment demonstrated in a different way how the CLF controls chain 
length and not the number of Claisen condensations.  By utilising a CLF mutant, the 
conserved glutamine mutated to an alanine, the decarboxylase activity of the KS-
CLF complex can be slowed, and allow hexanoyl ACP, β-keto-hexanoyl ACP, 
butyryl ACP, and β–keto-octanoyl ACP to load the respective starter units onto the 
KS.  Subsequently, the primed system can be incubated with malonyl-CoA 15 and 
holo-ACP 43, and allowed to produce polyketides.  New compounds are produced 
dependent upon the starter unit provided, however all of these compounds contain no 
more than 16 carbons, signifying that the KS-CLF controls the chain length and not 
the number of condensations.
66
 
Beltran-Alvarez et al. reported that the rate limiting step in the production of the 
octaketide chain is the reaction between malonyl CoA 15 and holo-ACP 43 to 
produce malonyl-ACP 7, called the loading step.  However, the rate increases from 
kcat = 0.49 min
-1
 to kcat = 2.3 min
-1
 in the presence of the KS-CLF complex (kcat is the 
number of molecules an enzyme converts to product per minute).  When malonyl-
ACP 7 is prepared separately and then incubated with KS-CLF the rate limiting step 
becomes the decarboxylation of malonyl-ACP 7, known as chain initiation.  The 
minimal system was supplied with an excess of acetyl-ACP 40 to remove the chain 
initiation step as a factor in order to decipher which was the rate limiting step in that 
reaction; it was concluded that, as no ACP-bound intermediates were detected, chain 
extension must be rate limiting, as the lack of detected intermediates indicates a fast 
release mechanism.
13
  
Later, similar experiments were carried out with point mutated ACPs.  The mutations 
were made at residues on helix II that have been suggested to have important 
interactions with KS-CLF, based upon NMR results from the type II FAS from E. 
24 
 
coli.
75
  In the presence of KS-CLF, the self-malonylation rate increases, mutation of 
Glu47 caused less of an increase in rate of self-malonylation, and mutation of Glu53 
reduced the rate to slower than in the absence of KS-CLF.  These results confirmed 
the involvement of helix II in self-malonylation, however, when Arg72, a residue far 
from helix II, was mutated, the rate decreased upon addition of KS-CLF, suggesting 
that more than just helix II is important to the interaction with KS-CLF (Figure 7).  
The rates of decarboxylation were decreased with all mutants barr the Arg72 mutant 
and similar results were seen for chain extension assays.
76
 
 
Figure 7  Solution NMR structure of the apo acyl carrier protein 44 from the actinorhodin 
minimal system, clearly indicating the four helices.  Helix I is shown in blue.  Helix II is 
shown in green.  Helix III is shown in yellow.  Helix IV is shown in red.  PDB: 2K0Y.
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1.3.2. Tailoring steps towards the biosynthesis of actinorhodin 2 
Post-minimal system, a great deal of enzymatic tailoring occurs to produce the final 
product, actinorhodin 2, as presented in Scheme 4. The act minimal system 
generates shunt products throughout the biosynthetic pathway (Scheme 5). 
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Scheme 5  Biosynthesis of shunt products, SEK4/4b 41 and 42 and mutactin 45, from the 
actinorhodin 2 biosynthetic pathway. 
 
The first cyclisation in the biosynthesis of actinorhodin 2, between C7-C12, is 
known to be produced by the minimal system, as the shunt product of the minimal 
system, SEK4 41, contains this correct cyclisation (Scheme 4 and Scheme 5).  
However, SEK4b 42, the other major product of the minimal system, contains a 
C10-C15 cyclisation.  When the KR, ActIII, is present, however, the shunt product 
becomes primarily mutactin 45, with the correct C7-C12 cyclisation.  The KR 
controls the C-9 ketoreduction, 32 to 33, which would, indeed, introduce the correct 
‘bend’, suggesting that the KR controls this first cyclisation (Scheme 5).77-80  
Following ketoreduction, there is an aromatisation producing 34, followed by 
activity of a cyclase, ActIV, which forms the second ring by intramolecular aldol 
condensation to make 35.
81
  
A dehydrogenase, ActVI, performs an enantioselective reduction at C-3 36, followed 
by a cyclisation to form a 6 membered lactone 37.
82-84
  The order of steps was 
investigated with N-acetylcysteamine β-ketothioester (SNAC) derivatives of 36 
26 
 
which did not possess carbons after C-12 in order to prevent the cyclisation.  In each 
case, the S enantiomer was the product of the dehydration.
84
  Spontaneous loss of 
water from 37 will produce (S)-DNPA 38, however, it is possible that the reaction is 
controlled enzymatically, but this has yet to be proven.  ActVI-ORF2 and ActVI-
ORF4 have high sequence similarity and resemble enoyl reductases.  Removal of 
ORF4, however, did not abolish production of actinorhodin 2, but deletion of ORF4 
did, therefore, ORF4 is thought to assist ORF2 in the reduction of the C-14 to C-15 
bond to synthesise 5-deoxy-dihydrokalafungin (5-deoxy-DHK) 23.
82, 85
  
The oxidation of the phenol of 23 to the quinone in DHK 24 is carried out by an 
anthrone-type monooxygenase, ActVA.  This monooxygenase does not require any 
cofactors or metal ions, and utilises molecular oxygen for the reaction.
55, 86, 87
  
It is not known in which order the last two steps, a dimerisation and an oxygenation, 
occur.
88, 89
  The oxygenation is carried out by a two-component NADH:flavin-
dependent monooxygenase system.  ActVB reduces oxidised flavin, which is then 
bound to ActVA-ORF5 to oxidise substrate 39.
88, 90, 91
  Interestingly, when ActVA-
ORF5 was deleted, a new dimerised, unoxidised, compound was produced, 
indicating that this protein may be necessary for controlling dimerisation.
92
  
However, it is likely that ActVA-ORF4 is the true dimerase as when actVA-ORF4 
was deleted, a previously uncharacterised gene, an oxidised DHK compound was 
produced, undimerised.
93
  The function of this protein is yet to be confirmed in vitro. 
The actinorhodin 2 PKS is the most extensively studied type II PKS, and is often 
referred to as a ‘model system’.  However, there are still questions regarding several 
the biosynthetic steps, in particular the chain extension by the minimal system, 
which is the reason why this system was the chosen subject for this thesis. 
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1.4. The role of carrier proteins in type II polyketide biosynthesis 
All type I and II polyketide synthases (PKSs) contain an acyl carrier protein (ACP).  
This small, acidic, protein bears a 4’-phosphopantetheinyl (PPant) arm that shuttles 
polyketide intermediates, bound to the thiol moiety as esters, between the different 
catalytic sites.  The ACP is expressed in its apo 44 form, and then, by means of a 
PPant transferase and coenzyme A 46, the ACP is converted to its holo form 43 
(Scheme 6). 
 
Scheme 6  Conversion of apo-ACP 44 to holo-ACP 43 with Coenzyme A 46 and a 
phosphopantetheinyl transferase.  The PPant arm is indicated on the structure of holo-ACP 
43. 
 
The structure of the actinorhodin ACP has been solved by solution NMR.
43, 46, 94
  
The ACP has four helices and a large loop between helix I and II.  Helix III is much 
smaller than the other two, and the ACP has a strong hydrophobic core except for 
two arginine residues, Arg72 and Arg79, which are conserved among PKS ACPs.
43
  
Evan et al. compared the structures of apo 44 and holo 43 ACPs.  Holo-ACP 43 
bears the PPant arm bound to an active site serine, residue 42, which is found on the 
loop just before helix II begins.  The structures revealed that, with the PPant arm 
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bound, helix III moves closer to helix II. Additionally, Leu43, next to Ser42 on helix 
II, originally solvent exposed, forms interactions with the PPant arm (Figure 8).  
 
Figure 8  Solution NMR structures of apo-ACP 44 (PDB: 2K0Y) (A and C) and holo-ACP 
43 (PDB: 2K0X) (B and D).  Presented at two different angles (A and B, C and D) showing 
the movement of helix III towards helix II upon binding of the phosphopantetheinyl arm.  
Blue ribbon is helix I, green ribbon is helix II, yellow ribbon is helix III and orange ribbon is 
helix IV. 
46
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Figure 9  Solution NMR structures of malonyl-ACP 7 (PDB: 2KG8) and octanoyl ACP 47 
(PDB: 2KGC) showing the growing cavity between helices II and III with the size of the 
polyketide chain.
94
  
 
It is thought that the movement of helix III plays a role in the dissociation of the 
PPant transferase after binding of the PPant arm to the ACP.  Mutation of Leu43 to 
an alanine residue affected the binding to the PPant transferase, ACPS, from FAS in 
S. coelicolor.
46
  The Leu43 residue is part of a motif that is highly conserved among 
type II PKS ACPs, as well as FAS ACPs and NRPS PCPs, which plays an important 
role in protein recognition.
26, 95, 96
 
Structural NMR studies of the actinorhodin ACP with bound intermediate and 
intermediate mimics have been performed.  Acetyl 40 and malonyl 7 were the only 
natural modifications of the ACP used that could be easily reproduced in vitro, 
whereas advanced intermediate mimics were used to investigate the changes to the 
ACP due to the inability to synthesise advanced intermediates, as well as their 
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inherent instability.  Butyryl and 2-oxo-butyl groups were used as mimics for a 
diketide, hexanoyl and 2,5-dioxohexyl for a triketide and octanoyl 47 for a 
tetraketide intermediate mimic.  No interaction was found between the acetyl 40, 
malonyl 7 and 2-oxo-butyl groups and the ACP.  Butyryl, hexanoyl, octanoyl 47 and 
3’5-dioxyhexyl groups all caused conformational changes to helices II and III, helix 
III moving away from helix II, and the cavity volume increasing with the size of the 
bound mimic (Figure 9).  The movements of helix II and III may aid dissociation 
from the KS-CLF once the full polyketide chain has been synthesised.  Alternatively, 
as the octaketide chain is a very unstable molecule, the helices may help to stabilise 
the polyketide.  Compared to similar experiments with FAS ACPs, the actinorhodin 
ACP showed more structural changes and there is a proposed binding cavity that is 
larger than in FAS ACPs which may accommodate the bulkier polyketide 
intermediates.
94
  
The structures solved thus far could potentially be non-natural conformations of the 
ACP.  Only mimics of polyketide intermediates were used, and, those intermediates 
are just putative.  Furthermore, the structure of the ACP could be entirely different 
when it is in complex with the KS-CLF.  Advances in NMR, X-ray crystallography 
and cryo-EM may help to solve these questions in the future.   
 
1.4.1. Engineering of carrier proteins 
Carrier proteins have been manipulated in vitro since, at least, 1964
97
 and, since 
then, a great deal of manipulation and engineering has been undertaken to probe 
primary and secondary metabolism.  
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One key mutation to the actinorhodin acyl carrier protein (ACP) is a cysteine to 
serine mutation for in vitro assays.  This mutation is introduced to avoid disulphide 
bonds forming between the cysteine and the thiol group of the phosphopantetheinyl 
(PPant) arm, but does not affect the activity of the enzyme.
98
   
The ACP can interact with many different partners, and as such it constitutes an 
attractive target for bioengineering.  For example, by making mutations to key 
residues of ACPs, interactions with different PKS enzymes could be prevented or 
allowed, leading to the generation of new compounds, or via modifications to the 
PPant arm to act as a tag.  The latter has already been proven to be an easier method 
of bioengineering acyl carrier proteins.   
 
1.4.1.1. Modifications to the phosphopantetheinyl arm of carrier proteins 
As previously described, apo-ACP 44 can be converted to holo-ACP 43 by the 
action of a PPant transferase which loads the PPant arm from coenzyme A 46 
(Scheme 6).  PPant transferases will accept a wide variety of analogues of coenzyme 
A 46 and load them onto ACPs.  In particular, a transferase from B. subtilis of broad 
substrate specificity, Sfp, is used frequently for generation of ACP analogues.
99, 100
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Scheme 7  Enzymatic preparation of Coenzyme A analogues via corresponding pantetheine 
analogues with the aid of enzymes that biosynthesise Coenzyme A 46 in E. coli.
101
 
 
Analogues of Coenzyme A 46 with thioester linkages are relatively simple to 
synthesise.  The two main methods commonly employed are via 
transthioesterification, e.g. by thiolysis of a symmetrical anhydride
102
, or by reaction 
of CoA 46 with a maleimide-reactive precursor.  Synthesis of analogues without 
thioester groups is more challenging.  Coenzyme A 46 is biosynthesised from 
pantetheine 48 with enzymes that are part of primary metabolism, analogues of 
coenzyme A 46 can also be enzymatically synthesised with that machinery in vitro 
from the corresponding pantetheine analogue (Scheme 7).
11, 101
   
The shortest peptide that the PPant transferase Sfp is capable of processing is named 
the ‘ybbR tag’, as its sequence is derived from ybbr ORF in B. subtilis.  The ‘ybbR 
tag’ is an 11 residue, helical peptide with the sequence DSLEFIASKLA; essentially, 
the sequence is helix II of carrier proteins (Figure 7).  The Ser2 is the active site 
serine that becomes loaded with the PPant arm.  This small sequence can be used to 
tag N- or C-terminals of proteins, or inserted in the flexible loop of proteins.  The 
uses for this tag are numerous, for example, a biotin label can be incorporated to the 
33 
 
tag for streptavidin-affinity purification, or for fluorescent labelling for imaging 
purposes.
100, 103, 104
  
Labelling of carrier proteins through modifications to the PPant arm can be 
particularly useful for probing the structures and mechanisms of PKSs (see Section 
1.5).
46, 94, 105
  The variety of ‘tags’ incorporated so far include fluorescent106-108, 
natural polyketide or NRPS intermediates
46, 109
, unnatural polyketide or NRPS 
intermediates
94, 110
, cross-linking
111-114
 and affinity
106
 tags.  In vivo labelling of 
carrier proteins is also possible by supplementing the organism with pantetheine 
analogues and enabling the endogenous CoA biosynthetic machinery, with the aid of 
a PPant transferase, to produce labelled ACPs.
115-118
  Aside from the investigation of 
PKSs, other applications for labelling of carrier proteins include cell surface 
labelling
119
, and expanding that to fluorescence resonance energy transfer (FRET) 
studies
120-122
, the use of ACPs as fusion tags
123, 124
, antibiotic activity by inhibition of 
FAS
125-127
 and as a scaffold for drug delivery
128
. 
 
1.5. Methods of investigation of modular and iterative biocatalysis 
The investigation of PKSs and their products began over 100 years ago when 
technology was very limited.  Orcinol 49 was the first polyketide structure to be 
solved, and its biosynthesis to be elucidated.  At that time, the techniques used were 
degradation chemistry, melting point, solubility, and taste to successfully deduce that 
Orcinol 49 was biosynthesised via a polyketone intermediate, and that the synthesis 
would take place within the cell.
4, 129
  Since then, the techniques utilised for the 
analysis of natural products and their biosynthesis has vastly improved, making the 
task today much simpler.  As molecular biology has improved, understanding and 
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manipulation of enzyme catalysis has too, and with the vast improvements in 
analytical chemistry techniques, such as mass spectrometry, NMR and X-ray 
crystallography, the detection and analysis of natural products and their biosynthetic 
machinery has become possible. 
 
1.5.1. Labelling techniques 
The biosynthesis of 6-methylsalicylic acid (6-MSA) 50 was one of the first natural 
products to be studied in any great detail.  6-MSA 50 is an intermediate in the 
biosynthesis of patulin from P. patulum.  Its biosynthesis was hypothesised to occur 
from four acetate units linking to produce a triketo acid.  This theory was tested by 
feeding 
14
C-labelled acetate to P. patulum, and analysing the resulting natural 
product by degradation chemistry and subsequent radioactivity measurement.  The 
results proved that these types of compounds were, indeed, generated from acetate 
building blocks (Scheme 8).
130
 
 
Scheme 8  Chemical degradation of 
14
C labelled 6-methylsalicylic acid (6-MSA) 50 
demonstrating the incorporation of four acetates.
4, 130
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After Birch and co-workers published their findings, advances in NMR and 
commercial availability of 
13
C labelled compounds meant that feeding experiments 
and the analysis of the results became simpler and faster.  More complex structures 
and biosynthetic pathways could be probed in this manner, such as the late stage 
reorganisation of aflatoxin B.
131
  Deuterium labelling could also be used as a tool for 
determining biosynthetic pathways and even specific mechanisms with NMR 
techniques.
132, 133
  C-H NMR correlations provide even more accurate structural 
characterisation, and at present, 2D, and even 3D, NMR correlations are available to 
aid the natural products community.  
Acetate labelling was used by Khosla et al. to confirm that SEK15b, the product of 
an engineered strain of S. coelicolor from the tetracenomycin 22 pathway, was 
derived from 10 acetate units.
79
  The structure of SEK4b 42 was also confirmed to 
contain 8 acetate units by sodium acetate-
13
C2 feeding, and the 
13
C labels also 
facilitated good quality 
13
C-NMR assignments for structural characterisation 
(Scheme 5).
37
 
Sodium acetate labelling experiments are still used for distinguishing biosynthetic 
pathways, however, with the improvements in the field of synthetic chemistry, 
labelled natural and unnatural precursors can by synthesised and fed in vivo or in 
vitro to determine whether the biosynthetic enzymes can uptake these compounds 
(Also see Section 1.5.3 and Section 1.5.4).  Additionally, incubating cultures in 
18
O2 
atmospheres or in H2
18
O media can probe the origin of certain oxygen incorporations 
within natural products, and similarly in D2O for deuterium labelling.
134, 135
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1.5.2. Enzyme engineering 
Manipulating the enzymatic machinery in PKSs is an effective technique for the 
investigation of polyketide biosynthesis, thanks to the advances in genetic and 
enzymatic engineering in recent years.  The expression and purification of the 
enzymes and domains from PKSs has allowed countless in vitro experiments to be 
carried out, from structural biology characterisation of the active sites and 
interactions with other enzymes or cofactors, to determining the substrate selectivity 
of the domains and probing the mechanisms.  Molecular biological techniques for 
gene knockouts, mutations or swapping in organisms have supplied knowledge of 
the importance of those genes and their functionality, and this is opening doors to 
creating engineered organisms for new and improved synthesis of agriculturally or 
medicinally relevant compounds. 
 
1.5.2.1. In vivo 
The first point of call for tentative assignment of the function of a gene is with 
bioinformatics analyses.  Amongst different tools available from the National Center 
for Biotechnology Information (NCBI) and other bioinformatics tools providers, the 
Basic Local Alignment Search Tool, known as BLAST, is the most popular.  The 
tool searches a vast database of known nucleotide and protein sequences to find 
similarities between the sequence or gene of interest and provide a statistical 
significance of that match to decipher a function for the gene.  When the statistical 
significance is very high, the likelihood of correct functional assignment is high.  
Nonetheless, there are examples where the predicted function of a gene or protein is 
incorrect or not specific enough.  This is particularly true for iterative PKSs: 
37 
 
bioinformatics analyses are limited in predicting the nature of the product and the 
timing of transformation.   
 
1.5.2.1.1. Gene deletions 
A common method for deducing the function of a gene is simply to delete that gene 
and decipher from the natural product produced what that function is, and at what 
point in the biosynthetic pathway it acts.  An example of this method was published 
by Khosla and co-workers reporting extensive knockouts of the actinorhodin gene 
cluster in S. coelicolor revealing the functions of multiple genes by the shunt 
products synthesised in each case.
37
  Unfortunately, you are often relying upon high 
yield of the product for characterisation.  Importantly, deletion of genes that are key 
to polyketide chain assembly would abolish production entirely. 
 
1.5.2.1.2. Mutagenesis 
Genetic mutations can be used to inactivate selected enzymes or to alter the enzyme 
substrate specificity.  For instance, as is demonstrated in a series of 
Saccharopolyspora erythraea (S. erythraea) mutants, short intermediates can 
accumulate along the erythromycin A biosynthetic pathway.
136
  In this way, the full 
structure of the megasynthase type I PKS is minimally affected.   
Gene mutations can also alter the specificity of the enzyme for substrates, allowing 
new polyketides to be synthesised from minor changes.  Mutations to the KS-CLF of 
the actinorhodin minimal system produced a larger active site for chain elongation, 
38 
 
allowing a decaketide to be produced instead of the natural octaketide, and in doing 
so created new polyketide structures.
40
 
 
1.5.2.1.3. Hybrid PKSs  
Khosla and co-workers combined genes from biosynthetic pathways to create hybrid 
PKSs, and in doing so they learnt more about the functions of the genes inserted, and 
their selectivity, alongside engineering new hybrid natural products.
72, 73, 78, 79
   
One of these hybrid PKSs included mutant S. coelicolor strains that contained a 
mixture of KSs, CLFs and ACPs from the actinorhodin 2, granaticin and 
tetracenomycin 22 PKSs.  Actinorhodin 2 and granaticin are generated from a 
primary octaketide chain, whereas tetracenomycin 22 is from a decaketide.  As 
expected, the hybrid PKSs provided compounds derived from either an octaketide or 
a decaketide polyketide chain, indicating the influence of the CLF on the chain 
length.
73
   
A second heterologous expression system in S. coelicolor also combined genes 
encoding for the three enzymes of the type II minimal system from the actinorhodin 
2 and frenolicin 13 PKSs, the latter natural product derives from a nonaketide chain.  
Again, the compounds that were produced either had 16 or 18 carbon backbones.
72
   
A third example replaced the ACP from the actinorhodin 2 PKS with homologues 
from granaticin, oxytetracycline 19, tetracenomycin 22, and frenolicin 13 
biosynthetic pathways.  Each hybrid PKS was functional in S. coelicolor, but 
quantitative differences in the shunt products were found.
78
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A final example hybrid PKS focused on combining the act KR and/or cyclase with 
either the actinorhodin 2, tetracenomycin 22 or frenolicin 13 type II PKS minimal 
systems.  These hybrid PKSs demonstrated that the minimal systems can control, to 
a degree, the first cyclisation without their respective KRs or cyclases.
79
  
 
1.5.2.1.4. Heterologous expression 
Many PKSs are expressed in organisms which are slow growing, or difficult to grow 
in a laboratory environment.  The expression of these PKSs in a faster growing, 
suitable organism is desirable for biosynthetic investigations, and has been carried 
out on a number of occasions: for example, the gene clusters encoding for the 
production of erythromycin A, 6-deoxyerthyronolide B (6dEB) 51 (from the soil 
bacterium Saccharopolyspora erythraea
137
), the quinolone antibiotic echinomycin 
52 (from S. lasaliensis
138
) and the cytotoxic agents patellamide A and C (from an 
unculturable obligate symbiont
139
) have all been successfully expressed in E. coli.   
 
1.5.2.1.5. Modifications to the phosphopantetheinyl arm of carrier proteins 
As mentioned previously, the labelling of acyl carrier proteins via their PPant 
arm.
105, 112, 116, 117
  can be used to investigate polyketide assembly in just its early 
stages.  Also, labelling of ACPs with fluorescent tags have been used to locate and 
quantify the carrier proteins within cells,
105
  and affinity tags, in combination with 
fluorescent tags, have been exploited for the identification of carrier proteins from 
organisms that have not yet been sequenced.
117
  A whole range of pantetheine 
analogues have been tested to determine their suitability for tagging ACPs, 
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demonstrating a wide substrate selectivity of both the PPant transferase and the 
ACP.
116
 
1.5.2.2. In vitro 
With the advances in the generation of recombinant proteins has come the ability to 
study the enzyme mechanisms in vitro, and to structurally characterise biosynthetic 
enzymes by NMR, crystallography, and, to some extent, mass spectrometry. 
Carrier proteins can be loaded with natural and unnatural starter units to probe the 
selectivity of other domains or enzymes.  An example of such experiment was 
performed by Oldham and co-workers to probe the selectivity of the initial acylation 
step of trans ATs from the psymberin (Psy) and bacillaene (Bae) PKSs.
140
  
Kinetic assays can be carried out, for example, to determine the rate limiting steps in 
reactions, which would not be possible in vivo, as was demonstrated in the work by 
Simpson et al. to investigate the interactions between the ACP and KS in the 
actinorhodin 2 PKS.
76
 
X-ray crystallography and NMR can be used to investigate substrate
94
 and co-factor 
binding, active site characterisation and protein-protein interactions
25
, to name a few.  
Recent advances in cryo-EM have allowed the characterisation of a large module of 
the pikromycin pathway and revealed important structural rearrangements during the 
biosynthesis.
141, 142
 
There are still several difficulties associated to the expression and purification of 
components of PKSs.  Finding alternative expression hosts, such as yeast and 
Pseudomonas species, is a growing field of research.
143
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1.5.3. Chemical probes: N-acetylcysteamine thioester (SNAC) substrate 
analogues 
Chemical methods of probing the mechanism of biosynthetic enzymes are based on 
the use of synthetic precursors or substrates in vivo or in vitro.  Mimics of PPant 
arms carrying putative precursors or substrates are widely used, as they have been 
shown to be uptaken by cells and processed by PKS enzymes (Figure 10).  These 
mimics, N-acetylcysteamine thioesters (SNACs) were first used in 1968 as an 
inhibitor of methylmalonyl-CoA mutase, which isomerises methylmalonic acid to 
succinic acid.
144
  The mimics have been used as standard substrates for investigating 
ACP catalysed reactions since then, due to the relative ease of synthesis compared to 
preparation of coenzyme A analogues.  
 
Figure 10  Structures of acetyl-ACP 40 and the N-acetylcysteamine (SNAC) ester derivative 
53 showing the priming of a ketosynthase with the acetyl groups from both 40 and 53. 
 
SNAC analogues are often used in vitro,
145, 146
 gaining insights into a specific 
catalytic step, or, due to their hydrophobic nature, it is possible to study their uptake 
and turn over in vivo.
147
  SNAC analogues can be used as surrogate starter units, 
such as hexanoyl SNAC for restoring sterigmatocystin biosynthesis in FAS gene 
knockouts in Aspergillus nidulans
148
.  They can also provide the extender units, such 
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as methylmalonyl SNAC incubation with DEBS3, the third module of the 6-
deoxyerythronolide B 51 synthase, which was able to act as the extender unit to 
successfully produce the expected triketide lactone.
145
  
New natural products can be generated by feeding unnatural substrates bound via the 
thioester linker, and, if they are taken up by the PKS, this unnatural precursor will be 
incorporated in the final product.
149, 150
  
 
1.5.3.1. Chemical synthesis of SNAC analogues 
The synthesis of SNAC analogues can only require a few steps, dependent upon the 
complexity of the R group.  The reaction of N-acetylcysteamine (NAC) 54 with an 
activated carboxylic acid group, typically by coupling to carbonyldiimidazole, 
creates the thioester linkage of the (N-acetylcysteamine β-ketothioester) SNAC 
analogues.
151, 152
  The complexity of the synthesis would depend upon the precursor, 
‘R’, being provided by the SNAC analogue (Scheme 9). 
 
Scheme 9  General synthesis of N-acetylcysteamine β-ketothioester (SNAC) analogues via 
coupling to carbonyldiimidazole (CDI). 
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1.5.4. Chain termination probes as new tools for the investigation of 
polyketide biosynthesis 
In 2005, Spiteller and co-workers
153
 reported the preparation of a nonhydrolysable 
malonyl-CoA mimic 55 bearing an additional methylene group, between the sulphur 
atom and the malonate group.  The compound was shown to be able to capture 
diketide and triketide intermediates in the biosynthesis of resveratrol 4 by the type III 
PKS stilbene synthase by mimicking malonyl-CoA 15 in decarboxylative 
condensation reactions.  However steric differences between this compound 55 and 
malonyl-CoA 15 limited its intermediate capturing ability, leading Tosin and co-
workers to prepare carba(dethia) and oxo(dethia) malonyl-CoA derivatives 56 and 57 
(Figure 11).  These analogues presented direct replacements of the sulphur atom 
with methylene 56 and oxygen 57 moieties respectively (Figure 11).
11, 153
   
When 56 and 57 were trialled in vitro on the type III PKS, stilbene synthase the 
carba(dethia) analogue 56 proved to be a very efficient probe of the biosynthesis by 
capturing all the intermediates involved in the assembly, revealing new insights into 
the mechanism of cyclisation, whereas the oxa(dethia) analogue 57 could undergo 
just one round of decarboxylation and chain extension.  The close steric match to 
malonyl-CoA 15, its ability to decarboxylate at faster rates than malonyl-CoA 15 and 
its robust nonhydrolysable nature have made the malonyl carba(dethia) substrate 56 
the perfect starting point for the development of simpler and more sophisticated tools 
named ‘chain termination’ probes for their ability to sample the biocatalysis by off-
loading prematurely truncated intermediates (Section 1.5.4.1, Scheme 10).  
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Figure 11 Malonyl-coenzyme A (CoA) 15 and nonhydrolysable malonyl-CoA analogues 55-
57 used for probing the biosynthesis of polyketides from type III PKSs. 
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Scheme 10 In vivo off-loading of polyketide intermediates from the model system, 6-
deoxyerythronolide B 51 synthase, with synthetic chain terminators.  Top right box 
highlights how the synthetic chain terminators mimic the acyl carrier protein 
phosphopantetheinyl moiety, and the ester hydrolysis in vivo to the active chain 
terminators.
136, 154
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1.5.4.1. Nonhydrolysable NAC chain termination probes 
Since the early results obtained using malonyl-CoA analogues 55-57, the Tosin 
group has been developing small molecule chemical chain termination probes based 
on nonhydrolysable NAC analogues.  These still efficiently mimic malonyl-ACP 7 
and are capable of diffusing into PKS active sites to off-load biosynthetic 
intermediates from KSs by competitive β-ketoacid decarboxylation and 
condensation.  The obtained captured intermediates cannot undergo 
transesterification back to the PKS and become available for LC-MS analyses 
(Scheme 10).
22, 136, 154-156
  
The Tosin group has also shown that these probes can be used in vivo: once fed to 
microorganisms as esters, in situ esterase hydrolysis generates the active β-ketoacid 
probe within cells for the direct capture of PKS biosynthetic intermediates (Scheme 
10).
11, 22, 136, 153, 154, 156
 
The use of small molecule chain termination probes has provided insights into the 
timing of ring formation in the biosynthesis of the polyether antibiotic lasalocid A 1 
in the host producer (S. lasaliensis, Scheme 11).
22
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Scheme 11  Off-loading of intermediates from the lasalocid A 1 synthase, with synthetic 
chain terminators from feeding experiments in S. lasaliensis.
22, 155, 156
 Not shown are the 
results from feeding with chain terminators with modifications to the malonyl group at α-
carbonyl positions.   
 
More recently, the use of functionalised small molecule probes bearing alkyne or 
azide groups as chemical handles for site-specific modifications
155
, and 
pharmaceutically relevant fluorine atoms, together with engineered S. lasaliensis 
bacteria has allowed the generation of a library of complex polyether analogues for 
activity testing (Scheme 11, Figure 12).  
Alternative probe protecting groups with improved bioavailability are being 
developed within the Tosin group, including a photolabile protecting group reported 
in this thesis and an acetoxymethyl (AM) ester group.   
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Figure 12  Small molecule chain termination probes used for the probing of PKS 
biosynthetic pathways, in particular in S. lasaliensis to generate a library of complex 
analogues.
155, 156
   
 
The small molecule probes have been successfully used to gain insights into 
polyketide assembly in a number of different systems, both modular and iterative.  In 
particular, the AM ester masking has significantly enhanced the quantity of captured 
biosynthetic intermediates from the lasalocid A 1 pathway, likely due to the 
increased bioavailability of this malonyl protection over the simple ester group.
156
 
The availability of tools makes it possible to obtain mechanistic details that were 
previously inaccessible.  The most challenging systems to investigate remain the 
iterative PKSs.  Developing novel probes to harness iterative polyketide catalysis in 
conjunction with advanced mass spectrometry analyses was the focus of my 
research. 
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1.5.5. The application of proteomics and metabolomics to the investigation 
of biocatalysis 
Mass spectrometry has become the preferred technique for the investigation of 
natural product biosynthesis in vitro and in vivo due to its swiftness, sensitivity, 
accuracy and availability.  Mass spectrometry based approaches have been 
developed in the Kelleher, Bafna and Burkart laboratories.
157-160
  Through these 
methods, described in depth in Section 1.6.5, expressed and functional PKSs can be 
rapidly identified in conjunction with their associated natural products in complex 
biological mixtures faster than genome sequencing. 
Further details on the use of proteomics will be given in section 1.6.5.2.2.  
 
1.6. Mass spectrometry 
Mass spectrometry is a widely used analytical technique, accessible in most modern 
laboratories.  At a basic level, it provides the mass and molecular formulae of 
compounds, however, an abundance of fragmentation techniques can be used to 
deduce structure with mass spectrometers.  The techniques available depend upon 
the instrument as well as the expertise of the user.  
 
1.6.1. Key ionisation techniques 
Nowadays, the most commonly used ionisation source is electrospray ionisation 
(ESI) for samples in solution.  This soft ionisation source is suitable for a variety of 
sample types including small molecules and proteins, generating multiply charged 
ions, and is typically the ionisation source that is coupled to liquid chromatography 
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(LC).  n-ESI, a miniaturised ESI source, is a variation of ESI for lower sample 
volumes.  Charged droplets are produced by the electrospray capillary tip, and 
solvent evaporation causes the charged droplets to get smaller until they are very 
small and highly charged.  A nitrogen counter current causes vaporisation of solvent 
and the ions are driven by an electric potential into the heated capillary pathway.  
Coulombic repulsion drives the ions away from one another.  Downstream ion optics 
transfer the ions into the high-vacuum mass spectrometer, and neutral ions are left 
behind.
161, 162
 
Matrix assisted laser desorption/ionisation (MALDI) is another soft ionisation source 
that generates singly charged ions, and is commonly used for polymers and 
biomolecules.  Samples are mixed with a matrix and a pulsed laser irradiates the 
sample.  The irradiation causes ablation and desorption of the matrix and sample, 
and the sample is ionised by protonation in the hot plume of gases.
163, 164
   
There are many other ionisation sources, out of the scope of this thesis, that are 
available to analytical scientists.  ESI is the only source that was used for this work 
as it was the most suitable for the samples that were generated. 
 
1.6.2. Key mass analysers 
Resolving power, resolution and mass accuracy are important specifications that are 
used in reporting mass spectral data and in comparing the instruments.  Resolving 
power is the ability of an instrument to separate neighbouring peaks, defined as the 
ratio of one of the masses of interest (m) to the difference between those masses 
(∆m).  It defines the resolution needed to separate those two peaks.  Resolution is 
calculated from a recorded peak, defined as the ratio of the mass of that peak (m) to 
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the full width of the peak at half the maximum height of the peak (FWHM).
165
  Mass 
accuracy is how close the experimental mass is to the theoretical mass, often 
reported in parts per million (ppm). 
 
Equation 1  Equations for calculation resolving power and resolution in mass spectrometry.  
m = mass of peak of interest, ∆m = difference between masses of neighbouring peaks, 
FWHM = full width at half maximum height. 
 
Three types of mass analyser herein used were Time-of-Flight (TOF), Ion Trap and 
Fourier Transform Ion Cyclotron Resonance (FTICR).  The instrument used for an 
application should be carefully chosen to provide the data necessary to answer the 
question being posed.   
In this work, for routine analysis of known small molecules, an ion trap mass 
analyser was used.  An ion trap is a highly sensitive analyser; however, the mass 
error and resolution are typically limited.  For the identification of unknown small 
molecules a high resolution TOF was used.  A TOF can provide accurate mass and 
high resolution, as well as rapid analysis, however the specifications widely vary for 
this type of mass analyser.  For the analysis of larger peptides and proteins with 
unknown small modifications, and also for complex fragmentation techniques, an 
FTICR was utilised.  This instrument is not as sensitive as an ion trap or a TOF, 
however, the mass accuracy and resolution are far superior.  FTICRs are often 
coupled with a range of fragmentation techniques such as CAD, IRMPD and ECD.  
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1.6.2.1. Time-of-flight (TOF) analysers 
A TOF analyser separates pulsed ions of different m/z by their flight time along a 
field-free drift path.  Lighter ions will arrive earlier at a TOF detector than heavier 
ions.  Calibrating with ions of known mass allows the calculation of m/z, the longer 
the drift path the more accurate the analyser can be.
166
  
 
1.6.2.2. Ion trap analysers 
An ion trap, or quadrupole ion trap (QIT), creates a three dimensional RF quadrupole 
field in which to store ions within certain m/z ranges.  Unwanted ions are removed 
when they are unstable and collide with the walls, or when they are resonantly 
ejected from the trap for detection.  
 
1.6.2.3. Fourier Transform Mass Spectrometers (FT-MS) 
FTICR-MS provides the highest resolving power and mass accuracy of all mass 
analysers. The basic principle of ICRs is that an ion entering a magnetic field 
perpendicular to its direction will move in a circular path by action of Lorentz force.  
The cyclotron frequency is unaffected by the ion’s initial velocity, instead it is a 
function of its mass and charge, and of the magnetic field.  To detect the ions, an 
electric field, alternating at their cyclotron frequency, will accelerate the ions and 
increase the radius of their orbit, inducing an image current each time they pass the 
detector plates.  Lighter ions will reach the same radius as heavier ions with fewer 
cycles, as they require less energy to accelerate.  Scanning all frequencies will excite 
all ions, for a full mass spectrum, whereas alternating at just a specific frequency will 
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only excite a particular m/z.  The transient free induction decay (FID) is recorded and 
Fourier transformed (FT) from the time domain to the frequency domain for 
conversion to m/z data.  The longer the FID is recorded, the higher the mass 
resolution will be and the greater the mass accuracy.
167-169
  Additionally, the higher 
the field strength, the resolving power also increases.  As the sample is not destroyed 
by detection in FTICR-MS, the same ion packet can be recorded repeatedly, 
generating a cumulative signal, and also the ability to perform numerous MS/MS 
experiments.
166, 170-174
  
Another category of FT-MS analyser is an Orbitrap, solely manufactured by Thermo 
Scientific, which radially traps ions about an electrode.  Mass to charge ratios are 
recorded, non-destructively, by measuring the image current generated by ion 
oscillations.
175
  These instruments provide higher resolution and mass accuracy than 
a TOF instrument, but less so than an FTICR-MS.  
 
1.6.2.4. Ion mobility analysers 
Lastly, a mass spectrometry specific separation technique of note is ion mobility MS.  
These instruments separate gas phase ions based upon their movement through drift 
tube containing a carrier gas and an electric field.  These instruments provide 
valuable structural information, particularly for proteins, and the ability to often 
separate isomers.
176
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1.6.3. Fragmentation techniques in mass spectrometry 
Fragmentation techniques are a powerful method for structural characterisation, also 
known as tandem MS or MS/MS.  The most common method of fragmentation is 
collisionally activated dissociation (CAD), also known as collisionally induced 
dissociation (CID).  Other modern techniques, particularly for the analysis of 
biomolecules, include, but are not limited to, infrared multiphoton dissociation 
(IRMPD), electron transfer dissociation (ETD), electron capture dissociation (ECD) 
and, covered in this thesis, electron induced dissociation (EID) (Table 1).  
Fragmentation 
Technique 
Instrument 
Applicable 
Mode of Action 
CAD 
TOF 
Ion trap 
FTICR 
Precursor ions collide with inert gas molecules. 1-100 
eV energies. 
ETD 
Ion trap 
FTICR 
Singly charged anions transfer electrons to multiply 
charged precursors to induce fragmentation. 
IRMPD 
Ion trap 
FTICR 
Low energy IR laser activates precursor ions by 
multiphoton absorption causing dissociation. 
ECD FTICR 
Low energy electrons (< 3 eV) causing electron 
capture on the precursor, and fragmentation by radical 
ion chemistry. 
EID FTICR 
10-25 eV electrons causing fragmentation of singly 
charged precursors. 
Table 1  Overview of notable fragmentation techniques, the instruments they are typically 
coupled with and their mode of action.
177, 178
  CAD = Collisionally activated dissociation.  
ETD = electron transfer dissociation.  IRMPD = infrared multiphoton dissociation.  ECD = 
electron capture dissociation.  EID = electron impact dissociation.  TOF = time-of-flight.  
FTICR = Fourier transform ion cyclotron resonance. 
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1.6.3.1. Collisionally activated dissociation (CAD) 
CAD fragments are caused by accelerating ions to a high kinetic energy and then 
allowing collisions with neutral gas molecules, typically helium, nitrogen or argon.  
Bond breaking is caused by kinetic energy being converted to internal energy and 
this energy dissociating along an available fragmentation pathway.
166
  The amide 
bond of peptides and proteins is the most common bond cleavage with CAD, 
generating ‘b’ and ‘y’ ions.179  The method can be useful for sequencing proteins, 
and locating post-translational modifications (PTMs) (Figure 13). 
 
Figure 13  Common fragmentation pathways of proteins and peptides.
179
 
 
1.6.3.2. Infrared multiphoton dissociation (IRMPD) 
IRMPD fragments trapped ions; typically used in FTICR-MS due to the ability to 
trap ions for a long period of time.  A carbon dioxide laser of wavelength 10.6 µm is 
focussed into the ICR cell and the amount of energy delivered to the trapped 
precursor ions is varied by the duration of the irradiation.  The energy is received by 
multiphoton absorption and causes dissociation of the ions.
180
  This technique is 
applicable to a variety of compounds both large and small, and singly and multiply 
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charged.  IRMPD of peptides and proteins causes bond cleavage of the amide bond, 
as in CAD, generating ‘b’ and ‘y’ ions (Figure 13).179  
 
1.6.3.3. Electron capture dissociation (ECD) 
ECD is a fragmentation technique that uses low energy electrons to produce 
fragments in multiply charged precursors, generated by the capture of an electron.  It 
is important to note that the weakest bond will not necessarily break.  ECD and other 
electron based fragmentation techniques need the highest expertise to generate useful 
information.  When fragmenting peptides and proteins, the most common 
fragmentation point is not the amide bonds, as in CAD, but the N-Cα bond, 
producing ‘c’ and ‘z’ type fragments (Figure 13).  IRMPD can be coupled with 
ECD, a kind of activated ion ECD, where the irradiation time is much shorter than in 
a regular IRMPD experiment, and the IR irradiation provides excitation of the 
precursor before electron capture and fragmentation by ECD, typically generating 
more backbone coverage than IRMPD or ECD alone.
181
 
 
1.6.3.4. Electron transfer dissociation (ETD) 
ETD requires trapped precursor ions, thus, it is usually carried out in either an ion 
trap or an ICR cell.  Anions, for example fluoranthene, with low electron affinities 
act as electron donors, and this electron transfer causes the release of a hydrogen 
radical, inducing radical ion fragmentation similar to ECD.
178
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1.6.3.5. Electron impact dissociation (EID) 
EID is a tandem MS technique for fragmentation of singly charged, positive or 
negative, ions with electrons of moderate kinetic energies in the range of 10 – 25 
eV.
182-184
   The technique has been shown to produce many of the same fragments 
that are produced by the more common CAD and IRMPD, but also to generate 
additional unique fragments.
185-188
   
 
1.6.4. Analysis of proteins by mass spectrometry 
The analysis of proteins can be performed in two main ways: ‘top-down’ or ‘bottom-
up’.  ‘Top-down’ refers to analysing proteins directly by MS: protein identification is 
carried out firstly by the accurate mass of the protein, and then by MS/MS 
fragmentation for sequencing and identifying post-translational modifications 
(PTMs).  Benefits of this technique include limited sample preparation and the 
analysis of ‘native’ conformations, reducing the risk of altering PTMs by extensive 
sample preparation.  The main disadvantage of the technique is that the detection of 
large molecules requires more advanced and high resolution instruments, and further 
characterisation needs experienced instrument users to gather the information 
needed.
189
  
The ‘bottom-up’ method of characterising and identifying proteins refers to the use 
of a protease, typically trypsin, to enzymatically hydrolyse proteins into peptides.  
The peptides are usually separated by LC before analysis by MS.  The peptides are 
smaller in mass, which is more suitable for lower resolution instruments, and by 
database searching it is possible to identify proteins.  Many PTMs are unaffected by 
the digestion and sample preparation, however, disulphide bonds will be disrupted, 
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and information regarding PTMs of unknown proteins and their location is not as 
reliable.  This technique is also not applicable to the identification and sequencing of 
proteins that are not in databases. 
 
1.6.5. Mass spectrometry for the investigation of natural product 
biosynthesis 
In natural product research, mass spectrometry is a key analytical technique.  The 
rapid identification of both small and large molecules, can be particularly 
advantageous for high throughput screening.  Highly sensitive instruments allow 
detection of compounds from both low sample volumes and low concentrations, as 
well as from complex samples.  Structural elucidation of compounds can be begun 
by MS; however, NMR would still be the technique of choice for structural 
characterisation.   
 
1.6.5.1. The use of isotope labelling in mass spectrometry 
Often, labelled precursors, such as 
13
C sodium acetate, are fed to organisms, and 
their uptake by PKSs is monitored by MS.  High resolution MS instruments can 
identify molecular formulae of products to a high degree of accuracy, for example, 
sub ppm accuracy on a FTICR-MS is routine, and with detailed calibration, sub ppb 
is possible.  Detecting mass differences caused by 
13
C or deuterium labelling is 
simple for most modern instruments. 
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1.6.5.2. Fragmentation techniques for natural product research 
CAD is the most utilised technique for structural characterisation of small molecules 
and proteins.  However, newer modes of fragmentation, such as EID and ECD, can 
provide structural information where CAD fails.  Electron based fragmentation 
techniques can produce different fragments to those seen with CAD.  Håkansson and 
coworkers have shown that it is possible to determine the location of double bonds in 
fatty acids by EID, combined with manganese adduction
190, and in the O’Connor 
group EID was able to differentiate between two isomers, lasalocid A 1 and iso-
lasalocid A.
191
  
 
1.6.5.2.1. Fragmentation of the phosphopantetheinyl (PPant) arm of carrier 
proteins 
CAD has proven especially useful in the identification and characterisation of ACPs, 
and in generating characteristic PPant ejection ions 58.  Upon CAD fragmentation, 
the phosphodiester bond adjacent to the pantetheinyl moiety is cleaved providing 58, 
or alternatively the phosphodiester bond adjacent to the protein is broken, generating 
the larger phospho-Pant ejection ion 59.  This technique has been used in proteomics 
for identifying PKSs, but also in off-loading intermediates from ACP-bound 
species.
157-159, 192, 193
  IRMPD also provides this Pant ion but fewer instruments are 
equipped with this tool for fragmentation (Scheme 13).   
A drawback to the “PPant ejection assay” is that it requires a degree of skill by the 
MS user.
157
  The assay has, however, been used effectively on several occasions.
141, 
142, 192, 194
  In particular, intermediates from the lovastatin 5 biosynthetic pathway, a 
non-iterative type I PKS, were trapped by performing a trypsin digest of the 277 kDa 
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megasynthase once the PKS had been activated in vitro, rendering it inactive.  The 
resulting peptides were fragmented, and intermediates, bound to the ejected Pant ion 
58/59, were detected, with additional 
13
C labelling for confirmation.
192
  Similarly, an 
enzyme bound intermediate was detected with the “PPant ejection assay” from the 
enediyne C-1027 pathway, and the result aided the understanding of the biosynthetic 
pathway.
195
 
 
Scheme 12 Generation of a pantetheine (Pant) ejection ion 58 or a phospho-Pant ejection 
ion 59 from the corresponding ACP by CAD or IRMPD. 
 
1.6.5.2.2. Proteomics based approaches to detect and characterise PKSs 
Bafna and co-workers developed a proteomics based method that combines 
enriching the abundance of PKSs in the MS sample by affinity tagging TE domains, 
followed by tryptic digestion, and then identification of PPant active sites either by 
MS
3
 or by machine learning from the MS
2
 spectra.  The machine-learning approach 
allows lower cost instruments to use a proteomics approach to identify PKSs without 
MS
3
, which is often out of reach for those instruments.
157
 
A similar method from the Burkart laboratory, called the Orthogonal Active Site 
Identification System (OASIS), uses active site probes to enrich the carrier protein 
and thioesterase peptides in complex biological samples.  The carrier proteins are 
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labelled either by incorporation of CoA precursors with azide groups for 
chemoselective ligation to reporters with alkyne groups or with biotinylated CoA 
analogues for purification with streptavidin.  Thioesterases can be enriched by 
modification of the active site serine using fluorophosphonate with a biotin linker for 
pull down.  The samples are then analysed by MudPIT
196, 197
 (Multidimensional 
Protein Identification Technology), which is a 2D LC-MS technology for separating 
and identifying individual peptides and proteins from complex samples.  PKSs and 
NRPSs are identified by cross-referencing the peptides identified by each probe.  
Thus far, OASIS has only been demonstrated on a model bacteria, B. subtilis, where 
they successfully detected and identified all of the modular synthases expressed in 
that organism.
160
   
Proteomics-based approaches to discovering PKSs have also proven successful in 
the Kelleher group, combined with the “PPant ejection assay” to find ACPs and 
identify the PKS from that information.  One such platform is the Proteomic 
Investigation of Secondary Metabolism (PrISM).
159
  In this way, only the expressed 
NRPS/PKSs are detected, avoiding traditional genome mining methods that cannot 
distinguish between expressed or ‘silent’ gene clusters.  Cultures of the bacteria are 
first screened for the presence of high molecular weight proteins, as those proteins 
are likely to be NRPSs or PKSs.  The bacteria are grown in different conditions, the 
large proteins (150 kDa or more) are analysed by MS and their peptide fragments 
from digestion are used to identify the biosynthetic machinery.   
Once the carrier protein has been found and its sequence deduced it is possible to 
design primers to pull down the gene and then identify the full PKS gene, even if the 
genome sequence of the organism is not known.  With that information, it is then 
possible to search for the natural product produced.  Koranimine, a cyclic imine
198
, 
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flavopeptins, a class of peptide aldehydes,
199
 and gobichelins A and B, siderophores 
produced by NRPSs,
200
 were detected for the first time using PrISM. 
 
1.7. Photolysis as a tool for investigating biological systems 
Photolysis is the breakdown of a compound by the application of light.  It is rapidly 
becoming a powerful tool of investigation.  Photoactivatable compounds are used for 
a wide range of applications, from chemical synthesis to probing, controlling or 
tuning biological systems.  There are several photolabile groups available to protect 
different chemical groups and can be selectively removed at specific wavelengths.  
Protecting groups for carboxylic acids will be further explored in chapter 2 as they 
are relevant to the probes I have developed in my research. 
 
1.7.1. Desirable traits of photolabile groups for biological applications 
Photolabile groups do not require the use of reagents for their cleavage, allowing the 
mild and selective uncaging of a wide range of molecules in different environments, 
including complex biological environments.   
Photolytic cleavage is the product of absorption of a photon and there are a limited 
number of pathways by which bond cleavage can occur.
201
 
A fast rate of cleavage, selective cleavage pathway, a limited or harmless by-
product, high quantum yield (Equation 2), and a narrow cleavage wavelength for 
cleavage are all desirable properties for photolabile groups.  A fast cleavage rate is 
important as long irradiation times may cause heating, and less stable molecules may 
degrade over time.  Additionally, for kinetic studies, being able to denote a starting 
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point is desirable.  The cleavage selectivity of a photolabile group is possibly the 
most important aspect when choosing the correct group.  Ideally, photolysis should 
yield just two products: the compound of interest and the cleaved photolabile group 
or by-product.  The by-product should be unreactive under the conditions in which it 
is required, and non-toxic when used for biological applications.   
Quantum yield is a measure of how efficiently a photoactivatable group is cleaved, 
calculated from the number of molecules cleaved per number of photons absorbed.  
It is used to compare different photolabile groups, a high quantum yield is desirable 
(Equation 2).
202
  Lastly, the wavelength for cleavage of the protecting group would, 
ideally, not be within the visible spectrum, as this makes sample handling more 
challenging.  Synthesis and preparation would need to be carried out in the dark, as 
well causing the time of activation difficult to define.   
 
Equation 2  Calculation of quantum yield
202
 
 
1.7.2. Photo-irradiation as a tool for the investigation of biosynthetic 
pathways 
There are a few examples of UV irradiation influencing, or causing, important 
biosynthetic pathways in organisms.  A significant example is the light absorption by 
chlorophyll that induces the electron transport chain in photosynthesis.  The 
absorption can also be released as heat, or re-emitted as fluorescence.  Therefore, by 
measuring the fluorescence, changes in the efficiency of photosynthesis can be 
monitored.
203
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Gene expression has been shown to be controlled to some degree by light irradiation.  
For example, heme oxygenase 1 following UVA irradiation of mammalian cell 
lines
204
, UVB irradiation of peach and nectarine fruits increased gene expression 
resulting in the synthesis of more phenolic compounds
205
, and the gene expression 
profiles of a cyanobacterium, irradiated with UVB or intense white light, showed 
both up and down regulation of a wide variety of genes, including those involved in 
secondary metabolite biosynthesis
206
. 
However, to the best of my knowledge, there are no examples of light-activated 
molecules being used to probe natural product assembly.  With the tools available to 
the community, this is an avenue of research ready to be explored. 
1.8. Research aims and objectives 
1.8.1. Primary research aim 
The principal aim of this PhD project was to develop a new method to probe the 
biosynthesis of iterative polyketide pathways by means of a photoactivatable 
nonhydrolysable malonyl acyl carrier protein probe 63.  Intermediates from iterative 
type II PKSs have never been detected or isolated before.  Nonhydrolysable probes 
of this type have never before been light activated.  Light activation negates the need 
for additional enzymes or reagents and their specific reaction conditions, provides 
controllable and tunable release of the ‘active’ probe, and is a mild deprotection 
method. 
The proposed method builds from an already established chain terminator 
methodology within the Tosin group,
11, 22, 136, 154, 155
 with the aim of looking at ACP-
bound biosynthetic intermediates otherwise unavailable (Scheme 13). 
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Scheme 13  Primary project aim: chemoenzymatic preparation of a photolabile 
carba(dethia) malonyl-ACP 63 that, following light irradiation generates a carrier protein 
‘trap’ for type II PKS intermediates from the actinorhodin minimal system. 
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Within this aim, the following objectives were pursued: 
 A robust chemoenzymatic preparation of an acyl carrier protein photolabile 
‘probe’ 63 (Scheme 13) 
 Demonstrate the light activation of a nonhydrolysable malonyl ACP probe  
 The investigation of polyketide biosynthesis for the actinorhodin minimal 
system, chosen as model system for type II PKSs, through the use of the 
newly devised protein probe 63 in vitro 
 The analysis of biosynthetic species trapped onto the ACP probe 64 by 
FTICR-MS. 
 
1.8.2. Secondary research aim 
The secondary project aim was to compare the efficiency of intermediate capture by 
a small molecule photolabile probe 65 with that of the ACP protein probe 64.  For 
this:  
 Demonstrate the photoactivation of a small molecule probe 
 A previously established system, the modular lasalocid A 1 biosynthetic 
pathway from S. lasaliensis, investigated with the aid of the synthesised 
small molecule probe 65.
155
   
 The small molecule probe 65 used for the capture of type II PKS 
intermediates form the reconstituted actinorhodin minimal system in vitro, as 
well as from actinorhodin 2 biosynthesis in S. coelicolor. 
 Identify and characterise trapped biosynthetic species by LC-HR-MS. 
(Scheme 14). 
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Scheme 14 Secondary project aim: Investigation of the actinorhodin minimal type II 
polyketide synthase by means of a photolabile small molecule chain termination probe 65 in 
vitro and in vivo. 
 
1.8.3. Tertiary research aim 
Lastly, this research aimed at improving and optimising the characterisation of 
biosynthetic intermediates in free or protein-bound form.  The incorporation of alkali 
metals to mass spectrometry samples obtained from experiments was explored to 
establish any influence on fragmentation pathways in collisionally activated 
dissociation (CAD) and electron impact dissociation (EID).  This could prove a new 
avenue of research for future mass spectrometry analyses of polyketides and 
proteins, in particular acyl carrier proteins. 
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Chapter 2: Synthesis of a nonhydrolysable 
photolabile N-acetyl cysteamine probe 
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2. Synthesis of a nonhydrolysable photolabile malonyl N-acetyl cysteamine 
probe 
2.1. Probe design 
As mentioned in Chapter 0, mimics of the acyl carrier protein pantetheinyl arm in the 
form of nonhydrolysable malonyl N-acetyl cysteamine analogues (Figure 14) have 
proven successful as tools to chemically ‘trap’ biosynthetic intermediates.22, 136, 154, 
155
  It has been shown that carba(dethia) analogues have been the most effective 
trapping agents, in comparison to oxa(dethia) and amino(dethia).
11, 154
  
 
Figure 14  A comparison between the ‘natural’ 4’-phosphopantetheinyl arm and its 
carba(dethia) mimic. 7 is the 4’-phosphopantetheinyl arm of ‘malonyl’ acyl carrier protein. 
66 is the ‘active’ malonyl carba(dethia) N-acetyl cysteamine probe.  
 
A photolabile N-acetyl cysteamine analogue 65 has been prepared for several 
motives.  The photoactivatable nonhydrolysable malonyl acyl carrier protein 
analogue (ACP probe 63) requires a lengthy chemoenzymatic synthesis to prepare, 
however, the N-acetyl cysteamine probes (NAC probes) can be prepared in as little 
as three steps.  Therefore, it was predicted that a larger quantity of probe 65 would 
be available for preliminary photolysis tests, such as to find the optimum light source 
and conditions for ‘uncaging’.  
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In addition to using the NAC probe 65 for optimising photolysis conditions, the 
comparison of this probe with the ACP probe 63 results in vitro would prove 
important in designing future probes.  Lastly, the photolabile NAC probe 65 would 
be the first photoactivatable probe of its kind, and would be able to be used in vivo as 
well as in vitro.  Photoactivation allows activation of the probe at different time 
points for the ‘trapping’ of biosynthetic intermediates.  Other generations of NAC 
probe rely on activation by esterases in the cell, which could occur at an uncontrolled 
point in the cell growth. 
11, 22, 136, 154
  
The following section presents the rationale for choosing the 4,5-dimethoxy-2-
nitrobenzyl (DMNB) photolabile protecting group for both probes 63 and 65. 
 
2.2. Photolabile protecting groups for carboxylic acids 
A variety of photolabile protecting groups for the protection of carboxylic acids are 
described in the literature: these include multicyclic (Section 2.2.1) and monocyclic 
aromatic (Section 2.2.2) moieties.  Those with cleavage wavelengths above 
approximately 300 nm
226
 can be used in biological environments as they are not 
protein damaging; however additional factors such as quantum yield, by-product 
interference or toxicity, solubility and bioavailability have to be taken into account in 
selecting an ideal group.  To the best of our knowledge, no malonyl or β-ketoacid 
photolabile protection has been reported.  
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2.2.1. Multicyclic groups  
2.2.1.1. Diisopropylsilyl groups 
There is a class of photoactivatable silyl protecting groups that include 
(hydroxystyryl)diisopropylsilyl (HSDIS) 85 and ((2-hydroxy-3-naphthy)vinyl)-
diisopropylsilyl (HNVDS) 86 that have been used for chemical synthesis 
applications, taking advantage of selective deprotection.  The HSDIS 85 group 
cleaves at 254 nm and the HNVDS 86 group at 350 nm, although quantum yields 
have not yet been reported (Figure 15).
227, 228
 
 
2.2.1.2. Thiochrome groups 
A thiochrome protecting group whose activity can be switched on by oxidation, 
providing thiochrome S,S-dioxide (TCSSD) 87, can also be used as a protecting 
group for carboxylic acids.  With wavelengths over 280 nm, TCSSD 87 will cleave 
the leaving group and generate a tetracyclic highly fluorescent product that can be 
used to monitor the deprotection (Figure 15).
229
 
 
2.2.1.3. Polycyclic aromatic hydrocarbons groups 
Also, activated at 350 nm are the polycyclic aromatic hydrocarbons, Phenanthren-9-
ylmethoxycarbonyl (Phmoc) 82, Pyren-1-ylmethoxycarbonyl (Pmoc) 83 and 
Anthroquinon-2-ylmethoxycarbonyl (Aqmoc) 84.  Aqmoc 84 is the best protecting 
group for alcohols with a quantum yield of 0.10, followed by Pmoc 83 (quantum 
yield of 0.003) and least reactive is Phmoc 82 (quantum yield of 0.0009).  The 
highest yields for Aqmoc 84 required THF in the solvent system, which limits its 
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biological applications.  Furthermore, it produces a reactive intermediate that may 
hinder its application in a number of fields (Figure 15).
230
  
 
2.2.1.4. Coumarin-4-ylmethyl (CM) groups 
Interest in coumarins has mainly focused on their fluorescent properties, however 
coumarin-4-ylmethyl (CM) groups are an entire class of protecting groups.  They can 
present a variety of modifications on the benzopyrone moiety which can affect 
photolysis quantum yield and rate.  Solvent trapped coumarin is the by-product of 
the photocleavage, and the leaving group is released as an anion.
226
  (7-
methoxycoumarin-4-yl)methyl ester (MCM) 92 was the first coumarin derivative to 
be explored as a protecting group for diethylphosphate.
231
  Later, MCM 92 was used 
to protect cyclic adenosine monophosphate (cAMP), releasing cAMP with 
irradiation of 340 nm.
232
   
Coumarin-4-ylmethanol (HCM) 88 has an absorption maximum at 310 nm, shifts to 
longer wavelengths can be made by modifications to the C6 or C7 of the coumarin 
ring.  (6-bromo-7-hydroxycoumarin-4-yl)methyl (Bhc) 89, for example, the addition 
of a bromine at the C6 position, shifts the maximum absorption to 375 nm.
226, 233
  
Further additions of bromine at the C2 and C8 positions increase the maximum to 
397 nm.
234
  A chlorine substitution at the C6 position, however, decreased the 
quantum yield by 40% compared to HCM 88 (Figure 15).
226, 234
 
Takaoka and co-workers
235
 compared coumarin based protecting groups with a 
nitrobenzyl (NB) protecting group, 4,5-dimethoxy 1-(2-nitrophenyl)ethyl (DMNPE) 
111, and found MCM 92 and (7-carboxymethoxycoumarin-4-yl)methyl (CMCM) 93 
to cleave much faster than DMNPE 111 (Figure 17 and Figure 15). 
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Figure 15  Multicyclic photocleavable protecting groups for carboxylic acids.  Phmoc = 
Phenanthren-9-ylmethoxycarbonyl 82, Pmoc = Pyren-1-ylmethoxycarbonyl 83, Aqmoc = 
Anthroquinon-2-ylmethoxycarbonyl 84, HSDIS = (hydroxystyryl)diisopropylsilyl 85, 
HNVDS = ((2-hydroxy-3-naphthy)vinyl)-diisopropylsilyl 86, TCSSD = thiochrome S,S-
dioxide 87, HCM = (7-hydroxycoumarin-4-yl)methyl 88, Bhc = (6-bromo-7-
hydroxycoumarin-4-yl)methyl 89, Chc = (6-chloro-7-hydroxycoumarin-4-yl)methyl 90, tBhc 
= 3,6,8-tribromo-7-hydroxycoumarin-4-ylmethyl 91, MCM = (7-methoxycoumarin-4-
yl)methyl 92, CMCM = (7-carboxymethoxycoumarin-4-yl)methyl 93. 
 
2.2.2. Monocyclic aromatic groups 
Simple aromatic moieties can also be used as photolabile protecting groups.  
Barltrop and Schofield, in 1962, demonstrated very simple protecting groups that 
could be cleaved by irradiation of wavelength 254 nm: benzyl (B) 96, para-
nitrobenzyl (pNB) 97, para-bromobenzyl (pBB) 98 and para-methoxybenzyl 
(pMOB) 99 (Figure 16).
236
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Two methoxy groups in the meta position (DMB) 94 has been shown to increase the 
photolysis rate, this has been coined the ‘meta effect’.237-239  The addition of two 
methyl groups on the α carbon (DMDMB) 95 makes the group even more reactive as 
it stabilises the positive charge on the benzyl ring, promoting O-C bond cleavage 
(Figure 16).
240, 241
 
 
Figure 16  Simple aromatic photolabile protecting groups for carboxylic acids.  DMB = 
3,5-dimethoxybenzyl 94.  DMDMB = α,α-dimethyl-3,5-dimethoxybenzyl 95.  B = Benzyl 96.  
pNB = para-nitrobenzyl 97.  pBB = para-bromobenzyl 98.  pMOB = para-methoxybenzyl 99.  
pHP = para-hydroxyphenacyl 100.  MO-pHP = 3-methoxy-para-hydroxyphenacyl 101.  
DMO-pHP = 3,5-dimethoxy-para-hydroxyphenacyl 102.  A-pHP = 3-acetamide-para-
hydroxyphenacyl 103.  MOC-pHP = 3-methoxycarbonyl-para-hydroxyphenacyl 104.  C-pHP 
= 3-carboxyl-para-hydroxyphenacyl 105.  DNPT = 2,4-dinitrophylthio 106. 
 
A range of photolabile groups based on para-hydroxyphenacyl (pHP) 100 with meta 
substitutions can act as protecting groups for carboxylic acids, cleaving at 300 nm. 
The quantum efficiency of these groups for releasing γ-Aminobutyric acid (GABA) 
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has been determined and a relationship between the ease of forming the phenoxide 
anion and the release of the substrate.  Of six meta substituted protecting groups, the 
3-acetamide-para-hydroxyphenacyl (A-pHP) 103 group had the highest quantum 
efficiency, whereas the methoxy derivatives 101 and 102 (3-methoxy-para-
hydroxyphenacyl (MO-pHP) 101 and 3,5-dimethoxy-para-hydroxyphenacyl (DMO-
pHP) 102) had the lowest quantum efficiency (Figure 16).
226, 242
  
A 2,4-dinitrophylthio (DNPT) 106 photolabile group was reported to protect 
carboxylic acids in the 1960s, however, since then this chemistry has not progressed 
any further, and applications have not been documented since (Figure 16).
243
  
A subset of monocyclic aromatic protecting groups comprises nitrobenzyl groups 
which will be discussed in depth in the following section. 
 
2.2.3. Nitrobenzyl (NB) groups 
The most common class of photolabile protecting groups are the nitrobenzyl (NB) 
derivatives (Figure 17).  A selection of these groups is shown in Figure 17.  NB 
protecting groups will cleave in a variety of solvents, and even in solid state, 
however the rate of photolysis is dependent on the solvent, with acetonitrile being 
the fastest for deprotection of carboxylates, and the rate is slowest at physiological 
pH.
244-248
  Most of the NB groups are ortho- isomers, however, para- and meta- NB 
alcohols have also been synthesised and photoisomerisation has been observed, but 
not used as photolabile protecting groups.
249
 
Analogues with modifications to the NB 114 have been synthesised on numerous 
occasions with mixed results.  The introduction of an α-methyl group to the NB 
group (α-CH3 NB) 118 has been demonstrated to not increase the quantum yield.
250
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Figure 17  A selection of nitrobenzyl type photolabile groups to protect carboxylates.  
DMNB = 4,5-dimethoxy-2-nitrobenzyl 107, DMNPE = 4,5-dimethoxy 1-(2-nitrophenyl)ethyl 
111, DMNPP = 2-(4,5-Dimethoxy-2-nitrophenyl)propyl 112, D(NB) = di(nitrobenzyl) 113, 
NB = nitrobenzyl 114, DNB = 2,6-dinitrobenzyl 115, β NB = β nitrobenzyl 116, MDNB = 
4,5-methylenedioxy nitrobenzyl 117, α-subst. NB = α-substituted (methyl 118, hydroxymethyl 
119 and carboxyl 120) nitrobenzyl. 
 
A carboxyl group at the α position, α-carboxylated nitrobenzyl (α-COOH NB) 120, 
however, does increase the rate of photolysis.  An additional para carboxylate does 
not increase the quantum yield, but can make the compound more hydrophilic, 
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beneficial for some applications.
251-253
  When a hydroxyl group is in the α position 
(α-hydroxymethyl nitrobenzyl (α-CH2OH NB) 119), it is more stable than the α-
carboxyl derivative 120, and the decay kinetics for this analogue were much 
faster.
254
   
Substitutions at the 4 and 5 positions on the benzene ring (107 to 110) do not 
negatively impact the group’s ability to photolyse, and the substitutions do not alter 
the quantum yield to a great degree.
255
  Two NB groups (di(nitrobenzyl)oxycarbonyl 
(D(NB)) 113) increased the quantum yield compared to a single NB group 114, but 
not as greatly as an additional nitro moiety on the other ortho position of a single NB 
ring, 2,6-dinitrobenzyl (DNB) 115.
250
  The latter improves the statistical likelihood 
of producing the aci-nitro group, necessary for photolysis to occur (Figure 17).
240
 
It is also possible to link the NB group 113 at the β position, β nitrobenzyl (β NB) 
116 as a photolabile group to protect nucleosides, and increased the photolysis rate 
compared to at the α position (Figure 17).256  
The 4,5-dimethoxy-2-nitrobenzyl (DMNB) group 107, is the most popular NB 
derivative, and presents two methoxy groups at the meta and para positions, 
however a methylenedioxy derivative, 4,5-methylenedioxy nitrobenzyl (MDNB) 
117, is also widespread (Figure 17).
257
  Both substitutions cause an increase in the 
maximum absorption, producing compounds more suitable for in vivo 
applications.
240
  Other modifications, as shown in Figure 17, 118-120, did little to 
alter the quantum yield, however, for Makings and Tsien
255
, hydrophilic or 
hydrophobic substitutions allowed control over the cell membrane permeability.   
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2.2.3.1. The 4,5-dimethoxy-2-nitrobenzyl (DMNB) group 107 
Modifications to the para and meta positions on the NB ring have been explored.  
The most popular protecting group is the 4,5-dimethoxy-2-nitrobenzyl (DMNB) 
group 107, also known as the 6-Nitroveratryloxycarbonyl (NVOC) group.
240
  The 
group can protect alcohol or carboxylic acid groups as well as amines.  A carbamate, 
carbonate or an ester linkage between the substrate and the protecting group, when 
photolytically cleaved, yields an aldehyde on the protecting group (by-product) and 
an amine, carboxylic acid or alcohol group, respectively, on the substrate (product).  
The methoxy moieties of the DMNB group 107 increase the cleavage wavelength to 
make the deprotection less toxic in biological systems.  In particular, tryptophan, the 
most sensitive amino acid to light, is not affected by the wavelength required for 
photolysis of the DMNB group 107.
201, 258
  In fact, the photolysis can be carried out 
at a range of wavelengths, 254nm, 350 nm, 365 nm, 380 nm, 400 nm, and 419 nm, 
which opens up more opportunities for different applications, as well as selective 
deprotection among other photolabile protecting groups.
240, 259
 
There are three steps towards the photolysis of the DMNB group 107, and this 
applies to most o-nitrobenzyl alcohol derivatives.  To begin with there is 
photoinduced hydrogen atom transfer to the nitro group that promotes cyclisation 
involving that nitro group, and then deprotonation of the hydroxyl group leads to 
cleavage that generates o-nitrobenzaldehyde 125 and the desired product 124 
(Scheme 15).  The by-product 125 is likely to undergo side-reactions, such as 
dimerisation and oxidation.
245, 258, 260
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Scheme 15  Mechanism of photolysis of the 4,5-dimethoxy-2-nitrobenzyl (DMNB) group 107 
protecting a carboxylic acid group.  Three key steps are involved in the photolysis: (i) the 
photoinduced H-atom transfer leading to 121, (ii) ground state cyclisation of 121 to 122, 
(iii) in basic conditions, 122 is deprotonated to 123, and cleaves irreversibly, releasing the 
carboxylic acid group 124 and o-nitrobenzaldehyde 125.
263
  
 
Derivatives of DMNB 107 have been synthesised to act as probes with alpha 
substitutions such as an α-methyl group, 4,5-dimethoxy 1-(2-nitrophenyl)ethyl 
(DMNPE) 111, which proved to increase the quantum yield from 0.006 to 0.65 when 
caging glutamate.
261, 262
   
A longer linker between the NB ring and the protected carboxylic acid was explored 
by Specht and co-workers
264
, including a beta methyl substitution.   
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The protecting group, 2-(4,5-Dimethoxy-2-nitrophenyl)propyl (DMNPP 112), when 
caging glutamate had a quantum yield of 0.36, which is also an improvement on the 
basic DMNB group 107.  DMNPP 112 has recently been utilised for light-induced 
protein dimerisation in live cells by caging gibberellic acid.
265
  Both DMNPE 111 
and DMNPP 112 are cleaved with wavelengths of approximately 364 and 350 nm, 
respectively
262, 264
, however, it has been reported that DMNPP 112 can be cleaved 
via two-photon uncaging.
265
  The DMNB alcohol is commercially available, 
therefore we pursed its straightforward incorporation into our probes as proof of 
concept. 
 
2.2.3.1.1. Applications for the 4,5-dimethoxy-2-nitrobenzyl 
(DMNB) photolabile protecting group 107 
The following are notable examples of the DMNB 107 group’s use in vivo and in 
vitro.  
DMNB 107 caged lipids have been shown to be able to be assembled into liposomes 
and upon irradiation, carboxylic acids at the end of each lipid were released, this 
destabilised the liposome and caused the contents, a fluorescent dye, of the 
liposomes to escape.
266, 267
 
An α-haemolysin pore has been prepared with DMNB 107 protection on the interior 
wall via an oligo(ethylene glycol) linker.  Upon irradiation a carbamic acid is 
released, which decarboxylates, producing a primary amine.  The pH dependence of 
the reactions was explored by electrical detection at the single-molecule level, 
revealing rate constants for each step.
268
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Hydroxy groups on carbohydrates and oligonucleotides have been protected with the 
DMNB 107 group for the selective deprotection during their complex synthesis.
269, 
270
  Similarly, peptide synthesis has utilised this photolabile protecting group by 
attaching the DMNB 107 protected amino groups via an amino linker to a glass 
plate, allowing light-directed spatially resolved synthesis.
271
 
Kinase activity has been monitored by protecting known phosphorylation sites on 
Pho4 by genetically encoding DMNB-caged 107 serine on the protein.  Once caged, 
Pho4 could not be exported from the cell, Saccharomyces cerevisiae.  Additional 
green fluorescent protein labelling allowed real-time detection of the export of the 
protein, initiated by photoactivated deprotection and subsequent phosphorylation.
272
 
Calcium concentrations in cells can be controlled with a DMNB-caged 107 inositol 
1,4,5-triphosphate (InsP3).  InsP3 causes the opening of calcium channels, releasing 
Ca
2+
 from the intracellular stores into the cytoplasm.  The three phosphates of InsP3 
were esterified to allow transport into the cell, then esterases within the cell cleaved 
the esters. Irradiation of the DMNB-caged 107 InsP3 released active InsP3, in a 
controlled manner, dependent on irradiation time and pulses, causing an increase in 
Ca
2+
 in the cell.
273
  
 
2.2.4. Choice of photolabile group for the NAC analogue 65 and the 
ACP analogue 64 
The 4,5-dimethoxy-2-nitrobenzyl (DMNB) group 107 was chosen for protecting the 
new chain termination probes (ACP 64 and NAC-based 66) reported in this thesis.  
The DMNB group 107 is the most widely studied photolabile group, and has already 
been used for many biological applications.
266-268, 272, 273
  This group has been 
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demonstrated in the literature to cleave steadily by irradiation with light of 
wavelengths between 350 and 370 nm,
201, 274-279
 both  in vitro
276
 and in vivo.
264, 280
  
This wavelength range is not protein damaging, and the by-product, o-
nitrosobenzaldehyde,
263
 is non-toxic at low levels, which has allowed this protecting 
group to be used in a variety of biological organisms and for a range of purposes, 
including in vivo.  
 
Figure 18  A comparison of the two probes synthesised in this work.  63 is the 
nonhydrolysable photolabile malonyl acyl carrier protein analogue, and 65 is the 
nonhydrolysable photolabile malonyl N-acetyl cysteamine analogue. 
 
Šolomek, et al., calculated quantum yields a small variety of compounds bearing the 
same photolabile group but presenting different leaving groups.  They showed that 
esters had the lowest quantum yield compared to ethers and amines, believing the 
electro-withdrawing substituents on the oxygen reduced the efficiency.
263
  Despite 
this drawback, we envisaged that, amongst all the photolabile group discussed, 
DMNB 107 would still be the easiest to synthetically introduce in our molecules 
(Chapters 0 and 0) and also the most compatible with the wide range of experiments 
in mind.  Therefore, it was adopted as a starting point for the generation of novel 
photolabile probes (Figure 18).   
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2.3.  Probe synthesis 
The route to synthesising the NAC probe 65 is distinctly shorter than the route to the 
synthesis of the ACP probe 63. The synthesis of the N-Ac-based photolabile probe 
65 was achieved in just three steps, with the first two following synthetic protocols 
previously established in the Tosin group.
6
  The first step involves the selective N-
acetylation of GABA 126 with acetyl chloride, followed by the coupling of the 
resulting carboxylate 127 with Meldrum’s acid.  This reaction afforded product 128, 
which was refluxed at 65
o
C and reacted with 72 to afford 65 (Scheme 16).  
 
Scheme 16  Synthesis of a nonhydrolysable photolabile malonyl N-acetyl cysteamine 
analogue 65. 
 
A deuterium labelled probe 65b, as a control, was also prepared by acetylating 
GABA 126 with d3-acetyl chloride, using the chemistry just described. A deuterium 
label could be incorporated into 65b (Figure 18), to further confirm the assignments 
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of any trapped intermediates.  The retention time of these species by HPLC or UPLC 
analyses is not affected, to a great extent
281
, by this isotope labelling, but a mass shift 
of 3.018 Da, as well as no effect on the molecule’s fragmentation pattern, allows for 
accurate assignment of intermediates off-loaded by the probes. 
The first two steps and purification by flash chromatography did not require further 
optimising as these steps have been widely utilised for the preparation of a number 
of other N-acetyl cysteamine probes in our group.
154, 155
  However, the thermal 
degradation of 128 to allow it to react with the alcohol 72 required some 
optimisation, as it did for the synthesis of pantetheine analogue 61 (Table 2).   
 
Conditions 
Yield after 
purification 
Temperature Solvent Catalyst 
Reaction 
Time 
65°C THF none 3 hrs 41% 
40°C DCM none 4 hrs 11% 
65°C THF ZnCl2 2.5 hrs 70% 
Table 2  Reaction conditions trialled for the synthesis of the nonhydrolysable photolabile 
malonyl N-acetyl cysteamine analogue 65 from 128, shown.  Yield shown is after 
purification by flash chromatography. 
 
The outcome of this reaction has proven to vary depending on the rest of the 
molecule.  Each reaction was left running until all the starting material had been 
consumed, and yields were calculated after purification.  Refluxing in THF yielded 
41% of NAC analogue 65, but just 29% of pantetheine analogue 61 and required 24 
hours refluxing to consume all of the starting material, compared to just 3 hours for 
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the synthesis of NAC analogue 65.  Reducing the temperature, by refluxing in DCM, 
decreased the yield of NAC analogue 65 to just 11% and increased the time for 
consumption of starting material 128.   
The addition of the catalyst, ZnCl2,
282
 proved beneficial to the synthesis of the NAC 
analogue 65, increasing the yield to 70% and decreasing the reaction time by half an 
hour compared to in the presence of the catalyst.  The addition of this catalyst for the 
synthesis of the pantetheine analogue 61 did dramatically reduce the reaction time, 
but the product yield dropped to just 5%. Increasing the temperature of reflux, by 
using toluene as the solvent, improved the yield of pantetheine analogue 61, as well 
as reducing the reaction time to 8 hours.  The addition of 3Å molecular sieves likely 
played a part in this increased yield.  
There does appear to be a link between reaction time and yield for this reaction.  It is 
likely that difficulty to maintain anhydrous conditions over long reaction times or 
product instability, may lead to reaction with water rather than the alcohol 72, and 
generation of a decarboxylated product.  Refluxing in toluene and the addition of 3Å 
molecular sieves was not tested for the synthesis of NAC analogue 65 as the yield of 
70% was sufficient at that time, however, it is hypothesised that this would increase 
the yield further.  
An efficient chemical synthesis of a nonhydrolysable photolabile malonyl N-acetyl 
cysteamine analogue 65 has been devised.  The final yield was 40% over 3 steps, 
with the coupling to meldrum’s acid, and the thermal degradation and reaction with 
the alcohol 72 being the weakest steps.  Analogue 65 is the first photoactivatable 
nonhydrolysable malonyl NAC analogue to be synthesised, with a wide range of 
applications, beyond the scope of this thesis.  
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2.4  Preliminary photolysis experiments 
The NAC 65, CoA 62 and ACP 63 analogues bearing the DMNB photolabile group 
require exposure to light in order to be uncaged in their active forms.  
Initially, LED light sources, handheld UVA lamps, and TLC plate viewers (equipped 
with 365 nm lamps) were employed to cleave the DMNB group, however, only 
starting material was evident by ESI-MS for these reactions over a variety of times 
up to six hours.  A KiloArc light source was tested, but only up to 45 minutes as it 
was expected that sufficient photolysis would be achieved within that time for 
detection by ESI-MS (Table 3).   
 
Figure 19  UV/Vis spectrum for the nonhydrolysable photolabile malonyl N-acetyl 
cysteamine probe 65.  Maximum absorptions are shown at 300 nm and 345 nm.  
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Test conditions for the photolysis of NAC analogue 65 
 Product 
detected? 
Light Source 
Concentration and 
Solvent/Media 
Irradiation 
Time 
UVA LED 73 mM in MeCN/H2O 30 mins - 2hrs N 
Bench UVA lamp within a 
photoreactor oven 
73 mM in MeCN/H2O 30 mins - 2hrs N 
TLC Plate Viewer 365 nm 50 mM in MeCN/H2O 15 mins - 6hrs N 
KiloArc Broadband Arc Lamp 
800W, 365 nm 
50 mM in MeCN/H2O 15 mins N 
KiloArc Broadband Arc Lamp 
1000W, 365 nm 
50 mM in MeCN/H2O 45 mins N 
KiloArc Broadband Arc Lamp 
1000W, 345 nm  
17 mM in MeCN/H2O 5.5 hrs N 
Femtosecond laser 345 nm 17.4 mM in MeCN/H2O 1 hr N 
Femtosecond laser 300 nm 17.4 mM in MeCN/H2O 30 mins N 
Femtosecond laser 345 nm 
17.4 mM in MeCN/H2O plus 
0.05M NaOH 
30 mins N 
KiloArc Broadband Arc Lamp 
1000W, 365 nm 
17 mM in MeCN/H2O 
adjusted to pH 10 with 
NaOH 
2 hours Y 
UVA tube lights within a 
photoreactor oven 
1 mM in DMSO 7 hrs N 
Femtosecond laser 365 nm 3 mM in MeCN/H2O 1 hr N 
In-house built light box 
containing a circular 22W UVA 
0.63 mM in MYM media 6 hrs Y 
In-house built light box 
containing a circular 22W UVA  
1.6 mM in H2O 4hrs Y 
Table 3  Conditions tested for the photolysis of a nonhydrolysable photolabile malonyl N-
acetyl cysteamine probe 65.  Reaction shows generation of a decarboxylated N-acetyl 
cysteamine analogue 129. 
 
A UV/Vis spectrum was recorded for the NAC analogue 65, showing two maximum 
absorptions at 300 nm and 345 nm (Figure 19).  The results from this analysis led on 
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to trialling 345 nm with the KiloArc light source, however, after a much longer 
irradiation time of 5.5 hrs, still no product 66 or 129 could be detected.  
The Stavros group at the University of Warwick were interested to test their 
powerful femtosecond pulsed laser to determine if photolysis of this compound 
could be achieved.  300, 345 and 365 nm wavelengths were tested with no detectable 
product:  it was hypothesised that the femtosecond pulse lengths are too short for the 
photolysis to occur.  The continuous light source, KiloArc™ Broadband Arc Lamp, 
1000W, was trialled again for much longer irradiation times than previously, at 365 
nm, and this finally provided the decarboxylated product 129 (Table 3).   
There was little difference in photolysis yield after pH adjustments, however, the 
extra sodium present in the sample allowed for detection of the sodiated product 129 
by MS.  The sodiated product 129 appears to ionise more efficiently than the 
protonated, it is likely that part of the problem with the photolysis trials was the low 
ionisation efficiency of the protonated product 129 for detection by MS. 
Once an adequate light source was found, it was necessary to determine how long to 
irradiate for to produce sufficient ‘active’ NAC probe 66.  It was found that the NAC 
analogue 65 is fully deprotected by 4 hours (Figure 20). 
The rate of deprotection by photolysis are dependent on concentration; the higher the 
concentration the more effective the photolysis.  This was demonstrated by 
comparing the relative intensities of NAC analogue 65 and decarboxylated product 
129 after one hour of irradiation at 365 nm.  The sample at 1 mM after one hour had 
approximately 50% conversion to the decarboxylated product 129, whereas the 
sample at 0.1 mM had approximately 33% conversion (Figure 21) 
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Figure 20  Irradiation of the nonhydrolysable photolabile NAC analogue 65 with 365 nm, 
1000 W from 0 to 4 hours (A to E, hourly), showing the generation of decarboxylated 
product 129.  After 4 hours, no more NAC analogue 65 could be detected. 
 
This rough estimate assumes identical ionisation efficiencies of the two compounds 
65 and 129, however the difference is sufficient to conclude that photolysis is faster 
at higher concentrations.  This behaviour has previously been reported in the 
photolysis of polycyclic aromatic hydrocarbons
283, 284
 and can be explained by Beer-
lambert law (Equation 3).  For photolysis to occur, the compound needs to absorb 
light, and, as stated by Beer-lambert law, absorbance increases with concentration, 
thus more product would be generated at higher concentrations. 
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Figure 21  Irradiation of the nonhydrolysable photolabile NAC analogue 65 with 365 nm, 
1000 W for 0 (A and C) and 1 (B and D) hours, at two different concentrations (0.1 mM (A 
and B) and 1 mM (C and D)), showing the increased photolysis yield of the decarboxylated 
product 129 at higher concentrations.  Analyses A and B were analysed by UPLC-MS, and 
C and D were analysed by HPLC-MS, resulting in the different retention times. 
 
𝐴 =  𝜀𝑐𝑙 
Equation 3  Beer-lambert law. A is absorbance (no units).  ε is molar extinction coefficient 
(M
-1 
cm
-1
).  c is concentration (M).  l is path length (cm). 
 
The KiloArc lamp was not a suitable light source for in vivo assays, due mainly to 
the larger sample volume required for such experiments, therefore a light source 
capable of holding larger volumes, and able to be placed within an Innova incubator 
was built in-house.  The light source contained a circular UVA lamp, with an 
attachment in the centre of the lamp for either a 5 mL petri dish, or a 50 mL 
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Erlenmeyer flask to be irradiated from each side.  The entire light source could be 
attached to the platform of an Innova incubator, and 180 rpm could be applied to the 
liquid cultures, and the contents could be kept at the appropriate temperature for 
continued growth of the cultures during irradiation experiments.  Surprisingly, the 
probe 65 could be efficiently deprotected by the much weaker, 22W, UVA lamp 
(Table 3, also Section 4.3 and 4.2).  
Once the conditions for the release of the probe 66 had been determined, the effect of 
the presence of biosynthetic enzymes, and also in vivo on the rate of photolysis was 
to be explored. 
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3. Chemoenzymatic preparation of a carrier protein probe 63 for the capture 
of polyketide intermediates 
3.1.  Probe rationale and design 
As previously described, mimics of the acyl carrier protein phosphopantetheinyl 
(PPant) arm, in the form of nonhydrolysable malonyl N-acetyl-cysteamine 
analogues, have proven successful as tools to chemically ‘trap’ biosynthetic 
intermediates.
22, 136, 154, 155
  It seemed plausible that altering the PPant arm attached to 
the acyl carrier protein (ACP), making it nonhydrolysable, would have the potential 
to off-load intermediates directly onto the acyl carrier protein.  
The proposed ACP probe 64 would be a very close mimic to the ‘natural’ malonyl-
ACP 7, and is likely to interact more efficiently with the PKSs than the NAC 
analogues.  Additionally, the ACP may stabilise the trapped intermediates more 
effectively than the small molecule chain terminators, allowing the off-loaded 
species to be detected in their natural structure, without cyclisation, for instance. 
It has been shown that carba(dethia) analogues have been the most effective trapping 
agents, in comparison to oxa(dethia).
11, 154
  In particular, this comparison was 
demonstrated in the context of malonyl-CoA analogues,
11
 as CoA represents the 
simplest form of malonyl/intermediate carrier that uses a PPant cofactor, it was 
decided to pursue the preparation of a malonyl carba(dethia) ACP 64 as a more 
advanced tool for the investigation of systems employing discrete carrier proteins 
(Scheme 17).  
As in the case of the previous malonyl carba(dethia) analogues, the carboxylic acid 
group must be readily released in situ, to react with PKS-bound intermediates ahead 
of its complete decarboxylation.  Previously a methyl ester
22
 protecting group was 
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employed for the protection and the use of small molecule probes in vitro, however, 
this requires an additional enzyme, for example pig liver esterase, to release the 
active probe.  This approach has shown limitations in the optimal pH range for 
esterases (approximately pH 8) as most of the β-keto acid promptly decarboxylates.11   
 
Scheme 17  ‘Protected’ 4,5-dimethoxy-2-nitrobenzyl malonyl carba(dethia) ACP analogue 
63 and its product after irradiation to the ‘active’ malonyl carba(dethia) ACP analogue 64. 
 
To remove the need for another enzyme within PKS assays and also to limit the fast 
and premature decarboxylation of the probe, a photolabile protecting group, 4,5-
dimethoxy-2-nitrobenzyl (DMNB), removable in mild conditions, was chosen 
(Scheme 17).  An in depth discussion on this particular protecting group choice will 
be given in section 2.2. 
 
Scheme 18  Products of the actinorhodin minimal system, SEK4 41 and SEK4b 42, via the 
synthesis of an octaketide chain. 
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In this work, a well-studied
13, 19, 76, 207, 208
 model system for type II PKS biosynthesis, 
the actinorhodin (act) 2 minimal system, has been used to develop and probe this 
new intermediate capture methodology.  The act ACP will be modified as 63 to 
investigate the generation of an octaketide intermediate chain, and its cyclisation to 
produce SEK4 41 and SEK4b 42 (Scheme 18, Section 1.3.1).
36, 208
  
While working on this project, the Townsend group demonstrated that by loading a  
nonhydrolysable pantetheine analogue onto the acyl carrier protein, from the 
aflatoxin PKS (a type I iterative PKS from Aspergillus parasiticus), a diketide 
intermediate could be captured by the ACP.
209
  They had not protected the malonyl 
group on the ACP analogue in their assays, and therefore the actual concentration of 
malonyl carba(dethia) pantetheine present on the ACP was very low.  Nonetheless, 
they had been successful in offloading an early stage polyketide intermediate.
209
  We 
then envisaged that photoactivatable acyl carrier proteins such as 63 would hold the 
promise of being a more effective trapping agent due to the possibility of uncaging in 
situ in mild conditions.  
 
3.2.  Preparation of a carrier protein probe 
In order to prepare the act ACP photolabile probe 63 a pantetheine derivative 61 had 
to be chemically synthesised, which could then be converted to the corresponding 
CoA analogue 62 utilising the enzymes pantothenate kinase (PanK), 
phosphopantetheine adenyltransferase (PPAT) and dephosphocoenzyme A kinase 
(DPCK),
101
 and that, from the CoA analogue 62, could be transferred to the apo act 
ACP 44 using the phosphopantheinyl transferase, Sfp (Scheme 19).
99, 100, 210
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Scheme 19  Overview of the planned chemoenzymatic synthesis of a nonhydrolysable 
photolabile malonyl acyl carrier protein 63 from pantothenic acid 60.  
 
3.2.1. Synthesis of the 4,5-dimethoxy-2-nitrobenzyl malonyl 
carba(dethia) pantetheine 61 
3.2.1.1. Synthesis via acetyl protection of the pantetheine diol moiety 
The initial route undertaken for synthesising a nonhydrolysable pantetheine analogue 
61 was based on a previously published route to synthesise a methyl ester protected 
malonyl carba(dethia) coenzyme A 71 (Scheme 20).
11
  This route was first trialled 
during research for my Masters project, and further investigated for this PhD project. 
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Scheme 20 Previous preparation of a nonhydrolysable malonyl carba(dethia) coenzyme A 
analogue 71 by Tosin and co-workers.
11
  PanK=Pantothenate kinase, 
PPAT=phosphopantetheine adenylyltransferase, and DPCK=dephosphocoenzyme A kinase. 
 
Compound 69 was provided by Dr Manuela Tosin.  This compound was reacted with 
4,5-dimethoxy-2-nitrobenzyl alcohol 72 under reflux, in order to provide 73 
(Scheme 21).  Difficulties were encountered during the deprotection of the acetyl 
groups in 73 towards the desired compound 61.  The DMNB ester proved sensitive 
to both acidic and basic conditions; despite a range of mild methods for acetyl 
deprotection (chemical and enzymatic) none of them succeeded in generating 61 in 
good yield.  Therefore, a new way of protecting the diol moiety of pantothenic acid 
60 had to be envisaged. 
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Scheme 21  Synthesis of a nonhydrolysable 4,5-dimethoxy-2-nitrobenzyl malonyl 
carba(dethia) pantetheine analogue with acetyl protection of the diol 73. 
 
3.2.1.2. Synthesis via di-tert-butylsilyl protection of the pantetheine 
41 diol moiety 
By considering the literature available on diol protecting groups, we envisaged that a 
silyl protecting group could be a good choice for pantetheine substrates; silyl groups 
are easy to introduce and can be selectively removed in the late stages of complex 
and multigram scale synthesis via mild fluoride ion donors.  In particular, a 2,4-O-di-
tert-butylsilylene (TBS) group,
211-213
 was chosen for its stability and for its ability to 
protect both the primary and secondary alcohols of pantothenic acid 60 
simultaneously  (Scheme 22).   
ᴅ-pantothenic acid 60 was then protected with a 2,4-O-di-tert-butylsilylene (TBS) 
group to afford the crude pantothenic acid 74, which was directly used in the next 
step.  Amide coupling of 74 to the γ-aminobutyric acid (GABA) benzyl ester 75 was 
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carried out with N,N,N′,N′-Tetramethyl-O-(7-azabenzotriazol-1-yl)uronium 
hexafluorophosphate (HATU) to afford 76 (66% yield over the two steps, and after 
flash chromatography purification).   
 
Scheme 22  Final synthesis of a nonhydrolysable 4,5-dimethoxy-2-nitrobenzyl malonyl 
carba(dethia) pantetheine analogue 61. 
 
Hydrogenolysis of 76 with palladium on carbon was carried out next to remove the 
benzyl ester.  It was observed that the yield of this reaction can be significantly 
affected by substrate concentration and reaction scale.   
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The resulting carboxylate 77 was coupled to Meldrum’s acid with the aid of 1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide) (EDC) to yield 78 in 68% after column 
chromatography.  
 
Conditions 
Yield 
Temperature Solvent Other 
Reaction 
Time 
65°C THF none 24 hrs 29% 
65°C THF 
ZnCl2 
(catalyst) 
11.5 hrs 5% 
65°C THF DMAP 30 hrs 26% 
100°C Toluene 
3Å molecular 
sieves 
8 hrs 56% 
Table 4  Reaction conditions trialled for the synthesis of 79 from 78, shown. Yields shown 
after purification by flash chromatography.  
 
78 was refluxed at 100
o
C in toluene in the presence of 4,5-dimethoxy-2-nitrobenzyl 
alcohol 72 for conversion to 61.  This step requires strict anhydrous conditions in 
order to avoid the nucleophilic attack of water and decarboxylation of the resulting 
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β-keto acid.  Limiting the reaction time to just 8 hours, refluxing at a high 
temperature in toluene, rather than THF, and the addition of 3Å molecular sieves to 
the reaction resulted in the best yield of 56% (Table 4).  
 
Reagent 
Conditions 
Yield 
Temperature Solvent 
Equivalents 
of Reagent 
Reaction 
Time 
TBAF RT THF 5 eq 24 hours 
traces, 
unpurified 
Fluoride on 
polymer support 
RT MeOH 2 eq 24 hours 0% 
Fluoride on 
polymer support 
RT MeOH 5 eq 24 hours 0% 
Fluoride on 
polymer support 
RT MeOH 10 eq 24 hours 0% 
HF-pyridine  RT THF 5 eq 2 mins 90% 
Table 5  Reaction conditions trialled for the deprotection 79.  Yields given were calculated 
after HPLC purification.  
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A range of fluoride ion donors were tested for the diol selective deprotection of 79.  
The use of fluoride for desilylation is very common as the Si-F bond is very strong 
and selective.
214, 215
     
Fluoride on polymer support
216
 and tetrabutylammonium fluoride (TBAF)
217
 were 
trialled, over long reaction times and different amounts, to no success, only starting 
material 79 remained (Table 5).  Eventually, the use of hydrogen fluoride-pyridine 
(HF·pyr) complex
218
 afforded the desired product in quantitative yield (Table 5).  
The overall yield of 61, from ᴅ-pantothenic acid 60, was approximately 23% over six 
steps on a gram scale.  This was overall satisfactory, although weak steps (74 to 75, 
77 to 78 and 78 to 79) could be improved.  
An efficient chemical preparation of 4,5-dimethoxy-2-nitrobenzyl malonyl 
carba(dethia) pantetheine 61 has been devised.  This pantetheine analogue 61 is an 
important analogue in its own right, however, for this project the compound was 
used to prepare 62 and 63, and also for mass spectrometry studies. 
The synthesis of coenzyme A (CoA) 46 from pantetheine 48 is possible in vitro 
utilising three enzymes, a pantothenate kinase (PanK), a phosphopantetheine 
adenylyltransferase (PPAT) and a dephosphocoenzyme A kinase (DPCK).
101
  PanK 
acts first to phosphorylate the primary alcohol of pantetheine 48, then PPAT 
adenylates 4’-phosphopantetheine, and lastly DPCK phosphorylates to generate 
CoA.  
PanK, PPAT and DPCK from E. coli have been shown to accept a wide variety of 
pantetheine derivatives, including those bearing bulky chemical groups.
219, 220
  These 
enzymes can be overexpressed, in E. coli, as His-tagged proteins, allowing for 
simple purification.
101
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The chemical synthesis of CoA derivatives was considered, however, due to the 
large number of potential steps towards a final CoA derivative with a likely low 
yield, it was decided to pursue a chemoenzymatic preparation. 
Each of the three enzymes (for which plasmids were available in the Tosin 
laboratory) were overexpressed in E. coli; in hexahistidine-tagged form for bench-
top Ni-NTA purification, as previously reported.
101
  Successful expression and 
purification were verified by SDS-PAGE (Figure 22).  
 
Figure 22  SDS-PAGE results showing expression of the Pantothenate Kinase (PanK or 
CoaA)
221
 (~38 kDa), the phosphopantetheine adenylyltransferase (PPAT or CoaD)
222
 (~19 
KDa) and the dephosphocoenzyme A kinase (DPCK or CoaE)
223
 (~24 kDa) from E. coli. 
 
The activity of the enzymes was preliminarily tested with pantetheine 48 as the 
starting material, as previously reported and carried out in my Master thesis.
224
   
The 4,5-dimethoxy-2-nitrobenzyl malonyl carba(dethia) pantetheine 61 was 
incubated with PanK, PPAT and DPCK, in the presence of ATP at room temperature 
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and overnight (Scheme 23).  The reaction outcome was analysed by LC-MS, which 
showed the formation of 62, but also the presence of unreacted intermediates in the 
pathway.  In particular, it is known that the last enzymatic step catalysed by DPCK is 
inhibited by the product itself.  Therefore, it was necessary to use additional enzyme 
amounts to achieve full conversion of 61 to 62.  After initial small scale trials, the 
enzymatic preparation of 62 was scaled up to 15 mg and the crude product purified 
by HPLC.  NMR analyses confirmed the coenzyme A nature of the product, and the 
presence of the DMNB group as protection of the carboxylate.  The overall yield of 
this enzymatic one-pot preparation was 70% after HPLC purification. 
 
 
Scheme 23  Enzymatic synthesis of a nonhydrolysable 4,5-dimethoxy-2-nitrobenzyl malonyl 
carba(dethia) coenzyme A analogue 62 from a corresponding, chemically synthesised, 
pantetheine analogue 61. Yield is shown after HPLC purification. PanK = Pantothenate 
kinase, PPAT = phosphopantotheine adenylyltransferase, and DPCK = dephosphocoenzyme 
A kinase.  
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The coenzyme A analogue 62, is already itself an important compound that can be 
directly used for the investigation of type III polyketide synthases (out of the scope 
of this work).  62 was herein used to prepare chemically modified holo-acyl carrier 
proteins for assaying type II PKS biosynthetic pathways. 
 
3.2.2. Enzymatic preparation of a 4,5-dimethoxy-2-nitrobenzyl malonyl 
carba(dethia) acyl carrier protein   
Acyl carrier proteins (ACPs) bear a 4’-phosphopantotheinyl (PPant) chain at the 
active site serine which facilitates interaction with other domains within a polyketide 
synthase.  Phosphopantetheinyl transferase enzymes catalyse the transfer of PPant 
cofactors from coenzyme A (CoA) 46 to apo-ACPs 44, in vitro and in vivo.
99, 121, 225
 
A phosphopantetheinyl transferase from B. subtilis, Sfp, presents broad substrate 
specificity and is widely used for the preparation of modified carrier proteins.
99
  The 
enzyme was overexpressed in E. coli in an hexahistidine-tagged form and purified by 
Ni-NTA chromatography (Figure 23).  
The apo act ACP 44 (plasmid gift from Dr Hui Hong, University of Cambridge) was 
also similarly expressed and purified (Figure 23).   
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Figure 23  SDS-PAGE analyses showing expression of the apo acyl carrier protein 44 (~11 
kDa) from the actinorhodin minimal system, and the phosphopantetheinyl transferase, Sfp, 
(~28 kDa) from B. subtilis. 
 
The activity of both apo act ACP 44 and Sfp was tested with commercially available 
coenzyme A 46.  Complete conversion of apo 44 to holo act ACP 43 was shown by 
LC-MS (Figure 24).  The same conditions were used for the CoA analogue 62 as 
substrate: the photolabile malonyl carba(dethia) act ACP 63 was obtained (Scheme 
24, Figure 24).  
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Scheme 24  Enzymatic preparation of a nonhydrolysable 4.5-dimethoxy-2-nitrobenzyl 
malonyl carba(dethia) acyl carrier protein analogue 63 from the corresponding 
chemoenzymatically synthesised coenzyme A analogue 62. apo-ACP = apo-acyl carrier 
protein 44, Sfp = phosphopantetheinyl transferase from B. subtilis, CoA = coenzyme A 46. 
 
The modified act ACP 63 was characterised by mass spectrometry, including 
fragmentation by collisionally activated dissociation (CAD) (Figure 24).  This 
method of fragmentation is known to preferentially cleave phosphodiester bonds, 
and it has previously been exploited as a reliable method to characterise PPant 
modifications of acyl carrier proteins (Scheme 13).  
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Figure 24 A: (Parent) mass spectrum of (hexahistidine-tagged) holo-acyl carrier protein 
(ACP) 43 from the actinorhodin minimal system.  B: Collisionally activated dissociation 
(CAD) of the 12
+ 
parent ion of holo-ACP 43, generating a singly charged, characteristic, 
pantetheine ion 80.  C: (Parent) mass spectrum of 4,5-dimethoxy-2-nitrobenzyl (DMNB) 
malonyl carba(dethia) ACP analogue.  ACP is from the actinorhodin minimal system.  D: 
CAD of the 12
+
 parent ion of DMNB malonyl carba(dethia) ACP analogue, generating a 
singly charged, characteristic, pantetheine ion 81. 
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Although not demonstrated within this project, we view that it is now possible to 
load acyl carrier proteins from different biosynthetic pathways with the new 
photolabile PPant arm.  For instance, the Tosin group has already begun to explore 
the use of this tool in the investigation of saturated and polyunsaturated fatty acid 
assembly.  In Chapter 5.2 of this thesis, the validation of 63 for the investigation of 
the actinorhodin 2 type II PKS will be presented. 
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4. Trapping of polyketide intermediates in vivo and in vitro with the aid of a 
photolabile malonyl N-acetyl cysteamine analogue 65 
4.1.  In vitro trapping of intermediates from the actinorhodin minimal 
system with the nonhydrolysable photolabile NAC probe 65 
4.1.1. Analysis by LC-MS 
The established irradiation conditions for the uncaging of the nonhydrolysable 
photolabile NAC probe 65 were applied in the study of the actinorhodin minimal 
system generating the polyketides SEK4 41 and SEK4b 42 in vitro (Chapter 1.3).  
These products have identical molecular formulae hence mass, however SEK4 41 
presents a shorter retention time by RP-LC than SEK4b 42 (Figure 25).
36
  
 
Figure 25  LC-MS chromatogram showing the protonated and sodiated EIC for the isomers 
SEK4 41 and SEK4b 42 produced by the actinorhodin minimal system.  Peak assignments of 
SEK4/4b 41/42 based on Fu, et al., 1994.
36
  A) Production of shunt metabolites, SEK4/4b 
41/42, by the actinorhodin minimal system.  B) Production of SEK4/4b 41/42 by the 
actinorhodin minimal system following photolysis for 2 hours at 365 nm, 1000W.  
112 
 
The ability of the minimal system to produce SEK4/4b 41/42 under the irradiation 
conditions was established by comparison of the yield of identical assays with and 
without 2 hours of irradiation.  This irradiation time was selected as a significant 
amount of shunt products can be generated by the type II PKS within this time.
13, 76, 
207, 285
  The yields of the two shunt products were shown to be unchanged (Figure 
25).  
 
Figure 26   LC-MS chromatograms showing the photolysis of the DMNB NAC analogue 65 
to 129 in the absence (A) and in the presence of the ketosynthase and chain length factor 
from the actinorhodin minimal system (B) with 365 nm, 1000W for 4 hours.  
 
Following these results, the yield of photolysis of the NAC analogue 65 with the 
ketosynthase and chain length factor (KS-CLF) of the actinorhodin minimal system 
was compared.  Identical assays were set up, and after 4 hours of irradiation, or 
bench top incubation for the control, the samples were compared by LC-MS 
following extraction.  Unfortunately, the yield of photolysis is substantially affected 
by the presence of KS-CLF, being almost null (Figure 26).  This is likely due to the 
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NAC analogue 65 diffusing within the KS-CLF which protects 65 from photolysis.  
Based on this evidence, it was decided that the NAC probe 65, and therefore likely 
the ACP probe 65 as well, would be irradiated prior to incubation with the minimal 
system.  
Results showed that almost 50% of active probe 66 is released within 10 minutes of 
irradiation of the protected probe 65, and that the decarboxylated product 129 is not 
the major product, even after 5 hours of irradiation (Figure 27).  
 
Figure 27  Irradiation of the nonhydrolysable photolabile NAC analogue 65 with 365 nm, 
1000 W for 0 mins (A), 10 mins (B), 30 mins (C), 1 hour (D), 2 hours (E) and 5 hours (F), 
showing the release of the active probe 66 after just 10 mins, and its stability after 5 hours.  
Also shown is the slow decarboxylation to 129.  Samples were stored in dry ice and 
defrosted just before analysis by HPLC-MS on the same day. 
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A light box was designed and specifically built for this project at the University of 
Warwick by Mr Rod Wesson of our in-house electrical workshop.  The light box is 
fitted with a 22W circular UVA lamp (Actinic BL TL-E 22W/10 1CT), cooling fans, 
an interchangeable mount for a 50 mL Erlenmeyer flask or a 5 mL petri dish, and the 
ability to fix the box within an Eppendorf Innova incubator shaker.  Photolysis yields 
were not expected to be much greater than with the handheld UVA lamps already 
tested, however, after 4 hours of irradiation approximately 75% of decarboxylated 
product 129 is produced. 
Following these preliminary experiments, the protected probe 65 was irradiated for 4 
hours and then added to the actinorhodin minimal system.
13, 76
  Each sample was 
extracted into EtOAc and then analysed by UPLC-MS.  pH adjustment to 
approximately 4 proved critical for the extraction of SEK4 41 and SEK4b 42 with 
EtOAc.  Predictions for the potential trapped intermediates are based upon the two 
different cyclisations observed in the octaketide shunt products, SEK4 41 and 
SEK4b 42.  The data were analysed for these compounds, but unfortunately no 
intermediates were detected.  
Additionally, varying the ratio of holo-ACP 43 to active probe 66 was explored.  It 
has been previously shown that this ratio can be important for trapping intermediates 
with other nonhydrolysable NAC probes in vitro.
11, 153
  For example, when probing 
the biosynthetic pathway of resveratrol 4 with a nonhydrolysable malonyl 
carba(dethia) analogue, it was found that a ratio of 3:4, malonyl-CoA 
analogue:malonyl-CoA 15, is the most effective.
11
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The ratios 10:1, 5:1, 1:1, 1:5 and 1:10 of holo-ACP 43 to active probe 66 were tested 
in duplicate copy experiments, however none of these experiments result in any 
detectable intermediates.   
 
4.1.2. Effect of delayed addition of active NAC probe 66 to the 
actinorhodin minimal system on SEK4/4b 41/42 production 
A series of additional experiments were set up to observe the effect of timing of the 
addition of the active probe 66 on SEK4/4b 41/42 production.  This was carried out 
by activating the minimal system, and subsequently adding the active probe 66 at set 
time points.  Each assay was left overnight at room temperature, and then extracted 
with EtOAc, and SEK4/4b 41/42 were detected by LC-MS (Figure 28).  Adding 
holo-ACP 43 and active probe 66 at the same time, a time delay of 0, would have 
introduced a significant error, so this was not attempted.  
There was an observation of a decrease in SEK4/4b 41/42 production the longer the 
time delay between activation of the minimal system and addition of the NAC probe 
66.  It was expected that SEK4/4b 41/42 production would be most affected by the 
addition of the active probe 66 at early time points, however, results showed that 
SEK4/4b 41/42 production was reduced by longer delays. (Figure 28).  
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Figure 28  The effect of delayed addition of active probe 66 to the actinorhodin minimal 
system on the production of SEK4 41 and SEK4b 42.  The actinorhodin minimal system was 
activated by the addition of final enzyme, holo-ACP 43, then 30 (A), 60 (B), 120 (C), 300 (D) 
and 600 (E) seconds later the active probe 66, obtained from a 4 hour irradiation of the 
nonhydrolyzable photolabile NAC analogue 65 in the home built UVA light source, was 
added.  Following incubation overnight at room temperature, EtOAc extracts were analysed 
by UPLC-MS.  The addition of active probe 66 at time point 0 seconds was not feasible by 
hand. This experiment was repeated with similar results (see Appendix 1). 
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A possible explanation for these results could be that diffusion of the probe 66 into 
the active site of the enzymes is affected by how long the biosynthesis has been 
proceeding for.  At the early stages of biosynthesis, there is an abundance of 
malonyl-ACP 7 and the PKS complex may be tightly associated, and therefore the 
probe 66 may not be able to interfere in this complex at early time points.  At later 
time points, 60 seconds onwards, there would be less malonyl-ACP 7 (see Chapter 
5.1.2), which could result in the PKS complex becoming more susceptible to 
interference from the probe 66.  These experiments require further verifications to 
draw definitive conclusions. 
 
4.1.3. Analysis by UV-Vis spectroscopy 
The ability to demonstrate the effect of the active probe 66 on the production of 
SEK4/4b 41/42 in real time is desirable.  A method published by Beltran-Alvarez et 
al.
13
 used UV spectroscopy to measure the production of SEK4/4b 41/42.  They 
found that the shunt products have a characteristic wavelength of 293 nm that can be 
monitored to detect their production in real time.  Our goal was to detect an effect of 
the addition of the active probe 66 on the production of SEK4/4b 41/42.   
The minimal system was activated with the addition of holo-ACP 43 and then 293 
nm was recorded from 1 to 90 minutes.  It was not possible to record absorbance 
from 0 minutes due to the UV/vis spectrophotometer basic operational settings.  
Differences between the experiments and control samples (Figure 29) indicated that 
it was possible to detect SEK4/4b 41/42 production by this method.  
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Figure 29  SEK4/4b 41/42 production in the actinorhodin minimal system monitored by 
absorbance at 293 nm.  The dashed line represents the average of three identical repeats.  
The control does not contain malonyl-CoA 15 and, therefore, no SEK4/4b 41/42 can be 
produced in that assay. 
 
The active probe 66 was generated as before, after 4 hours of irradiation, and then 
added 30 seconds after holo-ACP 43.  Attempts were made to record absorbance 
variations from 1 minute to 90 minutes, however the irradiated probe 65 absorbed 
very strongly at 293 nm, saturating the detector and effectively precluding the use of 
this method to monitor the biocatalysis. 
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4.2. In vivo trapping of intermediates from the actinorhodin 2 biosynthetic 
pathway in Streptomyces coelicolor with the nonhydrolysable 
photolabile NAC probe 65 
The actinorhodin 2 biosynthetic pathway is a model system for type II polyketide 
synthases (PKSs).  Actinorhodin 2 was first isolated from Streptomyces coelicolor in 
the 1950s
67, 68
 and has been studied extensively ever since.
77, 207, 208
 
S. coelicolor M510
287
 strain was used for feeding experiments with the protected 
probe 65.  M510 is a ∆redD mutant which is an activator gene of Red 
(undecylprodigiosin) synthesis.
287, 288
  Other than actinorhodin 2, Red is produced in 
significant quantities in S. coelicolor.  Utilising a strain that does not produce Red 
for in vivo feeding experiments allows a cleaner background for off-loading 
biosynthetic intermediates from actinorhodin 2.  CDA (calcium-dependent 
antibiotic) is still produced by the S. coelicolor M510 strain.
289
  
Solid media was used for the bacterium growth, as liquid culture growth appeared 
inconsistent.  A variety of different solid media, GYM, R5, SFM and R4, were 
compared for their reproducibility and the amounts of produced actinorhodin 2 
determined by the colour of the media.  R4 media proved to be superior to the other 
media types for growing S. coelicolor and for the expression of actinorhodin 2 
reliably.
290-292
  
R4 media was supplemented with 1 mM protected probe 65 and S. coelicolor was 
grown for five days, followed by plate extraction with EtOAc.  SEK4/4b 41/42 
proved too hydrophilic to be extracted from the aqueous layer with EtOAc alone, 
therefore, the media had to be adjusted to approximately pH 4 immediately prior to 
extraction with EtOAc.  Preliminary experiments were carried out with media 
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supplemented with, 0, 1 mM, 5 mM and 10 mM of protected probe 65 to find the 
maximum amount of 65 that S. coelicolor could tolerate.  There was very minimal 
growth after 5 days with 5 mM and no growth at all in 10 mM of 65, the plate with 
just 1 mM of 65 grew well, and the distinctive blue of actinorhodin 2 could be seen 
(Figure 30).  Therefore, all further experiments were carried out at a concentration 
of 1 mM 65, which was comparable to the cultures grown without 65.   
 
Figure 30  S. coelicolor M510 after 5 days growth supplemented with 1 mM, 5 mM and 10 
mM nonhydrolysable photolabile NAC probe 65 showing growth inhibition with increasing 
concentration.  Actinorhodin 2 has a strong blue colour, which can be seen in the plate 
grown with just 1 mM probe 65. 
 
The extent of deprotection of the DMNB probe 65 by S. coelicolor was monitored by 
extractions on each day of growth.  The protected probe 65 proved quite stable 
during the first two days, possibly due to the low cell density.  After three days of 
growth, however, extensive deprotection was observed and this did not increase 
much further across days 4 to 5 (Figure 31).  
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Figure 31  EIC from LC-MS analyses of the DMNB NAC analogue 65 showing its 
hydrolysis and subsequent decarboxylation to 129 after ethyl acetate extraction at the end of 
(A) day 2, (B) day 3, (C) day 4 and (D) day 5 of growth on solid media in the presence of S. 
coelicolor M510.  Hydrolysis of 65 begins on day 3. 
 
The production of SEK4/4b 41/42 was monitored by MS daily to evaluate the impact 
of the DMNB probe 65, whereas the presence of actinorhodin 2 itself was visually 
followed by the culture’s blue-colour increase.  In the absence of the protected probe 
65 SEK4 41 and 4b 42 appeared after four days, whereas in the presence of 65 they 
appeared in substantial amount after 3 days, remaining unaffected afterwards.  
Overall, more SEK4/4b 41/42 was produced in the absence of the probe 65 (Figure 
32): this indicates that the probe 65 likely interferes in SEK4/4b 41/42 polyketide 
assembly.  
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Figure 32  EIC from LC-MS analyses of shunt products of the actinorhodin minimal system, 
SEK4/4b 41/42, (shown underneath) produced by S. coelicolor M510 in the presence of 
DMNB NAC analogue 65 extracted on (A) day 2, (B) day 3, (C) day 4, (D) day 5 and 
absence of DMNB NAC analogue 65 extracted on (E) day 2, (F) day 3, (G) day 4 and (H) 
day 5.  Note the increase of the intensity scale in (H).  
 
4.2.1. Photolysis experiments 
Based on the previously tested deprotection of the DMNB probe 65 in S. coelicolor 
(Figure 31), irradiation experiments were carried out on days 3 and 4 of growth.  
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The plates were exposed to irradiation for one, two, and three hours in the home built 
UVA light box, on either day three or four, and afterwards left to grow until day 5 as 
usual.  In all irradiation experiments, very minimal quantities of protected probe 65 
remained in comparison with the amount present in control experiments not 
subjected to UVA exposure (Figure 33).  
 
Figure 33  EIC from LC-MS analyses of the DMNB NAC analogue 65 showing its 
hydrolysis and subsequent decarboxylation to 129 after ethyl acetate extraction on day 5 of 
growth on solid media in the presence of S. coelicolor M510 with (A) no irradiation, (B) 1 
hour, (C) 2 hours, (D) 3 hours of irradiation on day 3 and (E) 1 hour, (F) 2 hours, (G) 3 
hours of irradiation on day 4.   
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The biosynthesis of SEK4/4b 41/42 was negatively affected by UVA exposure in the 
presence and in the absence of the probe 65 (Figure 34).   
 
Figure 34  EIC from LC-MS analyses of shunt products of the actinorhodin minimal system, 
SEK4/4b 41/42, (shown underneath) produced by S. coelicolor M510 in the presence (A-G) 
and absence (H-N) of DMNB NAC analogue 65, extracted on day 5, following (A and H) no 
irradiation, (B and I) 1 hour, (C and J) 2 hours, (D and K) 3 hours of irradiation on day 3, 
and (E and L) 1 hour, (F and M) 2 hours, and (G and N) 3 hours of irradiation on day 4.  
Note: Samples A, H and I retention times vary due to analysis performed at an earlier date. 
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Nonetheless potential trapped intermediates deriving from SEK4 41 and SEK4b 42 
were searched for, such as an off-loaded triketide 141, tetraketide, etc. (Figure 35).  
Unfortunately, none of them were detected.  This could be due to the need for an 
alternative extraction protocol, or simply indicate that these probes are yet not 
optimal for intermediate capture in this system.   
 
Figure 35 A sample of potential intermediates off-loaded from the actinorhodin 2 
biosynthetic pathway by the DMNB NAC analogue 65.  Examples are a potential off-loaded 
diketide 140, triketide 141, pentaketide 142, and heptaketide 143. 
 
Recently the Tosin group have shown that increasing the bioavailability of chain 
termination probes (e.g. by increasing the hydrophobicity of the N-acyl chain) led to 
a substantial improvement in both the range and titre of off-loaded intermediates 
from lasalocid A 1 synthase in  S. lasaliensis
156
 and from 6-methylsalacylic acid 50 
synthase in vitro
293
.  It would therefore be useful in the near future to test newly 
prepared N-decanoyl probes bearing the DMNB photolabile group on both S. 
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coelicolor producing actinorhodin 2 in vivo and on the type II act minimal PKS in 
vitro.   
 
4.3. In vivo trapping of intermediates from the lasalocid 1 biosynthetic 
pathway in Streptomyces lasaliensis with the nonhydrolysable 
photolabile NAC probe 65 
Previously, NAC analogues (Figure 12) have been successfully used to probe the 
lasalocid A 1
22, 155
 pathway in vivo, resulting in a variety of complex off-loaded 
intermediates.  The malonate protecting group has, thus far, only been reported with 
methyl ester protection.  The efficiency of the DMNB photolabile group protection 
was directly compared with the ability of other NAC analogues to off-load 
intermediates from the lasalocid 1 biosynthetic pathway. 
Streptomyces lasaliensis is a producer of the polyether antibiotic, lasalocid A 1.  This 
compound is synthesised via a type I modular polyketide synthase (PKS).  A mutant 
strain (“ACP12 (S970A)”) of S. lasaliensis has been constructed previously,22 this 
contains a point mutation of the active site serine of the last acyl carrier protein to an 
alanine residue.  The strain does not yield the final product, lasalocid A 1, but results 
in intermediates remaining bound to the PKS.  Previously in the Tosin group, 
derivatised chemical probes bearing methyl ester protection of the malonyl group 
130, have been shown to successfully off-load intermediates from the lasalocid A 1 
PKS by feeding experiments with this ACP12 mutant strain.
155
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Scheme 25  A) In vivo generation of the active probe 66 from the methyl ester protected 
probe 130.
155
 B) In vivo generation of the active probe 66, via endogenous esterases, or 
photolysis, from the 4,5-Dimethoxy-2-Nitrobenzyl (DMNB) protected probe 65. 
 
Chemical protection of the malonyl group is essential to allow the probe to enter the 
cell, the malonyl group is too hydrophilic to pass through the cell membrane, and 
therefore activation of the probe must occur within the cell.  The methyl ester 
protection of the malonyl group, shown previously
155
, relies upon endogenous 
esterases present within the cell to hydrolyse the compound to provide the ‘active’ 
probe.  It was hypothesised that the ability to ‘trap’ intermediates from biosynthetic 
pathways could be improved upon if the activation of the probe was controlled 
(Scheme 25).  Thus, as described previously, the analogue, 65, with photolabile 
protection of the malonyl group was synthesised, with the view to be able to activate 
the probe at the optimal time in the growth of the culture, as this bulky ester linkage 
is less likely to be accepted by endogenous esterases.   
Initially, the DMNB NAC analogue 65 was fed to the S. lasaliensis ACP12 mutant 
strain without additional UV irradiation.  Cultures grown on solid and liquid media 
were supplemented with probe 65 and the amount of hydrolysis, and ‘trapped’ 
intermediates, were compared.  Additionally, cultures were supplied with probe 65 
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either daily, or once at the beginning of the incubation, each up to the same final 
concentration of 2.5 mM, based upon previous successful results in the Tosin 
group.
155
   
 
Figure 36  EIC from LC-MS analyses of the DMNB NAC analogue 65 hydrolysing and 
subsequent decarboxylating to 129 after ethyl acetate extraction of the media in the presence 
(A to D) and in the absence (E) of S. lasaliensis ACP12, with a comparison of the different 
supplementation strategies.  A) Ethyl acetate extraction of S. lasaliensis ACP12 grown on 
solid media (A) or liquid media (B to D) containing 2.5 mM substrate 65 from day one (A 
and B) or supplemented daily (C to E).  D contained deuterated substrate 65b.  NB. Small 
amounts of hydrolysed and decarboxylated probe 129 were detected in C, D and E.  
 
Figure 36 shows the significant hydrolysis in solid media, and also in liquid media, 
when all of the substrate 65 is fed on day one of growth.  However, the yield of the 
hydrolysed and decarboxylated product 129 from supplementing daily, up to a 
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concentration of 2.5 mM, in the presence and in the absence of S. lasaliensis ACP12 
is comparable, with the majority of probe 65 remaining after five days of incubation.  
 
Scheme 26 Lasalocid A 1 biosynthetic pathway from S. lasaliensis showing previously 
‘trapped’ intermediates generated by the incubation with NAC analogues.  Intermediates 
131 and 132 also detected by the photolabile probe 65 are shown.  
 
Extracted ion chromatograms were generated for expected biosynthetic intermediates 
from the lasalocid A 1 pathway (Scheme 26).  Two of those polyketide intermediates 
were detected in the ethyl acetate extracts of the cultures fed with probe 65 to the S. 
lasaliensis ACP12 deletion mutant.  The first intermediate 131 was off-loaded from 
the sixth module, LasAVI, prior to the extension with ACP11 and subsequent 
epoxidation (Figure 37).  Both the protonated and sodiated ions were detected, as 
well as the incorporation of deuterium labelling with the respective probe 65b, and 
these peaks were absent in control experiments.  This intermediate 131 has 
undergone further reduction by the KR of the next module, likely once it has been 
off-loaded.   
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Figure 37  EIC from LC-MS analyses of the extracts from feeding experiments with the 
DMNB NAC analogue 65 to S. lasaliensis ACP12 mutant.  Traces shown are the protonated 
and sodiated ions of compound 131, a ‘trapped’ intermediate from lasalocid A 1 
biosynthetic pathway, off-loaded from ACP10 and further reduced by KR11.  A-B) S. 
lasaliensis ACP12 grown in (A) solid media and (B) liquid media supplemented with 
substrate 65 to a concentration of 2.5 mM.  C-D) S. lasaliensis ACP12 grown in liquid 
media supplemented daily with (C) substrate 65 and (D) deuterated substrate 65b up to a 
final concentration of 2.5 mM. 
 
A second, more prominent, intermediate 132 was off-loaded from the seventh 
module, LasAVII, prior to the final extension with ACP12 and release from the PKS 
(Figure 38).  As mentioned previously, this mutant does not bear an active ACP12, 
thus, it is to be expected that this intermediate 132 would accumulate and increase 
the chances for off-loading by the NAC analogue.  This ‘trapped’ intermediate is 
detected as two peaks, but both having the same MS fragmentation pattern,
155
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therefore it has been hypothesised that this is due to conformational isomerism.  
NMR spectroscopy will be used to characterise the isomers, however, the low yield 
of ‘trapped’ intermediates does not facilitate NMR analysis at this stage.  
 
Figure 38  EIC from LC-MS analyses of the extracts from feeding experiments with the 
DMNB NAC analogue 65 to S. lasaliensis ACP12 mutant.  Trace shown is compound 132, a 
‘trapped’ intermediate from lasalocid A 1 biosynthetic pathway, offloaded from ACP11.  A-
B) S. lasaliensis ACP12 grown in (A) solid media and (B) liquid media supplemented with 
substrate 65 to a concentration of 2.5 mM.  C-D) S. lasaliensis ACP12 grown in liquid 
media supplemented daily with (C) substrate 65 and (D) deuterated substrate 65b up to a 
final concentration of 2.5 mM.  
 
132 
 
The yields of 132 were compared from experiments in solid and liquid media, and 
also from supplementing the media with the probe 65 on day one or stepwise on days 
two to five (Figure 37 and Figure 38).  For compound 131, the yield was 
considerably lower than that of intermediate 132 offloaded from ACP11, but the 
amount was also comparable for all experiments, both in solid and liquid media, and 
regardless of the method of feeding (Figure 37).  However, for compound 132, the 
yields varied by at least one order of magnitude from solid to liquid cultures, and 
also more than doubling from supplementing the media with probe 65 on day one, to 
stepwise feeding.  This result agreed with previous research from the Tosin group 
with different probe analogues.
155
 
It was initially thought that that the probe 65 might not be a suitable substrate for 
esterases within the cell due to the unnatural nature of the DMNB group.  However, 
the results showed that there must be a small amount of hydrolysis occurring to 
release the active probe 66 (Figure 36).  The stability of the malonyl group of the 
active probe 66 in vivo has not been investigated, although the active probe 66 
generated in vivo has not been detected in any of the feeding experiments.  
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Figure 39  EIC from LC-MS analyses of the extracts from feeding experiments with the 
DMNB NAC analogue 65 to S. lasaliensis ACP12 mutant.  Trace shown is the doubly 
charged ion of echinomycin 52, a natural product produced by a non-ribosomal peptide 
synthetase (NRPS) in S. lasaliensis.  A-C) Supplemented on day one (A-C) or daily (D-F) 
with substrate 65 to a final concentration of 2.5 mM and G-I) without supplementation.  (A, 
D and G) without irradiation, (B, E and H) with 1 hour or (C, F and I) with 2 hours of 
irradiation on days 2 to 5.  
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Following on from the success of the experiments without irradiation of the probe 
65, in vivo photolysis experiments were carried out within the home built light box, 
which is capable of being fixed to the base of an Eppendorf Innova incubator shaker.  
Preliminary experiments, reported in chapter 2, showed complete photolysis of the 
protected probe 65 within 4 hours (Table 3).  To minimise disruption on cell growth, 
just one and two hours a day of irradiation were applied to the cultures between days 
two to five.  Liquid cultures had provided the greatest amount of trapped 
intermediates thus far, therefore liquid media was utilised for the photolysis 
experiments.  Control cultures were grown to ensure that irradiation would not alter 
growth.  The production of echinomycin 52
286
, also known as quinomycin A, a 
natural product produced by a non-ribosomal peptide synthetase (NRPS) in S. 
lasaliensis, was monitored by LC-MS (Figure 39).  
The production of echinomycin 52 is largely unaffected by irradiation, its detection 
remained within the same order of magnitude for each experiment (Figure 39).  The 
combination of feeding the probe 65 on day one and two hours of daily irradiation 
during days 2-5 led to a decreased production of echinomycin 52 by an order of 
magnitude, although cell growth did not visually appear to be affected by irradiation 
alone.  
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Figure 40  EIC from LC-MS analyses of the DMNB NAC analogue 65 showing its 
hydrolysis and subsequent decarboxylation to 129 after ethyl acetate extraction of liquid 
media in the presence of S. lasaliensis ACP12.  A-C) Supplemented on day one (A-C) or 
daily (D-F) with substrate 65 to a final concentration of 2.5 mM, (A and D) without 
irradiation, (B and E) with 1 hour or (C and F) with 2 hours of irradiation on days 2 to 5.  
Retention times vary slightly due to when LC-MS was performed.  
 
The ratio of protected probe 65 to decarboxylated probe 129 after five days 
incubation in S. lasaliensis does depend upon both the feeding and the irradiation 
conditions (Figure 40).  Daily supplementation without any irradiation results in the 
greatest amount of protected probe 65 remaining intact after five days.  Both 
supplementation conditions were affected similarly by irradiation, with a decrease in 
amount of protected probe 65 (Figure 40).  Hence, it was not possible to establish 
the effective irradiation contribution to the deprotection process.      
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The same two putative intermediates 131 and 132 off-loaded from feeding 
experiments without irradiation were also off-loaded upon UV irradiation.  However 
both the yields of intermediates 131 and 132 increased following one hour of daily 
irradiation when the protected probe 65 was supplied daily (Figure 41 and Figure 
42); oppositely, irradiation did not improve the titer of the trapped species when the 
protected probe 65 supplied exclusively on the first day of growth.   
 
Figure 41  EIC from LC-MS analyses of the extracts from feeding experiments with the 
DMNB NAC analogue 65 to S. lasaliensis ACP12 mutant in liquid media.  Trace shown is 
compound 131, a ‘trapped’ intermediate from lasalocid A 1 biosynthetic pathway, off-loaded 
from ACP10 and further reduced by KR11.  A-C) Supplemented on day one (A-C) or daily 
(D-F) with substrate 65 to a final concentration of 2.5 mM, (A and D) without irradiation, 
(B and E) with 1 hour or (C and F) with 2 hours of irradiation on days 2 to 5. 
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The putative undecaketide intermediate 132 from ACP11 (Figure 42) titre increased 
approximately six-fold with one hour of daily irradiation compared to without 
irradiation.  When each irradiation event was increased to two hours a day, however, 
the yield decreased back to similar levels as without any irradiation.  It is possible 
that exposure to UV light for that length of time was damaging to the cell and 
resources are drawn away from PKS secondary biosynthesis.  The same response 
was observed with off-loaded intermediate 131 from ACP10.  
Two additional putative intermediates from the lasalocid A 1 biosynthetic pathway 
were observed upon cell feeding with the DMNB probe 65 and its UV activation.  
One species, allegedly off-loaded from ACP8 as 133, was detected and, from its MS 
fragmentation pattern
155
, it appears to have undergone epoxidation and cyclisation 
with dehydration to provide 135 (Figure 43).  An additional intermediate, 136, is 
likely the product of an oxidation of the same off-loaded intermediate 133, providing 
a compound that is 2 Da less than 135 (Figure 44); the ratio 135 to 136 was 
approximately 3:4.  
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Figure 42  EIC from LC-MS analyses of the extracts from feeding experiments with the 
DMNB NAC analogue 65 to S. lasaliensis ACP12 mutant in liquid media.  Trace shown is 
compound 132, a ‘trapped’ intermediate from lasalocid A 1 biosynthetic pathway, off-loaded 
from ACP11.  A-C) Supplemented on day one (A-C) or daily (D-F) with substrate 65 to a 
final concentration of 2.5 mM, (A and D) without irradiation, (B and E) with 1 hour or (C 
and F) with 2 hours of irradiation on days 2 to 5. 
 
The proposed pathway to intermediates 135 and 136 can be seen in Scheme 27.  The 
point of oxidation in the structure of 136 is approximated from the lack of MS 
fragment 138 in the MS/MS of the oxidised species 136 (Figure 44).   
Both one and two hour long daily irradiation events, when the media is 
supplemented daily with probe 65, improves the yield of both the reduced and the 
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unreduced intermediates 135 and 136 (Figure 43 and Figure 44).  As with more 
advanced off-loaded intermediates 131 and 132, for both cases, just one hour a day 
of irradiation is superior for off-loading these intermediates 131 and 132 than two 
hours a day.  In the case of species 135 and 136, a marginal improvement is seen in 
the samples that were supplemented on day one with probe 65 from no irradiation to 
one hour a day of irradiation.  Daily supplementation remained overall superior to 
feeding all of the protected probe 65 on day one for trapping intermediates 135 and 
136.  
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Figure 43  EIC from LC-MS and MS/MS analyses of the extracts from feeding experiments 
with the DMNB NAC analogue 65 to S. lasaliensis ACP12 mutant in liquid media.  Trace 
shown and MS/MS is compound 135, a ‘trapped’ intermediate from lasalocid A 1 
biosynthetic pathway, off-loaded from ACP8 with subsequent epoxidation and cyclisation.  
A-C) Supplemented on day one (A-C) or daily (D-F) with substrate 65 to a final 
concentration of 2.5 mM, (A and D) without irradiation, (B and E) with 1 hour or (C and F) 
with 2 hours of irradiation on days 2 to 5. 
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Figure 44  EIC from LC-MS and MS/MS analyses of the extracts from feeding experiments 
with the DMNB NAC analogue 65 to S. lasaliensis ACP12 mutant in liquid media.  Trace 
shown and MS/MS is compound 136, a ‘trapped’ intermediate from lasalocid A 1 
biosynthetic pathway, off-loaded from ACP8, with subsequent epoxidation, cyclisation and 
oxidation.  A-C) Supplemented on day one (A-C) or daily (D-F) with substrate 65 to a final 
concentration of 2.5 mM, (A and D) without irradiation, (B and E) with 1 hour or (C and F) 
with 2 hours of irradiation on days 2 to 5.  
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Scheme 27  Lasalocid A 1 biosynthetic pathway from S. lasaliensis showing newly putative 
‘trapped’ intermediates 135 and 136 generated by the incubation with DMNB NAC 
analogue 65 in an ACP12 deletion mutant following UV irradiation.  Compounds in grey 
133 and 134 were not detected. 
 
Unfortunately, trapped intermediates 135 and 136 were not detected with deuterium 
labelling in cultures fed with labelled ester probe 65b.  Time did not allow further 
repeats of these experiments, however MS fragmentation of the sodiated species 135 
and 136 showed common fragment ions (Figure 43 and Figure 44) strongly 
indicative of polyether ring formation.
155
  If these results are confirmed, the 
oxidative steps taking place through lasalocid A 1 polyketide chain assembly to 
generate the polyether rings would take place earlier than previously hypothesised. 
Irradiation with UV light produces significantly more active probe 66 than in its 
absence, as can be seen by more decarboxylated final product 129 present in the cell 
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extract (Figure 40).  Additionally, irradiation events catalysed more trapping of 
intermediates 131 and 132 from ACP10 and ACP11 than without irradiation, as well 
as two more newly detected intermediates off-loaded from ACP8 (Scheme 27).  
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Chapter 5: Capture of polyketide 
intermediates with the aid of a 
nonhydrolysable malonyl acyl carrier 
protein analogue 
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5. Capture of polyketide intermediates with the aid of a nonhydrolysable 
malonyl acyl carrier protein analogue 63 
5.1. Photolysis of the carrier protein 63 
5.1.1. Rate of photolysis of the nonhydrolysable photoactivatable 
malonyl acyl carrier protein analogue 63 
As described previously, the newly devised acyl carrier protein (ACP) 63 bears a 
photolabile 4,5-dimethoxy-2-nitrobenzyl (DMNB) group for the protection of the 
malonyl-like moiety.  Section 0 reports the photolysis conditions established for the 
small molecule NAC probe 65.  These conditions were tested on the carrier protein 
63 and proved to be equally suitable for the uncaging of 63 to 64.   
After 4 hours of irradiation at 365 nm in TrisCl (50 mM), KCl (20 mM), MgCl2 (10 
mM) at pH 8 almost all the DMNB group had been removed, and, subsequently, the 
malonyl group decarboxylates to produce 144 (Figure 45).  Similar results were 
obtained by using both a KiloArc Broadband Arc lamp at 365 nm, and also with a 
home built light box equipped with a circular UVA lamp.  
MS protein analyses showed no sign of protein degradation throughout the 
photolysis.  Furthermore, holo act ACP 43 was subjected to the same irradiation 
conditions and its activity proved to be unaffected by it, generating the same amount 
of SEK4 41 and SEK4b 42 in reaction with KS-CLF (Section 4.1, Figure 25).  
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Figure 45  Irradiation of the photolabile acyl carrier protein (ACP) analogue 63 in TrisCl 
(50 mM), KCl (20 mM), MgCl2 (10 mM) at pH 8, with 365 nm, 1000 W for 0 (A), 2 (B), 
and 4 (C) hours, showing the synthesis of the decarboxylated product 144 by TOF-MS.  
After 4 hours, only a minor amount of ACP analogue 63 could be detected. 
 
5.1.2. Incubation of Ketosynthase-Chain Length Factor (KS-CLF) with 
malonyl and acetyl acyl carrier proteins (ACPs) and the protein 
probe 63  
The components of the actinorhodin minimal system, KS-CLF and the discrete act 
ACP, work together and iteratively process acetyl 17 and malonyl-CoA 15, 
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generating an octaketide product 31 which spontaneously cyclises to SEK4 41 and 
SEK4b 42 (Section 1.3.2 and Scheme 5).  
More specifically, malonyl-ACP 7 is decarboxylated by the KS-CLF and then the 
acetate unit, from the newly generated acetyl-ACP 40, is loaded onto the KS-CLF 
which initiates polyketide chain extension, as described before.  The ability of the 
KS and the CLF to catalyse the polyketide synthesis has been studied using 
mutations of the active site cysteine of the KS to alanine, and the glutamine of the 
CLF to alanine.
27
   
The conversion of malonyl-ACP 7 to acetyl-ACP 40, and then to holo-ACP 43 was 
monitored with each mutant and it was found that both the KS and the CLF were 
able to catalyse the decarboxylation, but, not surprisingly, the KS was crucial to the 
full synthesis of SEK4 41 and SEK4b 42.
27
   
 
5.1.2.1. Incubation of KS-CLF with malonyl-ACP 7 and acetyl-ACP 
40 
Acetyl-ACP 40 and malonyl-ACP 7 were separately incubated with and without KS-
CLF, in a 1:1 ratio to prevent chain extension steps, and then analysed by FTICR-
MS.  Conversion of acetyl-ACP 40 to holo-ACP 43 was observed as expected from 
the loading of the KS with an acetate unit (Figure 46).
27
  When malonyl-ACP 7 was 
incubated with KS-CLF a substantial difference was seen in comparison to without 
KS-CLF.  Without KS-CLF, malonyl-ACP 7 decarboxylated to acetyl-ACP 40 and a 
small amount of holo-ACP 43 was also detected.  However, when malonyl-ACP 7 
was incubated with KS-CLF, only a very small amount of 7 was detected: the 
majority of the ACP was detected as acetyl-ACP 40 and there was also an increase in 
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the amount of holo-ACP 43 present in comparison to incubation without KS-CLF 
(Figure 47).  
 
Figure 46  Comparison of the ratio of acetyl 40 to holo 43 (not hexahistidine-tagged) acyl 
carrier protein (ACP) from the actinorhodin minimal system following 2 hours of incubation 
(A) with and (B) without the actinorhodin ketosynthase-chain length factor (KS-CLF).  
Simulated isotope distributions for the 7
+
 charge state of (C) acetyl-ACP 40 and (D) holo-
ACP 43.  
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Figure 47  Comparison of the ratios of malonyl 7, acetyl 40 and holo 43 acyl carrier 
proteins (ACPs) from the actinorhodin minimal system following 2 hours of incubation (A) 
with and (B) without the actinorhodin 2 ketosynthase-chain length factor (KS-CLF).  
Simulated isotope distributions for the 7
+
 charge state of (C) acetyl-ACP 40, (D) holo-ACP 
43 and (E) malonyl-ACP 7.  
 
The incubated samples were monitored from 2 to 5 hours to determine if the malonyl 
group would further decarboxylate in the presence or absence of the KS-CLF, or if 
further holo-ACP 43 would be produced from acetyl-ACP 40.  There was no change 
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in relative abundances over the 5 hours, suggesting that all action by the KS-CLF is 
complete within the first two hours.  Samples were not analysed within the first two 
hours.  Surprisingly, there is no increase in decarboxylation of malonyl-ACP 7 after 
the initial two hours, it was expected that even in the absence of KS-CLF that 
decarboxylation of the malonyl group would occur within five hours at room 
temperature. 
 
5.1.2.2. The impact of KS-CLF on photolysis of the ACP analogue 
63 
The photolytic cleavage of the DMNB group of the ACP analogue 63 in the presence 
and in the absence of the KS-CLF was investigated.  In the absence of KS-CLF and 
after 4 hour irradiation, approximately 50% of carba(dethia) malonyl-ACP analogue 
64 was generated, with only a minor amount of decarboxylated carba(dethia) acetyl-
ACP 144 present (Figure 48).  In comparison, when DMNB ACP 63 was irradiated 
in the presence of the KS-CLF, only a very minimal amount of carba(dethia) acetyl-
ACP 144 could be detected (Figure 49).  By magnifying, it can be seen that no 
carba(dethia) malonyl-ACP 64 was present and that some decarboxylated product 
144 was generated (Figure 49).  Rapid decarboxylation of the malonyl group of 64 
to provide 144 would explain this result, and this agrees with previous observation of 
the behaviour of malonyl carba(dethia) derivatives (Figure 47).  Nonetheless these 
results show how the presence of KS-CLF unequivocally hampers photodeprotection 
of 63. This is interesting as it suggests a tight association of the ACP to the KS-CLF, 
with the modified PPant arm possibly ‘buried’ within the KS hosting tunnel.    
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Figure 48  FTICR-MS analyses showing the irradiation of the nonhydrolysable photolabile 
acyl carrier protein (ACP) analogue 63 with 365 nm, 1000 W, without the ketosynthase 
chain length factor (KS-CLF), analysed immediately after 0 (A), 2 (B), and 4 (C) hours, 
showing the synthesis of the deprotected malonyl product 64 and limited decarboxylated 
product 144.  (D) Simulated isotope patterns for the 7
+
 ions. 
 
A more direct comparison between the rates of decarboxylation of the carba(dethia) 
malonyl-ACP analogue 64 and its ‘natural’ malonyl-ACP counterpart 7 in the 
presence of the KS-CLF was made by performing similar experiments to those 
shown in Figure 47 using a readily uncaged sample of deprotected ACP analogue 
64.  
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Figure 49  FTICR-MS analyses showing the irradiation of the nonhydrolysable photolabile 
acyl carrier protein (ACP) analogue 63 with 365 nm, 1000 W, in the presence of the 
ketosynthase chain length factor (KS-CLF), analysed immediately after 0 (A), 2 (B), and 4 
(C) hours: limited deprotected malonyl product 64 and decarboxylated product 144.  (D) 
Simulated isotope patterns for the 7
+
 ions.  (A), (B) and (C) underneath are magnified to 
show the presence of carba(dethia) acetyl-ACP 144 and the absence of carba(dethia) 
malonyl-ACP 64 in the spectra. 
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Figure 50  FTICR-MS time-dependant analysis showing a readily uncaged sample of 
photolabile carrier protein 63, in the absence, (A and B) and in the presence (C and D), KS-
CLF: the uncaged probe 64 decarboxylates instantaneously to 144 in the presence of the 
KS-CLF.  (E) Simulated isotope patterns for the 7
+
 ions.  ‘0 hours’ incubation refers to 
samples analysed immediately after the addition of KS-CLF. 
 
Carba(dethia) DMNB protected malonyl-ACP 63 was irradiated for 4 hours and then 
incubated either in the presence or in the absence of the KS-CLF for a further 4 
hours (Figure 50).  Samples were analysed hourly from 0 to 4 hours.  Samples at ‘0 
hours’ were infused into the FTICR mass spectrometer immediately after the 
addition of the KS-CLF.  As previously observed with the ‘natural’ malonyl-ACP 7, 
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carba(dethia) malonyl-ACP 64 is remarkably stable alone in buffer at pH 8 and at 
room temperature for 4 hours, whereas immediately upon the addition of KS-CLF it 
decarboxylates to produce carba(dethia) acetyl-ACP 144 (Figure 50).  
From observing that the photolysis of the DMNB group for 63 was hampered by the 
presence of KS-CLF, it was envisaged that the ‘active’ probe 64 had to be prepared 
separately by photolysis prior to its use with the minimal system enzymes.  The 
malonyl groups of both ‘natural’ and carba(dethia) malonyl-ACPs 7 and 64 are 
stable in the absence of KS-CLF up to approximately 4 hours at room temperature.  
This facilitates in vitro experiments with readily irradiated 63.  The rates of 
decarboxylation of the ‘natural’ malonyl-ACP 7 and the carba(dethia) malonyl-ACP 
64 do not appear to be that different, both in the presence and the absence of the KS-
CLF. 
 
5.2. In vitro trapping of intermediates from the actinorhodin minimal system 
with the nonhydrolysable photoactivatable malonyl acyl carrier protein 
analogue 63 
5.2.1. Experimental set up 
Each of the enzymes that reconstitute the act minimal system were expressed and 
purified with hexahistidine tags (His-tag) for purification by Ni-NTA-affinity 
chromatography.  The act ACP used to prepare the protein probe 63 was the only 
enzyme for which the His-tag was removed by thrombin, a protease selective for the 
short amino acid sequence linking the His-tag to the act ACP sequence.  This 
allowed the removal of all the proteins of the act minimal system by affinity 
chromatography, leaving the probe 63 and any other 63-derived species readily 
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isolated for analysis by FTICR-MS (Scheme 28).  Specific details of this 
experimental set up are provided in chapter 7.3. 
 
Scheme 28 Investigation of the actinorhodin minimal type II polyketide synthase by means 
of a protein probe 63.  Purification of enzymatic assays by Ni-NTA affinity chromatography 
allowed the protein probe 63 and any other derived species to be isolated in the flow 
through.  A hexahistidine tag is indicated by a red star. 
 
5.2.2. Analysis of chain termination assays with protein probe 63 by 
FTICR-MS 
The DMNB protected carba(dethia) ACP analogue 63 was irradiated for 4 hours 
prior to addition to the actinorhodin minimal system.  Malonyl-ACP 7 was either 
generated from apo-ACP 44 with a phosphopantetheinyl transferase, Sfp
99
, or from 
self-malonylation
19
 of holo-ACP 43 (kind gift of Dr John Crosby, Bristol). 
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To begin with, a ratio of 1:1 irradiated DMNB protected malonyl-ACP 63 to 
malonyl-ACP 7 was used for trapping experiments.  As discussed in Section 5.2.1, 
the protein probe 63 was not His-tagged, whereas the malonyl-ACP 7 and KS-CLF 
retained the His-tag for selective purification of the protein probe 63 and derived 
species by Ni-NTA affinity chromatography (Scheme 28). 
It was observed that each repeated experiment did not consistently generate identical 
results.  For example, only a few of the multiple repeats of the 1:1 ratio experiment 
led to the observation of putative intermediates from the minimal system (Table 6).  
This was not completely unexpected considering the variability of enzymatic activity 
within sample preparation, the lack of tight control over the timing of enzyme 
addition, and other experimental variables, coupled with the genuine challenge of 
analysing a highly heterogeneous sample by direct infusion MS.   
It has been previously shown that the ratio of probe to malonyl substrate can be 
crucial for PKS intermediate trapping in vitro.
11, 153
   Different ratios (10:1, 5:1, 1:1, 
1:5 and 1:10) of probe 63 to malonyl-ACP 7 were therefore trialled with both 
13
C 
labelled and unlabelled malonyl-ACP 7b.  The results of these experiments are 
reported in Table 6.  ACP probe 63 to malonyl-ACP 7 ratio of 5:1 and 1:10 proved 
to be the best conditions in which a range of putative intermediates were successfully 
captured (Table 6).  In lieu of MS
2
 data, these intermediates are putatively assigned 
based on accurate mass and isotope distribution.  
An additional set of experiments were carried out in a ‘step-wise’ or ‘reversed’ 
manner, whereby the minimal system enzymes (KS-CLF and malonyl-ACP 7) were 
added hourly during irradiation of the DMNB protected ACP probe 63, resulting in a 
ratio of 1:4 ACP probe 63 to malonyl-ACP 7.  These experiments led to the ACP 
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capture of a diketide 145 and a hexaketide 149 species, together with dehydrated and 
doubly dehydrated hexaketides 156 and 157, and of a 
13
C labelled pentaketide 148 in 
the corresponding labelled assay.  The MS analyses of these captured intermediates 
will be presented in the following sections.  
 (with unlabelled malonyl-ACP 7) 
(with 
13
C labelled 
malonyl-ACP 7b) 
(probe 63:malonyl-ACP 7) 1:1 
1:4 
(step-
wise) 
5:1 
1:1 
30s 
delay 
1:1 
5m 
delay 
1:1 1:10 5:1 
1:4 
(step-
wise) 
Diketide 145 
         
Triketide 146 
         
Tetraketide 147 
         
Pentaketide 148 
         
Hexaketide 149 
         
Heptaketide 150 
         
Octaketide 151 
         
Dehydro tetraketide 152 
         
Didehydro tetraketide 153 
         
Dehydro pentaketide 154 
         
Didehydro pentaketide 155 
         
Dehydro hexaketide 156 
         
Didehydro hexaketide 157 
         
Dehydro heptaketide 158 
         
Didehydro heptaketide 159 
         
Dehydro octaketide 160 
         
Didehydro octaketide 161 
         
Tridehydro octaketide 162 
         
Table 6  Intermediates from the actinorhodin minimal system trapped by the carba(dethia) 
malonyl-ACP probe 64 were detected by FTICR-MS direct injection.  Each column shows a 
separate experiment conducted with the respective ratio of probe 63 to malonyl-ACP 7.  
Blue in-fill represents an unlabelled trapped intermediate detected and red in-fill represents 
a 
13
C labelled trapped intermediate detected.  “Step-wise” indicates the reverse and gradual 
addition of the actinorhodin minimal system enzymes to an irradiated sample of the DMNB 
protected protein probe 63.  “30s delay” and “5 m delay” refer to the time delay upon 
addition of ‘active’ probe 64 to the actinorhodin minimal system. (See Appendices 1-68) 
 
The MS samples were very complex and variable, however the major ions observed 
in each spectrum were typically decarboxylated protein probe 144 and, in much less 
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intensity, the DMNB protected probe 63.  These species allowed accurate internal 
calibration of each spectrum, achieving sub ppm error on the majority of assigned 
peaks. 
With the complexity of the samples, control assays proved crucial for peak 
assignment.  These included the DMNB protected probe 63 without the presence of 
the act minimal system enzymes, the irradiated probe 64 without the minimal system 
enzymes and the DMNB protected probe 63 with the enzymes of the minimal 
system.  Each control assay was compared with the trapping assays for confirmation 
of the presence of novel isotopic distributions (See Appendices 51-58). 
 
5.2.2.1. Detection of a putative captured diketide intermediate 145 
A putative trapped diketide intermediate 145 was detected in a 1:1 ACP probe 63 to 
malonyl-ACP 7 standard experiments as well as 1:4 step-wise addition assays.  In 
both cases the isotopic distribution of 145 very closely overlaps with another 
unknown distribution (Figure 51).  Unfortunately, when the peaks merge, this 
increases the error on those peaks; for example, the A+3 peak shown in Figure 51 
presents a much higher error of 3.22 ppm than the subsequent peaks.  Discounting 
the A+3 peak reduces the average error to -0.60 ppm.  Unfortunately, there was no 
detectable labelled diketide found in any of the labelled assays.  Additionally, due to 
both the low intensity and the overlapping distributions, it is not possible to compare 
the ion abundance in the simulated isotopic distributions to that of the collected 
spectra.   
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Figure 51 FTICR-MS analysis of active acyl carrier protein (ACP) probe 64 incubated in 
the actinorhodin minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7) 
showing an off-loaded diketide 145.  (A) Acquired spectrum, (C) acquired spectrum 
magnified, (B) and (D) are simulated mass spectra (8
+
) of 145.  Underneath displays the 
peak list and errors for each.  
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5.2.2.2. Detection of a putative captured tetraketide intermediate 147 
On two accounts a labelled putative trapped tetraketide 147 was detected.  
Unfortunately, the respective unlabelled tetraketide intermediate 147 was not 
detected in any of the assays.  The intermediate 147 was detected in experiments at 
1:1, ACP probe 63 to malonyl-ACP 7, and in greater abundance at a ratio of 1:10 
(Figure 52).  Additionally, in the 1:10 assay the adduction of sodium to the 
tetraketide intermediate 147 can be seen in the spectra. 
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Figure 52  FTICR-MS analysis of active acyl carrier protein (ACP) probe 64 incubated in 
the actinorhodin minimal system (1:10 ratio, protected ACP probe 63 to labelled malonyl-
ACP 7b) showing an off-loaded labelled tetraketide 147.  (A) Acquired spectrum, (C) 
acquired spectrum magnified, (B) and (D) are simulated mass spectra (8
+
) of 147.  
Underneath displays the peak list and errors for each.  
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5.2.2.3. Detection of a putative captured pentaketide intermediate 
148 and dehydrated/cyclised pentaketides 154 and 155 
A putative pentaketide intermediate 148 was detected in a labelled 1:4 probe 63 to 
malonyl-ACP 7 added step-wise experiment.  Its intensity was very low and it 
appears to present another isotopic distribution within a similar m/z window which 
distorts the distribution (Figure 53).  A putative cyclised pentaketide 154 was 
detected in a 5:1 ACP probe 63 to malonyl-ACP 7 assay, in much greater abundance 
than 148 (Figure 54).   
 
Scheme 29  Capture of putative pentaketide intermediates from the actinorhodin minimal 
system: predicted linear intermediate 148 can undergo cyclisation and dehydration to 
produce 154 and 155.  
 
The low abundance of 148 is not surprising as, from a chemical perspective, 
polyketones longer than triketides do not exist in the commonly represented linear 
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form, but spontaneously undergo keto-enol tautomerisation and cyclisation.  
Nonetheless the fact that it has been detected in an uncyclised form suggests that this 
polyketone intermediate 148 is sequestered and stabilised within the ACP.
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Beside the putative uncyclised 148, a putative dehydrated cyclised pentaketide 154 
and of a further dehydrated species 155 were identified.  Their proposed structures 
are shown in Scheme 29 and have been inferred on the basis of the folding of the 
natural octaketide chain leading to dehydro SEK4 163 and dehydro SEK4b 164.
295
  
The presence of these species is reasonable on chemical grounds and consistent with 
the limited detection of the linear pentaketide 148. 
Pentaketide dehydration/cyclisation could take place either within the PKS, or 
following its capture by the ACP probe 64 if the pentaketide chain becomes exposed 
to the solvent.  However, without further characterisation of 154 and 155, the exact 
location of the cyclisation is unknown.  Additionally, the dehydration could take 
place elsewhere on the protein rather than on the putative intermediate.  Due to low 
intensity signal as well as multiple overlapping isotopic distributions, the “PPant 
ejection assay” could not be successfully carried out, and the errors on some of the 
assigned peaks are not consistently as low as they could be (Figure 55). 
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Figure 53  FTICR-MS analysis of ACP probe 64 incubated in the actinorhodin minimal 
system (1:4 protected ACP probe 63 to labelled malonyl-ACP 7b), showing a putative 
captured labelled linear pentaketide 148.  (A) Acquired spectrum, (C) Acquired spectrum 
magnified, (B) and (D) are simulated mass spectra (7
+
) of 148.  Underneath displays the 
peak list and errors for each.  
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Figure 54  FTICR-MS analysis of the ACP probe 64 incubated in the actinorhodin minimal 
system (5:1 protected ACP probe 63 to malonyl-ACP 7) showing a captured putative 
cyclised pentaketide 154.  (A) Acquired spectrum, (C) acquired spectrum magnified, (B) and 
(D) are simulated mass spectra (7
+
) of 154.  Underneath displays the peak list and errors for 
each.  
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Figure 55  FTICR-MS analysis of the ACP probe 64 incubated in the actinorhodin minimal 
system (5:1 protected ACP probe 63 to labelled malonyl-ACP 7b), showing a captured 
putative cyclised dehydrated pentaketide 155.  (A) Acquired spectrum, (C) acquired 
spectrum magnified, (B) and (D) are simulated mass spectra (8
+
) of 155.  Underneath 
displays the peak list and errors for each.  
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5.2.2.4. Detection of a putative captured hexaketide intermediate 149 
and dehydrated species 156 and 157 
A hexaketide 149, and two likely cyclised 156 and dehydrated 157 captured species 
were detected on a few occasions (Scheme 30).  The putative uncyclised hexaketide 
intermediate 149 was only detected once across all samples and at a very low 
intensity (Figure 56).  This is likely due to the unstable nature of a polyketide chain 
which will spontaneously undergo cyclisation. 149 was only detected in the 1:4 step-
wise experiment described previously.  
 
Scheme 30  Capture of putative hexaketide intermediates from the actinorhodin minimal 
system: predicted linear intermediate 149 can undergo cyclisation and dehydration to 
produce 156 and 157. 
 
The intensity of the detected species 156 was low, additionally overlapping isotopic 
distributions negatively affected the error in some cases.  156 was detected in 1:4 
step-wise assays, and also in a 5:1 probe 63 to malonyl-ACP 7 experiment (Figure 
57).  
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The last hexaketide derived intermediate 157 is the result of a further dehydration of 
156 (Scheme 30).  Loss of water is quite recurrent within compounds of this nature, 
and, as mentioned previously, has been observed in the minimal system products.
295
  
The intensity of the detected species 157 is greater than for the other hexaketide and 
hexaketide derived species 149 and 156, and there is possibly only one nearby 
isotopic distribution affecting the error and overall shape of the distribution (Figure 
58).  This intermediate 157 was the most recurrently detected intermediate in 1:1 
assays, including those with time delays and in step-wise 1:4 experiments.   
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Figure 56  FTICR-MS analysis of ACP probe 64 incubated in the actinorhodin minimal 
system (1:4 protected ACP probe 63 to malonyl-ACP 7), showing a putative captured linear 
hexaketide 149.  (A) Acquired spectrum, (C) acquired spectrum magnified, (B) and (D) are 
simulated mass spectra (8
+
) of 149.  Underneath displays the peak list and errors for each.  
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Figure 57  FTICR-MS analysis of ACP probe 64 incubated in the actinorhodin minimal 
system (5:1 protected ACP probe 63 to malonyl-ACP 7), showing a putative captured 
cyclised hexaketide 156.  (A) Acquired spectrum, (C) acquired spectrum magnified, (B) and 
(D) are simulated mass spectra (8
+
) of 156.  Underneath displays the peak list and errors for 
each.  
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Figure 58  FTICR-MS analysis of ACP probe 64 incubated in the actinorhodin minimal 
system (1:1 protected ACP probe 63 to malonyl-ACP 7), showing a putative captured 
cyclised dehydrated hexaketide 157.  (A) Acquired spectrum, (C) acquired spectrum 
magnified, (B) and (D) are simulated mass spectra (7
+
) of 157.  Underneath displays the 
peak list and errors for each.  
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5.2.2.5. Summary of off-loaded intermediates 
The samples obtained by chain termination experiments with the protein probe 63 
and directly infused into the FTICR-MS proved extremely complex to analyse, with 
multiple isotopic distributions overlapping throughout the spectra.  As discussed, 
major peaks found in the spectra included decarboxylated probe 144, residual 
DMNB protected probe 63, as well as apo-ACP 44 and holo-ACP 43 deriving from 
the photolabile probe 63 preparation, whereas the putative intermediates 145, 147-
149, and 154-157 were of considerably lower abundance.  Charge states ranging 
from 11
+
 to 7
+
 were observed for all these intermediates, with selected spectral 
regions shown within Section 5.2.2 and the appendices reporting further full peak 
lists and additional figures for the different charge states. 
Unfortunately, due to the low intensity of the species 145, 147-149, and 154-157 
(only detected after accumulation of spectra over 300 scans) and the complexity of 
the sample, no MS
n
 fragmentation of these ions could be carried out.   
LC retention times would have been useful to gain some insight into the nature of the 
detected intermediates.  LC-FTICR-MS was not possible on this occasion due to the 
large quantity of samples and file sizes reaching approximately 100 GB per LC-MS 
run.  However, as each direct infusion sample required approximately 20 mins of 
acquisition, it is possible that, although the LC would purify the sample, the low 
intensity intermediates would not be detected within the peak elution time.  
Analysis of these samples was only performed on an FTICR-MS as lower resolution 
instruments are not able to resolve the isotopic distributions necessary for confident 
identification of the species bound to the ~10 kDa protein.  
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Putative hexaketide derived intermediates 149, 156 and 157 were detected in the 
most number of samples, however shorter chain intermediates such as the diketide 
145 and the tetraketide 147 were more abundant when detected.  Putative longer 
chain polyketide intermediates, such as heptaketide 150 and octaketide 151 were not 
detected in any sample, including dehydrated species.  It is likely that the observed 
putative captured species are an indicator of the slow steps of polyketide chain 
extension.  Keatinge-Clay et al. suggested that the cyclisation event occurs after the 
heptaketide stage of chain elongation as the KS-CLF ‘tunnel’ was shown by X-ray 
crystallography to only accommodate a chain of this length.
25
  It is possible that as 
the chain length approaches its maximum the elongation becomes slower or more 
susceptible to interruption by the ACP probe 64.  
 
5.2.2.6. Autocorrelation of low intensity isotopic distributions for 
detecting trapped polyketide intermediates  
As the putative detected intermediates trapped by the ACP probe 64 were of very 
low intensity, additional data analysis of the isotopic distributions was performed to 
confirm their presence as ‘real’ peaks.  A ‘real’ set of peaks would have an isotopic 
distribution, the detection of such peaks can be accomplished by performing 
autocorrelation of the region in the spectrum.  This method of data analysis has been 
previously carried out for complex spectra such as polymer mixtures and 
naphthalene pitch.
296-301
  The autocorrelation algorithm, essentially, finds periodic 
patterns in data, or the cross-correlation of signals with themselves at different 
points.  These patterns infer the charge state, for example, a m/z 0.5 spacing indicates 
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a 2
+
 charge state.  If the region of the spectrum does not contain these patterns then 
that region is ‘noise’, or random data points.297, 302   
Figure 59 presents an example of the autocorrelation of a very intense region of the 
spectrum, the 8
+
 isotopic distribution of the signal for the protected ACP probe 63.  
A large peak in the autocorrelation spectrum (inset) can be seen at a charge state of 
8.  For comparison, a region of known ‘noise’ in the spectrum, at high m/z, was 
chosen and, as expected, no autocorrelation can be seen for that region (Figure 60).      
 
Figure 59  Example of a region of a spectrum with a very intense peak (protected ACP 
probe 63 at charge state 8
+
) with the inset showing the auto-correlation of the region 
indicated, confirming the 8
+
 charge state. 
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Figure 60  A blank region of a spectrum with the inset showing the auto-correlation of the 
region indicated, confirming that no isotopic distributions were detected, and this region of 
the spectrum is, indeed, noise. 
 
The autocorrelation algorithm was applied to those regions of low intensity that had 
been previously manually identified to contain isotopic distributions for putative 
captured intermediates by the ACP probe 64 (See appendices).   
The region of the spectrum generated from a ‘stepwise’ 1:4 protected ACP probe 63 
to malonyl-ACP 7 chain termination assay and suspected to contain a cyclised 
hexaketide intermediate 156 bound to the ACP, at a charge state of 8
+
, was analysed.  
These sets of peaks had previously been identified by comparison with the simulated 
isotopic distribution, and from A+3 to A+7 the average error was calculated to be -
0.41 ppm.  The autocorrelation of this region detected a strong 8
+
 charge state 
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(Figure 61).  The detection of this charge state confirms that this is not a region of 
noise or random data in the spectrum, but is a real set of peaks.  That information, 
combined with the low ppm error, confirms the annotation of that distribution to be a 
trapped dehydro hexaketide 156. 
 
Figure 61  Spectrum of a detected cyclised hexaketide 156 of charge state 8
+
 with inset 
showing autocorrelation of region indicated confirming an 8
+
 charge state.  
 
All other isotope distributions of low intensity were analysed with the 
autocorrelation algorithm.  This method allowed additional confirmation of the 
presence of intermediates manually identified.  Since completion of the analysis of 
this data, a way of using the algorithm to identify isotope distributions in the spectra 
simultaneously with their assignment has been developed.
303
  This greatly helps the 
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identification and characterisation of the multiple isotopic distributions observed in 
these complex samples. 
 
5.2.2.7. Tryptic digestion of the acyl carrier protein from the 
actinorhodin minimal system 
Trypsin is a widely used protease for ‘bottom-up’ proteomics, or cleavage of 
proteins for low resolution MS analysis.  The smaller peptides are more easily 
resolved and identified by LC and MS.  The protease cleaves the amide bond on the 
C-terminal side of arginine or lysine.  The act ACP contains two arginine residues 
flanking the active site serine, when cleaved this generates a 17 amino acid long 
peptide 165/166. 
 
Figure 62  EIC of the peptide containing the active site serine generated by trypsin digestion 
of the apo and holo acyl carrier proteins 44 and 45 from the actinorhodin minimal system. 
A) apo acyl carrier protein peptide 165. B) holo acyl carrier protein peptide 166.   
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Apo 44 and holo 43 act ACPs were separately digested with trypsin and analysed by 
LC-MS (Figure 62).  The peptide of interest containing the active site serine elutes 
at approximately 17.3 mins, with a very small difference in retention time between 
the apo 165 and holo 166 peptides.  However, the LC gradient was not optimised for 
separation of the two species, although this should be relatively easy to achieve 
given their chemical differences. 
Unfortunately, due to a combination of time constraints and instrument 
complications, no further samples were analysed with this method.  Ultimately, each 
trapping experiment utilising the ACP probe 63 would have been digested with 
trypsin, to allow LC-MS analysis on a lower resolution instrument than the FTICR-
MS.   
 
5.2.3. UV-Vis spectroscopy analyses of SEK4/SEK4b 41/42 production 
As was reported in Section 4.1.3, it is possible to monitor the production of the 
actinorhodin minimal system shunt products in real time by UV spectroscopy.
13
  
SEK4/4b 41/42 have a characteristic wavelength of 293 nm which can be seen to 
increase steadily upon activation of the minimal system.  It was hoped that the effect 
of the ACP probe 63 on the titer of SEK4/4b 41/42 could be monitored by this 
method, however, as in the case of the NAC probe 65, it was soon observed that 
either the ‘active’ ACP probe 64 or the by-product of its photolysis, 125, absorbed 
strongly at 293nm, saturating the detector.  Therefore LC-MS was used to fulfil this 
task. 
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5.2.4. Effect of delayed addition of active ACP probe 64 on SEK4/4b 
41/42 production 
Following on from the early time delay experiments with the NAC probe 65, which 
revealed an interesting and unexpected time dependent effect on SEK4/4b 41/42 
biosynthesis, a small set of experiments were carried out with the ACP probe 63.  As 
before, the actinorhodin minimal system was activated by addition of the holo-ACP 
43 and after 30 seconds or 5 minutes ‘active’ ACP probe 64 was added.  The assays 
were incubated overnight at room temperature and assay duplicates using 
13
C 
labelled malonyl-CoA 15b, instead of ‘natural’ malonyl-CoA 15, were also set up.  
Half of each assay was extracted as usual to analyse SEK4/4b 41/42, and the 
remainder was kept for analysis of the ACP probe 64 off-loading ability, as 
described previously (Table 6).  
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Figure 63  LC-MS chromatogram showing the EIC for the isomers SEK4 41 and SEK4b 42 
produced by the actinorhodin minimal system.  The (A and C)) unlabelled and (B and D) 
13
C 
labelled actinorhodin minimal system was activated by the addition of final enzyme, holo-
ACP 43, then (A and B) 30 seconds and (C and D) 5 minutes later ‘active’ ACP probe 64, 
irradiated for 4 hours in the home built UVA light source, was added. Following incubation 
overnight at room temperature, EtOAc extracts were analysed by low resolution LC-MS.  
“SEK4/4b 13C” 41b/42b are fully 13C labelled compounds. 
 
Analysis of the extracts was carried out by low resolution LC-MS, and thus the two 
shunt products, SEK4 41 and SEK4b 42, did not fully separate by HPLC (Figure 
63).  
In both the labelled and unlabelled minimal systems the addition of the ACP probe 
64 after 5 minutes produced approximately three times the quantity of SEK4/4b 
41/42 than when the probe 64 was added after just 30 seconds (Figure 63).  Adding 
the NAC probe 66 at later time points results in a decrease in SEK4/4b 41/42 
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production (section 4.1.2), whereas the ACP probe 64 caused the opposite effect.  
The NAC probe 66 was unable to offload biosynthetic intermediates under those 
conditions, however, the ACP probe 64, in the unlabelled system, can offload a 
cyclised dehydrated hexaketide 157 (Table 6).  The abundance of 157 by the ACP 
probe 64 seem comparable in the 30 second and 5 minute delays, whereas variations 
in SEK4/4b 41/42 production are more pronounced (See section 5.2.4).  This is 
likely due to the use of two different LC-MS methods and different analyses 
complexity; however, it should be further explored in the future. 
Unfortunately, due to time constraints and the sample costly nature of the assay, 
additional time points and more repetitions of these experiments were not carried 
out.  
 
5.3. In vivo labelling of the acyl carrier protein of the actinorhodin minimal 
system in E. coli 
Thus far, efforts have been made to reconstitute the actinorhodin minimal system in 
vitro and modifying the acyl carrier protein from the pathway after expression by E. 
coli for trapping experiments.  However, the Burkart group
115-117, 304
 have 
demonstrated that it is possible to utilise the CoA biosynthetic machinery to generate 
CoA and ACP analogues within cells.  Mercer and co-workers have been able to 
label endogenous carrier proteins in Gram-positive, Gram-negative bacteria and in a 
human carcinoma cell line with fluorescent reporter tags for imaging purposes.
117
  
When analogues of pantetheine are fed to cell cultures, they can be taken up by the 
cell and enzymatically transformed into CoA derivatives via the endogenous CoA 
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metabolic pathway.  These CoA derivatives can then be transferred to a carrier 
protein by a promiscuous phosphopantetheinyl transferase from B. subtilis. 
Co-expression of KS-CLF and ACP from the minimal system would allow for in 
vivo trapping experiments.  In our experience in vivo chain termination assays are 
generally more insightful than comparative experiments in vitro due to enzyme 
abundances and optimal working environment.
22, 154
  Additionally, for PKSs or FAS 
systems where purification of the proteins is challenging or not possible, this method 
would still allow the biosynthetic pathways to be probed. 
E. coli BAP1 cells
137
 harbouring the phosphopantetheinyl transferase Sfp
210
 were 
transformed with the actACP pET-28 plasmid resulting in the overexpression of 
holo-ACP 43.  To generate DMNB protected ACPs 63 in vivo the pantetheine 
analogue 61 was added to the LB media at the point of IPTG induction and the cells 
were incubated overnight at 15
o
C, as or normal protein expression.  Addition of the 
pantetheine analogue 61 at two different concentrations (1 mM and 10 mM final 
concentration) and at two different optical densities (0.3 and 0.6 at 600 nm) during 
IPTG induction were trialled.  Enzyme purification was carried out as usual via Ni-
NTA affinity chromatography, and protein analysis performed by LC-MS (Figure 
64).   
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Figure 64  LC-MS chromatograms showing EIC of holo-ACP 43 (red trace) and DMNB 
protected carba(dethia) malonyl-ACP analogue 63 (blue trace) expressed in E. coli BAP1 
cells by supplementing with (A and C) 1 mM and (B and D) 10 mM DMNB protected 
carba(dethia) malonyl pantetheine analogue 61 (shown) at the same time as induction with 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) at optical densities 600 nm of  (A and B) 0.6 
and (C and D) 0.3.  Ni-NTA affinity chromatography was used to purify the histidine tagged 
acyl carrier proteins prior to analysis by LC-MS. 
 
 In each condition, both holo-ACP 43 and ACP analogue 63 were detected and no 
apo-ACP 44.  It was not possible to compare the quantities of the holo-ACP 43 and 
the ACP analogue 63 as the latter contains more potential ionising sites than holo-
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ACP 43, which can affect their MS detection.  Additionally, the retention times of 
the two species, 43 and 63, are very similar which could lead to signal suppression.  
However, from these preliminary data, it is possible to say that 10 mM of 
pantetheine analogue 61 negatively affected the expression of ACPs; less of both 
holo-ACP 43 and ACP analogue 63 were detected at that concentration compared to 
the 1 mM 61 experiments.  
It is likely that at higher concentrations the pantetheine analogue 61 begins to inhibit 
the enzymes in the biosynthesis of coenzyme A 46.  There is not a substantial 
difference between induction at the two different optical densities, although there is a 
small increase in expression of ACP when induced earlier at OD600nm of 0.3.  Further 
repeats of these experiments are required to come to a definitive answer.  
Unfortunately, due to time constraints, no further experiments were carried out.  
Nonetheless, it has been shown that it is possible to generate the ACP probe 63 in E. 
coli.  In the future, it would be of interest to show that this is possible within other 
organisms, such as S. coelicolor, the actinorhodin 2 producer, for the capture of 
biosynthetic intermediates from PKSs and also fatty acid biosynthetic pathways. 
 
5.4. Conclusions and future work 
Comparative results from incubation of the malonyl-ACP 7 and the carba(dethia) 
malonyl-ACP 64 with the KS-CLF strongly indicate that the carba(dethia) malonyl-
ACP 64 interacts with the KS-CLF in a similar way to the ‘natural’ malonyl-ACP 7.  
With both ACPs, the KS-CLF can efficiently decarboxylate the malonyl groups to 
produce acetyl within the same time frame.  This result itself cannot directly indicate 
how they compare for chain extension, however. 
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Adding the ‘active’ ACP probe 64 after just 30 seconds from the activation of the 
minimal system, led to a decrease in SEK4/4b 41/42 production compared to a 5 
minute delayed addition.  These time delay experiments behaved in the way that we 
would have expected:  they suggest that the active probe 64 interferes in the 
biosynthesis of the SEK4/4b 41/42 in its early stages by interacting with the KS-CLF 
in competition with ‘natural’ malonyl-ACP 7.  
By utilising the nonhydrolysable photoactivatable malonyl-ACP analogue 63 
putative enzyme-bound captured intermediates from the actinorhodin minimal 
system were observed and preliminarily characterised by FTICR-MS.  Putative 
hexaketide species 149, 156, and 157 were the most recurrently observed species in 
samples deriving from a variety of different chain termination assays.  Off-loading of 
KS-bound intermediates at this stage of chain elongation may indicate that this stage 
is rate limiting, possibly due to a change in protein conformation or cyclisation of the 
polyketide chain.   
Burkart and co-workers modelled the linear and cyclic polyketide intermediates of 
the actinorhodin minimal system through selective atom replacement.  They 
substituted carbonyl groups that were not essential for cyclisation or reduction with 
either isoxazole rings or sulphur atoms, creating stable mimics of the intermediates 
for structural characterisation by NMR.  It was shown that heptaketide and 
octaketide substrates bound strongly to helices II and IV, whereas the tetraketide 
substrate did not bind within the ACP.
294
  This conformational change may be the 
reason why hexaketide intermediates were more easily off-loaded with the ACP 
probe 64.  It is worth highlighting that putative PKS-bound ‘linear’ pentaketides 148 
and hexaketides 149 were detected.  If further confirmed in their nature by additional 
MS
n
 studies, they would represent the first direct evidence of polyketone species 
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bound to an ACP; due to their intrinsic instability, we hypothesise that they must be 
residing within the ACP to avoid dehydration and further processing. 
Unfortunately, the isotopic distributions for the intermediates detected were all of 
relatively low intensity, and no further analyses of these ions, such as fragmentation, 
was possible.  Nonetheless we can be confident that the observed species are ‘real’ 
as autocorrelation of the regions can confirm the presence of isotopic distributions, 
alongside sub ppm mass errors on the peaks.   
Scaling up the experiments, by at least 10 fold, and isolating the intermediates by 
preparative LC or by other separation techniques, would likely lead to a more intense 
signal for characterisation.  Alternatively, further optimisation of the method in 
regards to the ratio of malonyl-ACP 7 to carba(dethia) malonyl-ACP 64 could 
improve the ability to capture intermediates in terms of amount and range.  
An additional way of looking at ACP-bound intermediates, not explored in this 
project, has been recently reported.  It involves the use of an acyl carrier protein 
hydrolase (AcpH) which can regenerate apo-ACPs by selectively hydrolysing the 
phosphopantetheinyl (PPant) cofactor.  S. coelicolor does not contain a protein of 
this type, however an AcpH from Pseudomonas fluorescens has been proven to 
cleave the PPant arm from the actinorhodin 2 holo-ACP 43.
305
  In theory, PPant arms 
could be hydrolysed from the carba(dethia) ACP providing the small molecule 
intermediates bound to the PPant for detection by LC-MS.  The small molecular ion 
is preferable for mass spectrometry, as the lower the molecular weight the lower the 
mass error will be.  Additionally, LC separation of these species could be carried out 
on a RP C18 column, aiding their identification and characterisation.  Conversely, 
significant information on substrate-protein interaction might be lost by using AcpH 
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or trypsin digestion, therefore the intact protein analysis, ‘top-down’ approach, for 
the dissection of type II PKS catalysis should be pursued in the future. 
Throughout this project, we have shown that the capture of intermediates from 
iterative polyketide biocatalysis is not trivial.  This confirms that type II PKS 
biosynthetic machineries are as challenging as previously assumed because of fast 
and tightly controlled chain extension.  Little is known about the interactions 
between the ACP and the KS-CLF during chain extension.  These results could 
indicate that chain extension is too fast, and tightly controlled, for efficient chain 
termination, however, the preliminary observation of putative captured intermediates 
with the ACP probe 64 in vitro is promising.  With the preliminary evidence that 
ACP probes such as 63 can be generated in vivo, the new chain termination approach 
herein developed holds the promise of gaining further in depth insights into natural 
product assembly.  In the future, alternative type II PKS systems, as well as other 
types of iterative enzymes, such as type I iterative and type I-II fatty acid synthases, 
should be probed with their respective ACP probes.  This will ultimately contribute 
to generate a detailed and comprehensive picture of how iterative systems operate, 
from which new synthetic biology can be developed. 
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6. Improving molecular structural determination by combining the results of 
alkali metal adduction assisted tandem mass spectrometry 
In chapters 4 and 5, the use of photolabile small molecule and protein probes for the 
investigation of type II iterative catalysis were reported.  This chapter will focus on 
the investigation of mass spectrometry methods to assist the characterisation of both 
pantetheines and acyl carrier proteins, in view of improving our ability to 
characterise ACP-bound intermediates.  The effect of alkali metals for the structural 
characterisation of pantetheines in their free and ACP-bound form will be described. 
 
6.1. The use of alkali metal assisted tandem mass spectrometry for 
structural determination 
The structural characterization of compounds by mass spectrometry is an essential 
analytical technique for the study of organic molecules.  Multiple fragmentation 
methods are frequently used to generate complementary sets of cleavages, which can 
produce extensive structural information.
182, 186, 191, 306-310
  The development of a 
robust method to obtain a wide range of structurally significant fragments for a 
molecule (or more specifically, an ion) of interest within one tandem mass 
spectrometry experiment would provide a useful tool for the mass spectrometry 
community.   
Protonated and sodiated ions are common in the mass spectra of most samples 
analysed by electrospray ionization mass spectrometry (MS) and they are the most 
commonly used parent ions for tandem MS.  Unfortunately, these ions can often 
produce limited fragmentation of the compound of interest; this is especially the case 
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with Collisionally Activated Dissociation (CAD), the most frequently used 
fragmentation technique.  This can lead to incorrect or non-specific identification of 
the compound of interest, or the need for an alternative, often costlier and more time 
consuming, method of analysis, such as NMR or X-ray crystallography. Both of 
these alternate techniques require pure and substantial amounts of the compound, 
which is frequently not possible.  
Metal adduction has been shown to alter the fragmentation pathways in Electron 
Capture Dissociation (ECD),
311, 312
 Electron induced dissociation (EID),
313-316
 
CAD,
313, 316, 317
 and Infra-Red Multiphoton Dissociation (IRMPD).
318
  Preparation of 
these metal adducted ions is facile, and applicable to a wide range of samples.  The 
addition of 1 mM LiCl to a sample will provide a lithiated ion that is suitable for 
analysis. 
EID is a tandem MS technique for fragmentation of singly charged, positive or 
negative, ions with electrons of moderate kinetic energies in the range of 10 – 25 
eV.
182-184
  The technique has been shown to produce many of the same fragments 
that are produced by the more common CAD and IRMPD, but also to generate 
additional unique fragments.
185-188
   
Mosely and co-workers
186
 analysed singly charged cations (proton, sodium, 
ammonium and potassium) of pharmaceutical molecules by EID and CAD.  They 
found that the fragmentation techniques, EID and CAD, produced complementary 
data, but EID produced far more product ions compared to CAD.  They also 
demonstrated that the charge carrying species had a very significant effect on the 
fragmentation as well as on the type of product ion after EID.  Wills et al.
191
 reported 
similar results when analysing the isomeric natural polyketide products lasalocid A 1 
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and iso-lasalocid A by EID and CAD; the collection of fragment ions obtained by 
competition with Li
+
 allowed, for the first time, the structural differentiation between 
the two isomers (Figure 65).   
 
Figure 65  Structures of lasalocid A 1 and iso-lasalocid A. 
 
Alkali adduction to enhance fragmentation of oligosaccharides is commonly 
employed.  Zhou and co-workers
319
 found that monolithiated disaccharides showed 
abundant reducing end cleavages, and with dilithiated disaccharides linkage isomers 
could be easily differentiated.
320
  Cancilla et al.
321
 demonstrated that fragmentation 
yields were inversely related to the size of the cation, following the order 
H
+
>Li
+
>Na
+
>K
+
>Rb
-
>Cs
+
.  There are three proposed fragmentation pathways for 
metal cationised oligosaccharides: either the loss of the metal ion (resulting in a 
neutral product ion), cross ring cleavage, or glycosidic bond cleavage.  It has been 
demonstrated that the loss of the metal ion increases with its size and dissociation 
was greatest for caesium and weakest for lithium and sodium.
320, 322
 
Triacylglycerols have been analysed as lithium, sodium and potassium cations by 
CAD; the sodiated species was the only species of the three, in this case, to provide 
192 
 
useful structural diagnostic fragmentation.
323
  Denekamp and co-workers
324
 
fragmented sodiated and lithiated product ions of dirhamnosyl lipids and discovered 
that, with high energy CAD, unique cross ring cleavages occurred, which was not 
detected with the protonated species.   
Beyond the cases mentioned above, there have been a few specific uses of EID 
reported in the literature.  For instance, electron-ion interactions can be used to 
differentiate between aspartic acid and isoaspartic acid, something that has not been 
proven possible with CAD.
325
  The location of double bonds in fatty acids has also 
been shown to be traceable by EID of manganese adducted ions.
190
   
Pantetheine 48 is a small molecule precursor to Coenzyme A 46, which functions as 
an acyl carrier in many biological processes such as transcription, cell-cell mediated 
recognition, the tricarboxylic acid cycle, and the biosynthesis of secondary 
metabolites.
326-328
  The 4-phosphopantetheinyl group of Coenzyme A 46 is 
transferred to apo-acyl carrier proteins (ACPs) and peptidyl carrier proteins (PCPs) 
by phosphopantetheinyl transferases.  These ‘active’ holo-ACPs and PCPs are 
further responsible for the biosynthesis of a variety of natural products, including 
polyketides, fatty acids and non-ribosomal peptides.
328
  Pantetheine 48 is, therefore, 
a fundamental molecule in both prokaryotes and eukaryotes.
328
 
The groups of Dorrestein and Kelleher have reported an important method for 
analysing the phosphopantetheinyl (PPant) group of carrier proteins.  The “PPant 
ejection assay” involves fragmentation by CAD which selectively cleaves the PPant 
moiety 58/59 from a conserved and specific serine residue of the carrier protein.  
This provides a characteristic fragment ion for detection and the low m/z allows 
accurate mass identification.   
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The PPant group covalently binds and causes a plethora of biosynthetic 
intermediates: detecting these and fully characterising them would provide key 
insights into the understanding of mechanisms and kinetics of natural product 
biosynthesis and other biological processes.
157, 192, 193, 329, 330
 
Dorrestein et al. reported the “PPant ejection assay” performed on holo-ACPC, a 
putative acyl carrier protein from Streptococcus agalactiae.  The ejection assay was 
followed by further fragmentation of the ejected ion by CAD and produced 12 
fragment ions.
330
  Nine of these fragments contained the thiol group of the 
pantetheine 48 group, which carries the substrate during the biosynthesis of natural 
products, whereas they reported just three ions that would provide a diagnostic 
pattern for the PPant arm itself.  These masses would remain unchanged even with 
biosynthetic intermediates bound to the thiol group.   
In this work, the tandem MS characterisation of a synthetic analogue of pantetheine 
61 is reported.  This analogue 61 contains a variety of functional groups, including a 
non-hydrolysable malonyl moiety and a photolabile group (Figure 66).  Sodium and 
lithium adducted ions were fragmented with CAD and EID to compare the 
fragmentation pathways in each case.  In addition, a caesiated precursor ion was 
prepared and analysed by EID.  
 
Figure 66  Structure of the nonhydrolysable photolabile carba(dethia) pantetheine 61. 
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Lithium and caesium adducted ACP analogues were prepared, and the impact of the 
alkali metal ions on the “PPant ejection assay” was explored.  
 
6.2.  Alkali metal adduction assisted CAD and EID of the nonhydrolysable 
photolabile malonyl carba(dethia) pantetheine analogue 61 
The pantetheine analogue 61 was chemically synthesised, as previously discussed in 
chapter 3 and its structure was elucidated by NMR prior to MS analysis.  The 
samples for MS analysis were prepared in 50% MeCN with 1 mM NaCl, LiCl or 
CsCO3 in H2O.  Samples were analysed on a 12T Bruker SolariX Fourier Transform 
Ion Cyclotron Resonance (FT-ICR) mass spectrometer (Bruker Daltonics, Billerica) 
with nanospray ionization; 1-5 µL of approximately 10 µM solutions were 
electrosprayed using custom-pulled glass capillary tips, grounded with a stainless 
steel wire.  The precursor ions were isolated in the quadrupole, then accumulated in 
the collision cell for 4 seconds, before being transferred to the ICR Infinity cell.
331
  
For EID, the ions were subsequently irradiated with electrons from a 1.7 A, heated, 
hollow cathode dispenser, biased with an offset potential of 14 V.  Fragmentation for 
CAD occurred in the collision cell (30 V), prior to the ICR cell.  The voltages 
applied were the same for every spectrum for an unbiased comparison of each 
condition.   
The FT-ICR mass spectra have been assigned in absorption mode, providing 
improved resolution, and signal to noise ratio over the normal magnitude mode 
spectra (Figure 67).  A software programme, Autophaser, was used to produce the 
absorption mode spectra.
332  
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The molecule of interest, a malonyl pantetheine analogue 61 (Figure 66), has been 
fragmented by CAD (Figure 68) and EID (Figure 69) with both sodium and lithium 
adduction separately.  The CAD spectra present noticeably fewer assigned fragments 
and peaks than the EID spectra.  Most peaks in the CAD spectra could be assigned 
potential fragment structures based on the known structure of the parent ion.  
However, several of the peaks in the EID spectra are still undetermined.  It is 
hypothesised that this may be due to an unknown rearrangement and secondary 
fragmentation occurring during fragmentation. To confirm this, further MS 
fragmentation of these peaks would have to be carried out, however, this was not 
possible due to the low intensity of the fragments generated in EID. Furthermore, 
this was not deemed essential for a comparison of the MS fragmentation techniques. 
 
Figure 67  Example peak displaying the increased resolving power before (top) and after 
(bottom) phasing.  Top is the magnitude mode spectrum, bottom is the absorption mode 
spectrum produced by Autophaser
332
. 
 
CAD tandem MS is commonly carried out on sodiated molecular ions.  This method 
produces few fragments when applied to the pantetheine analogue 61 herein 
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described, and none of these fragments are unique.  In this context, unique would 
mean that a fragment was not detected in the other MS/MS spectra resulting from the 
fragmentation of different alkali adducts, by either CAD or EID.  However, a 
sodiated molecular ion of the pantetheine analogue fragmented with EID or CAD 
does generate two unique fragments, as shown in Figure 69A.  Both of these (“x” 
and “gg”) have a mass which would be consistent with the loss of the nitro group, a 
loss of one or two methoxy groups, and cleavage around the hydroxyl and carbonyl 
groups.  Fragments are labelled in ascending order by mass (Da); ‘a’ is the smallest 
fragment and ‘vv’ is the fragment with the largest mass.  A fragment ion may be 
produced from fragmentation of multiple bonds as can be seen in Figure 68. For 
example, fragment ion ‘x’ is the result of the cleavage of three bonds: one cleavage 
between the two amide groups, and two cleavages on the DMNB ring. Fragment ions 
are listed from ‘a’ to ‘z’, and then ‘aa’, ‘bb’, ‘cc’, onwards. 
Two fragments exclusive for CAD are found in the fragmentation of both sodium 
and lithium adducted ions.  Both occur from simple fragmentation; “pp” has a mass 
which would be consistent with a loss of both methoxy groups and the nitro group, 
and fragment “tt” from a loss of one of the methoxy groups and loss of H2O (Figure 
68).   
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Figure 68  A) Mass spectrum of collisionally activated dissociation (CAD) of [M+Na]
+
 
parent ion 61.  B) Mass spectrum of CAD of [M+Li]
+
 parent ion 61.  Inset: assigned 
fragmentation diagram.  An asterisk indicates a peak used for internal calibration.  
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Figure 69  Mass spectra of: A) electron induced dissociation (EID) of [M+Na]
+
 parent ion 
61; B) EID of [M+Li]
+
 parent ion 61; C) EID of [M+Cs]
+
 parent ion 61. Inset: assigned 
fragmentation diagram. An asterisk indicates a peak used for internal calibration. 
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The adduction of a lithium ion to the molecule yields seven unique fragments with 
both CAD (Figure 68B) and EID (Figure 69B): “a”, “d”, “j”, “m”, “q”, “r” and 
“qq”.  Aside from fragment “a”, the majority of the fragments may come from 
carbon-oxygen bond cleavage.  EID with a lithium adducted produces two additional 
unique peaks corresponding to fragments “uu” and “vv”.  These new fragments 
would result from the loss of two methyl groups and, in the latter fragment, a loss of 
H2O.  CAD with the lithium adduct also provides two further unique fragments, 
absent in all other spectra.  Fragment “k” has an accurate mass which would be 
consistent with two fragmentations near to carbonyl groups, both in oxygen rich 
environments, and fragment “ss” has a mass which correlates with the loss of the 
nitro group and a methyl group from the parent ion.   
The pantetheine analogue 61 was also investigated in complex with caesium.  The 
caesiated molecular ion was fragmented with EID (Figure 69C).  Once again, the 
fragmentation pathways were different from the other alkali adducts.  In addition, 
complementary ions were also generated and these provide further insights into the 
molecular structure.  Fragment “u” is found in every spectrum, but is not detected 
with caesium adduction and EID.  This fragment has a mass which would be 
consistent with a cross ring cleavage and an amide bond cleavage, each cleavage at 
opposite ends of the compound.   
Amide bond fragmentation is abundant in peptide and protein fragmentation; 
therefore, it was expected that that amide bond cleavage would be one of the most 
prevalent bond cleavages.  However, this was not the case, this could be due to a 
lack of a mobile proton to induce fragmentation of this type.
179, 333-335
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Six fragments are detected exclusively in the EID spectrum with Cs adducted to the 
compound (Figure 69C).  All of the fragments, “b”, “c”, “f”, “o”, “cc”, and “ee”, 
have masses that correlate with containing two nitrogen atoms; only fragment “ee” 
has a mass indicating a fragment containing the nitrogen atom in the nitro group.  
Lastly, fragment “b” is the only fragment predicted to include a bond cleaved within 
the most aliphatic portion of the molecule.   
Lithium and caesium adductions cause quite similar behaviour under EID: there are 
many common fragments, “l”, “v”, “z”, “aa”, “bb”, “ff”, “hh”, “kk”, “mm” and “nn”.  
All of these fragments have masses consistent with bonds cleaved around the first 
carbonyl group, and, aside from “l”, cleavages in or around the benzene ring.   
There are also three fragments, “g”, “s”, and “t”, that are common to both lithium 
and caesium adduction with both CAD and EID and have masses which would be 
consistent with cleavage within the malonyl moiety.  The fragments “g” and “s” 
happen to be almost complementary fragments with additional side chain losses.   
There is a high degree of overlap of detected fragments across all of the spectra (i.e.  
the same proposed fragments arising from multiple different fragmentation 
experiments).  Certain fragments are common with both lithium and caesium 
adduction under EID and CAD, but are not found with sodium adduction.  “p” is not 
present with sodium adduction and CAD, and “y” is not present with sodium 
adduction and EID, but these ions are found in every other spectrum. “g”, “s”, “t” 
and “oo” are not found with sodium adduction with either fragmentation technique, 
but are found in all of the other spectra.   
A caesiated ion under EID produces fragment “jj”, having a mass which would be 
consistent with coming from a cleavage between the hydroxyl and carbonyl group, 
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loss of the nitro group and two methyl groups.  This fragment is not found in any of 
the other spectra. 
There are only a few peaks that are present in both CAD and EID spectra with each 
of the alkali metal adducts corresponding to the same fragments: “e”, “h”, “n”, “dd” 
and “w”.  Each of these fragments has a mass consistent with the ion containing the 
middle portion of the compound with two nitrogen atoms.  A hypothesis is that the 
presence of multiple nitrogen atoms could contribute to increased chance of 
protonation and, therefore, detection.  The most common fragmentation sites appear 
to fall within the malonyl moiety and near to the first amide bond where there is a 
neighbouring hydroxyl group. 
Simply in terms of the total number of identified fragments with each alkali ion, with 
EID, the lithiated compound generates the most fragments and sodiated, the least.  
Caesium adduction provides seven new assigned fragments, but a further 23 
complementary species.   
When switching from sodium to lithium adduction with CAD, only 8 of the 
fragments are found in both spectra, but, for this molecule, there was an increase 
from 11 assigned fragments to 25.  EID with a lithiated parent ion, however, 
generates 10 more identifiable fragmentation peaks than the 25 with CAD; 21 of the 
fragments are detected in both spectra.   
In conclusion, five spectra were collected of the malonyl pantetheine analogue 61 in 
the presence of different alkali ions.  The sodiated and lithiated ions were fragmented 
with CAD and EID, and, additionally, a caesiated ion was fragmented with EID.   
Each spectrum was unique; only four fragments are detected in all five conditions.  
There was a strong increase in the number of fragmentation sites by CAD when the 
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molecule was lithium adducted, compared to sodiated (Figure 70B).  Lithium 
adduction produced fragments from throughout the molecule, whereas sodium 
adduction tended towards more localised fragmentation patterns.  
Figure 70A shows the number of new fragments provided by EID compared to 
CAD.  It appears that cross ring cleavages are more prevalent with EID, and are also 
more common with lithium or caesium adduction.  These types of cleavages can 
assist with the important identification of the position of functional groups around an 
aromatic ring.  The compound is hypothesised to have undergone a cyclisation 
during fragmentation, leading to some, as yet, undefined rearrangements.  
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Figure 70  Fragmentation diagrams showing all the assigned fragments for: A) CAD and 
EID.  In blue are those fragments only seen with CAD, in red are the fragments only seen 
with EID, and in black are the fragments seen with both CAD and EID; B) CAD with sodium 
and lithium ion adduction. In purple are fragments only seen with lithium adducted, in green 
are fragments only seen with sodium adducted and in black are the fragments that are seen 
in both spectra; C) EID with sodium, lithium and caesium ion adduction. In blue are 
fragments only seen with sodium adduction, in red are fragments only see with lithium 
adduction, in green are fragments only seen with caesium adduction and in black are the 
fragments that are seen in more than one of the EID spectra. 
 
As shown in Figure 70C, the combinations of fragmentations with each of the 
different metal ions present varied, but only lithium and caesium gave new bond 
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cleavages that were not shown in any of the other spectra, including by CAD.  
Fragmentation between the two carbonyl groups in the malonyl moiety is a very 
abundant fragmentation pathway; fragment “w”, which has a mass which would be 
consistent with this cleavage, was present in all of the spectra and was always one of 
the most intense peaks in the spectrum.  This is likely due to the position of the alkali 
metal on the compound 61.   
The pantetheine 48 molecule holds strong biological importance, particularly for the 
natural products field.  Detailed insight into the fragmentation patterns for these 
types of compounds has been demonstrated by mass spectrometry.  Combining the 
“PPant ejection assay”158, 192, 193 with alkali metal adduction and EID at the MS3 
stage is promising for characterisation of biosynthetic intermediates bound to acyl 
carrier proteins.  The ejection assay provides a small, singly charged molecule which 
would be susceptible to fragmentation by EID for improved structural 
characterisation.  This work has demonstrated that fragmentation of the target 
compound is facilitated by the addition of the alkali metal as well as with EID as a 
fragmentation method.  Whether the metal ion remains bound to the ejected 
pantetheinyl is investigated in section 6.3.   
For this compound 61, carrying out EID with a lithiated ion produced the most 
assigned fragments compared to the other alkali metals tested in this study and 
provided sufficient information for a thorough analysis of the structure of the 
compound.  In the future, researchers may wish to consider investigating which is 
the best adduct, or adducts, for their particular molecule of interest.  For the 
characterisation of a new compound by mass spectrometry, preparing ions for 
fragmentation with each of the different alkali metals adducted is a worthwhile 
practice.  Also, due to the complementary nature of EID and CAD, combining the 
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data from both fragmentation techniques could reveal more detailed structural 
information.  
The method of alkali adduction to compounds is a facile sample preparation 
technique, applicable to a wide range of molecules with benefits including a greater 
amount of fragmentation throughout the molecule, as well as unique fragmentations.  
Alongside EID capabilities, robust structural characterisation by mass spectrometry 
is possible.   
 
6.3.  The effect of alkali metal adduction assisted CAD of modified acyl 
carrier proteins on the generation of phosphopantetheinyl (PPant) 
ejection ions 58/59 
6.3.1. Background and aim 
CAD has been used for the identification of ACPs and in generating characteristic 
phosphopantetheinyl (PPant) ejection ions 58/59.  This technique has been used in 
proteomics for identifying PKSs, but also in off-loading intermediates from ACPs 
(Scheme 13).
141, 142, 157-159, 192-195
  
Unfortunately, the “PPant ejection assay” often generates a fragment ion that is of 
low intensity, and the energy of CAD is key to producing the PPant ejection ions 
58/59.  Method development of that type can be time consuming, use up sample and 
can lead to missed ACPs when the technique is used in proteomics.
157
  Because of 
these drawbacks, the technique is only available to expert users on advanced 
instruments with the ability to trap ions, such as FT-ICRs.  Improvements to the 
method would be beneficial to the scientific community, and provide a robust tool 
for the investigation of biosynthetic pathways in more laboratories. 
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Following on from the work carried out on the small molecule pantetheine analogue 
61 explored in section 6.2, the effect of alkali metal ions bound to ACPs on their 
fragmentation, specifically in regards to the PPant ejection was explored. 
 
6.3.2. Generation of lithium and caesium adducted ACP species 
At just 7 Da the adduction of lithium to a ~10 kDa acyl carrier protein (ACP) makes 
a minimal difference to the isotope distribution, and this is complicated further by a 
mixture of multiply lithiated and protonated ions causing a ‘tailed’ isotope 
distribution (Figure 71).  Unfortunately, this meant that it was not possible to isolate 
a solely lithiated species for fragmentation.  However, the fragmentation patterns of 
the partially lithiated ions were still compared to solely protonated ions.  
Sodium adduction was also present in all spectra, due to the preparation of the ACP 
and its analogues.  Its close m/z to the protonated and lithiated species meant that the 
sodium adducted ACPs were not able to be separated in the isolations for 
fragmentation experiments.    
The affinity of the ACP analogues to caesium was surprisingly successful.  At a 
higher mass than lithium, a single adduction of caesium was sufficient to be isolated 
separately to the protonated species.  Up to five caesium adducted species were 
detected on the nonhydrolysable photolabile malonyl carba(dethia) ACP 63 (Figure 
72).  
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Figure 71  Adduction of lithium to the nonhydrolysable photolabile malonyl carba(dethia) 
acyl carrier protein (ACP) analogue 63 demonstrated on the 8
+
 ion.  A) ACP 63 without the 
addition of LiCl to the sample.  B) Simulated isotopic pattern for ACP 63 8
+
 ion.  C) ACP 63 
with the addition of 1 mM LiCl.  Multiple lithium adductions can be seen by the ‘tailing’ of 
the isotope distribution to higher m/z values.  
 
Five different ACP analogues, nonhydrolysable photolabile malonyl carba(dethia) 
ACP 63, acetyl-ACP 40, malonyl-ACP 7, acetoacetyl-ACP 167 and myristoyl-ACP 
168, were prepared from apo-ACP 44 using the corresponding CoA analogues and a 
phosphopantetheinyl transferase, Sfp.  The MS samples were prepared with 1 mM 
lithium chloride or caesium carbonate for fragmentation experiments.   
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Figure 72  (A, D, G) Mass spectra showing caesium adduction to the nonhydrolysable 
photolabile malonyl carba(dethia) acyl carrier protein (ACP) 63 by sample preparation with 
1 mM Cs2CO3.  Simulated isotopic distributions for the 8
+ 
ions for (B) one, (C) two, (E) 
three, (F) four and (G) five caesiums adducted and loss of a hydrogen for each caesium 
adduction. 
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Acetyl-ACP 40 and malonyl-ACP 7 both are necessary for the biosynthesis of 
polyketide and fatty acid biosynthesis.  Acetoacetyl-ACP 167 would be the product 
resulting from one round of the polyketide or fatty acid chain extension of acetyl-
ACP 40, whereas myristoyl-ACP 168 is a lipid modification produced by fatty acid 
synthases (FAS), and, therefore, would naturally be attached to those ACPs.  
A range of CAD voltages were applied to each sample, the upper voltage used in 
each case was the maximum possible before the signal of the precursor ion was lost.  
Each spectrum was acquired with the same parameters for comparative purposes.  
 
6.3.3. The effect of alkali metal adduction on generation of a 
pantetheinyl ion by CAD of the nonhydrolysable photolabile 
malonyl carba(dethia) ACP 63 
The nonhydrolysable photolabile malonyl carba(dethia) ACP 63 without lithium or 
caesium adduction can produce a Pant ion 81, as well as a phospho-Pant ion 169, 
with CAD of 25V.  Increasing the voltage to 28V improves the yield of phospho-
ACP 170, however, there is a decrease in the relative abundance of the Pant ion 81, 
and the phospho-Pant ion 169 was not able to be detected under those conditions.  
The adduction of caesium does not provide either ejection ion 81 or 169 upon CAD, 
however, lithium adduction does generate Pant ion 81.   
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Figure 73  The effect of adduction of lithium to the nonhydrolysable photolabile malonyl 
carba(dethia) acyl carrier protein (ACP) 63 on the yield of cleaved pantetheine analogue 81 
(m/z 524.2239) and the phosphopantetheine analogue 169 (m/z 622.2008) via bond cleavage 
under collisionally activated dissociation (CAD).  (A, C and F) CAD of 8
+
 ACP 63. B, D and 
E) CAD of lithium adducted 8
+
 ACP 63.  CAD voltages of 25V (A, B and F), 28V (C and D), 
30V (E) were used.  Scheme above shows the expected fragmentation pathway.  Phospho-
ACP 170 is a by-product of the cleavage. 
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The relative abundance of the Pant ion 81 produced at 25V is comparable to without 
lithium adduction.  However, at 28V, the intensity of the Pant ion 81 continues to 
increase when fragmenting the lithium adducted species.  Additionally, the CAD 
voltage could be increased up to 30V with lithium adduction, and the Pant ion 81 
intensity increases further (Figure 73).  Higher voltages were not able to be applied 
due to loss of signal strength over 30V.  
 
6.3.4. The effect of alkali metal adduction on generation of a 
pantetheinyl ion by CAD of acetyl-ACP 40 
Acetyl-ACP 40 without lithium adduction could be fragmented up to a CAD voltage 
of 25V before loss of signal.  At this voltage the corresponding acetyl Pant ion 171 is 
produced, but the acetyl phospho-Pant 172 is not.  A caesium adducted acetyl-ACP 
40 was generated, however the Pant 171 or phospho-Pant 172 were not produced by 
CAD fragmentation.  As with the nonhydrolysable photolabile malonyl carba(dethia) 
ACP 63, with lithium adduction, the CAD voltage could be increased up to 35V.  
From 25V to 30V, the signal strength of the Pant ion 171 increased, but past 30V the 
abundance of the Pant ion 171 did not increase any further (Figure 74).  
 
 
 
 
212 
 
 
Figure 74  Adduction of Lithium to acetyl acyl carrier protein (ACP) 40 shows improved 
yield of cleaved acetylated pantetheine 171 (m/z 303.1373) via phosphodiester bond 
cleavage under collisionally activated dissociation (CAD).  A) CAD of 8
+
 acetyl-ACP 40. B, 
C and D) CAD of lithium adducted 8
+
 acetyl-ACP 40.  CAD voltages of 25V (A and B), 30V 
(C) and 35V (D) were used.  Scheme above shows the expected fragmentation pathway.  
Phospho-ACP 170 is a by-product of the cleavage. 
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6.3.5. The effect of alkali metal adduction on generation of a 
pantetheinyl ion by CAD of malonyl-ACP 7 
 
Figure 75  The effect of adduction of lithium to malonyl acyl carrier protein (ACP) 7, on the 
yield of cleaved malonyl pantetheine 173 (m/z 347.1271) via phosphodiester bond cleavage 
under collisionally activated dissociation (CAD).  A, C, E, and G) CAD of 7
+
 malonyl-ACP 
7.  B, D, F and H) CAD of lithium adducted 7
+
 malonyl-ACP 7. CAD voltages of 25V (A and 
B), 30V (C and D), 35V (E and F), and 40V (G and H) were used.  Scheme above shows the 
expected fragmentation pathway.  Phospho-ACP 170 is a by-product of the cleavage. 
214 
 
 
CAD voltages up to 40V could be applied for malonyl-ACP 7 with and without 
lithium adduction.  As with the other ACPs, caesium adduction does not result in the 
corresponding Pant ion 173.  On this occasion, lithium adduction does not improve 
the ejection of the Pant ion 173.  No malonyl phospho-Pant ion 174 was detected in 
any of the spectra (Figure 75).  
 
6.3.6. The effect of alkali metal adduction on CAD of acetoacetyl-ACP 
167 
The acetoacetyl Pant ion 175 was detected with and without lithium or caesium 
adduction to the acetoacetyl-ACP 167.   At 25V and 30V, the precursor ion without 
alkali adduction produced the most intense Pant fragment ion 175, with lithium 
adduction the second most and with caesium adduction to the acetoacetyl-ACP 167, 
the fragment ion 175 generated is very low intensity.  A higher voltage could not be 
applied to the caesiated acetoacetyl-ACP 167 than 30V, but the protonated and 
lithiated ions could be fragmented with voltages of 35V and 40V.  At these higher 
voltages the signal of the Pant ion 175 is weaker than at lower voltages, but the 
intensities are comparable, whether lithiated or not (Figure 76).  No phospho-Pant 
ion 176 was detected in any of the spectra. 
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Figure 76  The effect of adduction of lithium or caesium to acetoacetyl-ACP 167, on the 
yield of cleaved acetoacetyl pantetheine 175 (m/z 345.1479) via phosphodiester bond 
cleavage under collisionally activated dissociation (CAD).  A, D, G, I) CAD of 7
+
 
acetoacetyl-ACP 167. CAD of lithium (B, E, H, and J) and caesium (C and F) adducted 7
+
 
acetoacetyl-ACP 167. CAD voltages of 25V (A, B and C), 30V (D, E and F), 35V (G and H) 
and 40V (I and J) were applied.  Scheme above shows the expected fragmentation pathway.  
Phospho-ACP 170 is a by-product of the cleavage. 
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6.3.7. The effect of alkali metal adduction on generation of a 
pantetheinyl ion by CAD of myristoyl-ACP 168 
Both the Pant ion 177 and the phospho-Pant ion 178 from myristoyl-ACP 168 were 
generated by CAD with and without lithium adduction.  Unfortunately, due to the 
low intensity of the caesium adducted ACP 168, CAD was not possible with that 
alkali metal.  The most abundant Pant ion 177 is generated with 30V CAD without 
lithium adduction to the parent ion 168, voltages above 30V were not achievable due 
to loss of signal of the parent ion 168.  35V CAD of the lithium adducted species 
168 is possible, however, it produces the most intense Pant ion 177 among those 
lithiated experiments, but the intensity was not as great as without this alkali metal 
(Figure 77).  Low abundant phospho-Pant ions 178 were detected in all spectra 
fragmented with 25V and 30V CAD, both with and without lithium adduction 
(Figure 78).  
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Figure 77  The effect of lithium adduction to myristoyl-ACP 168 on the yield of cleaved 
myristoyl pantetheine 177 (m/z 471.32511) via phosphodiester bond cleavage under 
collisionally activated dissociation (CAD).  A, B, C and E) CAD of 8
+
 myristoyl-ACP 168. 
D, F and G) CAD of lithium adducted 8
+
 myristoyl-ACP 168.  CAD voltages of 15V (A), 20V 
(B), 25V (C and D), 30V (E and F) and 35V (G) were applied.  Above shows the expected 
fragmentation pathway.  Phospho-ACP 170 is a by-product of this cleavage. 
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Figure 78  The effect of lithium adduction to myristoyl-ACP 168 on the yield of cleaved 
myristoyl phosphopantetheine 178 (m/z 569.3020) via phosphodiester bond cleavage under 
collisionally activated dissociation (CAD). A, B, C and E) CAD of 8
+
 myristoyl-ACP 168. D, 
F and G) CAD of lithium adducted 8
+
 myristoyl-ACP 168.  CAD voltages of 15V (A), 20V 
(B), 25V (C and D), 30V (E and F) and 35V (G) were applied.  Above shows the expected 
fragmentation pathway.  Phospho-ACP 170 is a by-product of this cleavage. 
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6.3.8. CAD of caesium adducted ACP species 
 The most common fragmentation pathway for caesiated ACP ions (63, 40, 167 and 
7) is the loss of the caesium ion and charge reduction.  For caesiated malonyl-ACP 7 
a decarboxylation was also produced by CAD (Figure 79).  This pathway is likely 
the cause of the low abundant, or absent, PPant ejection ions for all caesiated ACP 
species. 
 
Figure 79  The effect of caesium adduction to four different ACPs 63, 40, 167, and 7 on 
fragmentation pathways with collisionally activated dissociation (CAD).  A) 18V CAD of 
caesium adducted 8
+ 
nonhydrolysable photolabile malonyl carba(dethia) ACP analogue 63.  
B) 16V CAD of caesium adducted 8
+
 acetylated ACP 40.  C) 30V CAD of caesium adducted 
7
+
 acetoacetyl-ACP 167.  D) 35V CAD of caesium adducted 7
+
 malonyl-ACP 7. 
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6.3.9. Summary and conclusions 
Alkali metals were at no time found bound to the Pant or phospho-Pant ejection ions, 
in all cases the ions were detected as protonated species.  This could indicate that the 
alkali metal is adducting to somewhere within the protein, rather than along the 
PPant modification, however, it is equally likely that the alkali metal falls off upon 
fragmentation. 
It is still unclear whether the adduction of lithium is beneficial to the generation of a 
Pant ion.  The lithiated nonhydrolysable photolabile malonyl carba(dethia) ACP 
analogue 63 and the lithiated acetyl-ACP 40 provided more intense Pant ions 81 and 
171 than the respective non-lithiated species.  However, CAD of malonyl and 
acetoacetyl-ACP ions 7 and 167 generated similar intensities of their Pant ions 173 
and 175 with and without lithium.  Lithium adduction to myristoyl-ACP 168 was the 
only ACP species to show a decrease in abundance of the fragment ion 177 
compared to unlithiated.  It may be worthwhile to test ACP species of interest with 
and without lithium adduction, as the variation in the effect of the alkali metal is 
unpredictable with these preliminary results.  What can be deduced is that caesium 
adduction is not a favourable alkali metal ion for promoting the generation of a Pant 
ion or a phospho-Pant ion, as the primary fragmentation pathway is simply the loss 
of caesium. 
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6.4.  The effect of alkali metal adduction to acyl carrier proteins (ACPs) on 
the production of peptides by CAD, and the application to post-
translational modification mapping 
Collisionally activated dissociation (CAD) is the most common fragmentation 
technique for sequencing peptides and proteins.  The amide bonds of the proteins are 
highly susceptible to fragmentation by CAD, generating, so called, ‘b’ and ‘y’ 
ions.
179, 334, 335
  A ‘b’ ion is a fragment containing the N-terminus, whereas a ‘y’ ion 
is containing the C-terminus.  Typically, protonated and sodiated peptides and 
proteins are used for the sequencing.  The effect of metal binding to proteins has 
been explored in limited detail, in regards to the fragments generated by CAD.
336-338
  
The effect of alkali metals on CAD, in particular, has not been widely documented in 
the literature.
338
  
The same samples and spectra analysed for the ability to produce PPant ions by 
CAD were also analysed for the production of peptide fragment ions.  The effect of 
the alkali metal on the fragments produced was compared to without that metal ion.  
Five ACPs were prepared from apo act ACP 44 as previously described in Section 
6.3.2; acetyl 40, malonyl 7, acetoacetyl 167, myristoyl 168 ACPs and the ACP 
analogue 63 explored in detail in this thesis.  Each ACP was prepared with and 
without 1 mM LiCl or CsCO3, as before, and these ions were isolated and 
fragmented in the collision cell.  A range of CAD voltages were applied to the 
isolated parent ions, up to the point where signal was lost.  
The FT-ICR mass spectra have been assigned in absorption mode, providing 
improved resolution, and signal to noise ratio over the normal magnitude mode 
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spectra (Figure 67).  A software programme, Autophaser, was used to produce the 
absorption mode spectra.
332  
For this section, the same voltages are compared between each ACP, however, the 
effect of increasing voltages, where applicable, will be discussed.  
Locating the position of a post-translational modification (PTM) on a protein is 
important for biochemical characterisation.  As discussed, the acyl carrier protein 
from the actinorhodin minimal system used in this study bears a 
phosphopantetheinyl (PPant) arm at serine 45 of the protein.  CAD will often cleave 
the PTM from the protein, producing a Pant ion 58, or a phospho-Pant ion 59, this 
will leave a phosphorylated protein or peptide fragment ion.  The PTM can, 
however, remain bound, and the peptide fragment ions will contain the PTM.  This 
information can be used to locate which amino acid the PTM is bound to.  The 
influence of the metal ion on whether the PPant arm, or phosphorylation, remains 
bound to the peptide fragment ions is explored, as this is essential for PTM mapping.  
 
6.4.1. The effect of alkali metal adduction to modified ACPs from the 
actinorhodin minimal system from S. coelicolor on the production 
of peptide ions by CAD 
To identify proteins by mass spectrometry, ‘b’ and ‘y’ ions are compared against a 
library, the more of these types of ions produced will result in more confidence in the 
protein’s assignment.  This section explores whether the simple sample preparation 
with an alkali metal salt can improve the sequence coverage for a selection of ACPs 
from the model actinorhodin minimal system.  Identifying ACPs from organisms is a 
relatively new technique for detecting expressed polyketide synthases (PKSs).
158, 159
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This information can lead to discovering new compounds of pharmaceutical and 
agricultural significance. 
 
6.4.1.1. Acetyl-ACP 40 
Acetyl-ACP 40 is a ‘natural’ ACP analogue, it is used by the PKS and FAS for 
loading the ketosynthase domain, prior to chain extension and elongation, a key 
process for the biosynthesis of polyketides.  It would be likely that this ACP could 
be detected in a proteomics sample. 
25V is the highest voltage that is able to generate an adequate signal for the non-
lithiated acetyl-ACP 40, and this voltage was also applied to the lithium adducted 
acetyl-ACP 40.  The caesiated acetyl-ACP 40 does not produce any peptide 
fragments, therefore it was rapidly ruled out as an adduct that can improve sequence 
coverage for this sample.  
The cleavage coverage maps for each sample at 25V CAD are shown in Figure 80, 
and the corresponding spectrum is shown in Figure 81.  The difference between the 
sequence coverages for the two samples clearly shows improvements with lithium 
adduction.  In particular, there are six new ‘b’ and ‘y’ ions within the first ten amino 
acids at the N-terminus of the protein.  The other differences are distributed evenly 
throughout the protein.   
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Figure 80  Cleavage coverage maps showing b and y ions resulting from collisionally 
activated dissociation (25V) of acetyl-ACP 40 with (A, red) and without (B, blue) lithium 
adduction. The differences between the maps is shown (C). 
 
The adduction of lithium to the protein also allows for higher CAD voltages, up to 
35V.  The increased voltage produces a few different ‘b’ and ‘y’ ions, but the 
improvement in sequence coverage, compared to without lithium adduction, is not 
significant.  (Appendix 71) 
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Figure 81 Example spectrum showing b (top) and y (bottom) ions resulting from 
collisionally activated dissociation (25V) of acetyl-ACP 40 with lithium adduction. The 
parent ion (8
+
) is indicated with an asterisk. The corresponding cleavage coverage map is 
shown in Figure 80.    
 
6.4.1.2. Malonyl-ACP 7 
Chain elongation is initiated by malonyl-ACP 7 in PKSs and FASs, a key process for 
the production of polyketides and fatty acids. 35V can be applied to all samples; 
non-alkali adducted, lithiated and caesiated, without loss of signal (Figure 82).   The 
caesiated ACP 7 does not produce any unique fragments.  The lithium adducted 
sample produces a similar number of fragments to the sample without alkali 
adduction.  There are differences between with and without lithium adduction, 
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however, they are spread throughout the protein.  There is no clear difference 
between the sequence coverage of the two samples. 
The voltage applied to the samples with and without lithium adduction could be 
increased to 40V, but there is still no clear improvements to the sequence coverage 
with either sample.  (Appendix 72) 
 
Figure 82  Cleavage coverage maps showing b and y ions resulting from collisionally 
activated dissociation (35V) of malonyl-ACP 7 with lithium (A, red), with caesium (C, 
green) and without alkali (B, blue) adduction.  The differences between the maps is shown 
(D). 
 
6.4.1.3. Acetoacetyl-ACP 167 
Acetoacetyl-ACP 167 is the product of a single extension of the polyketide chain, a 
common intermediate to both PKS and FAS biosynthetic pathways.  CAD of 30V 
could be applied to all three samples.  The caesiated sample, again, provides the 
lowest sequence coverage, but does generate three unique ‘b’ and ‘y’ ions not 
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detected in the other spectra.  On this occasion, the sample without additional alkali 
metal adduction produces greater sequence coverage than with lithium adduction, 
most notably due to increased fragmentation between residues 17 and 27 (Figure 
83).  
 
 
Figure 83  Cleavage coverage maps showing b and y ions resulting from collisionally 
activated dissociation (30V) of acetoacetyl-ACP 167 with lithium (A, red), with caesium (C, 
green) and without alkali (B, blue) adduction.  The differences between the maps is shown 
(D). 
 
The voltage for the samples with and without lithium adduction could be increased 
to 40V.  At this voltage the sequence coverage shows more similarities between the 
samples, however, the sample without lithium adduction still provides the greatest 
sequence coverage.  (Appendix 73) 
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6.4.1.4. Myristoyl-ACP 168 
The myristoyl group is a lipid modification to proteins, biosynthesised by FASs, for 
promoting protein-membrane and protein-protein interactions, it is involved in a 
range of signal transduction cascades.
339
  Myristoyl-ACP 168 is a late stage 
biosynthetic intermediate following a number of chain extensions and reductions. 
 
Figure 84  Cleavage coverage maps showing b and y ions resulting from collisionally 
activated dissociation (25V) of myristoyl-ACP 168 with (A, red) and without (B, blue) 
lithium adduction.  The differences between the maps is shown (C). 
 
Unfortunately, the signal for the caesiated myristoyl-ACP 168 was too weak for 
isolation and subsequent fragmentation.  The maximum voltage that could be applied 
to the non-lithiated sample was 25V.  At this voltage, the lithiated sample, by far, 
provides the greater sequence coverage (Figure 84).   Increasing the voltage to 35V 
for the lithiated myristoyl-ACP 168 reduces the sequence coverage, but there was 
still more sequence coverage than without lithium adduction at 25V.  (Appendix 74) 
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6.4.1.5. Nonhydrolysable photolabile malonyl carba(dethia) ACP analogue 
63 
The nonhydrolysable photolabile malonyl carba(dethia) ACP analogue 63 was 
designed to be activated by light to act as a probe for polyketide chain extension.  It 
is not a ‘natural’ ACP, however, many polyketide intermediates contain bulky 
aromatic constituents, and its response to alkali adduction can still be worthwhile to 
investigate. 
 
Figure 85  Cleavage coverage maps showing b and y ions resulting from collisionally 
activated dissociation (28V and 18V) of nonhydrolysable photolabile malonyl carba(dethia) 
ACP analogue 63 with lithium (A, red), with caesium (C, green) and without alkali (B, blue) 
adduction.  The differences between the maps is shown (D). 
 
The maximum voltage that could be used for the caesiated ACP analogue 63 was just 
18V, and only generates two fragment ions.  The sample without alkali adduction 
could be fragmented with voltages up to 28V, which provides substantial sequence 
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coverage, more so than the lithium adducted sample at the same voltage.  The 
lithiated ACP 63 could be fragmented at 30V, providing a few different fragment 
ions, however, the non-lithiated sample is still superior for optimum sequence 
coverage.  (Appendix 75) 
 
6.4.2. The effect of alkali metal adduction to ACPs on the production of 
phospho-peptide ions for post-translational modification mapping 
The cleavage of the phosphodiester bond of the phosphopantetheinyl (PPant) arm of 
the ACP under CAD is a common fragmentation pathway, in doing so, a phospho 
group remains bound to the ACP.  Subsequent fragmentation of the protein can lead 
to locating the amino acid on which the PPant arm, the PTM, was originally bound.  
This technique is often called ‘PTM mapping’, a key technique in mass spectrometry 
for characterising known proteins, and identifying or classifying unknown proteins.  
The use of alkali metals in improving the technique of PTM mapping is explored in 
this section. 
 
6.4.2.1. Acetyl-ACP 40 
Phospho-peptide ions, only, are shown in Figure 86 produced from fragmentation of 
acetyl-ACP 40 with 25V.  The lithiated sample provides ten ‘b’ ions and just two ‘y’ 
ions bearing the phospho group, whereas the sample without additional alkali 
adduction provides eight ‘b’ ions and three ‘y’ ions.  There are eleven differences in 
the ions generated by the two samples, combining the data from the two samples’ 
spectra narrows down the location of the active site amino acid by just a single 
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amino acid.  However, the lithiated sample’s spectra has more phosphorylated 
fragment ions than the non-lithiated.  
Increasing the voltage to 35V for the lithiated ACP parent ion 40 reduces the number 
of ‘b’ ions to eight, but increases the number of ‘y’ ions to six.  It also restricts the 
location of the active site amino acid by two more amino acids.  Some of the new 
fragment ions were originally detected without the lithium adduction.  (Appendix 
76) 
 
Figure 86  Cleavage coverage maps only showing phosphorylated b and y ions resulting 
from collisionally activated dissociation (25V) of acetyl-ACP 40 with (A, red) and without 
(B, blue) lithium adduction.  The differences between the maps is shown (C). 
 
6.4.2.2. Malonyl-ACP 7 
There is good coverage of phosphorylated peptide ions for both malonyl-ACP 7 
samples with and without lithium adduction.  No phospho-peptides were detected in 
the caesiated sample 7.  At 35V, the sample without lithium adduction provides more 
phospho-peptides for PTM mapping, but both preparations allow mapping to within 
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twelve amino acids (Figure 87).  Increasing the CAD voltage to 40V reduces the 
number of phosphorylated fragment ions detected.  (Appendix 77) 
 
Figure 87  Cleavage coverage maps only showing phosphorylated b and y ions resulting 
from collisionally activated dissociation (35V) of malonyl-ACP 7 with lithium (A, red), with 
caesium (C, green) (Note: none detected) and without alkali (B, blue) adduction.  The 
differences between the maps is shown (D). 
 
6.4.2.3. Acetoacetyl-ACP 167 
The sample without additional alkali metal adduction maps the active site amino acid 
of acetoacetyl-ACP 167 to within twelve amino acids, substantially less than in the 
lithiated and caesiated samples.  Additionally, that sample without alkali adduction 
provides one extra ‘b’ ion, and three extra ‘y’ ions than the other two samples 
(Figure 88).  Increasing the CAD voltage did not increase the sequence coverage of 
the phospho-peptide ions, and did not improve the ability to map the PTM.  
(Appendix 78) 
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Figure 88  Cleavage coverage maps only showing phosphorylated b and y ions resulting 
from collisionally activated dissociation (30V) of acetoacetyl-ACP 167 with lithium (A, red), 
with caesium (C, green) and without alkali (B, blue) adduction.  The differences between the 
maps is shown (D). 
 
6.4.2.4. Myristoyl-ACP 168 
Lithium adduction to myristoyl-ACP 168 significantly improves the sequence 
coverage of phosphorylated fragment ions compared to without lithium adduction.  
However, fragments near to the active site serine are lacking (Figure 89).  Increasing 
the CAD voltage, on the lithiated parent ion, does not improve the sequence 
coverage, but it is still superior to the non-lithiated sample.  (Appendix 79) 
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Figure 89  Cleavage coverage maps only showing phosphorylated b and y ions resulting 
from collisionally activated dissociation (25V) of myristoyl-ACP 168 with (A, red) and 
without (B, blue) lithium adduction.  The differences between the maps is shown (C). 
 
6.4.2.5. Nonhydrolysable photolabile malonyl carba(dethia) ACP analogue 
63 
The sequence coverage of phospho-peptide ions is superior for the ACP analogue 63 
sample without alkali adduction, compared to both the lithiated and caesiated.  
However, sequence coverage specifically in the region of the active site serine is 
better in the lithiated sample, but would only narrow down the amino acid to within 
28 amino acids.  The caesiated sample fails to generate any phosphorylated fragment 
ions (Figure 90).  Increasing the voltage of CAD on the lithium adducted ACP 63 to 
30V reduces the sequence coverage, and decreases the number of phospho-peptide 
ions around the active site serine.  (Appendix 80) 
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Figure 90  Cleavage coverage maps only showing phosphorylated b and y ions resulting 
from collisionally activated dissociation (28V and 18V) of nonhydrolysable photolabile 
malonyl carba(dethia) ACP analogue 63 with lithium (A, red), with caesium (C, green) 
(Note: none detected) and without alkali (B, blue) adduction.  The differences between the 
maps is shown (D). 
 
6.4.3. The effect of alkali metal adduction to ACPs on the production of 
peptide ions bearing the phosphopantetheinyl arm for post-
translational modification mapping 
CAD will typically cleave a phosphodiester bond, or a phospho group from a peptide 
or protein, however, this is not favourable for PTM mapping.  This section explores 
whether the addition of an alkali metal salt to protein samples prior to CAD analysis 
can improve the technique of PTM mapping for modifications linked by a 
phosphodiester bond, by analysing a range of modified ACPs. 
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6.4.3.1. Acetyl-ACP 40 
The acetyl-phosphopantetheinyl (PPant) group remains bound to many of the ‘b’ and 
‘y’ ions upon 25V CAD fragmentation, both with and without lithium adduction, 
however, with lithium bound there is a greater number of both types of ions.  
Fragments near to the active site serine in the middle of the protein are lacking, 
however (Figure 91).  
 
Figure 91  Cleavage coverage maps only showing ‘b’ and ‘y’ ions with the acetyl-
phosphopantetheinyl arm bound, resulting from collisionally activated dissociation (25V) of 
acetyl-ACP 40 with (A, red) and without (B, blue) lithium adduction.  The differences 
between the maps is shown (C). 
 
The voltage, with lithium bound to the parent ion, could be increased to 35V, but this 
significantly reduces the number of ions with the PPant group remaining bound.     
(Appendix 81) 
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6.4.3.2. Malonyl-ACP 7 
The malonyl-PPant group remains bound to a small amount of the ‘b’ and ‘y’ ions, 
distributed evenly throughout the protein, with and without lithium adduction, but 
these ions are not detected from caesium adducted to the parent malonyl-ACP ion 7.  
Only two more ‘b’ ions are found in the spectra from CAD without lithium 
adduction (Figure 92).  When the voltage is increased to 40V, both with and without 
lithium adduction, no malonyl-PPant ‘b’ or ‘y’ ions are detected in the spectra.  
 
Figure 92  Cleavage coverage maps only showing ‘b’ and ‘y’ ions with the malonyl-
phosphopantetheinyl arm bound, resulting from collisionally activated dissociation (35V) of 
malonyl-ACP 7 with lithium (A, red), with caesium (C, green) (Note: none detected) and 
without alkali (B, blue) adduction.  The differences between the maps is shown (D). 
 
6.4.3.3. Acetoacetyl-ACP 167 
The addition of an alkali metal salt to the acetoacetyl-ACP 167 samples does not 
increase the number of ‘b’ or ‘y’ ions with the acetoacetyl-PPant group bound.  Six 
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more PPant ions are detected without the additional sample preparation (Figure 93).  
Increasing the CAD voltage from 30V to 40V to the parent ions with and without 
lithium adduction results in no acetoacetyl-PPant bound peptides.  
 
Figure 93  Cleavage coverage maps only showing ‘b’ and ‘y’ ions with the acetoacetyl-
phosphopantetheinyl arm bound, resulting from collisionally activated dissociation (30V) of 
acetoacetyl-ACP 167 with lithium (A, red), with caesium (C, green) and without alkali (B, 
blue) adduction.  The differences between the maps is shown (D). 
 
6.4.3.4. Myristoyl-ACP 168 
At 25V CAD, the lithiated myristoyl-ACP 168 produces many more myristoyl-PPant 
peptide ions than in the non-lithiated sample.  The ions are mainly from the termini 
of the protein, and not as many near to the active site serine, at amino acid 45 
(Figure 94).  Increasing the CAD voltage to 35V, only capable with the lithiated 
parent ion 168, abolishes all production of PPant bound peptide ions.  
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Figure 94  Cleavage coverage maps only showing ‘b’ and ‘y’ ions with the myristoyl-
phosphopantetheinyl arm bound, resulting from collisionally activated dissociation (25V) of 
myristoyl-ACP 168 with (A, red) and without (B, blue) lithium adduction.  The differences 
between the maps is shown (C). 
 
6.4.3.5. Nonhydrolysable photolabile malonyl carba(dethia) ACP analogue 63 
The CAD spectra resulting from fragmentation of both lithiated and non-lithiated 
ACP analogue 63 parent ions were quite similar in number of PPant peptide ions, but 
the peptide ions generated are slightly different.  Combining the data from the two 
spectra results in a much higher sequence cover.  The caesiated parent ion 63 does 
not provide PPant bound ‘b’ or ‘y’ ions (Figure 95).  Increasing the voltage to 30V 
for fragmentation of the lithiated parent ion 63 reduces the sequence coverage of 
PPant bound ions.  (Appendix 82) 
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Figure 95  Cleavage coverage maps only showing ‘b’ and ‘y’ ions with the nonhydrolysable 
photolabile malonyl carba(dethia)-phosphopantetheinyl arm bound, resulting from 
collisionally activated dissociation (28V and 18V) of nonhydrolysable photolabile malonyl 
carba(dethia) ACP analogue 63 with lithium (A, red), with caesium (C, green) (Note: none 
detected) and without alkali (B, blue) adduction.  The differences between the maps is shown 
(D). 
 
6.4.4. Summary and conclusions: The application of alkali metal 
adduction to acyl carrier proteins (ACPs) on the production of 
peptides by CAD, and the application to post-translational 
modification mapping 
Five different ACPs, acetyl 40, malonyl 7, acetoacetyl 167, myristoyl 168 and, an 
unnatural analogue, nonhydrolysable photolabile malonyl carba(dethia) 63, were 
241 
 
prepared for analysis by CAD on an FTICR-MS.  Each sample was prepared with 1 
mM of either lithium chloride or caesium carbonate, to provide the respective alkali 
adducted parent ions for isolation and subsequent fragmentation.  Lithium parent 
ions were produced for each ACP, however a caesiated precursor ion for myristoyl-
ACP 168 was not generated with sufficient intensity to be isolated for CAD analysis.  
Each lithium adducted parent ion could be fragmented with a higher CAD voltage 
than its respective non-lithiated ion; increasing the voltage did not increase the 
sequence coverage, however, it did alter the type of fragments.  
Caesiated parent ions never generated a substantial number of peptide fragments, in 
most cases they did not produce any.  This is likely due to the primary fragmentation 
pathway of the loss of the caesium ion and charge reduction.  
At the same voltages, the lithiated parent ion was not always the sample to provide 
the highest sequence coverage.  Acetyl 40 and myristoyl 168 ACPs were the only 
two samples to clearly show an increase in sequence cover with lithium adduction 
compared to without.  Malonyl-ACP 7 had similar sequence coverage with and 
without lithium adduction, but without the alkali adduction was marginally better.  
Acetoacetyl-ACP 167 and the unnatural ACP analogue 63 demonstrated clear 
improvements to the sequence cover without lithium adduction.  It would be hard to 
predict this outcome; however, the simple sample preparation and possible 
improvements could prove beneficial for identifying and characterising proteins.  An 
extended study on a wider variety of ACPs with varying chain lengths and chemical 
moieties may discover a link between the PPant group and the sequence cover. 
PTM mapping is an important characterisation technique for peptides and proteins.  
The PPant group of ACPs can either remain bound to the fragment peptide ions, be 
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partially cleaved, often leaving a phosphorylated ion, or be cleaved entirely resulting 
in an apo-peptide ion.  The latter is not useful for PTM mapping, however both the 
partially fragmented and intact PPant group can be used to locate the active site 
serine.  
Increasing the voltage for fragmentation of the lithiated precursor ions resulted in 
losses of phosphorylated or PPant peptide ions with all ACPs except for acetyl-ACP 
40, however that only resulted in two more phospho-peptide ions being detected.  
Increasing the voltage resulted in a more substantial loss of PPant bound ‘b’ and ‘y’ 
ions, it is likely that the group is being cleaved off at higher voltages.  
Caesium adduction resulted in very few peptides ions with either the phospho or 
PPant group bound. 
The adduction of lithium improved the sequence coverage of phosphorylated ‘b’ and 
‘y’ ions in the spectra of acetyl 40 and myristoyl 168 ACPs.  In all other spectra, the 
samples without additional alkali adduction generated more phosphorylated peptide 
ions.  
The number of PPant-peptide ions generated was improved by lithium adduction in 
the fragmentation of, again, acetyl 40 and myristoyl 168 ACPs.  In the spectra of the 
malonyl-ACP 7 and the ACP analogue 63 the difference between lithiated and non-
lithiated was marginal.  Acetoacetyl-PPant fragment ions, from fragmentation of 
acetoacetyl-ACP 167, were more abundant in the spectra produced without 
additional alkali adduction.   
The benefits of alkali adduction for mapping PTMs of proteins appears to depend 
upon the specific ACP as the results varied from ACP to ACP.  A wider study with a 
range of ACPs, as well as with a variety of modifications, such as polyketide 
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intermediates, would reveal when alkali metal adduction can be effective for locating 
PTMs.  
 
6.5.  Summary and conclusions: Alkali metal adduction assisted tandem 
mass spectrometry for molecular structural determination 
The influence of alkali metal adduction to a small molecule 61 and five ACPs has 
been explored through CAD, and with EID to the small molecule.  
The impact of the simple sample preparation technique on the fragmentation 
pathways of the small molecule 61 in both CAD and EID was determined by direct 
comparison with the same MS methods applied to each sample.  Although EID is the 
more advanced and time consuming technique, several new fragments were 
generated with this fragmentation method compared to CAD.  The adduction of 
lithium, by far, provided the most fragment ions by CAD, and lithium and caesium 
adduction generated new fragments by EID that were not seen with sodium 
adduction.  Although this study was carried out with just one compound, the 
improvements indicate that adding lithium chloride to a small molecule sample prior 
to fragmentation could be beneficial for structural characterisation.  Analysis of a 
database of small molecules could determine whether this increase in fragments is 
common to a variety of compounds when lithiated, as well as reveal why this 
enhancement occurs. 
The production of a small Pant ion upon CAD fragmentation of holo-ACPs was 
explored with lithium and caesium adduction.  The addition of caesium carbonate to 
the samples did not benefit the ‘ejection’ of a Pant ion, mostly due to the primary 
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fragmentation pathway being the loss of the caesium adduct and the reduction of 
charge.   
 
Table 7  Comparison of lithiated and non-lithiated ACP samples. A tick indicates whether 
samples with or without lithium adduction resulted in a more insightful spectrum from CAD 
fragmentation, either to produce a phosphopantetheinyl (PPant) ion, sequence cover, and 
for post-translational modification mapping (the detection of phosphorylated or Pant ions). 
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Lithium adduction had varying influence on providing the Pant ion, depending upon 
the specific ACP being analysed.  This response was also seen with the sequence 
coverage, and PTM mapping potential.  The acetyl 40 and myristoyl 168 ACPs 
responded most favourably towards lithium adduction of the five ACPs (Table 7). 
There was always a variance between samples prepared with lithium chloride and 
those without, although not necessarily to the benefit of the original goal, this aspect 
needs to be investigated further for its potential.  Both the types of modifications to 
the ACP, as well as the ACP protein itself, need to be broadened to discover a 
relationship between the alkali metal adducted and the influence on CAD 
fragmentation pathways. 
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Chapter 7: Conclusions and future work 
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7. Conclusions and future work 
The core aim of this project was to develop a new method to trap biosynthetic 
intermediates from an iterative type II PKS, a task that had yet to be accomplished 
before.  The method herein devised utilised a photoactivatable nonhydrolysable 
malonyl acyl carrier protein probe 63 to off-load and capture enzyme-bound 
biosynthetic intermediates from the minimal system of the actinorhodin 2 PKS. 
The secondary research aim was to compare the efficiency of intermediates caught 
by a small molecule photolabile probe 65 with the ACP probe 63.  Unfortunately, the 
small molecule probe 65 was unsuccessful in capturing any intermediates from the 
actinorhodin minimal system PKS.  There was insufficient time to explore this in 
more detail, however, the small molecule photolabile probe 65 proved capable of 
capturing intermediates from the lasalocid A 1 biosynthetic pathway in vivo.   
The final aim was to investigate the future potential for mass spectrometry in the 
analysis of polyketides, and proteins associated with natural product biosynthesis.  
Alkali metal adduction to samples showed promise for structural characterisation of 
small molecules, as well as boosting the signal of fragment ions from holo-ACPs.  In 
addition, a less known technique, electron impact dissociation (EID), was compared 
with the widely used collisionally activated dissociation (CAD) for its possible 
advantages for structural characterisation of small molecules. 
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7.1. Probing the biosynthesis of an iterative polyketide PKS with a 
photoactivatable nonhydrolysable malonyl acyl carrier protein probe 63 
and future work 
A photoactivatable ACP probe 63, the first of its kind, was chemoenzymatically 
synthesised via six chemical steps to pantetheine analogue 61, then over three 
enzymatic steps in a one pot reaction to CoA analogue 62, and finally enzymatically 
loaded onto apo actACP 44 to generate the protected ACP probe 63.  This synthesis 
was repeated numerous times throughout the project, and optimised to produce a 
robust protocol.  
The act ACP probe 64 proved promising in capturing selected putative intermediates 
from the actinorhodin minimal system, spanning from diketide 145 to hexaketide 
149 (Scheme 31).  If further confirmed by MS
n
 experiments, these would be the very 
first intermediates ever captured from type II PKS assembly.  
The intermediate capture via probe 64 did prove inconsistent though, with different 
intermediates captured in experiment repeats.  If this was somehow expected, 
reproducibility could perhaps be improved upon with the use of stopped flow 
equipment whereby each enzyme component is handled by a robot.  
An autocorrelation algorithm allowed confirmation of the presence of the putative 
species manually identified.  This is the first time that such a technique has been 
used within the natural products field and, in the future, it will be possible to use the 
algorithm to identify isotope distributions in the spectra simultaneously with their 
assignment.
303
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Scheme 31 Capture of putative intermediates from the actinorhodin minimal system. 
 
Due to the size of the protein and its relatively small modification, FTICR-MS was 
best suited for detection of putative captured intermediates bound to their ACP 
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‘trap’.  This instrument generates very high resolution data and can accumulate ions 
in the ICR cell resulting in high sensitivity.  Unfortunately, LC on the FTICR-MS 
was not feasible as the file size exceeded the capabilities at the time.  Retention time 
of the intermediates on a RP column would have provided additional characterisation 
by way of an insight into the polarity of the trapped intermediates, in particular for 
cyclised/dehydrated species.   
A trypsin digest of actACP was shown to provide two different peptides containing 
the active site serine, and these peptide ions were detected on a QTOF at sufficient 
resolution to be able to accurately identify species bound to the PPant arm.  
Optimising this method of analysis would allow those without access to FTMS to 
carry out the intermediate trapping; unfortunately, this was not pursued within the 
time constraints.     
Fragmentation by CAD of the ACP-bound intermediate ion to generate a PPant 
fragment ion was not possible because of their low intensity, but this challenge could 
be overcome by scaling up the reactions to provide enough material for further MS
n
 
characterisation.  Further fragmentation of the ejected Pant ion would generate of 
plethora of information towards structural characterisation.   
NMR or crystallography, however, would be the ideal techniques for characterisation 
of cleaved PPant moieties in detail, and this could be achieved by utilising an ACP 
hydrolase (AcpH) to cleave the PPant arm
305, 340
.  Additionally, the mixture of 
cleaved PPant arms produced from such a reaction could be analysed by LC-
MS/MS. 
Ion mobility MS is a mass spectrometric technique by which gas phase ions are 
separated by their movement through a drift tube containing a carrier gas and an 
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electric charge.  More compact ions travel through the drift tube faster than less 
compact ions resulting in separation of ions.  This method of separation could be 
used for characterisation of the biosynthetic intermediates bound to the ACP, and it 
could provide an insight into the structure of the ACP during biosynthesis.  
The use of UV analysis for real time detection of SEK4/4b
13
 41/42 was explored 
within this project, however the DMNB group absorbed too strongly at the 
wavelength of interest.  Either investigation into alternative wavelengths for 
detection of SEK4/4b 41/42 or the use of a different photolabile group may allow 
this highly valuable avenue of analysis to be explored further in the future. 
Labelling of the act ACP in vivo in E. coli was achieved showing the potential for in 
vivo off-loading of intermediates with the ACP probe 64.
115-117, 304
  Time constraints 
did not allow further experiments, however complete reconstruction of the minimal 
system within a suitable host, likely S. coelicolor, and similar labelling of the act 
ACP will be possible in the future for off-loading in vivo.   
Lastly, synthesising ACP probes from other PKSs is the next obvious step.  Type II 
PKSs were the aim in this project, but type I PKSs, both iterative and modular, as 
well as FASs, could also be investigated.  Not explored within this project is the 
potential for the CoA analogue 62 to be used as a probe for type III PKSs, but also in 
other processes that require malonyl-CoA 15 as a cofactor such as in the regulation 
of carnitine acyltransferase.
341
  Using AcpH to cleave the PPant arms with bound 
intermediates would generate a library of unnatural polyketide derivatives which 
could be more efficient that the natural compound, or even have a new 
bioactivity.
155, 156
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7.2. Capture of intermediates by the small molecule NAC probe 65 and 
future work 
A photoactivatable NAC probe 65, the first of its kind, was chemically synthesised 
via three chemical steps.  This probe was utilised both in vivo and in vitro.  66 was 
unable to off-load intermediates from the actinorhodin minimal system both in vivo 
and in vitro, whereas the ACP probe 64 was successful in capturing intermediates in 
vitro.  It may be possible to further optimise the in vitro conditions, such as the 
timing and length of photoirradiation, to enable the DMNB NAC probe 65 to capture 
intermediates, but, without further improvements, the ACP probe 64 is currently the 
most promising in vitro trapping agent for the actinorhodin minimal system.   
Delayed addition of the active DMNB probes 63 and 65 was explored in vitro with 
the actinorhodin minimal system (Sections 4.1.2 and 5.2.4).  The addition of active 
NAC probe 66 reduced the production of SEK4/4b 41/42 when it was added after 60 
seconds and later (Figure 28).  Further repeats (for example, with the use of stopped 
flow equipment to gather more time points and increase accuracy) would be able to 
confirm and rationalise this result, especially in comparison with the opposite effect 
obtained via the use of the ACP probe 64 in the same settings.  This could indeed 
indicate a difference in the interactions of the two probes 64 and 66 with the 
actinorhodin minimal system, but for which no definitive conclusion can be inferred 
at this stage.    
Within the Tosin group, success had been achieved in the investigation of the 
lasalocid A 1 biosynthetic pathway from S. lasaliensis utilising NAC probes.
22, 155, 156
  
Herein S. lasaliensis was fed with the DMNB probe 65 and this led to the capture of 
two lasalocid A advanced intermediates 131 and 132 previously observed.  Besides 
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two new putative intermediate species, the 135 and 136, resulting from off-loading 
from ACP8, and further modification was detected and characterised. 
Optimisation of these experiments with the DMNB NAC probe 65 in S. lasaliensis 
was not pursued within the project timeframe.  Further exploration of time and 
duration of irradiation events could play a crucial role in improving the ability to 
capture intermediates, as well as if other factors such as photolysis quantum yield 
and bioavailability.  
As discussed in Section 2.2, there are a variety of photolabile protecting groups that 
can be used for the masking of carboxylic acid groups.  The DMNB group was 
chosen as it is widely studied and easily introduced via established synthetic routes, 
however the use of alternative groups should be explored in the future.  The DMNPP 
group 112 has a higher quantum yield than the DMNB group
265
, however the 
synthetic route for its incorporation into chain termination probes would become 
more complex.  Cell permeability may be a factor affecting the efficiency of the 
NAC probe 65, and this could be altered by hydrophilic or hydrophobic substitutions 
to the benzene ring as in 108, 109 or 110.
255
  Coumarin based protecting groups can 
offer alternative non-protein damaging cleavage wavelengths, such as MCM 92 
(cleaving at 340 nm)
232
 or tBhc 91 (at 397 nm)
234
.  SEK4/4b 41/42 production was 
demonstrated to be affected by the irradiation with 365nm (Figure 34), therefore a 
different investigatory wavelength may prove useful.  Possible next generation 
photolabile probes are illustrated in Figure 96.  
Alternative photolabile protecting groups may open up opportunities for real time 
UV detection of SEK4/4b 41/42, which was prohibited by the strong absorption of 
the DMNB group at the wavelength required for detection of SEK4/4b 41/42.  
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Figure 96 Potential next generation photolabile NAC analogues for off-loading of 
biosynthetic intermediates.  179 presents the DMNPP group that is reported to have a 
higher quantum yield than the DMNB group
265
.  180 presents the tBhc group that cleaves at 
397 nm
234
.  181 presents the MCM group that cleaves at 340 nm
232
.  182-184 have 
hydrophobic or hydrophilic substitutions to the benzene ring affecting their membrane 
permeability
255
. 
 
Lasalocid A 1 present stereogenic centres that are likely crucial in determining its 
bioactivity, although this has not been explored extensively due to the complexity of 
its chemical synthesis.  At this point, the chirality of the putative off-loaded 
intermediates from the lasalocid A 1 PKS is unknown.  The putative undecaketide 
131 and the two putative nonaketides 135 and 136 present a single peak in the LC 
chromatograms (Figure 37, Figure 43, and Figure 44), however the off-loaded 
dodecaketide 132 is detected in two distinct peaks (Figure 42).  These are likely due 
to stereochemical differences.  The characterisation of these two stereoisomers 
would require large scale feeding experiments to produce enough material for a 
detailed NMR analysis.  A MS fragmentation technique, EID, has been proven to be 
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able to differentiate iso-lasalocid A from lasalocid A 1
191
.  EID of the two isolated 
peaks of dodecaketide 132 would aid the characterisation of the compounds, 
furthermore, EID analysis requires less material than NMR. 
Lastly, as discussed in greater detail in chapter 6, the addition of alkali metals, in 
particular lithium, to the LC solvent has the potential to boost the MS signal of off-
loaded biosynthetic intermediates from in vivo and in vitro feeding experiment 
extracts or aid MSMS analysis. 
 
7.3. Alkali metal assisted tandem MS and future work 
A synthetic analogue of pantetheine 61 was extensively analysed by CAD and EID 
with sodium, lithium or caesium ions.  The impact of the alkali metal ions on the 
“PPant ejection assay” was also explored.  The preliminary conclusion was that the 
addition of the alkali metal salts to samples was beneficial towards the goal of 
characterisation.  It is not possible, at this point, to determine which alkali metal 
provided the most useful information, but analysing compounds with each alkali 
metal in turn and combining the results would allow full structural characterisation.  
To gather a full picture of the benefits of this sample preparation requires a broader 
study using additional fragmentation techniques and mass spectrometers, more 
adducted ions, and many more compounds.  In particular, whether the type of ACP 
(type I iterative, type I modular, type II, etc.), the PPant arm of the ACP (acetyl-ACP 
40, malonyl-ACP 7, etc.) or the alkali metal ion have the greatest influence on the 
efficiency of the PPant ejection. 
A full library of fragmentation spectra could then be statistically analysed and 
predictions could be made as to the most useful adduct for the desired purpose. 
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8. Experimental 
8.1. General methods for synthetic chemistry 
NMR spectra were recorded on Bruker DPX 300, 400, 500 or 700 spectrometers.  
For 
1
H- and 
13
C-NMR the chemical shifts are reported relative to the solvent signal 
(CDCl3 δH 7.26, D2O δH 4.80, CDCl3 δC 77.0).  TLC was performed on aluminium 
sheets precoated with silica gel 60 (F254, Merck) and spots were visualized by UV 
and charring with permanganate dip.  Flash column chromatography was carried out 
with silica gel 60 (0.040-0.630 mm, Merck) using a stepwise solvent polarity 
gradient.  Anhydrous solvents were purchased from Sigma-Aldrich. Preparative 
HPLC was carried out on Agilent Technologies 1200 series HPLC with a C18 
column (Zorbax® XDB-C18 21.2x15mm, 5 µm), at a flow rate of 20 mL/min and 
UV detection set at 280, 254, and 210 nm.   
Semi-preparative HPLC was carried out on Agilent Technologies 1200 series HPLC 
with a C18 column (Phenomenex Synergi™ 4 µm Polar-RP 80 Å, 250 x 10 mm), at 
a flow rate of 2.5 mL/min and UV detection set at 280, 254, and 210 nm. 
High resolution mass spectrometry data was recorded on a Bruker MaXis mass 
spectrometer.  Ultra high resolution mass spectrometry data was recorded on a 
solariX 12T FT-ICR mass spectrometer (Bruker Daltonik GmbH, Bremen, 
Germany), equipped with an Infinity cell.
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8.2. Irradiation procedures 
8.2.1. In vitro 
Samples were placed in a quartz cuvette for irradiation with an OBB Tunable 
KiloArc™ Illuminator.  Unless otherwise stated, a wavelength of 365 nm was used 
for all irradiation events, at 1000W. 
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8.2.2. In vivo 
Cultures in liquid or solid media were placed within a home built light box, equipped 
with a circular 22W UVA lamp, able to be fixed to an Innova
TM
 4300 Incubator 
Shaker, New Brunswick Scientific platform for temperature and shaking.  The light 
box was purposely built by Rod Wesson (Electronics workshop, University of 
Warwick, UK).  Cultures were irradiated for varying lengths of time, as stated.   
 
8.3. Expression and purification of Histidine-tagged proteins in E. coli – act 
apoACP 44, Sfp, PanK, PPAT, and DPCK 
His-tagged proteins were expressed and purified from cultures of E. coli BL21*, 
DE3 and Rosetta 2* strains grown in autoclaved (Astell autoclave) LB broth media 
(Miller, BP1426-2, 25g/L).  The actACP and Sfp plasmids were gifts from Dr Hui 
Hong, University of Cambridge.  The actACP gene was inserted as Ndel-BamHI 
fragment in pET28a, PanK and DPCK genes were inserted as Ndel-HindIII 
fragments into pET28a, and the PPAT gene were inserted as NheI-HindIII fragments 
into pET28a, all with N-terminal hexa-histadine tags.  Precultures of approximately 
10 mL of LB media, containing the appropriate antibiotic (10 μL of 25 mg/mL 
kanamycin for actACP, Sfp, PanK and PPAT, 10 μL of 100 mg/mL Carbenicillin for 
DPCK, and 10 μL of 100 mg/mL ampicillin for ACPP and FabH) were incubated 
overnight at 30
o
C, at 180 rpm (Innova
TM
 4300 Incubator Shaker, New Brunswick 
Scientific).  The preculture was transferred to 1L flasks of LB media with 1 mL of 
the appropriate antibiotic (as previous), and incubated at 37
o
C, 180 rpm (Innova
(R)
 44 
Incubator shaker series) until an optical density of between 0.5 and 0.8 at 600 nm 
was reached.  At this point 1 mL of Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
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0.5M was added to each 1 L flask to induce protein expression.  The flasks were 
incubated at 15
o
C and 180 rpm overnight (Innova
(R)
 44 Incubator shaker series).  
The cultures were centrifuged at 5000 rpm at 4
o
C, for 15 minutes (Sorvall
(R)
 RC6 
Plus, SLA 3000 Super-lite rotor).  The pellets, containing the whole cells, were 
resuspended in binding buffer (100 mM potassium phosphate, 20 mM imidazole, 
10% glycerol, pH 7.3).  The cells were lysed with a cell disruptor (Constant systems, 
Ltd), at 20 kPSI, one shot.  The lysed cells were then centrifuged at 20000 rpm for 
30 minutes (Beckman Coulter Avanti
TM
 J-30I centrifuge).  The supernatant was 
added to 1 mL of charged Ni-sepharose
TM
 6 Fast Flow resin (equilibrated into the 
binding buffer), and mixed at 4
o
C. 
After 1 hour, the resin was washed with 20 mL of wash/binding buffer (100 mM 
potassium phosphate, 20 mM imidazole, 10% glycerol, pH 7.3) was used to wash off 
loosely bound proteins, and finally 6 mL of elution buffer (100 mM potassium 
phosphate, 500 mM imidazole, 10% glycerol, pH 7.3) was added to the column to 
elute the His-tagged proteins.  This final fraction was buffer exchanged with a PD10 
desalting column (GE Healthcare) into tris (50 mM), potassium chloride (20 mM), 
magnesium chloride (10 mM), pH 8 buffer and stored in 50% glycerol at -80
o
C. 
Bradford assay was used to determine protein concentration using bovine serum 
albumin (0.1 mg/mL to 0.7 mg/mL) as calibrant. 
 
8.4. SDS-PAGE analysis 
At each step of the expression and the purification a sample was kept for Sodium 
Dodecyl Sulphate-Protein Agarose Gel Electrophoresis (SDS-PAGE) analysis 
(Table 8).  A PageRuler
TM
 Plus Prestained Protein Ladder from Fermentas was run 
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alongside all samples. SDS-PAGE loading dye (4.8 mL H2O, 1.2 mL 1 M Tris-HCl 
pH 6.8, 1 mL 100% glycerol, 2 mL 10% w/v SDS, 0.5 mL 0.1% w/v bromophenol 
blue) was added to each sample.  A 10X SDS PAGE running buffer (10X) 288 g 
glycine, 60.4 g tris, 20g SDS in 2L distilled H2O, diluted by a factor of 10 for each 
SDS-PAGE analysis.  The gels were pre-run for 30 mins, then loaded with the 
samples and run at 200V.  The gels were stained with InstantBlue
TM
 Dye and viewed 
with white light. 
 
10% 
(5 mL) 
12% 
(5 mL) 
15% 
(5 mL) 
18% 
(5 mL) 
Stacking Gel 
(1 mL) 
Water 1.9 mL 1.6 mL 1.1 mL 0.6 mL 0.68 mL 
30% Acrylamide 
mix 
1.7 mL 2 mL 2.5 mL 3 mL 0.17 mL 
1.5 M Tris (pH 8.8) 1.3 mL 1.3 mL 1.3 mL 1.3 mL - 
1.0 M Tris (pH 6.8) - - - - 0.13 mL 
10% SDS 50 μL 50 μL 50 μL 50 µL 10 µL 
10% APS 50 μL 50 μL 50 μL 50 µL 10 µL 
Tetramethylethylene
diamine (TEMED) 
2 μL 2 μL 2 μL 2 µL 1 µL 
Table 8 SDS-PAGE recipes 
 
8.5. Expression and purification of act KS-CLF in S. coelicolor 
KS-CLF was expressed and purified from frozen S. coelicolor CH999/pRJC006, 
previously transformed with the required KS-CLF expression vector, pCB84, (gift of 
Dr Cosby, University of Bristol
14
) grown in autoclaved (Astell autoclave) Super 
YEME media (1.5 g yeast extract, 2.5 g bacto peptone, 1.5 g malt extract, 5 g 
glucose, 170 g sucrose in 500 mL dH2O and autoclaved, then 37.5 mg L-proline, 
37.5 mg L-arginine, 37.5 mg L-cysteine, 50 mg L-histidine, 7.5 mg uracil, 6.25 mL 
glycine (20%) and 500 µL MgCl2.6H2O (2.5 M)).  A preculture of 10 mL was 
261 
 
incubated at 30
o
C, 180 rpm for 5 days, and then 250 mL super YEME was 
inoculated with 5 mL preculture, 500 L kanamycin (50 mg/mL) and 250 L 
nalidixic acid (25 mg/mL) for a further 2 days at 30
o
C, 180 rpm.  The cultures were 
induced with 250 L fresh thiostrepton in DMSO (10 mg/mL), and incubated at 
30
o
C, 180 rpm for 5 days.   
The cells were pelleted at 9000 rpm for 25 mins, and the supernatant was discarded.  
The cells were resuspended in binding buffer (0.1 M potassium phosphate buffer, 
10% glycerol, pH 7.3) and disrupted with 30 kPsi, one shot.  The lysed cell 
suspension was centrifuged at 20000 rpm, for 30 mins.  Streptomycin sulphate was 
added (0.5 g per 25 mL) to the supernatant to precipitate the DNA, and mixed for 20 
mins before centrifugation at 20000 rpm, 30 mins.  The supernatant was purified by 
Ni-sepharose
TM
 resin as before (see section 8.3).  (Wash buffer: 0.1 M potassium 
phosphate, 40 mM imidazole, 10% glycerol, pH 7.3. Elution buffer: 0.1 M potassium 
phosphate, 500 mM imidazole, 10% glycerol, pH 7.3.  A PD10 column was used to 
buffer exchange into a storage buffer (0.1 M potassium phosphate, 2 mM DTT, 10% 
glycerol, pH 7.3), before storage in 50% glycerol at -80
o
C. 
SDS-PAGE analysis of the purified protein showed two discrete bands at 
approximately 50 kDa and 43 kDa, as previously reported.
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Bradford assay was used to determine protein concentration using bovine serum 
albumin (0.1 mg/mL to 0.7 mg/mL) as calibrant.  
8.6. Trypsin digestion of acyl carrier proteins 
0.38 µL trypsin (1 mg/mL) was added to 2 µmol acyl carrier protein in ammonium 
bicarbonate (100 mM) pH 8.5 to a final volume of 50 µL, and incubated for 4 hours 
at 37
o
C. 
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8.7. Thrombin cleavage of the Histidine-tag from act ACP 
The overexpressed ACP from the actinorhodin minimal system contains a His-tag 
linked with a thrombin cleavage site (Leu-Val-Pro-Arg-Gly-Ser).  Thrombin can be 
used to cleave the His-tag between the arginine and glycine, providing a cleaved 
protein, minus a His-tag. 
A Thrombin CleanCleave KitSigma, containing 50% slurry of immobilised 
bovine thrombin on agarose.  The resin was buffer exchanged into cleavage buffer 
(10X: 500 mM Tris-HCl, pH 8.0, 100 mM CaCl2) prior to use.  100 µL of thrombin-
agarose slurry will cleave 1 mg of target protein, at a concentration of 1 mg/mL 
(target protein) after six hours at room temperature with mixing by a see-saw rocker. 
 
The cleaved protein was purified from His-tagged protein by bench top purification 
with Ni-sepharose
TM
 6 Fast Flow resin, as described previously (Section 8.3).  
Cleavage of the His-tag was confirmed by SDS-PAGE and mass spectrometry. 
 
8.8. Phosphopantetheinylation of act apo-ACPs 44 in vitro 
Unless otherwise stated, in reaction buffer TrisCl (50 mM), KCl (20 mM), MgCl2 
(10 mM), pH 8, final concentrations of 0.3 mM of apo- acyl carrier protein 44, 0.03 
mM Sfp and 0.7 mM CoA analogue (3.2 mM malonyl-CoA 15, excess due to rapid 
decarboxylation), were incubated at room temperature for 2 hours.  Samples were 
monitored for full phosphopantetheinylation by UPLC-MS analysis (Section 8.16.3). 
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8.9. Loading of act KS-CLF 
Unless otherwise stated, KS-CLF was primed with acetyl groups by incubation of 
0.12 mM KS-CLF with 1.2 mM acetyl-CoA 17, 0.12 mM apo- acyl carrier protein 
44, 0.012 mM Sfp, final concentrations, in TrisCl (50 mM), KCl (20 mM), MgCl2 
(10 mM), pH 8, at room temperature for 2 hours. 
 
8.10. Reconstitution of enzymatic activity for the act PKS minimal 
system 
Unless otherwise stated, the actinorhodin minimal system was reconstituted in vitro 
as follows. Holo- ACPs and the acetyl loading of KS-CLF were generated 
immediately prior to this reaction.  
Final concentrations of 0.16 mM malonyl-ACP 7, 3 µM loaded acetyl-KSCLF and 
excess 1 mM malonyl-CoA 15 were incubated in TrisCl (50 mM) pH 8 buffer at 
room temperature, overnight.  Enzymes were tested for activity by the production of 
SEK4/4b 41/42 (Sections 8.15 and 8.16.4). 
 
8.11. Trapping of intermediates from the act minimal system with the 
protein probe 63 
The nonhydrolysable photolabile ACP analogue was not His-tagged for these 
experiments to enable selective isolation of these species and others related to it from 
the other enzymatic components.  The cleavage of the His-tag is described in section 
8.7.  
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Unless otherwise stated, cleaved apo-ACP 44 was phosphopantetheinylated with 
DMNB protected carba(dethia) CoA 63 as described in section 8.8.  His-tagged apo-
ACP 44 was phosphopantetheinylated with malonyl-CoA 15, also as described in 
section 8.8.    
DMNB protected ACP probe 63 was irradiated for 4 hours, either at 365 nm, 
1000W, with a KiloArc mercury lamp, or with a home built, 22W, UVA light 
source.  Following irradiation, malonyl-ACP 7 (0.16 mM), KS-CLF (3 µM) and 
excess malonyl-CoA 15 (1 mM) were added to the irradiated DMNB protected ACP 
probe 63, in TrisCl (50 mM) pH 8 buffer, and allowed to react over night at room 
temperature. 
The cleaved ACP analogue 63 and species deriving from it were separated from the 
other protein assay components by use of a Ni-NTA spin column (Thermo Scientific, 
HisPur Ni-NTA spin column, 0.2 mL resin bed).  Samples were mixed with the Ni-
NTA resin for 1 hour, at 4
o
C, and then washed three times with distilled H2O to elute 
the cleaved ACP of interest.  All other His-tagged proteins remained bound to the Ni 
resin. 
 
8.12. Trapping of intermediates from the act minimal system with the 
small molecule probe 65 
Unless otherwise stated, His-tagged apo-ACP 44 was phosphopantetheinylated with 
malonyl-CoA 15, as described in section 8.8.  The nonhydrolysable photolabile NAC 
analogue 65 was irradiated for 4 hours, either at 365 nm, 1000W, with a KiloArc 
mercury lamp, or with a home built, 22W, UVA light source.  Following irradiation, 
malonyl-ACP 7 (0.16 mM), KS-CLF (3 µM) and excess malonyl-CoA 15 (1 mM) 
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were added to the irradiated NAC analogue 65 and allowed to react over night at 
room temperature. 
HCl was added to each completed reaction, to acidify to pH 4, followed by EtOAc 
extraction three times, evaporation and reconstitution in 50 µL MeCN/H2O (1:1) for 
a 100 µL reaction volume. 
 
8.13. Feeding of DMNB NAC probe 65 to S. lasaliensis and preparation 
for LC-MS analysis 
All media and glassware were sterilized prior to use by autoclave (Astell).  Liquid 
cultures were incubated at 30
o
C, at 180 rpm (Innova 44 incubator/shaker (New 
Brunswick scientific)). 
M79 medium: 2.5 g glucose, 2.5 g peptone, 0.5 g yeast extract, 1.5 g NaCl, 2.5 g 
casein hydrolysate in 250 mL of tap water adjusted to pH 7.1. 
MYM medium: 1.0 g maltose, 1.0 g yeast extract, 2.5 g malt extract in 250 mL of 
tap water adjusted to pH 7.1. For solid medium, 2.2 g of agar was added to 100 mL 
of this media. 
Precultures of S. lasaliensis ACP12 (S970A) were grown in 10 mL M79 medium for 
3 days, then 100 µL of this preculture was used to inoculate 10 mL of MYM liquid 
cultures and grown for 5 days.  On days 2-5 6.25 µmol of probe 65 (previously 
dissolved in the minimum amount of DMSO), was added daily to the cultures to 
reach a final concentration of 2.5 mM.  Control cultures (without S. lasaliensis, 
without probe 65, without S. lasaliensis or probe 65, and with and without 
photolysis) were also grown in parallel.  After 5 days, the fermentation cultures were 
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extracted with EtOAc, evaporated and reconstituted in 1 mL MeCN/H2O (1:1) for 
LC-MS analysis. 
Solid MYM plates (5 mL) were prepared with 2.5 mM probe 65, and inoculated with 
5 µL S. lasaliensis ACP12 (S970A) spore stock, and grown at 30
o
C for 5 days.  
Plates were extracted with EtOAc, evaporated and reconstituted in 0.5 mL 
MeCN/H2O (1:1) for LC-MS analysis. 
 
8.14. Feeding to S. coelicolor and preparation for LC-MS analysis 
All media and glassware were sterilized prior to use by autoclave (Astell).  
Liquid cultures were incubated at 30
o
C, at 180 rpm (Innova 44 incubator/shaker 
(New Brunswick scientific)).  Solid cultures were incubated at 30
o
C. 
R4 medium: 2.5 g glucose, 750 mg proline, 2.5 g MgCl2·6H2O, 50 mg K2SO4, 25 mg 
Bacto casamino acids, 625 µL trace elements solution, 250 mg yeast extract and 1.4 
g TES in 250 mL of distilled water adjusted to pH 7.2.  (Trace elements solution: 40 
mg ZnCl2, 200 mg FeCl3·6H2O, 10 mg CuCl2·2H2O, 10 mg MnCl2·4H2O, 10 mg 
Na2B4O7·10H2O, (NH4)6Mo7O24·4H2O in 1 L distilled water).  For solid medium, 
2.2 g agar was added to 100 mL of this media. 
Precultures were grown in 10 mL R4 medium for 3 days, then 100 µL of the 
preculture was used to inoculate 10 mL R4 liquid media and grown for 5 days.  On 
days 2-5 (of 5) 6.25 µmol of probe, in DMSO, was added each day to the cultures, to 
a final concentration of 2.5 mM.  Control cultures were also grown in parallel: 
without S. coelicolor, without probe 65, without either S. coelicolor or probe 65, and 
with and without photolysis.   
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After 5 days, the liquid cultures were pH adjusted to pH 4 with HCl (conc.), 
extracted with EtOAc, evaporated and then reconstituted in 1 mL MeCN/H2O (1:1) 
for LC-MS analysis. 
Solid R4 plates (5 mL) were prepared with 2.5 mM probe 65, and inoculated with 5 
µL S. coelicolor M510 spore stock, and grown at 30
o
C for 5 days.  Cultures were 
extracted with EtOAc and 20 µL conc. HCl, evaporated, and reconstituted in 0.5 mL 
MeCN/H2O (1:1) for LC-MS analysis. 
8.15. Enzyme assay extraction 
Unless otherwise stated, all extractions from the actinorhodin minimal system in 
vitro assays were pH adjusted with conc.  HCl to approximately pH 4, and extracted 
into EtOAc three times.  EtOAc was removed in vacuo and reconstituted in 
MeCN/H2O. 
 
8.16. LC-MS analysis 
8.16.1. HPLC analysis of NAC probe 65 photolysis experiments 
The samples were analysed on an Agilent 1200 HPLC system coupled to a Bruker 
HCT Ultra mass spectrometer.  
HPLC Column: Waters Atlantis T3, 5µm, 2.1 x 150 mm C18 column. 
Flow rate: 0.3 mL/min 
Solvents: H2O/MeCN containing 0.1% formic acid 
Oven temperature: 25
o
C 
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Table 9 LC-MS gradient for the analysis of the nonhydrolysable photolabile SNAC analogue 
65 photolysis experiments 
 
8.16.2. UPLC-MS analysis of proteins (not including act ACPs) 
The samples were analysed on a Dionex UPLC system coupled to a Bruker MaXis 
mass spectrometer.  
Column: ACE C4-300 (UPLC) 
Flow rate: 0.2 mL/min 
Solvents: H2O/MeCN containing 0.05% trifluoroacetic acid 
Oven temperature: 30
o
C 
 
 
 
Table 10 UPLC-MS gradient for the analysis of proteins 
 
8.16.3. UPLC-MS analysis of act ACPs 
The samples were analysed on a Dionex UPLC system coupled to a Bruker MaXis 
mass spectrometer.  
Time (mins) % MeCN 
0 5 
5 5 
35 95 
40 95 
45 5 
Time (mins) % MeCN 
0 5 
5 5 
45 100 
50 100 
55 5 
60 5 
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Column: ACE C4-300 (UPLC) 
Flow rate: 0.2 mL/min 
Solvents: H2O/MeCN containing 0.05% trifluoroacetic acid 
Oven temperature: 30
o
C 
Time (mins) % MeCN 
0 5 
5 5 
10 40 
40 45 
50 100 
55 100 
60 5 
Table 11 UPLC-MS gradient for the analysis of acyl carrier proteins 
 
8.16.4. UPLC-MS analysis of cell and enzyme reaction extracts 
Samples were prepared as discussed in section 8.14 and 8.15.  
The samples were analysed on a Dionex UPLC system coupled to a Bruker MaXis 
mass spectrometer.  
Column: Eclipse plus C18, 1.8 µm, 2.1 x 100 mm (UPLC) 
Flow rate: 0.2 mL/min 
Solvents: H2O/MeCN containing 0.1% formic acid 
Oven temperature: 30
o
C 
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Time (mins) % MeCN 
0 5 
5 5 
35 100 
40 100 
45 5 
50 5 
Table 12 UPLC-MS gradient for the analysis of cell and enzyme reaction extracts 
 
8.16.5. UPLC-MS analysis of trypsin digested act ACPs 
Trypsin digested acyl carrier protein samples were prepared for LC-MS analysis by 
filtering and diluting through a 10 kDa cut off filter.  
Samples were analysed on a Dionex UPLC system coupled to a Bruker MaXis mass 
spectrometer.  
Column: Eclipse plus C18, 1.8 µm, 2.1 x 100 mm (UPLC) 
Flow rate: 0.2 mL/min 
Solvents: H2O/MeCN containing 0.1% formic acid 
Oven temperature: 30
o
C 
Time (mins) % MeCN 
0 5 
5 5 
35 100 
40 100 
45 5 
50 5 
Table 13  UPLC-MS gradient for the analysis of trypsin digested acyl carrier proteins 
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8.17. FTICR-MS analyses 
A calibration mix (Agilent HP tune mix) was used to externally calibrate the 
instrument prior to analysis of samples. Internal calibration was used to calibrate the 
data once it has been acquired from the instrument using Data Analysis software.  A 
series of peaks in the spectra were chosen, in as wide a range as possible.  The 
software was instructed to fit a calibration curve to the peaks chosen, and this was 
then applied to the spectrum.  Each spectrum was internally calibrated separately, 
with its own calibration curve, and a range spanning the whole m/z range required. 
Nanospray Ionisation (nESI) or Electrospray Ionisation (ESI) was used for sample 
injection. 
For CAD analyses the precursor ion was isolated in the quadrupole, and then 
fragmented in the collision cell (the collision gas was argon).  
 
8.18. Synthetic procedures 
 
3-[[(4R)-2,2-ditert-butyl-5,5-dimethyl-1,3,2-dioxasilinane-4-
carbonyl]amino]propanoic acid (74): To a solution of D-pantothenic acid 60 (1 g, 
4.2 mmol) in dry THF (10 mL) was added 2,6-lutidine (1.46 mL, 12.6 mmol).  This 
was cooled to 0
o
C and then Di-tert-butylsilyl bis(trifluoromethanesulfonate) (1.75 
mL, 5.4 mmol) was added, drop wise and the reaction mixture stirred for 18h at 
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room temperature.  The solvent was removed in vacuo to give 74 as a crude yellow 
oil; a portion of it was purified by prep-HPLC for characterisation whereas most of 
the crude material was utilised directly in the next reaction; 
1
H-NMR (400 MHz, 
CDCl3): δ 7.41 (t, 1H, J = 5.5 Hz, NH), 6.54 (br, 1H, OH), 4.44 (s, 1H, CH), 4.04 (d, 
1H, J = 11.5 Hz, CH), 3.67 (m, 1H, J = 5.5 Hz, 6.0 Hz, 6.5 Hz, CH), 3.51 (d, 1H, J = 
11.5Hz, CH), 3.48 (m, 1H, J = 6.5 Hz, 7.0 Hz, CH), 2.61 (t, 2H, J = 5.5 Hz, 6.0 Hz, 
CH2 ), 1.09 (s, 9H, CCH3), 1.08 (s, 9H, CCH3), 1.05 (s, 3H, CCH3), 1.04 (s, 3H, 
CCH3); 
13
C-NMR (100 MHz, CDCl3): δ 17.2, 171.4, 81.3, 75.4, 33.9, 28.7, 27.6, 
23.4, 23.3, 18.7; HRMS: m/z [M + Na]
+
, found: 382.2033, calculated: 382.2026. 
 
 
 
benzyl 4-[3-[[(4R)-2,2-ditert-butyl-5,5-dimethyl-1,3,2-dioxasilinane-4-
carbonyl]amino]propanoylamino]butanoate (76): To a solution of crude 74 (4.2 
mmol) and γ-aminobutyric acid benzyl ester p-tosylate 75 (0.97 g, 5.04 mmol) in dry 
THF (16 mL) was added N,N-Diisopropylethylamine (1.5 mL, 8.40 mmol).  This 
was cooled to 0
o
C for 10 minutes and O-(7-Azabenzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium hexafluorophosphate (HATU) (2.08 g, 5.46 mmol) was added.  
This was stirred at 0
o
C for 30 minutes, allowed to warm to room temperature, and 
then stirred at room temperature for a further 18h.  The solvent was removed in 
vacuo, and the product was extracted with EtOAc, washing the organic layer with 
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deionised water.  The organic layer was dried and concentrated, and the crude 
residue purified via flash chromatography with gradient elution (Rf = 0.4 in 
EtOAc:DCM 3:2 containing 1% Et3N) (1.48 g, 2.8 mmol, 66% over two steps) to 
afford 76; 
1
H-NMR (500 MHz, CDCl3): δ 7.37 (m, 6H, NH and ArH), 5.94 (t, J = 
5.0 Hz, 1H, NH), 5.14 (s, 2H, CH2), 4.43 (s, 2H, CH), 4.05 (d, 1H, J = 11.5 Hz, CH), 
3.66 (m, 1H, J = 6.0 Hz, 6.5 Hz, CH), 3.52 (d, 1H, J = 11.5 Hz, CH), 3.52 (m, 1H, J 
= 6.0 Hz, CH), 3.30 (m, 2H, J = 6.5 Hz, 7.0 Hz, CH2), 2.41 (m, 2H, J = 6.0 Hz, 
CH2), 2.41 (m, 2H, J = 7.0 Hz, 7.5 Hz, CH2), 1.87 (dt, 2H, J = 7.0 Hz, CH2), 1.11 (s, 
9H, CCH3), 1.10 (s, 9H, CCH3), 1.05 (s, 3H, CCH3), 1.05 (s, 3H, CCH3); 
13
C-NMR 
(126 MHz, CDCl3): δ 173.1, 171.4, 171.0, 135.8, 128.6, 128.3, 128.2, 81.3, 75.4, 
66.4, 38.8, 37.3, 35.8, 34.7, 31.7, 28.6, 27.6, 23.3, 20.3, 18.9; HRMS: m/z [M + H]+, 
found: 535.3201, calculated: 535.3198. 
 
 
4-[3-[[(4R)-2,2-ditert-butyl-5,5-dimethyl-1,3,2-dioxasilinane-4-
carbonyl]amino]propanoylamino]butanoic acid (77):  A solution of 76 (1.48 g, 
2.8 mmol) and Palladium on carbon,  10 wt. % (1.47 g, 1.39 mmol) in dry EtOAc 
(296 mL) was stirred for 2 hours flushing H2 throughout.  The reaction mixture was 
filtered through Celite and the solvent removed in vacuo affording 77 as a white 
solid (1.24 g, 100%); 
1
H-NMR (500 MHz, CDCl3): δ 7.37 (t, 1H, J = 6.0 Hz, NH), 
6.71 (t, 1H, J = 5.5 Hz, NH), 4.35 (s, 1H, CH), 3.96 (d, 1H, J = 11.5 Hz, CH), 3.55 
(m, 1H, J = 6.0 Hz, 6.5 Hz, 7.0 Hz, CH), 3.46 (m, 1H, J = 6.0 Hz, 6.5 Hz, CH), 3.43 
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(d, 1H, J = 11.5 Hz, CH), 3.21 (m, 2H, J = 6.5 Hz, 7.0 Hz, CH2), 2.40 (m, 2H, J = 
6.0 Hz, 6.5 Hz, 7.0 Hz, CH2), 2.30 (t, 2H, J = 7.0 Hz, CH2), 1.76 (quin, 2H, J = 7.0 
Hz, CH2), 1.02 (s, 9H, CCH3), 1.01 (s, 9H, CCH3), 0.97 (m, 3H, J = 5.0 Hz, 5.5 Hz, 
CCH3), 0.94 (s, 3H, CCH3); 
13
C-NMR (126 MHz, CDCl3): δ 175.5, 171.1, 170.5, 
80.3, 74.3, 38.0, 36.4, 34.9, 30.4, 27.6, 26.6, 23.5, 22.4, 22.3, 19.3, 17.8; HRMS: m/z 
[M - H]
-
, found: 443.2653, calculated: 443.2583. 
 
 
 
(4R)-2,2-ditert-butyl-N-[3-[[4-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)-4-
hydroxy-butyl]amino]-3-oxo-propyl]-5,5-dimethyl-1,3,2-dioxasilinane-4-
carboxamide (78): To a solution of 77 (317.3 mg, 0.71 mmol) and Meldrum’s acid 
(113.3 mg, 0.79 mmol) in dry THF (4 mL) was added 4-dimethylaminopyridine 
(109.2 mg, 0.89 mmol).  After 10 minutes, 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide) (154 mg, 1.0 mmol) (was added and the reaction mixture was stirred 
for 18 hours at room temperature.  The solvent was removed in vacuo, and the crude 
residue purified using flash chromatography with gradient elution (Rf = 0.4 in 
EtOAc:MeOH (4:1) containing 1% Et3N) to afford 78 as a yellow oil (274.2 mg, 
68%); 
1
H-NMR (400 MHz, CDCl3): δ 7.36 (t, 1H, J = 6.0 Hz, NH), 7.01 (t, 1H, J = 
5.0 Hz, NH), 4.40 (s, 2H, CH2), 4.02 (d, 1H, J = 11.5 Hz, CH), 3.64 (m, 1H, J = 6.5 
Hz, 7.0 Hz, CH), 3.49 (d, 1H, J = 11.5 Hz, CH), 3.49 (m, 1H, CH), 3.21 (m, 2H, J = 
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7.0 Hz, 7.5 Hz, CH2), 2.85 (m, 2H, J = 7.0 Hz, CH2), 2.44 (m, 2H, J = 6.5 Hz, 7.0 
Hz, CH2), 1.77 (dt, 2H, J = 6.0 Hz, 6.5 Hz, CH2), 1.64 (s, 6H, CCH3), 1.09 (s, 9H, 
CCH3), 1.08 (s, 9H, CCH3),  1.03 (s, 3H, CCH3), 1.01 (s, 3H, CCH3); 
13
C-NMR (100 
MHz, CDCl3): δ 198.3, 171.3, 171.0, 166.6, 101.2, 89.3, 81.2, 75.5, 39.1, 39.0, 37.3, 
36.0, 35.0, 28.6, 27.6, 26.2, 25.4, 23.3, 20.3, 18.9; HRMS: m/z [M + Na]
+
, found: 
593.2870, calculated: 593.2865. 
 
 
(4,5-dimethoxy-2-nitro-phenyl)methyl 6-[3-[[(4R)-2,2-ditert-butyl-5,5-dimethyl-
1,3,2-dioxasilinane-4-carbonyl]amino]propanoylamino]-3-oxo-hexanoate (79): 
To a solution of 78 (190 mg, 0.33 mmol) and 4,5-dimethoxy-2-nitrobenzyl alcohol 
72 (213 mg, 0.99 mmol) in dry toluene (10 mL), refluxed for 8 hours.  The solvent 
was removed in vacuo and purified by semi-preparative HPLC (H2O/MeCN 
containing 0.1% FA, 70 to 95% MeCN over 40 mins, Rf = 20.3 mins) to give 79 as a 
yellow solid (127 mg, 56%).  
1
H-NMR (700 MHz, CDCl3): δ 7.64 (s, 1H, ArH), 7.30 
(t, 1H, J = 6.0 Hz, 6.5 Hz, NH), 7.08 (s, 1H, ArH), 6.44 (t, 1H, J = 5.5 Hz, NH), 5.51 
(s, 2H, CH2), 4.33 (s, 1H, CH), 3.97 (s, 3H, OCH3), 3.95 (d, 1H, J = 11.5 Hz, CH), 
3.88 (s, 3H, OCH3), 3.56 (m, 1H,  J = 6.0 Hz, 6.5 Hz, CH), 3.52 (s, 2H, CH2), 3.42 
(m, 1H, J = 6.0 Hz, CH), 3.42 (d, 1H, J = 11.5 Hz, CH), 3.17 (m, 2H, J = 6.5 Hz, 
7.0Hz, CH2), 2.54 (t, 2H, J = 7.0 Hz, CH2), 2.35 (m, 2H, J = 5.5 Hz, 6.5 Hz, CH2), 
1.73 (m, 2H, J = 7.0 Hz, CH2), 1.01 (s, 9H, CCH3), 1.00 (s, 9H, CCH3), 0.96 (s, 3H, 
276 
 
CCH3), 0.95 (s, 3H, CCH3); 
13
C-NMR (126 MHz, CDCl3): δ 207.5, 201.3, 170.4, 
170.2, 165.6, 153.4, 152.9, 147.3, 138.6, 125.8, 109.5, 107.2, 80.3, 74.4, 63.1, 55.8, 
55.4, 48.1, 39.4, 37.5, 35.0, 33.7, 27.6, 26.6, 22.4, 22.3, 17.9;  HRMS: m/z [M + 
Na]+, found: 704.3188, calculated: 704.3185. 
 
 
(4,5-dimethoxy-2-nitro-phenyl)methyl 6-[3-[[(2R)-2,4-dihydroxy-3,3-dimethyl-
butanoyl]amino]propanoylamino]-3-oxo-hexanoate (61): A solution of 79 (79.1 
mg, 0.12 mmol) and hydrogen fluoride pyridine (70% HF) (11.6 mg, 0.58 mmol) in 
dry THF (0.5 mL) was stirred at room temperature for 2 mins to yield 61.  The 
solvent and hydrogen fluoride pyridine were removed in vacuo and product purified 
by semi-preparative HPLC (H2O/MeOH, 5 to 95% MeOH over 30 mins, Rf = 18 
mins) to give 61 as a yellow solid (58 mg, 90%); 
1
H-NMR (500 MHz, CDCl3): δ 
7.74 (s, 1H, ArH), 7.41 (t, 1H, J = 6.0 Hz, NH), 7.14 (s, 1H, ArH), 6.43 (t, 1H, J = 
5.5 Hz, 6.0 Hz, NH), 5.59 (s, 2H, CH2), 4.06 (s, 3H, OCH3), 4.01 (s, 1H, CH), 3.98 
(s, 3H, OCH3), 3.63 (s, 2H, CH2), 3.57 (m, 2H, J = 6.0 Hz, 6.5 Hz, 7.0 Hz, CH2), 
3.49 (s, 2H, HOCH2), 3.27 (m, 2H, 6.0 Hz, 6.5 Hz, 7.0 Hz, CH2), 2.65 (t, 2H, J = 7.0 
Hz, CH2), 2.45 (t, 2H, J = 6.0 Hz, CH2), 1.82 (q, 2H, J = 7.0 Hz, CH2); 
13
C-NMR 
(126 MHz, CDCl3): δ 202.6, 173.7, 171.7, 166.9, 153.8, 148.4, 139.8, 126.5, 110.9, 
108.3, 77.6, 70.9, 64.3, 56.8, 56.4, 49.1, 40.5, 39.3, 38.6, 35.9, 35.2, 23.3, 21.5, 20.4; 
HRMS: m/z [M + Na]
+
, found: 564.2156, calculated: 564.2164. 
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(4,5-dimethoxy-2-nitro-phenyl)methyl 6-[3-[[4-[[[5-(4-amino-7H-pyrrolo[3,2-
d]pyrimidin-7-yl)-4-hydroxy-3-phosphonooxy-tetrahydrofuran-2-yl]methoxy-
hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxy-2-hydroxy-3,3-dimethyl-
butanoyl]amino]propanoylamino]-3-oxo-hexanoate (62):  
A solution of adenosine-5'-triphosphate disodium salt (90 mg, 0.18 mmol) in Tris-
HCl (50 mM), KCl (20 mM), MgCl2 (10 mM) buffer and adjusted to pH 7.5.  61 (15 
mg, 0.28 mmol) was dissolved in this buffer and PanK, PPAT and DPCK (to a final 
concentration of 500 µg/mL, 500 µg/mL and 700 µg/mL) were added to a final 
volume of 7.5 mL.  After overnight incubation the enzymes were precipitated by 
addition of CHCl3 (7.5 mL) and purified immediately by semi-preparative HPLC 
(H2O/MeCN containing 0.05% TFA, 5 to 95% MeCN over 30 mins, tR = 16.1 mins) 
to yield 62 as a white powder (20 mg, 70%);  
1
H-NMR (500 MHz, D2O): δ 8.57 (s, 
1H, ArH), 8.33 (s, 1H, ArH), 7.64 (t, 1H, J = 6.0 Hz, ArH), 6.99 (t, 1H, J = 5.0 Hz, 
ArH), 6.08 (d, 1H, J = 6.0 Hz, ArH), 5.39 (s, 2H, CH2), 4.78 (m, 1H, J= 6.0 Hz, 
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ArH), 4.78 (m, 1H, ArH), 4.51 (s, 1H, ArH), 4.19 (s, 2H, CH2), 3.96 (s, 1H, CH), 
3.87 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 3.80 (m, 1H, J = 9.5 Hz, CH2), 3.53 (m, 1H, 
J = 9.5 Hz, CH2), 3.38 (t, 2H, J = 6.5 Hz, CH2), 3.04 (t, 2H, J = 7.0 Hz, CH2), 2.60 
(t, 2H, J = 7.0 Hz, 7.5 Hz, CH2), 2.36 (t, 2H, J = 6.5 Hz, 7.0 Hz, CH2), 1.66 (q, 2H, J 
= 7.0 Hz, CH2), 0.87 (s, 3H, CH3), 0.73 (s, 3H, CH3); 
13
C-NMR (151 MHz, D2O): δ 
207.1, 174.7, 173.8, 168.9, 153.1, 149.8, 148.3, 147.6, 144.4, 142.3, 139.6, 126.2, 
118.4, 111.1, 108.4, 87.5, 83.5, 74.1, 74.1, 74.1, 71.9, 71.9, 65.0, 64.3, 56.4, 56.1, 
40.1, 38.4, 38.4, 35.4, 35.3, 22.3, 20.8, 18.2; 
31
P-NMR (151 MHz, D2O): δ 0.25 (1P, 
OPO3H2), -11.01 (2P, O(PO3H)2). HRMS:  m/z [M-2H]
2-
, found: 514.0974, 
calculated:  514.0978. 
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N-(4-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)-4-hydroxybutyl)acetamide 
(128):  γ-aminobutyric acid 126 (2.00 g, 19.5 mmol) was suspended in dry methanol 
(120 mL) in the presence of triethylamine (11.60 mL, 83.2 mmol).  The mixture was 
cooled to 0ºC and acetyl chloride (1.57 mL, 20.0 mmol) was added dropwise.  The 
reaction was stirred at 0ºC for 1 h and at room temperature for 16 h.  The solvent 
was evaporated to afford crude N-acetyl-γ-butyric acid 127 (triethylammonium salt, 
5.69 g).  This material was directly treated with 2,2-dimethyl-1,3-dioxane-4,6-dione 
(Meldrum’s acid; 2.81 g, 19.5 mmol), 4-(dimethylamino)pyridine (2.95 g, 24.2 
mmol) and N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (4.11 g, 
21.5 mmol) in dry THF (300 mL) for 18 h.  The solvent was removed in vacuo and 
the crude residue was redissolved in dichloromethane (200 mL), washed with 1M 
HCl (200 mL) and water (200 mL).  After being dried (on MgSO4) and concentrated, 
the crude yellow residue was purified by silica gel chromatography by using a 
stepwise gradient of DCM and EtOAc to yield 128 (2.98 g, 57%); 
1
H-NMR (400 
MHz, CDCl3) δ 15.31 (br s, 1H, OH), 6.03 (br s, 1H, NH), 3.32 (apt q, J = 6.0 Hz, 
2H, CH2), 3.08 (apt t, J = 7.5 Hz, 2H, CH2), 1.98 (s, 3H, COCH3), 1.96–1.89 (m, 2H, 
CH2), 1.74 (s, 6H, C(CH3)2); 
13
C-NMR (100 MHz, CDCl3) δ 196.8, 170.3, 162.8, 
104.9, 91.5, 38.4, 32.7, 26.6, 25.8, 23.0; HRMS: m/z [M + H]
+
, found: 272.1130, 
calculated: 272.1134. 
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N-(4-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)-4-hydroxybutyl)acetamide-
d3 (128b): This compound was obtained in a similar manner as 128 but by using 
acetyl chloride-d3 to acetylate GABA; 1H-NMR (300 MHz, CDCl3) δ 15.29 (br s, 
1H, OH), 5.94 (br s, 1H, NH), 3.31 (apt q, J = 6.0 Hz, 2H, CH2), 3.06 (apt t, J = 7.5 
Hz, 2H, CH2), 1.92 (m, 2H, CH2), 1.74 (s, 6H, C(CH3)2); 13C-NMR (100 MHz, 
CDCl3) δ 196.0, 169.5, 159.6, 104.1, 90.7, 37.5, 31.8, 25.8, 25.1, 23.3; HRMS: m/z 
[M + Na]+, found: 297.1129, calculated: 297.1136. 
 
 
(4,5-dimethoxy-2-nitro-phenyl)methyl 6-acetamido-3-oxo-hexanoate (65): To a 
solution of 128 (20 mg, 0.07 mmol), 4,5-dimethoxy-2-nitrobenzyl alcohol 72 (15.7 
mg, 0.07 mmol) and zinc chloride (4.8 mg, 0.04 mmol, cat.) in dry THF (0.2 mL).  
This reaction mixture was refluxed at 65
o
C for 2.5 h.  The solvent was removed in 
vacuo and 65 was purified by semi-preparative HPLC (with MeCN/H2O) (50 to 
100% MeCN over 15 mins, Rf = 14.3 mins) (18.7 mg, 70%); 
1
H-NMR (400 MHz, 
CDCl3) δ 7.66 (s, 1H, CH), 7.08 (s, 1H, CH), 5.57 (br s, 1H, NH), 5.53 (s, 2H, CH2), 
3.99 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 3.54 (s, 2H, CH2), 3.20 (dt, 2H, J = 6.5 Hz, 
CH2), 2.56 (t, 2H, J = 7.0 Hz, CH2), 1.90 (s, 3H, CCH3), 1.75 (tt, 2H, J = 7.0 Hz, 
CH2); 
13
C-NMR (100 MHz, CDCl3) δ 201.4, 169.7, 16.7, 12.9, 146.9, 138.7, 131.5, 
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109.9, 107.1, 63.1, 55.5, 55.4, 39.4, 37.7, 22.5, 22.5, 22.3; HRMS: m/z [M + Na]
+
, 
found: 405.1270, calculated: 405.1268. 
 
 
(4,5-dimethoxy-2-nitro-phenyl)methyl 6-acetamido-3-oxo-hexanoate (65b): This 
compound was obtained in a similar manner as 65 but with 128b as starting material; 
1
H-NMR (400 MHz, CDCl3) δ 7.66 (s, 1H, CH), 7.08 (s, 1H, CH), 5.57 (br s, 1H, 
NH), 5.53 (s, 2H, CH2), 3.99 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 3.54 (s, 2H, CH2), 
3.20 (dt, 2H, J = 6.5 Hz, CH2), 2.56 (t, 2H, J = 7.0 Hz, CH2), 1.75 (tt, 2H, J = 7.0 
Hz, CH2); 
13
C-NMR (100 MHz, CDCl3) δ 201.4, 169.7, 16.7, 12.9, 146.9, 138.7, 
131.5, 109.9, 107.1, 63.1, 55.5, 55.4, 39.4, 37.7, 22.5, 22.3; HRMS: m/z [M + Na]
+
, 
found: 408.1456, calculated: 408.1457. 
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Appendix 1 The effect of delayed addition of active NAC probe 66 to the actinorhodin minimal 
system on the production of SEK4 41 and SEK4b 42.  The actinorhodin minimal system was 
activated by the addition of final enzyme, holo-ACP 43, then 30 (A and F), 60 (B and G), 120 
(C and H), 300 (D and I) and 600 (E and J) seconds later active probe 66, irradiated for 4 
hours in the home built UVA light source, was added.  Following incubation overnight at room 
temperature, EtOAc extracts were analysed by UPLC-MS.  The addition of active NAC probe 
66 at time point 0 seconds was not feasible by hand. F to J are repeats of A to E. 
2 
 
 
Appendix 2  FTICR-MS analysis of active acyl carrier protein (ACP) probe 64 incubated in 
the actinorhodin minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7) 
showing an off-loaded putative diketide 145.  (A) Acquired spectrum, (C) acquired spectrum 
magnified, (B) and (D) are simulated mass spectra (6+) of 145.  Underneath displays the 
peak list and errors for each.  
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Appendix 3  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7) showing an off-loaded 
putative diketide 145.  (A) Acquired spectrum, (C) acquired spectrum magnified, (B) and (D) 
are simulated mass spectra (7+).  Underneath displays the peak list and errors for each. 
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Appendix 4  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7) showing an off-loaded 
putative diketide 145.  (A) Acquired spectrum, (C) acquired spectrum magnified, (B) and (D) 
are simulated mass spectra (8+).  Underneath displays the peak list and errors for each. 
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Appendix 5  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7) showing an off-loaded 
putative diketide 145.  (A) Acquired spectrum, (C) acquired spectrum magnified, (B) and (D) 
are simulated mass spectra (9+).  Underneath displays the peak list and errors for each. 
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Appendix 6  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7) showing an off-loaded 
putative diketide 145.  (A) Acquired spectrum, (C) acquired spectrum magnified, (B) and (D) 
are simulated mass spectra (10+).  Underneath displays the peak list and errors for each. 
7 
 
 
Appendix 7  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:4 ratio, protected ACP probe 63 to malonyl-ACP 7) showing an off-loaded 
putative diketide 145.  (A) Acquired spectrum, (C) acquired spectrum magnified, (B) and (D) 
are simulated mass spectra (6+).  Underneath displays the peak list and errors for each. 
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Appendix 8  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:4 ratio, protected ACP probe 63 to malonyl-ACP 7) showing an off-loaded 
putative diketide 145.  (A) Acquired spectrum, (C) acquired spectrum magnified, (B) and (D) 
are simulated mass spectra (7+).  Underneath displays the peak list and errors for each. 
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Appendix 9 FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:4 ratio, protected ACP probe 63 to malonyl-ACP 7) showing an off-loaded 
putative diketide 145.  (A) Acquired spectrum, (C) acquired spectrum magnified, (B) and (D) 
are simulated mass spectra (8+).  Underneath displays the peak list and errors for each. 
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Appendix 10  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:4 ratio, protected ACP probe 63 to malonyl-ACP 7) showing off-loaded 
putative diketide 145.  (A) Acquired spectrum, (C) acquired spectrum magnified, (B) and (D) 
are simulated mass spectra (9+).  Underneath displays the peak list and errors for each. 
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Appendix 11  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:1 ratio, protected ACP probe 63 to labelled malonyl-ACP 7b) showing an 
off-loaded putative labelled tetraketide 147.  (A) Acquired spectrum, (C) acquired spectrum 
magnified, (B) and (D) are simulated mass spectra (6+).  Underneath displays the peak list 
and errors for each. 
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Appendix 12  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:1 ratio, protected ACP probe 63 to labelled malonyl-ACP 7b) showing an 
off-loaded putative labelled tetraketide 147.  (A) Acquired spectrum, (C) acquired spectrum 
magnified, (B) and (D) are simulated mass spectra (7+).  Underneath displays the peak list 
and errors for each. 
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Appendix 13  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:1 ratio, protected ACP probe 63 to labelled malonyl-ACP 7b) showing an 
off-loaded putative labelled tetraketide 147 at a charge state of 7+.  Inset shows 
autocorrelation of region indicated confirming a 7+ charge state. 
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Appendix 14  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:10 ratio, protected ACP probe 63 to labelled malonyl-ACP 7b) showing an 
off-loaded putative labelled tetraketide 147.  (A) Acquired spectrum, (C) acquired spectrum 
magnified, (B) and (D) are simulated mass spectra (6+).  Underneath displays the peak list 
and errors for each. 
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Appendix 15  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:10 ratio, protected ACP probe 63 to labelled malonyl-ACP 7b) showing an 
off-loaded putative labelled tetraketide 147.  (A) Acquired spectrum, (C) acquired spectrum 
magnified, (B) and (D) are simulated mass spectra (7+).  Underneath displays the peak list 
and errors for each. 
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Appendix 16  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:10 ratio, protected ACP probe 63 to labelled malonyl-ACP 7b) showing an 
off-loaded putative labelled tetraketide 147.  (A) Acquired spectrum, (C) acquired spectrum 
magnified, (B) and (D) are simulated mass spectra (8+).  Underneath displays the peak list 
and errors for each. 
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Appendix 17  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:10 ratio, protected ACP probe 63 to labelled malonyl-ACP 7b) showing an 
off-loaded putative labelled tetraketide 147.  (A) Acquired spectrum, (C) acquired spectrum 
magnified, (B) and (D) are simulated mass spectra (9+).  Underneath displays the peak list 
and errors for each. 
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Appendix 18  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:10 ratio, protected ACP probe 63 to labelled malonyl-ACP 7b) showing an 
off-loaded putative labelled tetraketide 147.  (A) Acquired spectrum, (C) acquired spectrum 
magnified, (B) and (D) are simulated mass spectra (10+).  Underneath displays the peak list 
and errors for each. 
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Appendix 19  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:4 ratio, protected ACP probe 63 to labelled malonyl-ACP 7b) showing an 
off-loaded putative labelled linear pentaketide 148.  (A) Acquired spectrum, (C) acquired 
spectrum magnified, (B) and (D) are simulated mass spectra (7+).  Underneath displays the 
peak list and errors for each.  
 
20 
 
 
Appendix 20  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (5:1 ratio, protected ACP probe 63 to malonyl-ACP 7) showing an off-loaded 
putative cyclised pentaketide 154.  (A) Acquired spectrum, (C) acquired spectrum magnified, 
(B) and (D) are simulated mass spectra (6+).  Underneath displays the peak list and errors for 
each.  
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Appendix 21 FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (5:1 ratio, protected ACP probe 63 to malonyl-ACP 7) showing an off-loaded 
putative cyclised pentaketide 154.  (A) Acquired spectrum, (C) acquired spectrum magnified, 
(B) and (D) are simulated mass spectra (7+).  Underneath displays the peak list and errors for 
each. 
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Appendix 22  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (5:1 ratio, protected ACP probe 63 to malonyl-ACP 7) showing an off-loaded 
putative cyclised pentaketide 154.  (A) Acquired spectrum, (C) acquired spectrum magnified, 
(B) and (D) are simulated mass spectra (8+).  Underneath displays the peak list and errors for 
each. 
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Appendix 23  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (5:1 ratio, protected ACP probe 63 to labelled malonyl-ACP 7b) showing an 
off-loaded putative cyclised dehydrated pentaketide 155.  (A) Acquired spectrum, (C) acquired 
spectrum magnified, (B) and (D) are simulated mass spectra (6+).  Underneath displays the 
peak list and errors for each. 
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Appendix 24  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (5:1 ratio, protected ACP probe 63 to labelled malonyl-ACP 7b) showing an 
off-loaded putative cyclised dehydrated pentaketide 155.  (A) Acquired spectrum, (C) acquired 
spectrum magnified, (B) and (D) are simulated mass spectra (7+).  Underneath displays the 
peak list and errors for each. 
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Appendix 25  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (5:1 ratio, protected ACP probe 63 to labelled malonyl-ACP 7b) showing an 
off-loaded putative cyclised dehydrated pentaketide 155.  (A) Acquired spectrum, (C) acquired 
spectrum magnified, (B) and (D) are simulated mass spectra (8+).  Underneath displays the 
peak list and errors for each. 
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Appendix 26  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (5:1 ratio, protected ACP probe 63 to labelled malonyl-ACP 7b) showing an 
off-loaded putative cyclised dehydrated pentaketide 155.  (A) Acquired spectrum, (C) acquired 
spectrum magnified, (B) and (D) are simulated mass spectra (9+).  Underneath displays the 
peak list and errors for each. 
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Appendix 27  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:4 ratio, protected ACP probe 63 to malonyl-ACP 7b) showing an off-loaded 
putative linear hexaketide 149.  (A) Acquired spectrum, (C) acquired spectrum magnified, (B) 
and (D) are simulated mass spectra (6+).  Underneath displays the peak list and errors for 
each. 
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Appendix 28  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:4 ratio, protected ACP probe 63 to malonyl-ACP 7b) showing an off-loaded 
putative labelled tetraketide 147 at a charge state of 6+.  Inset shows autocorrelation of region 
indicated confirming a 6+ charge state. 
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Appendix 29  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:4 ratio, protected ACP probe 63 to malonyl-ACP 7) showing an off-loaded 
putative linear hexaketide 149.  (A) Acquired spectrum, (C) acquired spectrum magnified, (B) 
and (D) are simulated mass spectra (7+).  Underneath displays the peak list and errors for 
each. 
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Appendix 30  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:4 ratio, protected ACP probe 63 to malonyl-ACP 7) showing an off-loaded 
putative linear hexaketide 149.  (A) Acquired spectrum, (C) acquired spectrum magnified, (B) 
and (D) are simulated mass spectra (8+).  Underneath displays the peak list and errors for 
each. 
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Appendix 31  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:4 ratio, protected ACP probe 63 to malonyl-ACP 7) showing an off-loaded 
putative linear hexaketide 149 at a charge state of 8+.  Inset shows autocorrelation of region 
indicated confirming an 8+ charge state. 
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Appendix 32  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:4 ratio, protected ACP probe 63 to malonyl-ACP 7) showing an off-loaded 
putative cyclised hexaketide 156.  (A) Acquired spectrum, (C) acquired spectrum magnified, 
(B) and (D) are simulated mass spectra (8+).  Underneath displays the peak list and errors for 
each. 
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Appendix 33  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:4 ratio, protected ACP probe 63 to malonyl-ACP 7) showing an off-loaded 
putative cyclised hexaketide 156 at a charge state of 8+.  Inset shows autocorrelation of region 
indicated confirming an 8+ charge state. 
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Appendix 34  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:4 ratio, protected ACP probe 63 to malonyl-ACP 7, repeat) showing an 
off-loaded putative cyclised hexaketide 156.  (A) Acquired spectrum, (C) acquired spectrum 
magnified, (B) and (D) are simulated mass spectra (7+).  Underneath displays the peak list 
and errors for each. 
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Appendix 35  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:4 ratio, protected ACP probe 63 to malonyl-ACP 7, repeat) showing an 
off-loaded putative cyclised hexaketide 156.  (A) Acquired spectrum, (C) acquired spectrum 
magnified, (B) and (D) are simulated mass spectra (8+).  Underneath displays the peak list 
and errors for each. 
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Appendix 36  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:4 ratio, protected ACP probe 63 to malonyl-ACP 7, repeat) showing an 
off-loaded putative cyclised hexaketide 156 at a charge state of 8+.  Inset shows 
autocorrelation of region indicated confirming an 8+ charge state. 
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Appendix 37  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (5:1 ratio, protected ACP probe 63 to malonyl-ACP 7) showing an off-loaded 
putative cyclised hexaketide 156.  (A) Acquired spectrum, (C) acquired spectrum magnified, 
(B) and (D) are simulated mass spectra (7+).  Underneath displays the peak list and errors for 
each. 
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Appendix 38  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (5:1 ratio, protected ACP probe 63 to malonyl-ACP 7) showing an off-loaded 
putative cyclised hexaketide 156.  (A) Acquired spectrum, (C) acquired spectrum magnified, 
(B) and (D) are simulated mass spectra (8+).  Underneath displays the peak list and errors for 
each. 
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Appendix 39  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7) showing an off-loaded 
putative cyclised dehydrated hexaketide 157.  (A) Acquired spectrum, (C) acquired spectrum 
magnified, (B) and (D) are simulated mass spectra (6+).  Underneath displays the peak list 
and errors for each. 
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Appendix 40  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7) showing an off-loaded 
putative cyclised dehydrated hexaketide 157.  (A) Acquired spectrum, (C) acquired spectrum 
magnified, (B) and (D) are simulated mass spectra (7+).  Underneath displays the peak list 
and errors for each. 
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Appendix 41  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7, repeat) showing an 
off-loaded putative cyclised dehydrated hexaketide 157.  (A) Acquired spectrum, (C) acquired 
spectrum magnified, (B) and (D) are simulated mass spectra (6+).  Underneath displays the 
peak list and errors for each. 
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Appendix 42  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7, repeat) showing an 
off-loaded putative cyclised dehydrated hexaketide 157 at a charge state of 6+.  Inset shows 
autocorrelation of region indicated confirming a 6+ charge state. 
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Appendix 43  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7, repeat) showing an 
off-loaded putative cyclised dehydrated hexaketide 157.  (A) Acquired spectrum, (C) acquired 
spectrum magnified, (B) and (D) are simulated mass spectra (7+).  Underneath displays the 
peak list and errors for each. 
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Appendix 44  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7, repeat) showing an 
off-loaded putative cyclised dehydrated hexaketide 157.  (A) Acquired spectrum, (C) acquired 
spectrum magnified, (B) and (D) are simulated mass spectra (8+).  Underneath displays the 
peak list and errors for each. 
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Appendix 45  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:4 ratio, protected ACP probe 63 to malonyl-ACP 7) showing an off-loaded 
putative cyclised dehydrated hexaketide 157.  (A) Acquired spectrum, (C) acquired spectrum 
magnified, (B) and (D) are simulated mass spectra (7+).  Underneath displays the peak list 
and errors for each. 
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Appendix 46  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:4 ratio, protected ACP probe 63 to malonyl-ACP 7) showing an off-loaded 
putative cyclised dehydrated hexaketide 157.  (A) Acquired spectrum, (C) acquired spectrum 
magnified, (B) and (D) are simulated mass spectra (8+).  Underneath displays the peak list 
and errors for each. 
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Appendix 47  FTICR-MS analysis of active acyl carrier protein (ACP) probe 64 incubated in 
the actinorhodin minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7, probe 
added after 30 seconds) showing an off-loaded putative cyclised dehydrated hexaketide 157.  
(A) Acquired spectrum, (C) acquired spectrum magnified, (B) and (D) are simulated mass 
spectra (7+).  Underneath displays the peak list and errors for each. 
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Appendix 48  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7, probe added after 30 
seconds) showing an off-loaded putative cyclised dehydrated hexaketide 157.  (A) Acquired 
spectrum, (C) acquired spectrum magnified, (B) and (D) are simulated mass spectra (8+).  
Underneath displays the peak list and errors for each. 
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Appendix 49  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7, probe added after five 
minutes) showing an off-loaded putative cyclised dehydrated hexaketide 157.  (A) Acquired 
spectrum, (C) acquired spectrum magnified, (B) and (D) are simulated mass spectra (7+).  
Underneath displays the peak list and errors for each. 
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Appendix 50  FTICR-MS analysis of active ACP probe 64 incubated in the actinorhodin 
minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7, probe added after five 
minutes) showing an off-loaded putative cyclised dehydrated hexaketide 157.  (A) Acquired 
spectrum, (C) acquired spectrum magnified, (B) and (D) are simulated mass spectra (8+).  
Underneath displays the peak list and errors for each. 
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Appendix 51  FTICR-MS analysis of the ACP probe 63 (A) with irradiation but without the 
actinorhodin minimal system, (B) without irradiation and incubated in the actinorhodin 
minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7), (C) without 
irradiation and without the actinorhodin minimal system. (D) Simulated mass spectrum (7+) 
of an off-loaded putative diketide 145.   
52 
 
 
Appendix 52  FTICR-MS analysis of the ACP probe 63 (A) with irradiation but without the 
actinorhodin minimal system, (B) without irradiation and incubated in the actinorhodin 
minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7), (C) without 
irradiation and without the actinorhodin minimal system. (D) Simulated mass spectrum (7+) 
of an off-loaded putative labelled linear tetraketide 147.   
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Appendix 53  FTICR-MS analysis of the ACP probe 63 (A) with irradiation but without the 
actinorhodin minimal system, (B) without irradiation and incubated in the actinorhodin 
minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7), (C) without 
irradiation and without the actinorhodin minimal system. (D) Simulated mass spectrum (7+) 
of an off-loaded putative labelled linear pentaketide 148.   
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Appendix 54  FTICR-MS analysis of the ACP probe 63 (A) with irradiation but without the 
actinorhodin minimal system, (B) without irradiation and incubated in the actinorhodin 
minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7), (C) without 
irradiation and without the actinorhodin minimal system. (D) Simulated mass spectrum (7+) 
of an off-loaded putative cyclised pentaketide 154.   
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Appendix 55  FTICR-MS analysis of the ACP probe 63 (A) with irradiation but without the 
actinorhodin minimal system, (B) without irradiation and incubated in the actinorhodin 
minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7), (C) without 
irradiation and without the actinorhodin minimal system. (D) Simulated mass spectrum (7+) 
of an off-loaded putative labelled cyclised dehydrated pentaketide 155.   
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Appendix 56  FTICR-MS analysis of the ACP probe 63 (A) with irradiation but without the 
actinorhodin minimal system, (B) without irradiation and incubated in the actinorhodin 
minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7), (C) without 
irradiation and without the actinorhodin minimal system. (D) Simulated mass spectrum (7+) 
of an off-loaded putative linear hexaketide 149.   
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Appendix 57  FTICR-MS analysis of the ACP probe 63 (A) with irradiation but without the 
actinorhodin minimal system, (B) without irradiation and incubated in the actinorhodin 
minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7), (C) without 
irradiation and without the actinorhodin minimal system. (D) Simulated mass spectrum (7+) 
of an off-loaded putative cyclised hexaketide 156.   
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Appendix 58  FTICR-MS analysis of the ACP probe 63 (A) with irradiation but without the 
actinorhodin minimal system, (B) without irradiation and incubated in the actinorhodin 
minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7), (C) without 
irradiation and without the actinorhodin minimal system. (D) Simulated mass spectrum (7+) 
of an off-loaded putative cyclised and dehydrated hexaketide 157.   
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Peak and error tables – Results of trapping experiments with the ACP probe 63 
1:1 ACP probe: 
malonyl-ACP 7   
Internal calibrant 
Charge 
State 
Average error 
of peaks A+3 to 
A+8 (ppm) 
Holo-ACP 43 6 -0.55  
Calibrated with 
A+4, A+5 and A+6 7 0.18  
Decarboxylated 
ACP probe 144 6 1.13  
Calibrated with 
A+4, A+5 and A+6 7 -0.05  
Protected ACP 
probe 63 6 -1.09  
Calibrated with 
A+4, A+5 and A+6 7 -0.76  
Off-loaded 
intermediate 
Charge 
State Peak 
Theoretical 
m/z 
Experimental 
m/z 
Error 
(ppm) 
Average 
error of 
A+3 to 
A+8 
(where 
applicable) 
(ppm) 
Cyclised 
dehydrated 
hexaketide 157 
C432H688N115O154PS2 6 A+3 1675.82093 1675.82296 1.21  
 6 A+4 1675.98814 1675.99097 1.69  
 6 A+5 1676.15534 1676.15824 1.73  
 6 A+6 1676.32254 1676.32383 0.77  
 6 A+7 1676.48972 1676.49132 0.95  
 6 A+8 1676.65688 1676.65938 1.49 1.31 
 6 A+9 1676.82407 1676.82372 -0.21  
 6 A+10 1676.99118 1676.99002 -0.69  
 7 A+2 1436.41851 1436.41800 -0.36  
 7 A+3 1436.56184 1436.56125 -0.41  
 7 A+4 1436.70516 1436.70504 -0.08  
 7 A+5 1436.84847 1436.84860 0.09  
 7 A+6 1436.99179 1436.99219 0.28  
 7 A+7 1437.13509 1437.13581 0.50  
 7 A+8 1437.27837 1437.27800 -0.26 0.02 
 7 A+9 1437.42167 1437.42191 0.17  
 7 A+10 1437.56491 1437.56350 -0.98  
Appendix 59 Peak list - FTICR-MS analysis of active ACP probe 64 incubated in the 
actinorhodin minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7) showing 
an off-loaded putative cyclised dehydrated hexaketide 157 and internal calibration performed 
with holo-ACP, decarboxylated ACP probe 144 and protected ACP probe 63.   
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1:1 ACP probe 
63:malonyl-ACP 7   
Internal calibrant 
Charge 
State 
Average 
error of 
peaks A+3 
to A+8 
(ppm) 
Apo-ACP 44 7 0.39 
Calibrated with  8 -0.02 
A+4, A+5 and A+6 9 -0.25 
 10 0.23 
Holo-ACP 43 6 -0.73 
Calibrated with  7 -0.94 
A+4, A+5 and A+6 8 -0.21 
 9 -0.48 
 10 -0.53 
Decarboxylated 
ACP probe 144 6 0.83 
Calibrated with  7 -0.34 
A+4, A+5 and A+6. 8 -0.52 
 9 -0.51 
 10 -0.03 
Protected ACP  6 -0.27 
probe 63 7 0.83 
Calibrated with  8 0.79 
A+4, A+5 and A+6 9 -0.03 
 10 -0.04 
Off-loaded 
intermediate 
Charge 
State Peak 
Theoretical 
m/z 
Experimental 
m/z 
Error 
(ppm) 
Average 
error of 
A+3 to 
A+8 
(where 
applicable) 
(ppm) 
Diketide 145 6 A+4 1653.98462 1653.97619 -5.10  
C424H684N115O152PS2 6 A+5 1654.15181 1654.14877 -1.84  
 6 A+6 1654.31900 1654.31695 -1.24  
 6 A+7 1654.48620 1654.48074 -3.30 -2.82 
 6 A+8 1654.65336 1654.64899 -2.64  
 7 A+2 1417.55835 1417.55528 -2.17  
 7 A+3 1417.70168 1417.69829 -2.39  
 7 A+4 1417.84502 1417.84459 -0.30  
 7 A+5 1417.98831 1417.98766 -0.46  
 7 A+6 1418.13169 1418.13052 -0.83  
 7 A+7 1418.27492 1418.27390 -0.72 -0.92 
 7 A+8 1418.41820 1418.41706 -0.80  
 7 A+9 1418.56151 1418.56025 -0.89  
 7 A+10 1418.70474 1418.70002 -3.33  
 8 A+2 1240.48947 1240.48227 -5.80  
 8 A+3 1240.61488 1240.61088 -3.22  
 8 A+4 1240.74028 1240.74020 -0.06  
 8 A+5 1240.86568 1240.86476 -0.74  
 8 A+6 1240.99107 1240.98928 -1.44  
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Off-loaded 
intermediate 
Charge 
State Peak 
Theoretical 
m/z 
Experimental 
m/z 
Error 
(ppm) 
Average 
error of 
A+3 to 
A+8 
(where 
applicable) 
(ppm) 
 8 A+7 1241.11647 1241.11641 -0.05 -1.03 
 8 A+8 1241.24184 1241.24099 -0.68  
 8 A+9 1241.36723 1241.36560 -1.31  
 8 A+10 1241.49256 1241.49023 -1.88  
 9 A+3 1102.88070 1102.88109 0.35  
 9 A+4 1102.99217 1102.98733 -4.39  
 9 A+5 1103.10364 1103.10344 -0.18  
 9 A+6 1103.21509 1103.21563 0.49  
 9 A+7 1103.32656 1103.32587 -0.63 -0.71 
 9 A+8 1103.43800 1103.43811 0.10  
 9 A+9 1103.54946 1103.54643 -2.75  
 9 A+10 1103.66086 1103.66068 -0.16  
 10 A+1 992.49269 992.48840 -4.32  
 10 A+2 992.59303 992.58718 -5.89  
 10 A+3 992.69336 992.69396 0.60  
 10 A+4 992.79368 992.79438 0.71  
 10 A+5 992.89400 992.89482 0.83  
 10 A+6 992.99431 992.99405 -0.26  
 10 A+7 993.09463 993.09417 -0.46 0.19 
 10 A+8 993.19493 993.19467 -0.26  
 10 A+9 993.29524 993.29200 -3.26  
 10 A+10 993.39550 993.39254 -2.98  
Cyclised  6 A+4 1675.98814 1675.99429 3.67  
dehydrated  6 A+5 1676.15534 1676.15331 -1.21 0.60 
hexaketide 157 6 A+6 1676.32254 1676.32146 -0.64  
C432H688N115O154PS2 7 A+2 1436.41850 1436.41587 -1.83  
 7 A+3 1436.56184 1436.56272 0.61  
 7 A+4 1436.70518 1436.70626 0.75  
 7 A+5 1436.84849 1436.84983 0.93  
 7 A+6 1436.99185 1436.99342 1.09  
 7 A+7 1437.13519 1437.13371 -1.03 0.65 
 7 A+8 1437.27852 1437.28070 1.52  
 7 A+9 1437.42167 1437.42104 -0.44  
 8 A+2 1256.99211 1256.99244 0.26  
 8 A+3 1257.11752 1257.11768 0.13  
 8 A+4 1257.24292 1257.24549 2.04  
 8 A+5 1257.36832 1257.36821 -0.09  
 8 A+6 1257.49372 1257.49096 -2.19  
 8 A+7 1257.61911 1257.61761 -1.19 -0.59 
 8 A+8 1257.74448 1257.74165 -2.25  
 8 A+9 1257.86987 1257.86959 -0.22  
 8 A+10 1257.99520 1257.99499 -0.17  
 8 A+11 1258.12058 1258.11786 -2.16  
 9 A+3 1117.54971 1117.55286 2.82  
 9 A+4 1117.66118 1117.66599 4.30  
 9 A+5 1117.77265 1117.77308 0.38  
 9 A+6 1117.88412 1117.88019 -3.52  
 9 A+7 1117.99557 1117.99339 -1.95 0.58 
 9 A+8 1118.10701 1118.10863 1.45  
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Off-loaded 
intermediate 
Charge 
State Peak 
Theoretical 
m/z 
Experimental 
m/z 
Error 
(ppm) 
Average 
error of 
A+3 to 
A+8 
(where 
applicable) 
(ppm) 
 9 A+9 1118.21847 1118.21782 -0.58  
Appendix 60  Peak list – Repeated FTICR-MS analysis of active ACP probe 64 incubated in 
the actinorhodin minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7) 
showing off-loaded putative diketide 145 and cyclised dehydrated hexaketide 157 and internal 
calibration performed with apo-ACP 44, holo-ACP 43, decarboxylated ACP probe 144 and 
protected ACP probe 63.   
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1:4 ACP probe 
63:malonyl-ACP 7   
Internal calibrant 
Charge 
State 
Average 
error of 
peaks 
A+3 to 
A+8 
(ppm) 
Holo ACP 6 -1.38 
Calibrated with 
A+4, A+5 and A+6 7 -1.08 
 8 -0.50 
 9 0.70 
 10 -0.18 
Decarboxylated 
ACP probe 144 6 1.74 
Calibrated with 
A+4, A+5 and A+6 7 -0.62 
 8 -1.02 
 9 -0.52 
 10 0.06 
Protected ACP 
probe 63 6 -1.29 
Calibrated with 
A+4, A+5 and A+6 7 1.76 
 8 0.96 
 9 -0.26 
 10 -0.21 
Off-loaded 
intermediate 
Charge 
State Peak 
Theoretical 
m/z 
Experimental 
m/z 
Error 
(ppm) 
Average 
error of 
A+3 to 
A+8 
(where 
applicable) 
(ppm) 
Linear hexaketide 6 A+3 1681.82445 1681.82139 -1.82  
C432H692N115O156PS2 6 A+4 1681.99166 1681.98838 -1.95  
 6 A+5 1682.15886 1682.15083 -4.77  
 6 A+6 1682.32606 1682.32705 0.59  
 6 A+7 1682.49324 1682.49185 -0.83 -1.76 
 7 A+2 1441.56439 1441.56330 -0.76  
 7 A+3 1441.70771 1441.70609 -1.12  
 7 A+4 1441.85103 1441.84975 -0.89  
 7 A+5 1441.99435 1441.99327 -0.75  
 7 A+6 1442.13766 1442.13457 -2.14  
 7 A+7 1442.28096 1442.27734 -2.51 -1.48 
 8 A+1 1261.36933 1261.36995 0.49  
 8 A+2 1261.49475 1261.49307 -1.33  
 8 A+3 1261.62016 1261.61952 -0.51  
 8 A+4 1261.74558 1261.74539 -0.15  
 8 A+5 1261.87096 1261.87056 -0.32  
 8 A+6 1261.99636 1261.99651 0.12  
 8 A+7 1262.12175 1262.12040 -1.07  
 8 A+8 1262.24712 1262.24384 -2.60 -0.75 
 9 A+2 1121.44058 1121.43947 -0.99  
 9 A+3 1121.55206 1121.55135 -0.63  
 9 A+4 1121.66353 1121.66326 -0.24  
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Off-loaded 
intermediate 
Charge 
State Peak 
Theoretical 
m/z 
Experimental 
m/z 
Error 
(ppm) 
Average 
error of 
A+3 to 
A+8 
(where 
applicable) 
(ppm) 
 9 A+5 1121.77500 1121.77315 -1.65  
 9 A+6 1121.88646 1121.88510 -1.21  
 9 A+7 1121.99792 1121.99707 -0.76 -0.90 
Cyclised  8 A+2 1259.24343 1259.23993 -2.78  
hexaketide 156 8 A+3 1259.36884 1259.36689 -1.55  
C432H690N115O155PS2 8 A+4 1259.49424 1259.49644 1.75  
 8 A+5 1259.61964 1259.61832 -1.05  
 8 A+6 1259.74504 1259.74536 0.25  
 8 A+7 1259.87043 1259.86857 -1.48 -0.41 
Appendix 61  Peak list – FTICR-MS analysis of active ACP probe 64 incubated in the 
actinorhodin minimal system (1:4 ratio, protected ACP probe 63 to malonyl-ACP 7) showing 
off-loaded putative linear hexaketide 149 and cyclised hexaketide 156 and internal calibration 
performed with holo-ACP, decarboxylated ACP probe 144 and protected ACP probe 63.   
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1:4 ACP probe 
63:malonyl-ACP 7   
Internal calibrant 
Charge 
State 
Average 
error of 
peaks 
A+3 to 
A+8 
(ppm) 
Holo ACP 6 0.00 
Calibrated with A+4,  7 -0.69 
A+5 and A+6 8 -0.40 
 9 0.33 
 10 -0.08 
Decarboxylated 
ACP probe 144 6 -1.17 
Calibrated with A+4, 
A+5 and A+6 7 -0.16 
 8 -0.98 
 9 -0.14 
 10 0.20 
Protected ACP  6 0.14 
probe 63 7 1.43 
Calibrated with A+4,  8 0.68 
A+5 and A+6 9 -0.52 
Off-loaded 
intermediate 
Charge 
State Peak 
Theoretical 
m/z 
Experimental 
m/z 
Error 
(ppm) 
Average 
error of 
A+3 to 
A+8 
(where 
applicable) 
(ppm) 
Diketide 145 6 A+4 1653.98462 1653.97367 -6.62  
C424H684N115O152PS2 6 A+5 1654.15181 1654.14142 -6.28  
 6 A+6 1654.31900 1654.31068 -5.03  
 6 A+7 1654.48620 1654.47462 -7.00 -6.23 
 7 A+5 1417.98831 1417.98772 -0.42  
 7 A+6 1418.13161 1418.12920 -1.70  
 7 A+7 1418.27492 1418.27396 -0.68  
 7 A+8 1418.41820 1418.41549 -1.91 -1.18 
 7 A+9 1418.56151 1418.56031 -0.85  
 8 A+4 1240.74028 1240.74005 -0.19  
 8 A+5 1240.86568 1240.86458 -0.89  
 8 A+6 1240.99107 1240.99037 -0.56  
 8 A+7 1241.11647 1241.11613 -0.27  
 8 A+8 1241.24184 1241.23946 -1.92 -0.77 
 9 A+4 1102.99217 1102.98835 -3.46  
 9 A+5 1103.10364 1103.09795 -5.16  
 9 A+6 1103.21509 1103.21444 -0.59  
 9 A+7 1103.32656 1103.32070 -5.31  
 9 A+8 1103.43800 1103.43790 -0.09 -2.92 
Cyclised hexaketide  7 A+3 1439.13478 1439.13587 0.76  
156 7 A+4 1439.27810 1439.27318 -3.42  
C432H690N115O155PS2 7 A+5 1439.42141 1439.41802 -2.36  
 7 A+6 1439.56472 1439.56253 -1.52  
 7 A+7 1439.70803 1439.70502 -2.09  
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Off-loaded 
intermediate 
Charge 
State Peak 
Theoretical 
m/z 
Experimental 
m/z 
Error 
(ppm) 
Average 
error of 
A+3 to 
A+8 
(where 
applicable) 
(ppm) 
 7 A+8 1439.85131 1439.84924 -1.44 -1.68 
 8 A+2 1259.24343 1259.24246 -0.77  
 8 A+3 1259.36884 1259.36942 0.46  
 8 A+4 1259.49424 1259.49288 -1.08  
 8 A+5 1259.61964 1259.61846 -0.94  
 8 A+6 1259.74504 1259.74249 -2.02  
 8 A+7 1259.87043 1259.87111 0.54 -0.61 
Cyclised  7 A+1 1436.27518 1436.27556 0.26  
dehydrated  7 A+2 1436.41851 1436.41785 -0.46  
hexaketide 157 7 A+3 1436.56184 1436.56183 -0.01  
C432H688N115O154PS2 7 A+4 1436.70516 1436.70413 -0.72  
 7 A+5 1436.84849 1436.85095 1.71  
 7 A+6 1436.99179 1436.99271 0.64  
 7 A+7 1437.13509 1437.13508 -0.01  
 7 A+8 1437.27837 1437.27768 -0.48 0.19 
 7 A+9 1437.42167 1437.41941 -1.57  
 7 A+10 1437.56491 1437.56488 -0.02  
 7 A+11 1437.70820 1437.70694 -0.88  
 7 A+12 1437.85151 1437.85151 0.00  
 8 A+1 1256.86669 1256.86952 2.25  
 8 A+2 1256.99211 1256.98951 -2.07  
 8 A+3 1257.11752 1257.11530 -1.77  
 8 A+4 1257.24292 1257.24303 0.09  
 8 A+5 1257.36832 1257.36943 0.88  
 8 A+6 1257.49372 1257.49388 0.13  
 8 A+7 1257.61911 1257.61901 -0.08  
 8 A+8 1257.74448 1257.74372 -0.60 -0.23 
 8 A+9 1257.86987 1257.87187 1.59  
 8 A+10 1257.99520 1257.99230 -2.31  
 9 A+3 1117.54971 1117.55364 3.52  
 9 A+4 1117.66118 1117.65869 -2.23  
 9 A+5 1117.77265 1117.77083 -1.63  
 9 A+6 1117.88412 1117.88502 0.81  
 9 A+7 1117.99557 1117.99518 -0.35 0.02 
Appendix 62  Peak list – Repeated FTICR-MS analysis of active ACP probe 64 incubated in 
the actinorhodin minimal system (1:4 ratio, protected ACP probe 63 to malonyl-ACP 7) 
showing off-loaded putative diketide 145, cyclised hexaketide 156 and cyclised dehydrated 
hexaketide 157 and internal calibration performed with holo-ACP, decarboxylated ACP 
probe 144 and protected ACP probe 63.   
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5:1 ACP probe 
63:malonyl-ACP 7   
Internal calibrant 
Charge 
State 
Average 
error of 
peaks 
A+3 to 
A+8 
(ppm) 
Apo-ACP 44 6 1.30 
Calibrated with  7 0.63 
A+4, A+5 and A+6 8 -0.01 
 9 0.06 
Holo-ACP 43 6 -1.28 
Calibrated with  7 -1.07 
A+4, A+5 and A+6 8 -0.19 
Decarboxylated  6 1.39 
ACP probe 144 7 -0.75 
Calibrated with 8 -0.57 
A+4, A+5 and A+6 9 -0.45 
 10 0.14 
Protected ACP  6 -2.05 
probe 63 7 1.08 
Calibrated with 
A+4, A+5 and A+6 8 0.63 
Off-loaded 
intermediate 
Charge 
State Peak 
Theoretical 
m/z 
Experimental 
m/z 
Error 
(ppm) 
Average 
error of 
A+3 to 
A+8 
(where 
applicable) 
(ppm) 
Cyclised  6 A+2 1671.65372 1671.65470 0.59  
pentaketide 154 6 A+3 1671.82093 1671.82420 1.96  
C430H688N115O154PS2 6 A+4 1671.98814 1671.99072 1.54  
 6 A+5 1672.15534 1672.15757 1.33  
 6 A+6 1672.32254 1672.32613 2.15  
 6 A+7 1672.48972 1672.48898 -0.44 1.31 
 7 A+1 1432.84661 1432.84570 -0.64  
 7 A+2 1432.98994 1432.99025 0.22  
 7 A+3 1433.13327 1433.13271 -0.39  
 7 A+4 1433.27659 1433.27623 -0.25  
 7 A+5 1433.41990 1433.41998 0.06  
 7 A+6 1433.56321 1433.56222 -0.69  
 7 A+7 1433.70652 1433.70564 -0.61  
 7 A+8 1433.84980 1433.84896 -0.59 -0.41 
 7 A+9 1433.99310 1433.98883 -2.98  
 8 A+2 1253.99211 1253.99377 1.32  
 8 A+3 1254.11752 1254.11967 1.71  
 8 A+4 1254.24292 1254.24306 0.11  
 8 A+5 1254.36832 1254.37029 1.57  
 8 A+6 1254.49372 1254.49500 1.02  
 8 A+7 1254.61911 1254.62100 1.51  
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Off-loaded 
intermediate 
Charge 
State Peak 
Theoretical 
m/z 
Experimental 
m/z 
Error 
(ppm) 
Average 
error of 
A+3 to 
A+8 
(where 
applicable) 
(ppm) 
 8 A+8 1254.74448 1254.74703 2.03 1.33 
Cyclised  7 A+3 1439.13478 1439.13084 -2.74  
hexaketide 156 7 A+4 1439.27810 1439.27435 -2.61  
C432H690N115O155PS2 7 A+5 1439.42141 1439.41851 -2.01  
 7 A+6 1439.56472 1439.56219 -1.76  
 7 A+7 1439.70803 1439.70483 -2.22 -2.27 
 8 A+1 1259.11801 1259.11646 -1.23  
 8 A+2 1259.24343 1259.24340 -0.02  
 8 A+3 1259.36884 1259.36780 -0.83  
 8 A+4 1259.49424 1259.49350 -0.59  
 8 A+5 1259.61964 1259.61923 -0.33  
 8 A+6 1259.74504 1259.74627 0.98  
 8 A+7 1259.87043 1259.86563 -3.81  
 8 A+8 1259.99580 1259.99272 -2.44 -0.19 
Appendix 63  Peak list – FTICR-MS analysis of active ACP probe 64 incubated in the 
actinorhodin minimal system (5:1 ratio, protected ACP probe 63 to malonyl-ACP 7) showing 
off-loaded putative cyclised pentaketide 154 and cyclised hexaketide 156 and internal 
calibration performed with apo-ACP 44, holo-ACP 43, decarboxylated ACP probe 144 and 
protected ACP probe 63.   
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1:1 ACP probe 
63:Malonyl-ACP 7 
(30 seconds delay)   
Internal calibrant 
Charge 
State 
Average 
error of 
peaks 
A+3 to 
A+8 
(ppm) 
Apo-ACP 44 7 0.58 
Calibrated with  8 -0.43 
A+4, A+5 and A+6. 9 -0.06 
 10 -0.11 
Holo-ACP 43 6 -0.75 
Calibrated with  7 -1.34 
A+4, A+5 and A+6. 8 -0.42 
 9 0.46 
Decarboxylated  7 -0.59 
ACP probe 144 8 -0.35 
Calibrated with  9 0.29 
A+4, A+5 and A+6 10 0.56 
Off-loaded 
intermediate 
Charge 
State Peak 
Theoretical 
m/z 
Experimental 
m/z 
Error 
(ppm) 
Average 
error of 
A+3 to 
A+8 
(where 
applicable) 
(ppm) 
Cyclised  7 A+1 1436.27518 1436.27393 -0.87  
dehydrated 7 A+2 1436.41851 1436.41741 -0.77  
hexaketide 157 7 A+3 1436.56184 1436.56259 0.52  
C432H688N115O154PS2 7 A+4 1436.70516 1436.70402 -0.79  
 7 A+5 1436.84847 1436.84635 -1.48  
 7 A+6 1436.99179 1436.99042 -0.95  
 7 A+7 1437.13509 1437.13476 -0.23  
 7 A+8 1437.27837 1437.27890 0.37 -0.43 
 7 A+9 1437.42167 1437.41924 -1.69  
 7 A+10 1437.56491 1437.56295 -1.36  
 7 A+11 1437.70820 1437.70669 -1.05  
 8 A+4 1257.24292 1257.24266 -0.21  
 8 A+5 1257.36832 1257.36922 0.72  
 8 A+6 1257.49372 1257.49325 -0.37  
 8 A+7 1257.61911 1257.61865 -0.37  
 8 A+8 1257.74448 1257.74394 -0.43 -0.13 
 8 A+9 1257.86987 1257.86932 -0.44  
 8 A+10 1257.99520 1257.99600 0.64  
Appendix 64 Peak list – FTICR-MS analysis of active ACP probe 64 incubated in the 
actinorhodin minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7 with 30 
seconds delay upon addition of the ACP probe 64) showing an off-loaded putative cyclised 
dehydrated hexaketide 157 and internal calibration performed with apo-ACP 44, holo-ACP 
43, and decarboxylated ACP probe 144.   
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1:1 ACP probe 
63:malonyl-ACP 7 
(5 mins delay)   
Internal calibrant 
Charge 
State 
Average 
error of 
peaks 
A+3 to 
A+8 
(ppm) 
Apo-ACP 44 7 0.73 
Calibrated with  8 0.32 
A+4, A+5 and A+6. 9 -0.04 
 10 -0.25 
Holo-ACP 43 7 -1.04 
Calibrated with  8 -0.24 
A+4, A+5 and A+6. 9 0.73 
Decarboxylated  7 -0.61 
ACP probe 144 8 -0.66 
Calibrated with  9 -0.22 
A+4, A+5 and A+6. 10 0.07 
Off-loaded 
intermediate 
Charge 
State Peak 
Theoretical 
m/z 
Experimental 
m/z 
Error 
(ppm) 
Average 
error of 
A+3 to 
A+8 
(where 
applicable) 
(ppm) 
Cyclised  7 A+3 1436.56184 1436.56035 -1.04  
dehydrated 7 A+4 1436.70483 1436.70556 0.51  
hexaketide 157 7 A+5 1436.84847 1436.84746 -0.70  
C432H688N115O154PS2 7 A+6 1436.99179 1436.99606 2.97  
 7 A+7 1437.13509 1437.13635 0.88  
 7 A+8 1437.27837 1437.28000 1.13 0.52 
 7 A+9 1437.42167 1437.42201 0.24  
 7 A+10 1437.56383 1437.56572 1.31  
 7 A+11 1437.70783 1437.70445 -2.35  
 8 A+3 1257.11752 1257.11542 -1.67  
 8 A+4 1257.24292 1257.24324 0.25  
 8 A+5 1257.36832 1257.36724 -0.86  
 8 A+6 1257.49372 1257.49383 0.09  
 8 A+7 1257.61911 1257.61916 0.04  
 8 A+8 1257.74448 1257.74451 0.02 -0.35 
 8 A+9 1257.86987 1257.86990 0.02  
 8 A+10 1257.99520 1257.99530 0.08  
 8 A+11 1258.12058 1258.11945 -0.90  
Appendix 65  Peak list – FTICR-MS analysis of active ACP probe 64 incubated in the 
actinorhodin minimal system (1:1 ratio, protected ACP probe 63 to malonyl-ACP 7 with 30 
seconds delay upon addition of the ACP probe 64) showing an off-loaded putative cyclised 
dehydrated hexaketide 157 and internal calibration performed with apo-ACP 44, holo-ACP 
43, and decarboxylated ACP probe 144.   
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1:1 ACP probe 63:13C-
malonyl-ACP 7   
Internal calibrant 
Charge 
State 
Average 
error of 
peaks 
A+3 to 
A+8 
(ppm) 
Holo ACP 6 -0.67 
Calibrated with A+4,  7 -0.70 
A+5 and A+6 8 1.20 
Decarboxylated ACP 
probe 144 6 0.75 
Calibrated with A+4,  7 -0.16 
A+5 and A+6 8 -0.10 
Protected ACP probe  
63 6 -0.23 
Calibrated with A+4,  7 0.46 
A+5 and A+6 8 0.71 
Off-loaded 
intermediate 
Charge 
State Peak 
Theoretical 
m/z 
Experimental 
m/z 
Error 
(ppm) 
Average 
error of 
A+3 to 
A+8 
(where 
applicable) 
(ppm) 
Labelled tetraketide  6 A+4 1668.82428 1668.82025 -2.41  
147 6 A+5 1668.99148 1668.98598 -3.30  
C422
13C6H688N115O154PS2 6 A+6 1669.15868 1669.15082 -4.71  
 6 A+7 1669.32587 1669.32488 -0.59  
 6 A+8 1669.49307 1669.49166 -0.84 -2.37 
 6 A+9 1669.66023 1669.65847 -1.05  
 6 A+10 1669.82742 1669.82305 -2.62  
 7 A+3 1430.42138 1430.41961 -1.24  
 7 A+4 1430.56471 1430.56358 -0.79  
 7 A+5 1430.70803 1430.70592 -1.47  
 7 A+6 1430.85134 1430.85160 0.18  
 7 A+7 1430.99464 1430.99400 -0.45 -0.75 
 7 A+8 1431.13796 1431.13462 -2.33  
 7 A+9 1431.28124 1431.27960 -1.15  
 7 A+10 1431.42454 1431.42412 -0.29  
 7 A+11 1431.56777 1431.56554 -1.56  
Appendix 66  Peak list – FTICR-MS analysis of active ACP probe 64 incubated in the 
actinorhodin minimal system (1:1 ratio, protected ACP probe 63 to 13C-malonyl-ACP 7b) 
showing an off-loaded putative 13C-labelled tetraketide 147 and internal calibration 
performed with holo-ACP, decarboxylated ACP probe 144 and protected probe 63.   
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1:10 ACP 
probe 63:13C-
malonyl-ACP 
7b   
Internal 
calibrant 
Charge 
State 
Average error of 
peaks A+3 to A+8 
(ppm) 
Apo-ACP 44 6 0.99 
Calibrated with  7 0.06 
A+4, A+5 and  8 -0.08 
A+6 9 -0.53 
 10 -0.12 
Holo-ACP 43 6 -1.00 
Calibrated with  7 -0.98 
A+4, A+5 and  8 -0.54 
A+6 9 0.20 
 10 -0.25 
Protected  6 -0.31 
ACP probe 63 7 0.61 
Calibrated with  8 0.65 
A+4, A+5 and  9 -0.41 
A+6 10 -0.55 
Off-loaded 
intermediate 
Charge 
State Peak 
Theoretical 
m/z 
Experimental 
m/z 
Error 
(ppm) 
Average 
error of 
A+3 to A+8 
(where 
applicable) 
(ppm) 
Labelled  6 A+3 1668.65707 1668.65435 -1.63  
tetraketide 147 6 A+4 1668.82428 1668.82099 -1.97  
C422
13C6H688N115 6 A+5 1668.99148 1668.98766 -2.29  
O154PS2 6 A+6 1669.15868 1669.15663 -1.23  
 6 A+7 1669.32587 1669.32337 -1.50  
 6 A+8 1669.49307 1669.49014 -1.76 -1.73 
 6 A+9 1669.66023 1669.65695 -1.96  
 7 A+1 1430.13471 1430.13074 -2.78  
 7 A+2 1430.27805 1430.27631 -1.22  
 7 A+3 1430.42138 1430.42117 -0.15  
 7 A+4 1430.56471 1430.56471 0.00  
 7 A+5 1430.70803 1430.70824 0.15  
 7 A+6 1430.85134 1430.85093 -0.29  
 7 A+7 1430.99464 1430.99435 -0.20  
 7 A+8 1431.13796 1431.13797 0.01 -0.08 
 7 A+9 1431.28124 1431.28033 -0.64  
 7 A+10 1431.42454 1431.42381 -0.51  
 7 A+11 1431.56777 1431.56275 -3.51  
 7 A+12 1431.71106 1431.70872 -1.63  
 8 A+2 1251.61920 1251.61793 -1.01  
 8 A+3 1251.74462 1251.74349 -0.90  
 8 A+4 1251.87003 1251.86902 -0.81  
 8 A+5 1251.99543 1251.99470 -0.58  
 8 A+6 1252.12083 1252.12025 -0.46  
 8 A+7 1252.24622 1252.24565 -0.46  
 8 A+8 1252.37162 1252.37089 -0.58 -0.63 
 8 A+9 1252.49699 1252.49628 -0.57  
 8 A+10 1252.62238 1252.62158 -0.64  
 8 A+11 1252.74771 1252.74693 -0.62  
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Off-loaded 
intermediate 
Charge 
State Peak 
Theoretical 
m/z 
Experimental 
m/z 
Error 
(ppm) 
Average 
error of 
A+3 to A+8 
(where 
applicable) 
(ppm) 
 8 A+12 1252.87309 1252.87177 -1.05  
 8 A+13 1252.99771 1252.99650 -0.97  
 8 A+14 1253.12392 1253.11966 -3.40  
 9 A+2 1112.66232 1112.66353 1.09  
 9 A+3 1112.77380 1112.77367 -0.12  
 9 A+4 1112.88528 1112.88584 0.50  
 9 A+5 1112.99675 1112.99602 -0.66  
 9 A+6 1113.10821 1113.10723 -0.88  
 9 A+7 1113.21967 1113.21928 -0.35  
 9 A+8 1113.33114 1113.33070 -0.40 -0.32 
 9 A+9 1113.44258 1113.44198 -0.54  
 9 A+10 1113.55404 1113.55328 -0.68  
 9 A+11 1113.66544 1113.66359 -1.66  
 9 A+12 1113.77689 1113.77493 -1.76  
 9 A+13 1113.88766 1113.88630 -1.22  
 10 A+2 1001.49682 1001.49407 -2.75  
 10 A+3 1001.59778 1001.59627 -1.51  
 10 A+4 1001.69748 1001.69769 0.21  
 10 A+5 1001.79780 1001.79751 -0.29  
 10 A+6 1001.89812 1001.89816 0.04  
 10 A+7 1001.99843 1001.99801 -0.42  
 10 A+8 1002.09875 1002.09870 -0.05 -0.34 
 10 A+9 1002.19905 1002.19860 -0.45  
 10 A+10 1002.29936 1002.29770 -1.66  
 10 A+11 1002.39962 1002.39845 -1.17  
Appendix 67  Peak list – FTICR-MS analysis of active ACP probe 64 incubated in the 
actinorhodin minimal system (1:10 ratio, protected ACP probe 63 to 13C-malonyl-ACP 7b) 
showing an off-loaded putative 13C-labelled tetraketide 147 and internal calibration 
performed with apo-ACP 44, holo-ACP 43, and protected probe 63.   
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1:5 ACP probe 63:13C-
malonyl-ACP 7b   
Internal calibrant 
Charge 
State 
Average 
error of 
peaks 
A+3 to 
A+8 
(ppm) 
Apo-ACP 44 6 0.51 
Calibrated with A+4, 
A+5 and A+6 7 0.12 
 8 0.05 
 9 -0.02 
 10 -0.09 
Holo-ACP 43 6 -0.64 
Calibrated with A+4, 
A+5 and A+6 7 -0.64 
 8 -1.95 
 9 0.42 
Decarboxylated ACP 
probe 144 6 0.61 
Calibrated with A+4, 
A+5 and A+6 7 -0.30 
 8 -0.42 
 9 -0.18 
 10 -0.16 
Protected ACP probe 
63 6 -0.53 
Calibrated with A+4, 
A+5 and A+6 7 0.54 
 8 0.11 
 9 0.29 
 
Charge 
State Peak 
Theoretical 
m/z 
Experimental 
m/z 
Error 
ppm 
Average 
error of 
A+3 to 
A+8 
(where 
applicable) 
ppm 
Labelled cyclised  6 A+2 1669.82253 1669.82268 0.09  
dehydrated  6 A+3 1669.98975 1669.98955 -0.12  
pentaketide 155 6 A+4 1670.15697 1670.15646 -0.31  
C422
13C8H686N115O153PS2 6 A+5 1670.32417 1670.32341 -0.46  
 6 A+6 1670.49137 1670.49038 -0.59  
 6 A+7 1670.65856 1670.64836 -6.11  
 6 A+8 1670.82576 1670.81528 -6.27 -0.37 
 7 A+3 1431.56369 1431.56706 2.35  
 7 A+4 1431.70701 1431.70795 0.66  
 7 A+5 1431.85033 1431.85052 0.13  
 7 A+6 1431.99364 1431.99146 -1.52  
 7 A+7 1432.13695 1432.13409 -2.00  
 7 A+8 1432.28026 1432.27674 -2.46 -0.47 
 7 A+9 1432.42354 1432.41942 -2.88  
 8 A+3 1252.74413 1252.74834 3.36  
 8 A+4 1252.86954 1252.87019 0.52  
 8 A+5 1252.99495 1252.99460 -0.28  
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Off-loaded 
intermediate 
Charge 
State Peak 
Theoretical 
m/z 
Experimental 
m/z 
Error 
(ppm) 
Average 
error of 
A+3 to 
A+8 
(where 
applicable) 
(ppm) 
 8 A+6 1253.12015 1253.11904 -0.89  
 8 A+7 1253.24574 1253.24477 -0.77  
 8 A+8 1253.37114 1253.36798 -2.52 -0.10 
 8 A+9 1253.49651 1253.49377 -2.19  
 8 A+10 1253.62190 1253.61957 -1.86  
 9 A+1 1113.32781 1113.33014 2.09  
 9 A+2 1113.43930 1113.44041 1.00  
 9 A+3 1113.55078 1113.55371 2.63  
 9 A+4 1113.66226 1113.66226 0.00  
 9 A+5 1113.77374 1113.77336 -0.34  
 9 A+6 1113.88521 1113.88372 -1.34  
 9 A+7 1113.99667 1113.99510 -1.41  
 9 A+8 1114.10813 1114.10751 -0.56 -0.17 
 9 A+9 1114.21960 1114.21794 -1.49  
 9 A+10 1114.33104 1114.32939 -1.48  
 9 A+11 1114.44250 1114.44086 -1.47  
 9 A+12 1114.55389 1114.55236 -1.37  
 9 A+13 1114.66535 1114.66388 -1.32  
 9 A+14 1114.77681 1114.77441 -2.15  
 9 A+15 1114.88760 1114.88698 -0.56  
 9 A+16 1114.99930 1114.99756 -1.56  
Appendix 68  Peak list – FTICR-MS analysis of active ACP probe 64 incubated in the 
actinorhodin minimal system (1:5 ratio, protected ACP probe 63 to 13C-malonyl-ACP 7b) 
showing an off-loaded putative 13C-labelled cyclised dehydrated pentaketide 155 and internal 
calibration performed with apo-ACP 44, holo-ACP, decarboxylated ACP probe 144 and 
protected probe 63.   
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1:4 ACP probe 63:13C-
malonyl-ACP 7b (step-wise 
addition)   
Internal calibrant 
Charge 
State 
Average error 
of peaks A+3 
to A+8 (ppm) 
Apo-ACP 44 7 0.76 
Calibrated with A+4, A+5 and 8 -0.03 
A+6 9 -0.26 
 10 0.15 
Holo-ACP 43 6 0.74 
Calibrated with A+4, A+5 and  7 -0.64 
A+6 8 -0.58 
 9 0.40 
Decarboxylated ACP probe  7 0.20 
144 8 -0.54 
Calibrated with A+4, A+5 and  9 -0.30 
A+6 10 0.52 
Off-loaded 
intermediate 
Charge 
State Peak 
Theoretical 
m/z 
Experimental 
m/z 
Error 
ppm 
Average 
error of 
A+3 to 
A+8 
(where 
applicable) 
(ppm) 
Labelled linear  7 A+1 1436.42290 1436.41883 -2.83  
pentaketide 148 7 A+2 1436.56623 1436.56234 -2.71  
C422
13C8H690N115O155PS2 7 A+3 1436.70956 1436.71089 0.93  
 7 A+4 1436.85289 1436.85112 -1.23  
 7 A+5 1436.99620 1436.99638 0.13  
 7 A+6 1437.13952 1437.13834 -0.82  
 7 A+7 1437.28282 1437.28033 -1.73  
 7 A+8 1437.42614 1437.42234 -2.64 -0.90 
 7 A+9 1437.56942 1437.56605 -2.34  
Appendix 69  Peak list – FTICR-MS analysis of active ACP probe 64 incubated in the 
actinorhodin minimal system (1:4 ratio, protected ACP probe 63 to 13C-malonyl-ACP 7b, 
step-wise addition) showing an off-loaded putative 13C-labelled linear pentaketide 148 and 
internal calibration performed with apo-ACP 44, holo-ACP 43, and decarboxylated ACP 
probe 144 and protected probe 63.   
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EID CAD 
m/z detected 
(m/z before phasing) 
Absolute Error 
(Error before phasing) 
(ppm) 
m/z detected 
(m/z before phasing) 
Absolute Error 
(Error before 
phasing) (ppm) 
 Predicted 
Formula 
Theoretical 
Mass (Da) 
Na Li Cs Na Li Cs Na Li Na Li 
 C8H12N2O 152.09496 
  
285.00057 
(285.00047)   
0.59 
(0.24)    
 
 C8H14N2O 154.11061 
 
161.12672 
(161.12664)   
0.66 
(0.16)      
a C8H13NO2 155.09463 
 
162.11070 
(162.11061)   
0.41 
(0.15)   
162.11060 
(162.11020)  
0.21 
(2.68) 
b C6H10N2O3 158.06914 
  
290.97469 
(290.97464)   
0.37 
(0.20)     
c C8H14N2O2 170.10553 
  
303.01098 
(303.01092)   
0.03 
(0.17)     
d C8H13NO3 171.08954 
 
178.10555 
(178.10550)   
0.03 
(0.25)   
178.10554 
(178.10558)  
0.02 
(0.20) 
e C8H16N2O2 172.12118 
195.11095 
(195.11095) 
179.13719 
(179.13718) 
305.02665 
(305.02659) 
0.01 
(0.01) 
0.03 
(0.02) 
0.10 
(0.10) 
195.11095 
(195.11093) 
179.13718 
(179.13718) 
0.01 
(0.11) 
0.02 
(0.02) 
 C9H12N2O2 180.08988 
 
187.10586 
(187.10577)   
0.13 
(0.61)   
187.10590 
(187.10594)  
0.09 
(0.30) 
 C9H14N2O2 182.10553 
 
189.12154 
(189.12150)   
0.03 
(0.18)   
189.12155 
(189.12141)  
0.08 
(0.66) 
f C8H14N2O3 186.10044 
  
319.00586 
(319.00579)   
0.07 
(0.29)     
 C10H11NO3 193.07389 
 
200.08988 
(200.09002)   
0.07 
(0.63)      
g C9H9NO4 195.05316 
 
196.06100 
(196.06079) 
327.95859 
(327.95860)  
2.87 
(1.80) 
0.03 
(0.00)  
196.06101 
(196.06102)  
2.93 
(2.98) 
 C9H12N2O3 196.08479 
  
328.99026 
(328.99019)   
0.09 
(0.12)     
h C9H14N2O3 198.10044 
221.09028 
(221.09026) 
205.11642 
(205.11643) 
331.00585 
(331.00586) 
0.31 
(0.22) 
0.12 
(0.07) 
0.09 
(0.06) 
221.09021 
(221.09032) 
205.11642 
(205.11645) 
0.00 
(0.49) 
0.12 
(0.03) 
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   EID CAD 
   
m/z detected 
(m/z before phasing) 
Absolute Error 
(Error before phasing) 
(ppm) 
m/z detected 
(m/z before phasing) 
Absolute Error 
(Error before 
phasing) (ppm) 
 
Predicted 
Formula 
Theoretical 
Mass (Da) 
Na Li Cs Na Li Cs Na Li Na Li 
i C9H16N2O3 200.11609 
 
207.13207 
(207.13202) 
333.02144 
(333.02154)  
0.12 
(0.36) 
0.27 
(0.03) 
223.10586 
(223.10585)  
0.00 
(0.05)  
j C9H15NO4 201.10011 
 
208.11606 
(208.11609)   
0.25 
(0.11)   
208.11611 
(208.11610)  
0.01 
(0.06) 
 C10H12N2O3 208.08479 
 
215.10067 
(215.10059)   
0.58 
(0.95)   
215.10080 
(215.10078)  
0.03 
(0.07) 
k C10H16N2O3 212.11609 
       
219.13207 
(219.13207)  
0.11 
(0.11) 
l C9H16N2O4 216.11101 
 
223.12695 
(223.12696) 
349.01634 
(349.01642)  
0.29 
(0.24) 
0.32 
(0.09)     
m C9H17NO5 219.11067 
 
226.12661 
(226.12663)   
0.28 
(0.19)   
226.12665 
(226.12666)  
0.11 
(0.06) 
 C12H15NO3 221.10519 
 
228.12117 
(228.12119)   
0.11 
(0.02)   
228.12117 
(228.12114)  
0.11 
(0.24) 
 C10H12N2O4 224.07971 
 
231.09567 
(231.09573) 
356.98500 
(356.98511)  
0.19 
(0.07) 
0.42 
(0.11)  
231.09567 
(231.09577)  
0.19 
(0.24) 
 C10H14N204 226.09536 
 
233.11130 
(233.11132) 
359.00067 
(359.00077)  
0.27 
(0.19) 
0.36 
(0.09)  
233.11132 
(233.11140)  
0.19 
(0.15) 
n C10H16N2O4 228.11101 
251.10078 
(251.10081) 
235.12695 
(235.12701) 
361.01635 
(361.01646) 
0.00 
(0.12) 
0.27 
(0.02) 
0.28 
(0.02) 
251.10077 
(251.10089) 
235.12701 
(235.12702) 
0.04 
(0.43) 
0.02 
(0.03) 
o C10H18N2O4 230.12666 
  
363.03199 
(363.03177)   
0.31 
(0.91)     
 C13H15NO3 233.10519 
       
240.12119 
(240.12119)  
0.02 
(0.02) 
 C13H20N2O2 236.15248 
 
243.16838 
(243.16842)   
0.43 
(0.26)   
243.16844 
(243.16835)  
0.18 
(0.55) 
 C13H22N2O2 238.16813 
       
245.18408 
(245.18413)  
0.22 
(0.02) 
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   EID CAD 
   
m/z detected 
(m/z before phasing) 
Absolute Error 
(Error before phasing) 
(ppm) 
m/z detected 
(m/z before phasing) 
Absolute Error 
(Error before 
phasing) (ppm) 
 
Predicted 
Formula 
Theoretical 
Mass (Da) 
Na Li Cs Na Li Cs Na Li Na Li 
 C12H17NO4 239.11576 
  
372.02116 
(372.02093)   
0.11 
(0.73)     
 C10H14N2O5 242.09027 
 
249.10620 
(249.10634) 
374.99554 
(374.99554)  
0.30 
(0.26) 
0.46 
(0.46)     
p C11H20N2O4 244.14231 
267.13209 
(267.13208) 
251.15825 
(251.15832) 
377.04761 
(377.04760) 
0.03 
(0.00) 
0.25 
(0.02) 
0.37 
(0.40)  
251.15827 
(251.15765)  
0.18 
(2.64) 
 C10H18N2O5 246.12157 
 
253.13750 
(253.13755) 
379.02684 
(379.02684)  
0.29 
(0.09) 
0.45 
(0.45)     
 C14H20N2O2 248.15248 
 
255.16844 
(255.16843)   
0.17 
(0.21)   
255.16843 
(255.16833)  
0.21 
(0.60) 
 C11H14N2O5 254.09027 
 
261.10623 
(261.10628) 
386.99562 
(386.99550)  
0.17 
(0.02) 
0.24 
(0.55) 
277.08008 
(277.08011) 
277.08008 
(277.08011) 
0.14 
(0.25) 
0.05 
(0.02) 
 C13H22N2O3 254.16304 
 
261.17900 
(261.17908) 
387.06831 
(387.06830)  
0.17 
(0.14) 
0.44 
(0.47) 
277.15281 
(277.15289) 
261.17905 
(261.17905) 
0.00 
(0.29) 
0.02 
(0.02) 
q C12H20N2O4 256.14231 
 
263.15828 
(263.15823)   
0.13 
(0.32)   
263.15825 
(263.15828)  
0.24 
(0.13) 
r C13H24N2O3 256.17870 
 
263.19463 
(263.19475)   
0.28 
(0.17)   
263.19464 
(263.19463)  
0.24 
(0.28) 
s C12H22N2O4 258.15796 
 
265.17391 
(265.17397) 
391.06322 
(391.06322)  
0.20 
(0.02) 
0.46 
(0.46)  
265.17391 
(265.17396)  
0.20 
(0.02) 
 C14H16N2O3 260.11609 
 
267.13199 
(267.13205)   
0.39 
(0.16)   
267.13204 
(267.13209)  
0.20 
(0.01) 
 C14H18N2O3 262.13174 
       
269.14766 
(269.14765)  
0.31 
(0.35) 
 C14H16O5 264.09977 
  
397.00516 
(397.00529)   
0.13 
(0.20)     
 C14H22N2O3 266.16304 
 
273.17901 
(273.17914)   
0.12 
(0.35)   
273.17903 
(273.17902)  
0.05 
(0.09) 
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   EID CAD 
   
m/z detected 
(m/z before phasing) 
Absolute Error 
(Error before phasing) 
(ppm) 
m/z detected 
(m/z before phasing) 
Absolute Error 
(Error before 
phasing) (ppm) 
 
Predicted 
Formula 
Theoretical 
Mass (Da) 
Na Li Cs Na Li Cs Na Li Na Li 
t C13H22N2O4 270.15796 
 
277.17393 
(277.17395) 
403.06332 
(403.06344)  
0.12 
(0.05) 
0.20 
(0.10)  
277.17389 
(277.17391)  
0.27 
(0.19) 
 C11H16N2O6 272.10084 
 
279.11681 
(279.11695) 
405.00614 
(405.00612)  
0.12 
(0.38) 
0.35 
(0.40)     
 C12H22N2O5 274.15287 
 
281.16880 
(281.16875) 
407.05819 
(407.05818)  
0.26 
(0.44) 
0.30 
(0.32)     
 C14H20N2O4 280.14231 
 
287.15829 
(287.15824) 
413.04780 
(413.04780)  
0.08 
(0.26) 
0.12 
(0.12)  
287.15829 
(287.15825)  
0.08 
(0.22) 
 C14H22N2O4 282.15796 
 
289.17391 
(289.17393)   
0.19 
(0.12)   
289.17398 
(289.17403)  
0.06 
(0.23) 
u C14H24N2O4 284.17361 
307.16337 
(307.16331) 
291.18959 
(291.18973)  
0.04 
(0.23) 
0.08 
(0.40)  
307.16339 
(307.16328) 
291.18960 
(291.18960) 
0.03 
(0.33) 
0.05 
(0.05) 
 C13H22N2O5 286.15287 
 
293.16887 
(293.16890) 
419.05820 
(419.05820)  
0.01 
(0.09) 
0.26 
(0.26)     
 C15H20N2O4 292.14231 
 
299.15835 
(299.15860)   
0.12 
(0.96)   
299.15850 
(299.15850)  
0.62 
(0.62) 
 C9H17N3O8 295.10157 
  
428.00659 
(428.00674)   
0.98 
(0.63)     
 C14H19NO6 297.12124 
 
304.13729 
(304.13733)   
0.15 
(0.28)   
304.13713 
(304.13714)  
0.37 
(0.34) 
 C14H22N2O5 298.15287 
 
305.16886 
(305.16890) 
431.05829 
(431.05814)  
0.05 
(0.09) 
0.05 
(0.40)     
v C14H24N2O5 300.16852 
 
307.18452 
(307.18456) 
433.07397 
(433.07382)  
0.01 
(0.12) 
0.02 
(0.33)     
w C14H26N2O5 302.18417 
325.17394 
(325.17397) 
309.20022 
(309.20005) 
435.08962 
(435.08976) 
0.00 
(0.09) 
0.15 
(0.40) 
0.02 
(0.34) 
325.17393 
(325.17401) 
309.20017 
(309.20016) 
0.03 
(0.21) 
0.01 
(0.05) 
x C16H21NO5 307.14197 
330.13176 
(330.13186)   
0.06 
(0.36)   
330.13172 
(330.13178)  
0.06 
(0.12)  
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   EID CAD 
   
m/z detected 
(m/z before phasing) 
Absolute Error 
(Error before phasing) 
(ppm) 
m/z detected 
(m/z before phasing) 
Absolute Error 
(Error before 
phasing) (ppm) 
 
Predicted 
Formula 
Theoretical 
Mass (Da) 
Na Li Cs Na Li Cs Na Li Na Li 
y C15H22N2O5 310.15287 
 
317.16890 
(317.16895) 
443.05836 
(443.05852)  
0.08 
(0.24) 
0.11 
(0.47) 
333.14264 
(333.14271) 
317.16886 
(317.16885) 
0.00 
(0.21) 
0.04 
(0.08) 
z C14H22N2O6 314.14779 
 
321.16383 
(321.16405) 
447.05332 
(447.05332)  
0.11 
(0.80) 
0.20 
(0.20)     
aa C14H24N2O6 316.16344 
 
323.17955 
(323.17985) 
449.06888 
(449.06888)  
0.33 
(1.26) 
0.00 
(0.00)     
bb C15H18N2O6 322.11649 
 
329.13253 
(329.13267) 
455.02192 
(455.02176)  
0.11 
(0.53) 
0.02 
(0.38)     
cc C15H22N2O6 326.14779 
  
459.05329 
(459.05312)   
0.13 
(0.24)     
dd C15H24N2O6 328.16344 
351.15321 
(351.15320) 
335.17956 
(335.17941) 
461.06902 
(461.06924) 
0.00 
(0.03) 
0.35 
(0.10) 
0.30 
(0.78) 
351.15322 
(351.15334) 
335.17947 
(335.17944) 
0.03 
(0.37) 
0.08 
(0.01) 
ee C15H18N2O7 338.11140 
  
471.01685 
(471.01685)   
0.02 
(0.02)     
 C17H26N2O5 338.18417 
  
471.08970 
(471.08953)   
0.19 
(0.17)     
ff C15H24N2O7 344.15835 
 
351.17452 
(351.17448) 
477.06396 
(477.06397)  
0.47 
(0.36) 
0.35 
(0.38)     
gg C18H26N2O5 350.18417 
373.17395 
(373.17397)   
0.02 
(0.08)   
373.17396 
(373.17406)  
0.05 
(0.32)  
hh C15H24N2O8 360.15327 
 
367.16947 
(367.16998) 
493.05889 
(493.05910)  
0.53 
(1.92) 
0.36 
(0.79)     
 C17H21N3O6 363.14304 
  
496.04886 
(496.04908)   
0.76 
(1.21)     
 C18H26N2O6 366.10632 
 
373.12258 
(373.12288) 
499.01187 
(499.01190)  
0.69 
(1.49) 
0.22 
(0.28)     
ii C17H25N3O6 367.17434 
 
374.19056 
(374.19087)   
0.58 
(1.41)   
374.19014 
(374.19014)  
0.55 
(0.55) 
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   EID CAD 
   
m/z detected 
(m/z before phasing) 
Absolute Error 
(Error before phasing) 
(ppm) 
m/z detected 
(m/z before phasing) 
Absolute Error 
(Error before 
phasing) (ppm) 
 
Predicted 
Formula 
Theoretical 
Mass (Da) 
Na Li Cs Na Li Cs Na Li Na Li 
 C17H20N2O8 380.12197 
  
513.02770 
(513.02794)   
0.56 
(1.03)     
jj C18H26N2O7 382.17400 
  
515.07981 
(515.07941)   
0.72 
(0.06)     
 C22H30NO5 387.20457 
388.21240 
(388.21251)   
1.43 
(1.71)       
kk C18H23N3O7 393.15360 
 
400.16992 
(400.17014) 
526.05963 
(526.05967)  
0.79 
(1.34) 
1.12 
(1.20)     
ll C17H23N3O8 397.14852 
 
404.16481 
(404.16478) 
530.05447 
(530.05428)  
0.71 
(0.63) 
0.96 
(0.60)     
 C24H34NO4 399.24096 
400.24873 
(400.24873)   
1.23 
(1.23)       
mm C19H23N3O7 405.15360 
 
412.17004 
(412.17055) 
538.05967 
(538.05924)  
1.06 
(2.30) 
1.17 
(0.37)     
 C18H23N3O 409.14852 
 
416.16485 
(416.16537) 
542.05464 
(542.05422)  
0.78 
(2.03) 
1.25 
(0.48)     
nn C18H25N3O8 411.16417 
 
418.18062 
(418.18044) 
544.07015 
(544.07020)  
1.07 
(0.64) 
0.99 
(1.08)     
 C24H32NO5 413.22022 
414.22796 
(414.22795)   
1.12 
(1.09)       
 C24H30O6 414.20424 
       
421.21985 
(421.21966)  
0.94 
(1.39)  
 C19H23N3O8 421.14852 
 
428.16507 
(428.16503) 
554.05488 
(554.05341)  
1.28 
(1.18) 
1.66 
(0.99)     
 C21H26O9 422.15768 
 
429.17288 
(429.17358) 
555.06260 
(555.06291)  
1.87 
(0.24) 
0.94 
(0.38)     
oo C19H25N3O8 423.16417 
 
430.18080 
(430.18136) 
556.07025 
(556.07031)  
1.46 
(2.76) 
1.15 
(1.26)  
430.17995 
(430.17980)  
0.52 
(0.87) 
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EID CAD 
m/z detected 
(m/z before phasing) 
Absolute Error 
(Error before phasing) 
(ppm) 
m/z detected 
(m/z before phasing) 
Absolute Error 
(Error before 
phasing) (ppm) 
 
Predicted 
Formula 
Theoretical 
Mass (Da) 
Na Li Cs Na Li Cs Na Li Na Li 
pp C22H34N2O7 438.2366 
       
445.25226 
(445.25198)  
0.77 
(1.40) 
qq C22H31N3O7 449.21620 
 
456.23304 
(456.23300)   
1.83 
(1.74)   
456.23182 
(456.23163)  
0.84 
(1.26) 
 C22H28O10 452.16825 
 
459.18356 
(459.18437) 
585.07350 
(585.07358)  
1.51 
(0.25) 
0.33 
(0.19)     
 C23H31N3O7 461.2162 
       
468.23188 
(468.23150)  
0.69 
(1.50) 
 C23H34N2O8 466.23152 
       
473.24717 
(473.24660)  
0.75 
(1.95) 
rr C23H34N3O8 479.22677 
480.23516 
(480.23510) 
486.24347 
(486.24360)  
2.32 
(2.19) 
1.43 
(1.70)   
486.24245 
(486.24237)  
0.67 
(0.83) 
ss C23H34N2O9 482.22643 
       
489.24197 
(489.24149)  
0.95 
(1.93) 
tt C23H35N3O9 497.23733 
      
520.22709 
(520.22711) 
504.25304 
(504.25327) 
0.02 
(0.02) 
0.58 
(0.13) 
 C22H33N3O10 499.21659 
       
506.23243 
(506.23186)  
0.32 
(1.45) 
uu C22H33N3O11 515.21151 
 
516.21809 
(516.21866)   
1.35 
(0.24)      
vv C24H33N3O10 523.21659 
 
530.23370 
(530.23384)   
2.09 
(0.24)      
M+ C24H35N3O11 541.22716 
564.21692 
(564.21693) 
548.24305 
(548.24320) 
674.13251 
(674.13251) 
0.02 
(0.00) 
0.21 
(0.07) 
0.13 
(0.13) 
564.21691 
(564.21704) 
548.24316 
(548.24318) 
0.04 
(0.19) 
0.01 
(0.03) 
 
Average Absolute Error (Average Absolute 
Error before phasing) (ppm) : 
0.47 
(0.53) 
0.49 
(0.57) 
0.40 
(0.40) 
  0.03 
(0.24) 
0.32 
(0.56) 
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Appendix 70  Peak list – FTICR-MS electron induced dissociation (EID) or collisionally activated dissociation (CAD) of the nonhydrolysable photolabile 
carba(dethia) pantetheine 81 with sodium, lithium or caesium adduction.  Those with a predicted structure have a designated letter that correlates with chapter 
6. 
  
87 
 
 
Appendix 71 Cleavage coverage maps showing b and y ions resulting from collisionally 
activated dissociation (35V and 25V) of acetyl-ACP 40 with (A, red) and without (B, blue) 
lithium adduction. The differences between the maps is shown (C). 
 
 
Appendix 72 Cleavage coverage maps showing b and y ions resulting from collisionally 
activated dissociation (40V and 35V) of malonyl-ACP 7 with lithium (A, red), with caesium 
(C, green) and without alkali (B, blue) adduction.  The differences between the maps is 
shown (D). 
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Appendix 73 Cleavage coverage maps showing b and y ions resulting from collisionally 
activated dissociation (40V and 30V) of acetoacetyl-ACP 167 with lithium (A, red), with 
caesium (C, green) and without alkali (B, blue) adduction.  The differences between the 
maps is shown (D). 
 
 
Appendix 74 Cleavage coverage maps showing b and y ions resulting from collisionally 
activated dissociation (35V and 25V) of myristoyl-ACP 168 with (A, red) and without (B, 
blue) lithium adduction.  The differences between the maps is shown (C). 
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Appendix 75 Cleavage coverage maps showing b and y ions resulting from collisionally 
activated dissociation (30V, 28V and 18V) of nonhydrolysable photolabile malonyl 
carba(dethia) ACP analogue 63 with lithium (A, red), with caesium (C, green) and without 
alkali (B, blue) adduction.  The differences between the maps is shown (D). 
 
 
Appendix 76 Cleavage coverage maps only showing phosphorylated b and y ions resulting 
from collisionally activated dissociation (35V and 25V) of acetyl-ACP 40 with (A, red) and 
without (B, blue) lithium adduction.  The differences between the maps is shown (C). 
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Appendix 77 Cleavage coverage maps only showing phosphorylated b and y ions resulting 
from collisionally activated dissociation (40V and 35V) of malonyl-ACP 7 with lithium (A, 
red), with caesium (C, green) (Note: none detected) and without alkali (B, blue) adduction.  
The differences between the maps is shown (D). 
 
Appendix 78 Cleavage coverage maps only showing phosphorylated b and y ions resulting 
from collisionally activated dissociation (40V and 30V) of acetoacetyl-ACP 167 with lithium 
(A, red), with caesium (C, green) and without alkali (B, blue) adduction.  The differences 
between the maps is shown (D). 
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Appendix 79 Cleavage coverage maps only showing phosphorylated b and y ions resulting 
from collisionally activated dissociation (35V and 25V) of myristoyl-ACP 168 with (A, red) 
and without (B, blue) lithium adduction.  The differences between the maps is shown (C). 
 
 
Appendix 80 Cleavage coverage maps only showing phosphorylated b and y ions resulting 
from collisionally activated dissociation (30V, 28V and 18V) of nonhydrolysable photolabile 
malonyl carba(dethia) ACP analogue 63 with lithium (A, red), with caesium (C, green) 
(Note: none detected) and without alkali (B, blue) adduction.  The differences between the 
maps is shown (D). 
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Appendix 81 Cleavage coverage maps only showing ‘b’ and ‘y’ ions with the acetyl-
phosphopantetheinyl arm bound, resulting from collisionally activated dissociation (35V 
and 25V) of acetyl-ACP 40 with (A, red) and without (B, blue) lithium adduction.  The 
differences between the maps is shown (C). 
 
 
Appendix 82 Cleavage coverage maps only showing ‘b’ and ‘y’ ions with the nonhydrolysable 
photolabile malonyl carba(dethia)-phosphopantetheinyl arm bound, resulting from 
collisionally activated dissociation (30V, 28V and 18V) of nonhydrolysable photolabile 
malonyl carba(dethia) ACP analogue 63 with lithium (A, red), with caesium (C, green) (Note: 
none detected) and without alkali (B, blue) adduction.  The differences between the maps is 
shown (D). 
